<PAGE>
________________________________________________________________________________
SECURITIES AND EXCHANGE COMMISSION
------------------------
SCHEDULE 14A INFORMATION
------------------------
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Filed by Registrant [x]
Filed by a Party Other than Registrant [ ]
Check the Appropriate Box:
[ ] Preliminary Proxy Statement
[ ] Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
[x] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material Pursuant to 'SS'240.14a-11(c) or 'SS'240.14a-12
------------------------
PUREPAC, INC.
(NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
(NAME OF PERSON(S) FILING PROXY STATEMENT, IF OTHER THAN THE REGISTRANT)
------------------------
Payment of Filing Fee (Check the Appropriate Box):
[ ] $125 per Exchange Act Rules 0-11(c)(1)(ii), 14a-6(i)(1) or 14a-6(i)(2) or
Item 22(a)(2) of Schedule 14A.
[ ] $500 per each party to the controversy pursuant to Exchange Act Rule
14a-6(i)(3).
[x] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each Class of Securities to which transaction applies: Common
Stock $.01 par value, of Registrant.
(2) Aggregate Number of Securities to which transaction applies: 2,321,261
shares of Registrant.
(3) Per unit price or the underlying value of transaction computed pursuant
to Exchange Act Rule 0-11: $20,000,000.
(4) Proposed maximum aggregate value of transaction: $20,000,000.
(5) Total fee paid: $4,000.00.
[x] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing:
(1) Amount Previously Paid:
(2) Form Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:
------------------------
COPIES OF ALL COMMUNICATIONS TO:
WILLIAM R. GRIFFITH, ESQ.
PARKER DURYEE ROSOFF & HAFT
529 FIFTH AVENUE
NEW YORK, NEW YORK 10017
________________________________________________________________________________
<PAGE>
<PAGE>
[LOGO]
January 26, 1996
Dear Purepac, Inc. Stockholder:
Enclosed is a Notice of Annual Meeting of Purepac, Inc. Stockholders to be
held on Thursday, February 29, 1996 at the Newark Airport Marriott in Newark,
New Jersey, and a Proxy Statement containing information about the various
matters to be acted upon at the Annual Meeting. Also enclosed is a Proxy which
we urge you to complete and promptly return to ensure that your shares are voted
at the Annual Meeting.
In addition to the election of directors of Purepac, Inc ('Purepac'), the
ratification of the selection of independent auditors and the approval of an
increase in the number of authorized shares of Purepac common stock from 25
million to 35 million, you are being asked to consider, vote upon and approve,
as a single proposal, the following transactions (together, the 'Faulding
Transaction') between Purepac and Faulding Holdings Inc. ('Faulding'), which is
the holder of the majority of the outstanding Purepac common stock:
1. The acquisition by Purepac, in exchange for 2,253,521 shares of
Purepac's common stock (subject to adjustment), of three operating
subsidiaries of Faulding (collectively the 'Faulding Subsidiaries') --
(a) Faulding Medical Device Co., which is engaged in the
development of drug-dependent and stand-alone injectable devices and
systems which it plans to commercialize in the United States in the
coming years,
(b) Faulding Puerto Rico, Inc. ('FPR'), which operates a parenteral
product manufacturing facility producing a variety of generic
pharmaceuticals in injectable form, and
(c) Faulding Pharmaceutical Co., a recently organized sales and
marketing company holding the United States marketing rights to the
products manufactured by FPR and to certain injectible generic drug
products manufactured by F.H. Faulding & Co. Limited ('F.H. Faulding'),
the Australian international health care products company which is the
parent corporation of Faulding.
2. The sale by Purepac to Faulding of shares of a new class of
preferred stock of Purepac, bearing an annual dividend of 4.5% and
convertible into an aggregate of 1,564,950 shares of Purepac common stock,
for $15 million, which will be used primarily to finance certain of the
working capital needs of the Faulding Subsidiaries.
The Purepac Board of Directors believes that the Faulding Transaction
represents an attractive business opportunity for Purepac. It provides your
company with a chance to diversify and expand its range of product offerings in
the generic pharmaceutical industry, by adding both the manufacture and sale of
injectable generic pharmaceutical products, and the development and sale of
related devices. Your Board believes that this product diversification can be
accomplished while permitting Purepac to benefit from certain operating
efficiencies resulting from the addition of such businesses.
The Board also believes that the Faulding Transaction will further
establish Purepac as a base of F. H. Faulding's generic and related
pharmaceutical product technology and product offerings in the United States.
You are also being requested to approve the change of name of Purepac to
'Faulding Inc.', which name change will be effectuated only in the event of the
consummation of the Faulding Transaction. This name change will permit your
company to capitalize upon the international reputation which is attached to the
Faulding name. Should this name change occur, Purepac's existing operating
subsidiary, Purepac Pharmaceutical Co., will continue to operate under its
current name.
<PAGE>
<PAGE>
The Purepac Board of Directors is of the view that, although this is a
transaction between affiliated parties, the $20 million negotiated valuation of
the businesses to be acquired (which is based primarily upon their aggregate net
asset value as of June 30, 1995, as adjusted), as well as the terms of the
preferred stock issuance, are fair both to Purepac and to its non-Faulding
stockholders.
Because Faulding is a party to the transaction, Faulding has agreed to vote
all shares of common stock held by it with respect to the proposals to approve
the Faulding Transaction and to change the name of the company in the same
manner as are the majority of the votes cast by the other Purepac stockholders
at the Annual Meeting. Accordingly, votes cast by Purepac stockholders other
than Faulding will determine whether the Faulding Transaction and the name
change are approved or disapproved.
The proposals being submitted for the approval of the Purepac stockholders
at the Annual Meeting are of great significance to the future business
operations of your company. Therefore, we ask that you please review carefully
the enclosed Proxy Statement which contains a detailed discussion concerning the
background of the Faulding Transaction and the factors considered by the Purepac
Board of Directors in approving the transaction. It is important that your views
with respect to such proposals be represented at the Annual Meeting. You are
urged to mark, sign and date the enclosed Proxy, which should be returned
promptly in the enclosed envelope, even if you plan to attend the Annual
Meeting. Completing and returning the Proxy will not limit your right to vote in
person if you attend the Annual Meeting.
If you have any questions regarding the Annual Meeting or the matters
submitted for stockholder approval, please call the company's proxy solicitation
agent, D.F. King & Co., Inc., toll free at (800) 859-8508.
We look forward to seeing you at the Annual Meeting.
Sincerely,
RICHARD F. MOLDIN
RICHARD F. MOLDIN,
President and Chief Executive Officer
<PAGE>
<PAGE>
PUREPAC, INC.
200 ELMORA AVENUE
ELIZABETH, NEW JERSEY 07207
------------------------
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON FEBRUARY 29, 1996
------------------------
To the Stockholders:
The Annual Meeting of Stockholders of Purepac, Inc., a Delaware corporation
('Purepac'), will be held on Thursday, February 29, 1996 at 10:00 A.M., Eastern
time, at the Newark Airport Marriott, Newark International Airport, Newark, New
Jersey, for the following purposes:
1. To approve, as a single proposal, two transactions initially
contemplated by a Letter of Intent dated August 9, 1995 (the 'Letter of
Intent') by and between Purepac and Faulding Holdings Inc. ('Faulding'),
Purepac's principal stockholder, being, respectively:
(i) the acquisition by Purepac (the 'Acquisition Transaction') of
all of the outstanding capital stock of each of Faulding Medical Device
Co., Faulding Puerto Rico, Inc. and Faulding Pharmaceutical Co. (each a
subsidiary of Faulding and collectively, the 'Faulding Subsidiaries')
from Faulding, in exchange for 2,253,521 shares of Purepac Common Stock
(determined by dividing $20.0 million, the negotiated value of the
Faulding Subsidiaries, by $8.875, the closing price of a share of
Purepac Common Stock on August 9, 1995, the date of the execution of the
Letter of Intent), subject to adjustment, as set forth in a Stock
Purchase Agreement dated January 23, 1996 between Purepac and Faulding;
and
(ii) the sale to Faulding by Purepac, for a cash purchase price of
$100 per share or an aggregate of $15.0 million, of 150,000 shares of
Purepac Class B Preferred Stock, paying an annual dividend of $4.50 per
share or an aggregate of $675,000 per year, and convertible into shares
of Purepac Common Stock at a rate of 10.433 shares of Common Stock for
each share of Class B Preferred Stock, representing an 8% premium over
the closing price of a share of Purepac Common Stock on August 9, 1995,
the date of the execution of the Letter of Intent, as set forth in a
Preferred Stock Purchase Agreement dated January 23, 1996 between
Purepac and Faulding (the 'Preferred Stock Purchase' and, together with
the Acquisition Transaction, the 'Faulding Transaction').
If the Faulding Transaction is approved, Faulding's ownership interest in
Purepac would increase from 54.4% to 61.5% of the issued and outstanding
Purepac Common Stock (as adjusted as of September 30, 1995). Furthermore,
if Faulding were to convert all of the Class B Preferred Stock into Purepac
Common Stock, and convert into Purepac Common Stock all of the Class A
Preferred Stock also owned by Faulding, Faulding's ownership of Purepac
Common Stock would increase to 73.3%;
2. To approve an amendment to Purepac's Certificate of Incorporation
to change Purepac's name to 'Faulding Inc.';
3. To approve an amendment to Purepac's Certificate of Incorporation
to increase Purepac's authorized Common Stock from 25,000,000 shares to
35,000,000 shares;
4. To elect five directors for the ensuing year;
5. To approve the selection of Deloitte & Touche LLP as Purepac's
independent auditors for its fiscal year ending June 30, 1996; and
6. To transact such other business incidental to the Annual Meeting as
may properly come before the Annual Meeting or any adjournment or
postponement thereof.
<PAGE>
<PAGE>
Only stockholders of record at the close of business on January 24, 1996
are entitled to notice of and to vote at the Annual Meeting or any adjournment
thereof.
WILLIAM R. GRIFFITH
Secretary
Elizabeth, New Jersey
January 26, 1996
WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING, PLEASE SIGN THE
ENCLOSED PROXY WHICH IS SOLICITED BY PUREPAC'S BOARD OF DIRECTORS AND
RETURN IT IN THE PRE-ADDRESSED ENVELOPE WHICH HAS BEEN PROVIDED. ANY
STOCKHOLDER MAY REVOKE HIS PROXY AT ANY TIME BEFORE THE MEETING BY WRITTEN
NOTICE TO SUCH EFFECT, BY SUBMITTING A SUBSEQUENTLY DATED PROXY OR BY
ATTENDING THE MEETING AND VOTING IN PERSON.
<PAGE>
<PAGE>
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
SUMMARY.................................................................................................... i
The Proposed Faulding Transaction..................................................................... i
Introduction..................................................................................... i
The Annual Meeting............................................................................... ii
The Parties...................................................................................... ii
Purepac..................................................................................... ii
Faulding Subsidiaries....................................................................... ii
Faulding.................................................................................... iii
Relationships Between Purepac and Faulding; Potential Conflicts of Interest...................... iii
Required Vote.................................................................................... iv
Background of the Faulding Transaction........................................................... v
Recommendation of the Purepac Board; Reasons for the Faulding Transaction........................ v
Opinion of Financial Advisor..................................................................... v
Risk Factors..................................................................................... vi
Closing Date..................................................................................... vi
Conditions to Consummation of the Faulding Transaction........................................... vi
Right to Terminate, Amend or Waive Conditions.................................................... vi
Absence of Regulatory Filings and Approvals...................................................... vi
Certain Tax Consequences of the Faulding Transaction............................................. vi
Accounting Treatment............................................................................. vi
Absence of Appraisal Rights...................................................................... vii
Market Price of Purepac's Common Stock........................................................... vii
Summary Historical Financial Information.............................................................. viii
Faulding Subsidiaries............................................................................ viii
Purepac.......................................................................................... x
Summary Pro Forma Financial Information............................................................... xi
THE ANNUAL MEETING......................................................................................... 1
Purposes of Meeting................................................................................... 1
Date, Time and Place; Record Date..................................................................... 1
Required Vote......................................................................................... 2
THE PROPOSED FAULDING TRANSACTION.......................................................................... 3
The Acquisition Transaction........................................................................... 3
The Preferred Stock Purchase.......................................................................... 4
Closing Date.......................................................................................... 5
Operations of Purepac After the Faulding Transaction.................................................. 5
Background............................................................................................ 6
Recommendation of the Purepac Board; Reasons for the Faulding Transaction............................. 15
Opinion of Financial Advisor.......................................................................... 16
Relationships Between Purepac and Faulding; Potential Conflicts of Interest........................... 21
Stock Purchase Agreement.............................................................................. 21
Preferred Stock Purchase Agreement.................................................................... 24
Certain Tax Consequences of the Faulding Transaction.................................................. 24
Absence of Regulatory Filings and Approvals........................................................... 24
Absence of Appraisal Rights........................................................................... 24
Accounting Treatment.................................................................................. 24
Expenses.............................................................................................. 24
SELECTED FINANCIAL DATA OF THE FAULDING SUBSIDIARIES....................................................... 25
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS -- FAULDING
SUBSIDIARIES............................................................................................. 27
Overview.............................................................................................. 27
Operations of FMDC.................................................................................... 27
Operations of FPR..................................................................................... 28
</TABLE>
<PAGE>
<PAGE>
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
Operations of FPC................................................................................ 28
Liquidity and Capital Resources.................................................................. 29
PROPOSAL TO CHANGE PUREPAC'S NAME.......................................................................... 30
Background............................................................................................ 30
Board Recommendation.................................................................................. 31
PROPOSAL TO INCREASE CAPITALIZATION........................................................................ 31
Recommended Increase in Authorized Common Stock....................................................... 31
Currently Authorized Capital Stock.................................................................... 31
Description of Capital Stock.......................................................................... 31
Required Vote......................................................................................... 33
ELECTION OF DIRECTORS...................................................................................... 33
Information Concerning Nominees....................................................................... 33
Information Concerning the Purepac Board.............................................................. 34
Section 16(a) Reporting Delinquencies................................................................. 35
RATIFICATION OF SELECTION OF INDEPENDENT AUDITORS.......................................................... 35
PRICE RANGES OF PUREPAC COMMON STOCK....................................................................... 35
SELECTED FINANCIAL DATA OF PUREPAC......................................................................... 36
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS -- PUREPAC........... 37
Results of Operations................................................................................. 37
Financial Condition, Liquidity and Capital Resources.................................................. 39
New Accounting Pronouncements......................................................................... 40
Unknown Effect of Recent Medical Study................................................................ 41
PRO FORMA FINANCIAL STATEMENTS............................................................................. 41
Notes to Pro forma Financial Statements............................................................... 44
BUSINESS OF THE FAULDING SUBSIDIARIES...................................................................... 46
Certain Risks Relating to the Faulding Subsidiaries................................................... 46
FMDC.................................................................................................. 48
FPR................................................................................................... 48
FPC................................................................................................... 50
BUSINESS OF PUREPAC........................................................................................ 50
Introduction.......................................................................................... 50
Products.............................................................................................. 51
New Product Development............................................................................... 51
Marketing and Customers............................................................................... 52
Manufacturing and Sources of Supply................................................................... 52
Environmental Matters................................................................................. 52
Competition........................................................................................... 53
Governmental Regulation............................................................................... 53
Employees............................................................................................. 54
Properties............................................................................................ 54
Litigation............................................................................................ 54
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS............................................................. 55
PERFORMANCE GRAPH.......................................................................................... 57
EXECUTIVE OFFICERS OF PUREPAC.............................................................................. 58
Compensation of Executive Officers.................................................................... 58
Agreements with Officers......................................................................... 60
Pension Plan..................................................................................... 60
Savings Plan..................................................................................... 61
Compensation Committee Report on Executive Compensation.......................................... 61
Compensation Committee Interlocks and Insider Participation...................................... 63
PRINCIPAL STOCKHOLDERS OF PUREPAC.......................................................................... 63
STOCKHOLDER PROPOSALS...................................................................................... 63
FINANCIAL STATEMENTS....................................................................................... F-1
</TABLE>
<PAGE>
<PAGE>
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
Financial Statements of the Faulding Subsidiaries
Faulding Medical Device Co., for the years ended June 30, 1995 and 1994.......................... F-2
Faulding Medical Device Co., for the three months ended September 30, 1995 (unaudited)........... F-9
Faulding Pharmaceutical Co., for the period from April 7, 1995 (date of inception) through June
30, 1995......................................................................................... F-14
Faulding Pharmaceutical Co. for the three months ended September 30, 1995 (unaudited)............ F-21
Faulding Puerto Rico, Inc., for the period April 7, 1995 (date of inception) to
June 30, 1995.................................................................................. F-26
Faulding Puerto Rico, Inc. for the three months ended September 30, 1995 (unaudited)............. F-34
Aguadilla Branch Operations of DuPont Merck Pharma for the period from January 1, 1995 through
April 6, 1995 (unaudited)........................................................................ F-39
Aguadilla Branch Operations of DuPont Merck Pharma for the years ended December 31, 1994 and
1993............................................................................................. F-44
Financial Statements of Purepac, Inc.
For the years ended June 30, 1995 and 1994....................................................... F-53
For the three months ended September 30, 1995 and 1994 (unaudited)............................... F-72
EXHIBITS
Stock Purchase Agreement.............................................................................. A-1
Preferred Stock Purchase Agreement.................................................................... B-1
Opinion of Salomon Brothers Inc....................................................................... C-1
</TABLE>
<PAGE>
<PAGE>
[THIS PAGE INTENTIONALLY LEFT BLANK]
<PAGE>
<PAGE>
PUREPAC, INC.
200 ELMORA AVENUE
ELIZABETH, NEW JERSEY 07207
------------------------
PROXY STATEMENT
------------------------
SUMMARY
The following summary is qualified in its entirety by the detailed
information appearing elsewhere in this Proxy Statement. Capitalized terms used
and not otherwise defined in this summary have the meanings given to them
elsewhere in this Proxy Statement.
THE PROPOSED FAULDING TRANSACTION
INTRODUCTION
This Proxy Statement relates to the solicitation of proxies by the Board of
Directors of Purepac, Inc., a Delaware corporation ('Purepac' or the 'Company'),
to approve, as a single proposal, two transactions initially contemplated by a
Letter of Intent dated August 9, 1995 (the 'Letter of Intent') between Purepac
and Faulding Holdings Inc. ('Faulding'), Purepac's principal stockholder,
providing for (i) Purepac's acquisition (the 'Acquisition Transaction') of all
of the outstanding shares of capital stock of Faulding Medical Device Co.,
Faulding Puerto Rico, Inc. and Faulding Pharmaceutical Co. (each a subsidiary of
Faulding and collectively, the 'Faulding Subsidiaries') from Faulding in
exchange for 2,253,521 shares of Purepac Common Stock (determined by dividing
$20.0 million, the negotiated value of the Faulding Subsidiaries, based
primarily upon their aggregate Net Asset Value as of June 30, 1995, by $8.875,
being the closing price of Purepac's Common Stock on The Nasdaq National Market
on August 9, 1995, the date of the execution of the Letter of Intent), which
number of shares is subject to adjustment in the event of any change in the Net
Asset Value of the Faulding Subsidiaries between June 30, 1995 and the
consummation of the Acquisition Transaction, as set forth in a Stock Purchase
Agreement dated January 23, 1996 (the 'Stock Purchase Agreement') between
Purepac and Faulding, and (ii) the sale to Faulding by Purepac, for a purchase
price of $100 per share or an aggregate of $15.0 million, of 150,000 shares of
Purepac's Class B Preferred Stock (the 'Class B Preferred Stock'), paying an
annual dividend of $4.50 per share or an aggregate of $675,000 per year, and
convertible into shares of Purepac Common Stock at a rate of 10.433 shares of
Common Stock for each share of Class B Preferred Stock, representing an 8%
premium, over the closing price of Purepac's Common Stock on August 9, 1995, the
date of the execution of the Letter of Intent, as set forth in a Preferred Stock
Purchase Agreement dated January 23, 1996 (the 'Preferred Stock Purchase
Agreement') between Purepac and Faulding (the 'Preferred Stock Purchase' and,
together with the Acquisition Transaction, the 'Faulding Transaction'). See 'The
Proposed Faulding Transaction.'
Because the negotiated value of the Faulding Subsidiaries, $20 million, was
based primarily upon the Net Asset Value of the Faulding Subsidiaries
($17,878,028 at June 30, 1995), the Stock Purchase Agreement provides for a
'dollar-for-dollar' adjustment to the purchase price in accordance with changes
in the Net Asset Value of the Faulding Subsidiaries through the closing date of
the Acquisition Transaction, utilizing the same $8.875 per share price to
calculate such adjustment as was used to determine the original number of shares
constituting the purchase price. As of September 30, 1995, the Net Asset Value
of the Faulding Subsidiaries had increased from approximately $17,878,028 at
June 30, 1995 to approximately $18,479,219. Assuming that the Faulding
Subsidiaries' Net Asset Value were to remain unchanged between September 30,
1995 and the date of the consummation of the Faulding Transaction (the 'Closing
Date'), as to which there can be no assurance, the number of shares of Purepac
Common Stock issuable to Faulding at the Closing would increase from 2,253,521
shares to 2,321,261 shares. See 'The Proposed Faulding Transaction -- The
Acquisition Transaction -- Purchase Price Adjustment.'
i
<PAGE>
<PAGE>
On the Closing Date, Faulding will contribute to the capital of the
respective Faulding Subsidiaries all indebtedness then owed by the Faulding
Subsidiaries to Faulding. Such indebtedness aggregated $22,748,555 at September
30, 1995. See 'The Proposed Faulding Transaction -- Stock Purchase Agreement.'
If the Faulding Transaction is approved, Faulding's ownership interest in
Purepac would increase from 54.4% to 61.5% of the issued and outstanding Purepac
Common Stock (as adjusted as of September 30, 1995). Furthermore, if Faulding
were to convert all of the Class B Preferred Stock and all of the Class A
Preferred Stock currently owned by Faulding into Purepac Common Stock,
Faulding's ownership of Purepac Common Stock would increase to 73.3%. See 'The
Proposed Faulding Transaction' and 'Principal Stockholders of Purepac.'
Copies of the Stock Purchase Agreement and the Preferred Stock Purchase
Agreement are attached as Exhibits A and B to this Proxy Statement.
THE ANNUAL MEETING
At the Annual Meeting of Purepac's stockholders (the 'Purepac
Stockholders') and at any adjournment or postponement thereof (the 'Annual
Meeting'), the Purepac Stockholders will be asked to approve the Faulding
Transaction. The Purepac Stockholders will also be asked to consider and vote
upon proposals to amend Purepac's Certificate of Incorporation to change
Purepac's name to Faulding Inc. (the 'Name Change') and to increase Purepac's
authorized Common Stock from 25,000,000 shares to 35,000,000 shares (the 'Stock
Increase'), to elect five directors for the ensuing year and to ratify the
Purepac Board's selection of Deloitte & Touche LLP as Purepac's independent
auditors for its fiscal year ending June 30, 1996.
The Annual Meeting is scheduled to be held at 10:00 A.M., Local Time, on
Thursday, February 29, 1996, at the Newark Airport Marriott, Newark
International Airport, Newark, New Jersey. Purepac's Board of Directors (the
'Purepac Board') has fixed the close of business on January 24, 1996 as the
record date (the 'Record Date') for the determination of holders of Purepac
Common Stock entitled to notice of and to vote at the Annual Meeting. See 'The
Annual Meeting.'
THE PUREPAC BOARD HAS UNANIMOUSLY APPROVED THE FAULDING TRANSACTION AND
RECOMMENDS THAT THE PUREPAC STOCKHOLDERS VOTE 'FOR' THE PROPOSAL TO APPROVE THE
FAULDING TRANSACTION. THE PUREPAC BOARD HAS ALSO UNANIMOUSLY APPROVED THE NAME
CHANGE, THE STOCK INCREASE AND EACH OF THE OTHER PROPOSALS TO BE SUBMITTED TO
THE PUREPAC STOCKHOLDERS AT THE ANNUAL MEETING AND RECOMMENDS THAT THE PUREPAC
STOCKHOLDERS VOTE 'FOR' EACH OF THESE MATTERS AS WELL. See 'The Proposed
Faulding Transaction -- Recommendation of the Purepac Board; Reasons for the
Faulding Transaction,' 'Proposal to Change Purepac's Name,' 'Proposal to
Increase Capitalization,' 'Election of Directors' and 'Ratification of Selection
of Independent Auditors.'
THE PARTIES
PUREPAC
Purepac is a holding company which, through Purepac Pharmaceutical Co., its
wholly-owned subsidiary, is primarily engaged in the development, manufacture
and sale of generic oral drug products. Unless otherwise indicated, all
references to Purepac include Purepac Pharmaceutical Co. Purepac's principal
executive offices are located at 200 Elmora Avenue, Elizabeth, New Jersey 07207.
Its telephone number is (908) 527-9100. See 'Business of Purepac.'
FAULDING SUBSIDIARIES
The three Faulding Subsidiaries, each of which is currently a wholly-owned
subsidiary of Faulding, are Faulding Medical Device Co. ('FMDC'), Faulding
Puerto Rico, Inc. ('FPR') and Faulding Pharmaceutical Co. ('FPC').
ii
<PAGE>
<PAGE>
FMDC was established by Faulding in 1989 to develop and commercialize a
range of drug-dependent and stand-alone injectable devices and systems,
all designed to enhance the speed and safety of injectable drug delivery,
and to market such products in the United States. While affiliates of
Faulding have commercialized products incorporating certain drug dependent
devices outside of the United States, none of FMDC's products is currently
commercially available in the United States.
FMDC's principal executive offices are located at 8777 East Via de
Ventura, Scottsdale, Arizona 85258. Its telephone number is (602)
951-9500. See 'Businesses of the Faulding Subsidiaries -- FMDC.'
FPR was established by Faulding to acquire a parenteral product and oral
liquid pharmaceutical manufacturing facility located in Aguadilla, Puerto
Rico (the 'Aguadilla Facility') from The DuPont Merck Pharmaceutical
Company and DuPont Merck Pharma in April 1995, together with certain
intellectual property rights relating to the products manufactured at the
Aguadilla Facility. Such products include ampules and vials of 2ml to 30ml
containing pharmaceuticals in injectable form, including Tridil'r',
Intropin'r', Bretylol'r', acetylcysteine, metoclopramide and amikacin. The
Aguadilla Facility also acts as a contract manufacturer for non-affiliated
pharmaceutical companies.
FPR's principal executive offices are located at 1071 Parallel Road, P.O.
Box 250471, Ramey Branch, Aguadilla, Puerto Rico 00604. Its telephone
number is (809) 890-3000. See 'Businesses of the Faulding
Subsidiaries -- FPR.'
FPC was established by Faulding concurrently with FPR's acquisition of the
Aguadilla Facility to undertake United States marketing activities for
certain of the products produced by FPR at the Aguadilla Facility, as well
as for certain products manufactured by F.H. Faulding & Co. Limited,
Faulding's parent, at its Mulgrave, Australia manufacturing facility and
for products sourced from unaffiliated third parties.
FPC's principal executive offices are located at 33971 Selva Road, Dana
Point, California 92629. Its telephone number is (714) 443-5353. See
'Businesses of the Faulding Subsidiaries -- FPC.'
Unless otherwise indicated, all references to the Faulding Subsidiaries
include each of FPR, FPC and FMDC. See 'Businesses of the Faulding
Subsidiaries.'
FAULDING
Faulding is a holding company which owns all of the capital stock of FPR,
FPC and FMDC. Faulding also owns all of the capital stock of Faulding Services
Inc. ('Faulding Services'), which holds United States marketing and intellectual
property rights to certain non-generic pharmaceutical products and technologies.
Faulding, the principal stockholder of Purepac, is a wholly-owned subsidiary of
F.H. Faulding & Co. Limited ('F.H. Faulding'), an Australian publicly held
corporation, which is an international health care products company
headquartered in Adelaide, South Australia.
Faulding's principal executive offices are located at 529 Fifth Avenue,
Eighth Floor, New York, NY 10017. Its telephone number is (212) 681-4375. See
'The Proposed Faulding Transaction -- Relationships Between Purepac and
Faulding; Potential Conflicts of Interest.'
RELATIONSHIPS BETWEEN PUREPAC AND FAULDING; POTENTIAL CONFLICTS OF INTEREST
The Chairman of the Purepac Board, Dr. Edward D. Tweddell, is the Group
Managing Director and Chief Executive Officer of F.H. Faulding, as well as a
director of Faulding, a director of each of the Faulding Subsidiaries and a
director of Faulding Services. Alan G. McGregor, the Chairman of the Board of
F.H. Faulding, serves as a member of the Purepac Board. Michael R.D. Ashton, a
current member of the Purepac Board, is a director and officer of each of the
Faulding Subsidiaries, Faulding and Faulding Services, respectively. William R.
Griffith, the Secretary of Purepac, is a director and officer of each of the
Faulding Subsidiaries, Faulding and Faulding Services. In addition, Lee Craker,
Purepac's Chief Financial Officer, and Garth Boehm, Purepac's Vice
President -- Quality Assurance and
iii
<PAGE>
<PAGE>
Quality Control, have each previously held management positions with affiliates
of F.H. Faulding. These interlocking offices and relationships may be viewed as
giving rise to potential conflicts of interest.
Faulding holds 6,839,980 shares of Purepac Common Stock, representing 54.4%
of the currently outstanding Purepac Common Stock. Faulding also holds 834,188
shares of Purepac's Class A Preferred Stock, being all of the currently
outstanding shares of such class, convertible into shares of Purepac Common
Stock at a rate of six shares of Common Stock for each share of Class A
Preferred Stock, or an aggregate of 5,005,128 shares of Common Stock if fully
converted, representing, together with Faulding's current ownership of Purepac
Common Stock, a 67.4% equity interest in Purepac. Accordingly, Faulding has, and
will continue to have, the ability to elect all of the members of the Purepac
Board and to control Purepac's management and operations.
Faulding's parent, F.H. Faulding, is a party to several supply, licensing
and research and development agreements with Purepac. In addition, Faulding
Services has entered into agreements with Purepac which require Purepac to act
as a contract manufacturer for, and to provide Faulding Services with, certain
technical, distribution and warehousing services with respect to a
pharmaceutical product for which Faulding Services acts as licensee of F.H.
Faulding. Purepac is also party to an agreement with FPC which requires Purepac
to provide certain warehousing, distribution and record keeping services to FPC.
In view of the relationships among Purepac, Faulding, F.H. Faulding and
their respective affiliates, summarized above, the terms of the Faulding
Transaction may be viewed as having been negotiated on a non-arms-length basis.
During the negotiation and execution of the Letter of Intent, Faulding was
represented by F.H. Faulding's in-house legal counsel. After execution of the
Letter of Intent, Faulding retained the law firm of Reid & Priest LLP to act as
its counsel. Purepac's counsel, Parker Duryee Rosoff & Haft ('Parker Duryee'),
represented Faulding in connection with its acquisition of the Aguadilla
Facility and currently represents Purepac and the Purepac Board in connection
with the Faulding Transaction. Such firm also currently represents, and in the
past has represented, F.H. Faulding and its affiliates, including Faulding, with
respect to certain matters in the United States. William R. Griffith, who, as
noted above, is Secretary of Purepac and a director and officer of each of the
Faulding Subsidiaries, Faulding Services and Faulding, is a member of Parker
Duryee. Such representation may be viewed as giving rise to potential conflicts
of interest.
See 'The Proposed Faulding Transaction -- Background,' ' -- Relationships
Between Purepac and Faulding; Potential Conflicts of Interest,' 'Principal
Stockholders of Purepac,' 'Compensation Committee Interlocks and Insider
Participation' and 'Certain Relationships and Related Transactions.'
REQUIRED VOTE
Faulding. The Faulding Transaction has been approved by Faulding as the
owner of all of the outstanding shares of each of FMDC, FPR and FPC.
Purepac. The Purepac Board is submitting the Faulding Transaction to the
Purepac Stockholders for their approval in accordance with the requirements of
The Nasdaq National Market. The effect of such submission under applicable
Delaware law is that any Purepac Stockholder who votes in favor of the Faulding
Transaction may be effectively precluded from asserting any claim against the
Purepac Board subsequent to the consummation of the Faulding Transaction which
would allege, among other things, that the Purepac Board breached its fiduciary
duty to the Purepac Stockholders in approving the Faulding Transaction.
The presence, either in person or by proxy, of the holders of a majority of
the outstanding shares of Purepac Common Stock entitled to vote at the Annual
Meeting is necessary to constitute a quorum at the Annual Meeting. The
affirmative vote of a majority of the shares present and voting, in person or by
proxy, at the Annual Meeting is necessary to approve the Faulding Transaction,
the election of directors and the ratification of independent auditors. The
affirmative vote of a majority of the outstanding shares of Purepac Common Stock
on the Record Date is required to approve the Name Change and the Stock
Increase.
iv
<PAGE>
<PAGE>
FAULDING, WHICH HOLDS APPROXIMATELY 54.4% OF PUREPAC'S OUTSTANDING COMMON
STOCK ON THE RECORD DATE, HAS AGREED, WITH RESPECT TO THE PROPOSALS TO APPROVE
AND RATIFY THE FAULDING TRANSACTION AND THE NAME CHANGE, TO VOTE ALL SUCH SHARES
IN THE SAME MANNER AS THE MAJORITY OF SHARES OF PUREPAC COMMON STOCK HELD BY
PUREPAC STOCKHOLDERS OTHER THAN FAULDING PRESENT IN PERSON OR BY PROXY AND
VOTING AT THE ANNUAL MEETING. CONSEQUENTLY, VOTES CAST BY PUREPAC STOCKHOLDERS
OTHER THAN FAULDING WILL DETERMINE WHETHER THESE PROPOSALS WILL BE APPROVED OR
DISAPPROVED. By virtue of its majority ownership of Purepac's outstanding Common
Stock, Faulding will have the ability to determine the outcome of the proposed
Stock Increase, the election of directors and the ratification of the selection
of independent auditors. Faulding has orally indicated to Purepac its intention
to vote its shares in favor of the Stock Increase for each of the nominees for
election as directors and in favor of the ratification of the selection of
independent auditors. Consequently, it is a virtual certainty that such
proposals will each be approved. See 'The Annual Meeting -- Required Vote.'
BACKGROUND OF THE FAULDING TRANSACTION
The terms of the Faulding Transaction resulted from negotiations between
representatives of Purepac and Faulding. Such representatives, in most
instances, were officers and/or directors of both Purepac and Faulding or of
F.H. Faulding, Faulding's parent and, indirectly, the majority equity owner of
Purepac. Consequently, such negotiations and the terms of the Faulding
Transaction, as embodied in the Stock Purchase Agreement and the Preferred Stock
Purchase Agreement, respectively, may be viewed as being of a non-arms-length
nature. Although the terms of the Faulding Transaction were reviewed and
approved by a special committee of Purepac directors not affiliated with
Faulding, the Purepac Board determined to structure the proposal for Purepac
stockholder approval of the Faulding Transaction so as to leave the outcome of
such proposal to be determined by the vote of the Purepac stockholders other
than Faulding. See 'The Proposed Faulding Transaction -- Background' and
' -- Relationships Between Purepac and Faulding; Potential Conflicts of
Interest.'
RECOMMENDATION OF THE PUREPAC BOARD; REASONS FOR THE FAULDING TRANSACTION
On August 9, 1995, the Purepac Board, with one director absent, unanimously
approved the Letter of Intent which contemplated the Faulding Transaction as
ultimately embodied in the Stock Purchase Agreement and the Preferred Stock
Purchase Agreement. On January 23, 1996, the Purepac Board unanimously approved
Purepac's execution of both the Stock Purchase Agreement and the Preferred Stock
Purchase Agreement. The Purepac Board recommends that the Purepac Stockholders
vote 'FOR' approval of the Faulding Transaction.
The recommendation of the Purepac Board is based upon its conclusion that
the terms of the Faulding Transaction are fair and in the best interests of
Purepac and the Purepac Stockholders and its belief that the Faulding
Transaction should result in benefits to the Purepac Stockholders. See 'The
Proposed Faulding Transaction -- Recommendation of the Purepac Board; Reasons
for the Faulding Transaction.'
OPINION OF FINANCIAL ADVISOR
Salomon Brothers Inc ('Salomon Brothers'), as financial advisor to the
Purepac Board, was asked to render an opinion to the Purepac Board as to the
fairness to Purepac, from a financial point of view, of the consideration to be
paid by Purepac to Faulding for all of the capital stock of the Faulding
Subsidiaries, as well as the consideration to be received by Purepac from
Faulding for the Class B Preferred Stock.
On August 9, 1995, the date the Letter of Intent was signed, Salomon
Brothers delivered its opinion (the 'Salomon Brothers Opinion') to the Purepac
Board to the effect that, as of such date, the consideration to be paid by
Purepac in the Acquisition Transaction and to be received by Purepac in the
Preferred Stock Purchase was fair, from a financial point of view, to Purepac.
On October 24, 1995 and again, on January 23, 1996, Salomon Brothers, at the
request in each instance of the Purepac Board, reaffirmed the Salomon Brothers
Opinion as of such dates. See 'The Proposed Faulding Transaction -- Opinion of
Financial Advisor.'
v
<PAGE>
<PAGE>
RISK FACTORS
The businesses conducted by the Faulding Subsidiaries involve certain
significant risks including, among others, those relating to limited operating
history, need for additional future funding, uncertainty and variability of
results of operations, dependence on product development efforts and engaging in
competitive and highly regulated industries. See 'Businesses of the Faulding
Subsidiaries -- Certain Risks Relating to the Faulding Subsidiaries.'
CLOSING DATE
The Faulding Transaction is expected to be consummated on February 29,
1996, assuming approval by the Purepac Stockholders of the Faulding Transaction
at the Annual Meeting, or on such later date which shall be the first business
day immediately following that day upon which the last of the conditions to
closing of the Faulding Transaction is satisfied or waived. See 'The Proposed
Faulding Transaction -- Closing Date,' ' -- Stock Purchase
Agreement -- Conditions to Consummation of Acquisition Transaction' and
' -- Preferred Stock Purchase Agreement.'
CONDITIONS TO CONSUMMATION OF THE FAULDING TRANSACTION
The respective obligations of Purepac and of Faulding to effect the
Faulding Transaction are subject to a number of conditions including, among
others, that the Faulding Transaction shall have been approved by the Purepac
Stockholders and that all indebtedness owed by the Faulding Subsidiaries to
Faulding, which aggregated $22,748,555 at September 30, 1995, shall have been
contributed by Faulding to the capital of the respective Faulding Subsidiaries.
See 'The Proposed Faulding Transaction -- Stock Purchase Agreement -- Conditions
to Consummation of Acquisition Transaction' and ' -- Preferred Stock Purchase
Agreement.'
RIGHT TO TERMINATE, AMEND OR WAIVE CONDITIONS
The Stock Purchase Agreement and the Preferred Stock Purchase Agreement may
each be terminated by either Purepac or Faulding, as applicable, under certain
circumstances prior to the Closing. Amendment of such agreements, or waivers, by
either Purepac or Faulding, as applicable, of their respective conditions to
consummation, may occur subsequent to the vote of the Purepac Stockholders upon
the Faulding Transaction only if such amendments are, or waivers relate to, non-
material provisions of such agreements. If the Stock Purchase Agreement and the
Preferred Stock Purchase Agreement are terminated as a result of the failure of
the Purepac Stockholders to approve the Faulding Transaction, Faulding will
reimburse Purepac for one-half of Purepac's expenses incurred in connection with
the Faulding Transaction.
ABSENCE OF REGULATORY FILINGS AND APPROVALS
The consummation of the Faulding Transaction is not subject to obtaining
any regulatory approvals or complying with any regulatory filing requirements.
See 'The Proposed Faulding Transaction -- Absence of Regulatory Filings and
Approvals.'
CERTAIN TAX CONSEQUENCES OF THE FAULDING TRANSACTION
No gain or loss will be recognized by either Purepac or the Purepac
Stockholders as a result of the Faulding Transaction. See 'The Proposed Faulding
Transaction -- Certain Tax Consequences of the Faulding Transaction.'
ACCOUNTING TREATMENT
Faulding, by virtue of its majority equity interest in Purepac will
continue to indirectly control each of FMDC, FPR and FPC following consummation
of the Faulding Transaction. Accordingly, the Acquisition Transaction will be
viewed for accounting purposes as a reorganization of Faulding's interests in
the United States. Consequently, for accounting and financial reporting
purposes, the
vi
<PAGE>
<PAGE>
Acquisition Transaction will be accounted for at historical cost in a manner
similar to a 'pooling of interests'.
ABSENCE OF APPRAISAL RIGHTS
Holders of Purepac Common Stock will not be entitled to appraisal rights in
connection with the Faulding Transaction. See 'The Proposed Faulding
Transaction -- Absence of Appraisal Rights.'
MARKET PRICE OF PUREPAC'S COMMON STOCK
On August 9, 1995, (the last trading day prior to the public announcement
of the execution of the Letter of Intent), the closing price of Purepac Common
Stock was $8.875 per share. On January 23, 1996, the date of the execution of
the Stock Purchase Agreement and the Preferred Stock Purchase Agreement, the
closing price of Purepac's Common Stock was $6.125 per share. Purepac's Class A
Preferred Stock is not publicly traded. See 'Price Ranges of Purepac Common
Stock.'
vii
<PAGE>
<PAGE>
SUMMARY HISTORICAL FINANCIAL INFORMATION
The following summary historical financial information, which does not give
effect to the Faulding Transaction, should be read in conjunction with the
financial statements of the Faulding Subsidiaries, with the consolidated
financial statements of Purepac and with the pro forma financial information
regarding the Faulding Transaction, all appearing elsewhere in this Proxy
Statement.
SUMMARY HISTORICAL FINANCIAL INFORMATION OF THE FAULDING SUBSIDIARIES
FMDC
<TABLE>
<CAPTION>
THREE MONTHS ENDED
SEPTEMBER 30, YEAR ENDED JUNE 30,
---------------------- --------------------------------------------------------
1995 1994 1995 1994 1993 1992 1991
---------- ---------- ------ ------ ------------ ------------ ------------
(UNAUDITED) (UNAUDITED) (UNAUDITED) (UNAUDITED)
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C> <C>
Statement of Operations Data:
Net sales.................... $ 338 $ 681 $2,455 $1,947 $1,183 $ 701 $ 75
Net income (loss)............ (214) 8 (336) (305) (222) (675) (355)
</TABLE>
<TABLE>
<CAPTION>
YEAR ENDED JUNE 30,
SEPTEMBER 30, -----------------------------------------------------------
1995 1995 1994 1993 1992 1991
--------------- ------- ------ ------------ ------------ ------------
(UNAUDITED) (UNAUDITED) (UNAUDITED) (UNAUDITED)
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C>
Balance Sheet Data:
Working capital, net of inter-company
balances............................. $ 325 $ 423 $ 629 $ 308 $ 399 $ 256
Total assets........................... 2,712 2,848 2,936 2,754 2,969 2,385
Net intercompany balances payable...... 4,997 4,929 4,735 4,238 4,212 2,971
Stockholders' (deficiency)............. (2,365) (2,151) (1,814) (1,509) (1,287) (612)
</TABLE>
FPR
<TABLE>
<CAPTION>
APRIL 7
THREE MONTHS (INCEPTION) JANUARY 1 TO YEAR ENDED DECEMBER 31,
ENDED SEPTEMBER 30, TO JUNE 30, APRIL 6, -------------------------------------------
1995 1995 1995(a) 1994(a) 1993(a) 1992(a) 1991(a)
--------------- ------------ ------------ ------- -------- ------------ -----------
(UNAUDITED) (UNAUDITED) (UNAUDITED)
(UNAUDITED) (IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C> <C>
Statement of Operations Data:
Net sales to unaffiliated
parties(b)........................ $ 530 $789 $ 717 $ 1,490 $ 1,840 $ -- $ --
Net (loss).......................... (912) (182) N/A N/A N/A N/A N/A
Costs attributable to owners'
interest(c)....................... N/A N/A 2,804 9,826 14,563 11,070 10,241
</TABLE>
viii
<PAGE>
<PAGE>
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
SEPTEMBER 30, JUNE 30, APRIL 6, ----------------------------------------------
1995 1995 1995(a) 1994(a) 1993(a) 1992(a) 1991(a)
-------------- ---------- ------------ -------- -------- ------------ ------------
(UNAUDITED) (UNAUDITED) (UNAUDITED)
(UNAUDITED) (IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C> <C>
Balance Sheet Data:
Working capital, net of
intercompany balances to
Faulding................... $ 4,208 $ 3,054 $ 92 $ 393 $ 13,929 $ 2,741 $ 4,665
Total assets................. 17,508 16,158 12,498 12,715 25,348 12,656 19,107
Net intercompany balances
payable.................... 14,663 15,156 N/A N/A N/A N/A N/A
Stockholders' equity
(deficiency)............... (1,094) (182) N/A N/A N/A N/A N/A
Joint Venture equity(d)...... N/A N/A 9,538 10,090 23,817 11,013 17,926
</TABLE>
----------------------
(a) Represents operating data of the Aguadilla Facility while under
the ownership of DuPont Merck Pharma or its predecessor.
(b) Excludes intercompany sales to affiliates of FPR or of DuPont
Merck Pharma.
(c) Based upon the cost of product supplied from the Aguadilla
Facility to DuPont Merck Pharma's affiliates, net of any income or
loss from net sales to third parties and administrative costs.
(d) Represents net investment in the Aguadilla Facility.
N/A means not applicable
FPC
<TABLE>
<CAPTION>
APRIL 7, 1995
(INCEPTION)
THREE MONTHS ENDED THROUGH JUNE
SEPTEMBER 30, 1995 30, 1995
------------------ --------------
(UNAUDITED)
(IN THOUSANDS)
<S> <C> <C>
Statement of Operations Data:
Net sales................................................... $ 538 $516
Net (loss).................................................. (648) (253)
</TABLE>
<TABLE>
<CAPTION>
SEPTEMBER 30, 1995 JUNE 30, 1995
------------------ -------------
(UNAUDITED)
(IN THOUSANDS)
<S> <C> <C>
Balance Sheet Data:
Working capital, net of intercompany balances to Faulding... $ (463) $ 1,243
Total assets........................................... 2,482 1,456
Net intercompany balances payable........................... 3,179 1,549
Stockholders' (deficiency).................................. (901) (253)
</TABLE>
ix
<PAGE>
<PAGE>
SUMMARY HISTORICAL FINANCIAL INFORMATION OF PUREPAC
<TABLE>
<CAPTION>
SEPTEMBER 30, YEAR ENDED JUNE 30,
---------------- -----------------------------------------------
1995 1994 1995 1994 1993 1992 1991
------- ------- ------- ------- ------- ------- -------
(UNAUDITED)
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<S> <C> <C> <C> <C> <C> <C> <C>
Statement of Operations Data:
Net sales................. $14,167 $16,876 $61,146 $70,005 $70,508 $64,531 $52,279
Income (loss) before
preferred stock
dividends............... (1,076) (25) (847) 8,447(a) 9,160 14,979 4,866
Preferred stock
dividends............... 520 520 2,080 2,080 2,080 2,081 2,237
Net income (loss),
available for Common
Stock................... (1,596) (545) (2,927) 6,367(a) 7,080 12,776(b) 5,985(c)
Net income (loss) per
common share, primary... (.13) (.04) (.23) .51 .57 1.05 .54
</TABLE>
- ------------
(a) Net income available for common stock for the year ended June 30, 1994
included the cumulative effect of a change in accounting for income taxes
of $4,149.
(b) Net income available for common stock for the year ended June 30, 1992
included the cumulative effect, on prior years, of a change in the method
of accounting for income taxes of $122.
(c) Net income available for common stock for the year ended June 30, 1991
included an extraordinary item -- reduction of income taxes due to carry
forward of prior year operating losses of $3,356.
<TABLE>
<CAPTION>
YEAR ENDED JUNE 30,
-------------------------------------------
SEPTEMBER 30, 1995 1995 1994 1993 1992 1991
------------------- ------- ------- ------- ------- -------
(UNAUDITED)
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C>
Balance Sheet Data:
Working capital....... $ 20,605 $21,811 $24,221 $23,150 $20,460 $12,072
Total assets.......... 64,440 64,929 67,267 63,017 52,269 35,247
Long-term debt........ -- -- -- -- -- --
Stockholders'
equity.............. 51,065 52,557 54,860 48,060 39,699 24,927
</TABLE>
x
<PAGE>
<PAGE>
SUMMARY PRO FORMA FINANCIAL INFORMATION
The unaudited summary pro forma statements of operations consolidate the
statements of operations of the Faulding Subsidiaries for the year ended June
30, 1995 and the three month period ended September 30, 1995 with the
consolidated statement of operations of Purepac for the year ended June 30, 1995
and the three month period ended September 30, 1995, respectively; however such
statements do not include dividends which would have accrued with respect to the
Class B Preferred Stock during such periods, if such shares had been issued and
outstanding during such periods. The statements of operations of the Faulding
Subsidiaries for the year ended June 30, 1995 includes the operations of FMDC
for the full fiscal year and the operations of each of FPR and FPC for the
period April 7, 1995 (inception) through June 30, 1995.
The unaudited summary pro forma statements of operations may not be
indicative of the results that actually would have been achieved if the Faulding
Transaction had been in effect as of the date and for the periods indicated, and
is not expected to be indicative of the results which may be obtained in the
future. In particular, the statement of operations data for the period ended
June 30, 1995 include less than three months of operations of FPR and FPC, which
period, in the case of FPR, was the first three months in which FPR owned the
Aguadilla Facility, and which, in the case of FPC, was the first three months of
operations of a newly organized business.
The unaudited summary pro forma statement of operations should be read in
conjunction with the pro forma financial statements and notes thereto and with
the Financial Statements of the Faulding Subsidiaries and the Consolidated
Financial Statements of Purepac contained elsewhere herein.
<TABLE>
<CAPTION>
ELIMINATIONS/ FAULDING PRO FORMA
FMDC FPC FPR ADJUSTMENTS(a) SUBSIDIARIES PUREPAC CONSOLIDATED
------ ---- ------ --------------- ------------- -------- -------------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<S> <C> <C> <C> <C> <C> <C> <C>
Summary Pro Forma
Statement of
Operations Data
(unaudited) for the
year ended June 30,
1995:
Net sales.......... $2,455 $516 $1,960 $ (1,171) $ 3,760 $ 61,146 $ 64,906
Cost of sales...... 1,956 350 1,954 (1,171) 3,089 46,476 49,565
Gross profit....... 499 165 5 669 14,671 15,340
(Loss) from
operations....... (197) (223) 5 (415) (1,888) (2,303)
Net (loss) before
preferred stock
dividends........ (336) (253) (182) (771) (847) (1,618)
Preferred stock
dividends........ 2,080 2,080
Net income (loss),
available for
common stock..... (336) (253) (182) (771) (2,927) (3,698)
Net (loss) per
common share,
primary.......... ($.23) ($.25)
Weighted average
number of common
shares
outstanding...... 12,539 14,792
</TABLE>
- ------------
(a) In combining the financial accounts of the Faulding Subsidiaries, sales by
FPR to FPC are eliminated along with the respective accounts receivable and
accounts payable on the subsidiary balance sheets.
xi
<PAGE>
<PAGE>
<TABLE>
<CAPTION>
ELIMINATIONS/ FAULDING PRO FORMA
FMDC FPC FPR ADJUSTMENTS(a) SUBSIDIARIES PUREPAC CONSOLIDATED
---- ---- ------ --------------- ------------- -------- -------------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<S> <C> <C> <C> <C> <C> <C> <C>
Summary Pro Forma
Statement of
Operations Data
(unaudited) for the
three months ended
September 30, 1995:
Net sales........ $338 $538 $1,954 $(1,424) 1,405 $ 14,167 $ 15,572
Cost of sales.... 290 518 2,690 (1,424) 2,073 11,655 13,728
Gross profit..... 48 20 (736) (668) 2,512 1,844
(Loss) from
operations..... (182) (648) (743) (1,573) (1,694) (3,266)
Net (loss) before
preferred stock
dividends...... (214) (648) (912) (1,773) (1,076) (2,849)
Preferred stock
dividends...... -- -- -- 520 520
Net income
(loss),
available for
common stock... (214) (648) (912) (1,773) (1,596) (3,369)
Net (loss) per
common share,
primary........ ($.13) ($.23)
Weighted average
number of
common shares
outstanding.... 12,581 14,902
</TABLE>
- ------------
(a) In combining the financial accounts of the Faulding Subsidiaries, sales by
FPR to FPC are eliminated along with the respective accounts receivable and
accounts payable on the subsidiary balance sheets.
xii
<PAGE>
<PAGE>
The unaudited summary pro forma balance sheet data combines the balance
sheets of the Faulding Subsidiaries at September 30, 1995, with the consolidated
balance sheet of Purepac at September 30, 1995. The summary pro forma balance
sheet also reflects the receipt of $15,000,000 of cash proceeds from the
Preferred Stock Purchase and the deduction of expenses of the Faulding
Transaction, estimated to be $950,000.
<TABLE>
<CAPTION>
EFFECT OF
ELIMINATIONS/ FAULDING FAULDING PRO FORMA
FMDC FPC FPR ADJUSTMENTS(a) SUBSIDIARIES PUREPAC TRANSACTION CONSOLIDATED
------ ------ ------- --------------- ------------- -------- ------------ ------------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Summary Pro Forma Balance
Sheet Data (unaudited)
at September 30, 1995:
Working capital, net
of intercompany
balances to
Faulding.......... $ 325 $ (463) $ 4,208 -- $ 4,070 $ 20,605 $ 13,881 $ 38,556
Total assets........ 2,712 2,482 17,508 (2,595) 20,108 64,439 14,050 98,597
Net intercompany
payables to
Faulding(b)....... 4,997 494 17,258 (22,749) -- -- -- --
Total current
liabilities(b).... 5,076 3,383 18,602 (25,343) 1,718 13,375 -- 15,093
Total stockholders'
equity(deficiency)(b).. (2,365) (901) (1,094) 22,749 18,389 51,065 14,050 83,504
</TABLE>
- ------------
(a) In combining the financial accounts of the Faulding Subsidiaries, sales by
FPR to FPC are eliminated along with the respective accounts receivable and
accounts payable on the subsidiary balance sheets.
(b) As part of the transaction, net intercompany amounts payable to Faulding
will be eliminated through a capital contribution to each of the Faulding
Subsidiaries prior to the consummation of the Faulding Transaction.
xiii
<PAGE>
<PAGE>
[THIS PAGE INTENTIONALLY LEFT BLANK]
<PAGE>
<PAGE>
INTRODUCTION
This Proxy Statement is provided to the Purepac Stockholders in connection
with the Annual Meeting. The Annual Meeting will be held on the date, at the
time and in the location, and will be held to consider the matters, set forth
under 'The Annual Meeting.' The Purepac Board is soliciting proxies hereby for
use at the Annual Meeting. A form of proxy is being provided to the Purepac
Stockholders with this Proxy Statement. Information with respect to the
execution and revocation of proxies is provided under the 'The Annual
Meeting -- Voting Rights.' This Proxy Statement and the enclosed form of proxy
are first being mailed to Purepac Stockholders on or about January 30, 1996.
The costs of solicitation of Purepac Stockholder proxies will be borne by
Purepac. Purepac will reimburse brokers, fiduciaries, custodians and other
nominees for reasonable out-of-pocket expenses incurred in sending this Proxy
Statement and other proxy materials to, and obtaining instructions relating to
such materials from, the beneficial owners of Purepac Common Stock. Purepac
Stockholder proxies may be solicited by directors, executive officers or regular
employees of Purepac, in person, by letter or by telephone or telegram.
Purepac has retained D.F. King & Co., Inc. ('D.F. King') to assist it in
the solicitation of proxies at an estimated cost of $10,000, plus reimbursement
of such company's accountable expenses.
THE ANNUAL MEETING
PURPOSES OF MEETING
At the Annual Meeting, Purepac Stockholders eligible to vote thereat will
be asked to consider and vote upon (i) a single proposal to approve the Faulding
Transaction, which proposal will encompass as integral components (A) the
Acquisition Transaction and (B) the Preferred Stock Purchase, (ii) the Name
Change, (iii) the Stock Increase, (iv) the election of five directors for the
ensuing year, and (v) ratification of the Purepac Board's selection of Deloitte
& Touche LLP as Purepac's independent auditors for Purepac's fiscal year ending
June 30, 1996.
THE PUREPAC BOARD HAS UNANIMOUSLY APPROVED THE FAULDING TRANSACTION, THE
NAME CHANGE AND THE STOCK INCREASE AND RECOMMENDS THAT THE PUREPAC STOCKHOLDERS
VOTE 'FOR' EACH OF THESE PROPOSALS. THE PUREPAC BOARD HAS ALSO UNANIMOUSLY
APPROVED THE NOMINATION OF EACH OF THE FIVE PERSONS NAMED ELSEWHERE HEREIN AS
NOMINEES FOR ELECTION AS PUREPAC'S DIRECTORS FOR THE ENSUING YEAR, AS WELL AS
THE SELECTION OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT AUDITORS AND
RECOMMENDS THAT THE PUREPAC STOCKHOLDERS VOTE 'FOR' EACH OF SUCH NOMINEES AND
'FOR' THE RATIFICATION OF THE PUREPAC BOARD'S SELECTION OF SUCH AUDITORS.
See 'The Proposed Faulding Transaction -- Recommendation of the Purepac
Board; Reasons for the Faulding Transaction,' 'Proposal to Change Purepac's
Name,' 'Proposal to Increase Capitalization,' 'Election of Directors' and
'Ratification of Selection of Independent Auditors.'
DATE, TIME AND PLACE; RECORD DATE
The Annual Meeting is scheduled to be held at 10:00 A.M., Local Time, on
Thursday, February 29, 1996, at the Newark Airport Marriott, Newark
International Airport, Newark, New Jersey. The Purepac Board has fixed the close
of business on January 24, 1996 as the record date (the 'Record Date') for the
determination of holders of Purepac Common Stock entitled to notice of and to
vote at the Annual Meeting. On January 24, 1996, there were 12,581,223 shares of
Purepac Common Stock (held by approximately 514 persons of record) outstanding
and entitled to vote. Each share of Purepac Common Stock is entitled to one
vote. A majority of the shares of Common Stock issued and outstanding and
entitled to vote must be present at the Annual Meeting in person or by proxy in
order to constitute a quorum for the transaction of business. Because Faulding
holds a majority of the issued and outstanding Purepac Common Stock, and
Faulding has indicated that it will be present at the Annual Meeting, it is a
virtual certainty that a quorum will be present at the Annual Meeting.
1
<PAGE>
<PAGE>
REQUIRED VOTE
The Purepac Board is submitting the Faulding Transaction to the Purepac
Stockholders for their approval in accordance with the requirements of The
Nasdaq National Market pertaining to proposed transactions between an issuer and
a person or persons controlling such issuer. The effect of such submission under
applicable Delaware law is that any Purepac Stockholder voting in favor of the
Faulding Transaction may be effectively precluded from asserting any claim
against the Purepac Board subsequent to the consummation of the Faulding
Transaction which would allege, among other things, that the Purepac Board
breached its fiduciary duty to the Purepac Stockholders in approving the
Faulding Transaction.
The affirmative vote of the holders of a majority of the shares of Purepac
Common Stock present and voting, in person or by proxy, at the Annual Meeting is
required to approve each of the matters to be presented at the Annual Meeting,
with the exception of the Name Change and Stock Increase, which require the
affirmative vote of a majority of all of the outstanding shares of Purepac
Common Stock.
FAULDING, WHICH OWNS APPROXIMATELY 54.4% OF THE COMPANY'S OUTSTANDING
COMMON STOCK, HAS AGREED, WITH RESPECT TO THE PROPOSALS TO APPROVE THE FAULDING
TRANSACTION AND THE NAME CHANGE, TO VOTE ALL SUCH SHARES IN THE SAME MANNER AS
THE MAJORITY OF SHARES OF PUREPAC COMMON STOCK HELD BY PUREPAC STOCKHOLDERS
OTHER THAN FAULDING PRESENT IN PERSON OR BY PROXY AND VOTING AT THE ANNUAL
MEETING. CONSEQUENTLY, VOTES CAST BY PUREPAC STOCKHOLDERS OTHER THAN FAULDING
WILL DETERMINE WHETHER THESE PROPOSALS WILL BE APPROVED OR DISAPPROVED.
By virtue of its majority ownership of Purepac's outstanding Common Stock,
Faulding will have the ability to determine the outcome of the proposed Stock
Increase, the election of directors and the ratification of the selection of
independent auditors. Faulding has orally indicated to Purepac its intention to
vote its shares in favor of the Stock Increase, for each of the nominees for
election as directors, and in favor of the ratification of the selection of
independent auditors. Consequently, it is a virtual certainty that such
proposals will each be approved.
The Purepac Board is soliciting proxies so that each Purepac Stockholder on
the Record Date has the opportunity to vote on the proposals to be considered at
the Annual Meeting. When a proxy card is returned properly signed and dated, the
shares represented thereby will be voted in accordance with the instructions on
the proxy card. If a Purepac Stockholder does not return a signed proxy card,
his or her shares will not be voted, unless such stockholder attends and votes
at the Annual Meeting, and thus will have the effect of a vote against the
proposals to approve the Name Change and the Stock Increase.
A broker who holds shares in street name will not be entitled to vote on
the Faulding Transaction or the Name Change without instructions from the
beneficial owner. This inability to vote is referred to as a broker non-vote.
Purepac Stockholder abstentions and broker non-votes will be counted for
purposes of determining the existence of a quorum at the Annual Meeting.
However, since the proposals for the Name Change and the Stock Increase to be
considered at the Annual Meeting require the affirmative vote of at least a
majority of the shares of Purepac Common Stock outstanding as of the Record
Date, abstentions and broker non-votes will have the effect of a negative vote
with respect to such proposals, but not as to the other proposals to be
considered at the Annual Meeting. Purepac Stockholders are urged to mark the
boxes on the proxy card to indicate how their shares will be voted. If a Purepac
Stockholder (other than a broker which holds shares in street name for its
customers) returns a signed proxy card, but does not indicate how his or her
shares are to be voted, the shares represented by the proxy card will be voted
'FOR' the proposals to approve the Faulding Transaction, the Name Change and the
Stock Increase, 'FOR', each of the nominees for election of directors and 'FOR'
ratification of the Purepac Board's selection of independent auditors.
The proxy card also confers discretionary authority on the individuals
appointed by the Purepac Board and named on the proxy card to vote the shares
represented thereby on any other matter incidental to the Annual Meeting that is
properly presented for action at the Annual Meeting or any adjournment or
postponement thereof. THE PUREPAC BOARD WILL NOT VOTE PROXIES SOLICITED BY THIS
PROXY STATEMENT IN FAVOR OF ANY PROPOSAL PRESENTED AT THE ANNUAL MEETING TO
ADJOURN OR POSTPONE THE ANNUAL MEETING TO A LATER DATE.
2
<PAGE>
<PAGE>
Any stockholder may revoke his proxy at any time before the Annual Meeting
by written notice to such effect received by the Company at 200 Elmora Avenue,
Elizabeth, New Jersey 07207, Attention: Corporate Secretary, by delivery of a
subsequently dated proxy, or by attending the Annual Meeting and voting in
person.
A list of stockholders entitled to vote at the Annual Meeting will be
available for examination by any stockholder at the Company's offices for a
period of ten days prior to the Annual Meeting and at the Annual Meeting itself.
THE PROPOSED FAULDING TRANSACTION
THE ACQUISITION TRANSACTION
GENERAL
On the Closing Date, Purepac will acquire from Faulding all of the issued
and outstanding capital stock of each of FMDC, FPR and FPC in exchange for
2,253,521 shares of Purepac Common Stock, subject to adjustment based upon
changes in the Net Asset Value of the Faulding Subsidiaries from June 30, 1995
through the Closing Date (the 'Purepac Acquisition Stock'). As a result of the
Acquisition Transaction, each of the Faulding Subsidiaries will become a
wholly-owned subsidiary of Purepac. The business, operations and prospects of
the Faulding Subsidiaries are subject to certain significant risks including,
among others, those relating to limited operating history, uncertainty and
variability of results of operations, dependency on continued availability of
funding, dependence on product development efforts, and engaging in competitive
and highly regulated industries. See 'Businesses of the Faulding
Subsidiaries -- Certain Risks Relating to the Faulding Subsidiaries.'
The number of shares of Purepac Acquisition Stock to be issued by Purepac
to Faulding in exchange for the shares of capital stock of each of the Faulding
Subsidiaries was determined based upon an agreement between Purepac and Faulding
of a $20.0 million valuation of the Faulding Subsidiaries, divided by $8.875,
being the closing price of the Purepac Common Stock as reported by The Nasdaq
National Market on August 9, 1995, the date of the Letter of Intent. The
negotiated valuation of $20.0 million was based primarily on the aggregate Net
Asset Value of the Faulding Subsidiaries as of June 30, 1995 of $17,878,028,
plus additional amounts attributable to certain intangible assets of the
Faulding Subsidiaries. The Purepac Acquisition Stock will not be registered
under the Securities Act of 1933, as amended (the 'Securities Act'), and
therefore will be subject to restrictions on resale by Faulding. However,
pursuant to the Stock Purchase Agreement, Purepac has agreed to grant to
Faulding certain demand and piggyback registration rights under the Securities
Act with respect to the Purepac Acquisition Stock.
On the Closing Date, Faulding will contribute to the capital of the
respective Faulding Subsidiaries all indebtedness then owed by the Faulding
Subsidiaries to Faulding. Such indebtedness aggregated $22,748,555 at September
30, 1995. See 'The Proposed Faulding Transaction -- Stock Purchase Agreement.'
PURCHASE PRICE ADJUSTMENT
The Stock Purchase Agreement provides for an adjustment in the number of
shares of Purepac Acquisition Stock issuable to Faulding based upon changes in
the aggregate net asset value of the Faulding Subsidiaries (the 'Net Asset
Value') from June 30, 1995 through and including the Closing Date. 'Net Asset
Value' is defined as the value of the tangible assets of the Faulding
Subsidiaries, plus the book value of patents and trademarks held by the Faulding
Subsidiaries, less the liabilities of the Faulding Subsidiaries other than
inter-company indebtedness owing to Faulding, all as determined in accordance
with generally accepted accounting principles in the United States. The Net
Asset Value as of the Closing Date shall be determined by Faulding, which
determination shall be subject to audit by Purepac's auditors. To the extent
that the Net Asset Value as of the Closing Date exceeds $17,878,028 (the Net
Asset Value as of June 30, 1995), Purepac shall issue to Faulding such
additional number of shares of Purepac Acquisition Stock as shall equal the
amount of such excess divided by 8.875. To the extent that the Net Asset Value
as of the Closing Date is less than $17,878,028, the number of shares of
3
<PAGE>
<PAGE>
Purepac Acquisition Stock to be issued to Faulding shall be reduced by such
number of shares as shall equal the amount of such shortfall divided by 8.875.
The Stock Purchase Agreement does not limit the number of additional shares of
Purepac Acquisition Stock which may be issuable to Faulding as a result of
increases in the Net Asset Value. However, it is a condition to Purepac's
obligation to consummate the Acquisition Transaction that the Net Asset Value of
the Faulding Subsidiaries shall not be less than $17,000,000.
As of September 30, 1995, the aggregate Net Asset Value of the Faulding
Subsidiaries had increased by $601,191 to $18,479,219. If such Net Asset Value
were to remain unchanged through the Closing Date, of which there can be no
assurance, the number of shares of Purepac Acquisition Stock issuable to
Faulding at the Closing would increase by 67,740 shares to an aggregate of
2,321,261 shares.
THE PREFERRED STOCK PURCHASE
GENERAL
Faulding has agreed to purchase from Purepac, and Purepac has agreed to
sell to Faulding on the Closing Date, pursuant to the Preferred Stock Purchase
Agreement, 150,000 shares of Purepac's newly designated Class B Preferred Stock
for an aggregate cash purchase price of $15.0 million. The closing of the
Preferred Stock Purchase is contingent upon the closing of the Acquisition
Transaction. The $15.0 million to be received from Faulding upon its purchase of
the Class B Preferred Stock is intended to be used by Purepac to finance, in
part, the post-acquisition operations of the Faulding Subsidiaries. See
'Management's Discussion and Analysis of Financial Condition and Results of
Operations -- Purepac' and ' -- The Faulding Subsidiaries.'
The Certificate of Incorporation of Purepac authorizes shares of Common
Stock, shares of Class A Preferred Stock (all of which are issued and
outstanding) and shares of 'blank check' preferred stock. See 'Proposal to
Increase Capitalization' for a discussion of the currently authorized capital
stock and proposed changes thereto. The rights and preferences of the Class B
Preferred Stock were established by the Purepac Board by resolution in
accordance with the provisions of Purepac's Certificate of Incorporation for
issuance of the shares of the 'blank check' preferred stock. If the Purepac
Stockholders approve the Faulding Transaction, Purepac will file a Certificate
of Designation with the Secretary of State of the State of Delaware immediately
prior to the Closing Date setting forth the rights and preferences of the Class
B Preferred Stock (the 'Certificate of Designation'). A copy of the Certificate
of Designation is annexed to the Preferred Stock Purchase Agreement appearing as
Exhibit B to this Proxy Statement.
ATTRIBUTES OF CLASS B PREFERRED STOCK
The Certificate of Designation will provide that each share of Class B
Preferred Stock will accrue dividends at the rate of $4.50 per annum (4.5% of
the liquidation/redemption preference), payable on a quarterly basis, and will
have a liquidation preference of $100 per share, plus the amount of any accrued
but unpaid dividends, in the event of the liquidation, dissolution or winding up
of the affairs of Purepac. Shares of Class B Preferred Stock will not have any
voting rights, except as required by the General Corporation Law of Delaware,
and will be convertible, commencing one year after the Closing Date, at the
option of the holder into shares of Purepac Common Stock at the ratio of 10.433
shares of Common Stock for each share of Class B Preferred Stock, or an
aggregate of 1,564,950 shares of Purepac Common Stock if all of the Class B
Preferred Stock were to be converted. This conversion ratio represents a premium
of 8% over the closing price of the Purepac Common Stock on August 9, 1995, the
date of the execution of the Letter of Intent. The number of shares of Purepac
Common Stock into which the Class B Preferred Stock is convertible will be
subject to adjustment in the event of the declaration of stock dividends or
stock splits, or in the event of the reclassification or combination of the
Purepac Common Stock or upon the occurrence of certain other events such as a
merger or consolidation of Purepac with or into another corporation. The Class B
Preferred Stock will be subject to redemption by Purepac at its option at any
time after the third anniversary of the Closing Date at a redemption price equal
to the liquidation value of the Class B Preferred Stock at the date of
redemption. The Class B Common Stock will rank pari passu with Purepac's Series
A Preferred Stock,
4
<PAGE>
<PAGE>
all of the outstanding shares of which are owned by Faulding, as to the payment
of dividends and liquidating distributions. See 'Proposal to Increase
Capitalization -- Preferred Stock.'
IMPACT OF ISSUANCE UPON PUREPAC STOCKHOLDERS
Because the Class B Preferred Stock will have a preference over the Purepac
Common Stock with respect to the payment of dividends and liquidating
distributions, earnings of Purepac which otherwise may be available for
distribution to the holders of Purepac Common Stock may be diminished or
eliminated in their entirety. In addition, conversion of the Class B Preferred
Stock will have the effect of increasing Faulding's percentage ownership of
Purepac's then outstanding Common Stock, thereby diluting the equity interests
of the other Purepac Stockholders. See 'The Proposed Faulding
Transaction -- Preferred Stock Purchase Agreement,' 'Proposal to Increase
Capitalization' and 'Principal Stockholders of Purepac.'
CLOSING DATE
The closing of the Acquisition Transaction (the 'Closing') is expected to
be consummated on February 29, 1996, assuming approval by the Purepac
Stockholders of the Faulding Transaction at the Annual Meeting, or on such later
date which shall be the first business day immediately following the day upon
which the last of the conditions to Closing is satisfied.
OPERATIONS OF PUREPAC AFTER THE FAULDING TRANSACTION
Faulding Subsidiaries as Purepac Subsidiaries. If the Faulding Transaction
is consummated, each of the Faulding Subsidiaries will become a wholly-owned
subsidiary of Purepac. The businesses conducted by the Faulding Subsidiaries
have experienced historical operating losses and are not expected to generate
adequate revenues to finance their combined operating expenses until at least
1998. Accordingly, the Faulding Subsidiaries will require additional capital to
fund their ongoing operations. Although it is anticipated that the $15.0 million
to be received by Purepac from the Preferred Stock Purchase will be used in
substantial part for this purpose, additional funding is expected to be
required. In such event, Purepac will be required to utilize funds available
under its then existing credit facilities or from cash flow from operations to
finance any shortfalls. The use of Purepac's credit facilities and other sources
of capital would diminish funding available to Purepac to sustain or expand its
current business operations. Purepac's operations and results of operations are
subject to many of the same risks identified for the Faulding Subsidiaries, such
as uncertainty and variability of financial results, competition, dependence on
product development and the timing of regulatory approvals permitting the
introduction of new products. It is expected that Purepac will need to utilize
some of its existing credit facilities to fund its own operations. Consequently,
there can be no assurance that Purepac's operating results will be sufficient to
permit Purepac to adequately fund the Faulding Subsidiaries, or that satisfying
such financing obligations will not adversely affect Purepac's ongoing business
operations or its ability to finance its current long range objectives.
Accordingly, Purepac may be forced to seek additional credit facilities or to
seek additional funding from sales of its securities or from other sources.
There can be no assurance that such financing will be available when required,
if at all, or will be available upon terms Purepac deems commercially
reasonable. See 'Management's Discussion and Analysis of Financial Condition and
Results of Operations -- Purepac' and ' -- The Faulding Subsidiaries' and
'Businesses of the Faulding Subsidiaries -- Certain Risks Relating to the
Faulding Subsidiaries.'
Name Change. Faulding will grant to Purepac, on the Closing Date, a
worldwide, royalty-free license to use the name 'Faulding' in Purepac's
corporate name, in connection with Purepac's business, generally, and also for
continued use by each of the Faulding Subsidiaries in connection with their
respective businesses. Such license may be terminated at Faulding's option on
three years prior notice at any time after Faulding ceases to own greater than
50%, on a fully diluted basis, of Purepac's outstanding Common Stock. Purepac's
existing operating subsidiary, Purepac Pharmaceutical Co., will continue to
operate under its present name subsequent to the Closing Date.
5
<PAGE>
<PAGE>
Managerial Responsibilities. The officers and directors of Purepac and of
each of the Faulding Subsidiaries will continue to serve in their respective
capacities after the Closing. In addition, Richard F. Moldin, currently the
President and Chief Executive Officer and a director of Purepac, will be
appointed to serve as a director of each of the Faulding Subsidiaries. Michael
R. D. Ashton, a current director of Purepac and each of the Faulding
Subsidiaries, and an officer of each of the Faulding Subsidiaries, has advised
Purepac that he will not stand for re-election as a director of Purepac and of
his intention to resign as an officer and director of each of the Faulding
Subsidiaries on or before the Closing Date.
Relationship with Faulding. After giving effect to the Acquisition
Transaction and the Preferred Stock Purchase (assuming an adjustment to the
purchase price based on the Net Asset Value of the Faulding Subsidiaries as of
September 30. 1995), Faulding would hold 9,161,241 shares of Purepac Common
Stock, representing 61.5% of the then outstanding Purepac Common Stock, as well
as shares of Preferred Stock convertible into an aggregate of 6,570,078
additional shares of Purepac Common Stock, representing an aggregate equity
interest in Purepac, assuming full conversion of all such shares of Preferred
Stock, of 73.3% of the issued and outstanding Purepac Common Stock. In addition,
except as otherwise set forth in this Proxy Statement, all licensing,
distribution, product development, warehousing and other agreements between
Purepac, the Faulding Subsidiaries, F.H. Faulding and their respective
affiliates will continue in effect pursuant to their respective terms and
conditions.
BACKGROUND
As part of F.H. Faulding's goal of expanding its worldwide presence, it
established FMDC in 1989 to develop and commercialize a range of drug-dependent
and stand-alone injectable devices and systems, all designed to enhance the
speed, safety or sterility of injectable drug delivery. F.H. Faulding also
granted FMDC exclusive marketing rights in the United States with respect to
certain injectable products developed by F.H. Faulding for oncological disease
treatment. These products, which require specialized production facilities, are
currently manufactured by F.H. Faulding in its own facilities in Mulgrave,
Australia.
Although FMDC had developed its own proprietary devices relating to shell
glass vials ('SGV') pre-filled with injectable drugs, and had also designed the
molds and other tooling required for their production, it maintained no
manufacturing facilities and was therefore required to contract with
unaffiliated persons for these services. Furthermore, because FMDC, primarily a
product research and development organization, lacked its own marketing
capability, it was compelled to contract with unaffiliated third parties,
particularly Steris Inc. ('Steris'), to market and sell F.H. Faulding's
injectable oncological treatment products in the United States.
In 1994, F.H. Faulding initiated negotiations with The DuPont Merck
Pharmaceutical Company and DuPont Merck Pharma (collectively, 'DuPont Merck')
with the goal of acquiring DuPont Merck's injectable pharmaceutical production
facility located in Aguadilla, Puerto Rico (the 'Aguadilla Facility') and the
United States marketing rights to substantially all of the products manufactured
at the Aguadilla Facility. In seeking to acquire the Aguadilla Facility, F.H.
Faulding noted particularly that this facility, which was then engaged in the
manufacture of six generic injectable drugs for DuPont Merck and other third
parties, had under-utilized manufacturing capabilities, which F.H. Faulding
envisioned could be used to manufacture products incorporating FMDC's SGV
injectable technology, as well as other injectable products principally for
United States distribution.
F.H. Faulding had initially considered contracting with a third party for
the marketing in the United States of the injectable products manufactured at
the Aguadilla Facility. However, as the negotiations between F.H. Faulding and
DuPont Merck progressed towards their conclusion in April 1995, ultimately
resulting in FPR's acquisition of the Aguadilla Facility for approximately $13.0
million, F.H. Faulding determined that it would be more economical in the long
term, and it would permit F.H. Faulding to have greater managerial control, if
F.H. Faulding were to establish its own marketing operation for such products.
F.H. Faulding determined that, by establishing FPC to market the products
produced at the Aguadilla Facility, it could expand its presence in the United
States pharmaceutical product marketplace by utilizing FPC as F.H. Faulding's
marketing arm in the United States for certain injectable products developed by
F.H. Faulding and its affiliates as well as for products sourced from
6
<PAGE>
<PAGE>
unrelated third parties. Recognizing the commonality of distribution channels
for Purepac's oral generic pharmaceutical products and those injectable generic
products to be sold through FPC, Faulding concurrently negotiated a service
agreement with Purepac pursuant to which Purepac undertook to provide FPC with
certain warehousing, distribution and record keeping services for products to be
marketed by FPC.
Contemporaneously with FPR's acquisition of the Aguadilla Facility, Dr.
Edward D. Tweddell, F.H. Faulding's Managing Director as well as Chairman of the
Purepac Board, and Michael R.D. Ashton who at that time and through July 1995
served as Chief Executive Officer of each of Faulding, the Faulding Subsidiaries
and Purepac, in a series of informal meetings relating to the conduct of the day
to day operations of each of Purepac and the Faulding Subsidiaries, reflected
upon the possibility of consolidating the injectable pharmaceutical businesses
of FPR and FPC, as well as FMDC's research and development activities, with
Purepac's existing business. In considering the potential of such a
consolidation, Dr. Tweddell and Mr. Ashton noted the fact that the Aguadilla
Facility had unused production capacity which, after appropriate capital
improvements, could be utilized for the production of products incorporating
FMDC's SGV injectable technology. Note was also taken of the fact that
utilization of Purepac's distribution capabilities would permit F.H. Faulding to
sell directly, through a United States subsidiary, its oncological treatment
products in the United States, which would result in greater profit margins than
continuing to sell through Steris. See 'Business of the Faulding Subsidiaries.'
Dr. Tweddell and Mr. Ashton also considered the fact that over the past
several years, the oral generic pharmaceutical product industry, generally, had
experienced increased levels of supplier and customer consolidation, as well as
intense competitive pricing. As a result of these factors, Purepac's revenues
were decreasing and new product introductions were not at such time occurring at
a level of frequency to replace its diminution of revenues. Further, Purepac's
customers were indicating their preference to deal with 'one-stop'
pharmaceutical suppliers, those which could offer broad product lines rather
than solely oral generic products. Consequently, Dr. Tweddell and Mr. Ashton
concluded that Purepac's long-term profitability could be enhanced by a
consolidation of the respective businesses of the Faulding Subsidiaries with
Purepac.
In furtherance of the possibility of effectuating some form of
consolidation between the Faulding Subsidiaries and Purepac, Dr. Tweddell, Mr.
Ashton, Mr. Geoffrey Pritchard, the Chief Financial Executive of F.H. Faulding,
and Mr. Lee Craker, who was at that time Chief Financial Officer of Faulding and
who subsequently, on May 26, 1995, became Chief Financial Officer of Purepac,
reviewed and discussed on several occasions during April 1995 the then current
operations of each of the Faulding Subsidiaries and their future business plans.
The feasibility of effectuating such a consolidation and the potential benefits
to both Purepac and the Faulding Subsidiaries were also discussed. However,
these discussions were limited to a preliminary analysis of the potential
business advantages of such a combination in general and no specific
consolidation transaction was discussed nor were there any discussions as to the
valuation of any of the Faulding Subsidiaries.
On April 18, 1995, a video teleconference was held among Dr. Tweddell,
Messrs. Pritchard, Ashton and Craker and certain members of their respective
staffs and Parker Duryee, Purepac's legal counsel, to preliminarily explore
alternative forms of transactions which, if consummated, would result in
Purepac's acquisition of the Faulding Subsidiaries. In addition, at the request
of Mr. Ashton, representatives of Salomon Brothers were invited to participate
in this meeting with a view toward Salomon Brothers' engagement by the Purepac
Board, in light of the affiliated nature of the proposed acquisition
transaction, to pass upon the fairness to Purepac, from a financial point of
view, of the consideration to be paid by Purepac to Faulding should Purepac
determine to acquire the Faulding Subsidiaries.
Prior to April 18, 1995, Salomon Brothers had not been retained to
represent either Faulding or Purepac or any of their respective affiliates
(collectively, the 'Faulding Group') in any transaction, nor had Salomon
Brothers charged, nor had it received, any fees from any of such entities for
its services. In early 1994, however, Salomon Brothers had advised, although
never been formally retained by Faulding Services, a wholly-owned subsidiary of
Faulding, in connection with a prospective acquisition transaction, which never
reached the stage of an agreement in principle between Faulding Services and
7
<PAGE>
<PAGE>
the acquisition target. Mr. Ashton, however, believed that Salomon Brothers, in
performing its preliminary analysis of the potential synergies arising from this
proposed acquisition transaction, had attained a level of familiarity with the
structure, operations, strategic direction of, and relationships among, the
several entities comprising the Faulding Group, including Purepac, to be the
logical candidate to pass upon fairness of the proposed transaction to Purepac,
from a financial point of view, should Purepac determine to acquire the Faulding
Subsidiaries from Faulding.
Over the following two weeks, informal discussions continued between
members of Purepac's and Faulding's management, particularly Dr. Tweddell and
Messrs. Ashton and Craker, Parker Duryee and Salomon Brothers, concerning the
Faulding Subsidiaries' respective business plans, as well as Purepac's own
business plan. During this period, it became apparent that a transaction between
Purepac and Faulding relating to Purepac's acquisition of the Faulding
Subsidiaries was becoming a realistic possibility. Accordingly, Faulding and
Purepac agreed that Parker Duryee would continue to act as Purepac's legal
counsel in connection with such a transaction, and that, initially, F.H.
Faulding's in-house counsel would advise Faulding in the negotiation of the
structure of a proposed acquisition transaction, with outside counsel to be
engaged only at such time as an acquisition transaction became probable.
In evaluating alternative structural approaches to an acquisition
transaction, Messrs. Ashton and Craker observed that Purepac's working capital
requirements, given its diminishing revenues and operating losses, precluded
Purepac's acquisition of the Faulding Subsidiaries for cash. A stock for stock
exchange was therefore determined to be the most feasible structure for an
acquisition, especially in light of its anticipated treatment for federal income
tax purposes as a reorganization, which would not require either Purepac or
Faulding to recognize any taxable gain as a consequence of its implementation.
However, no definitive decision was made as to transaction structure, pending
the performance of a preliminary evaluation of the Faulding Subsidiaries by
Messrs. Ashton and Craker.
The initial discussions between Messrs. Ashton and Craker concerning a
valuation of the Faulding Subsidiaries centered upon selecting recognized
methodologies to most accurately value the Faulding Subsidiaries in light of
their initial stages of development, their need for significant capital
resources to finance future operations, and the uncertainty of financial
projections for such businesses as a result of their limited operating
histories. Also considered were the benefits to be derived by the Faulding
Subsidiaries from their license, distribution, service and other agreements with
other members of the Faulding Group, including, Purepac, and marketing,
manufacturing and distribution synergies, which could enhance the valuation of
the Faulding Subsidiaries if acquired by Purepac as contrasted with their
acquisition by an unaffiliated third party. Dr. Tweddell insisted that in
setting a benchmark for such valuation, they would begin with the purchase price
of approximately $13.0 million paid to DuPont Merck by FPR for the Aguadilla
Facility and certain related business operations currently conducted by FPC,
which price resulted from arms-length negotiations with DuPont Merck, and which
was primarily based upon the net asset value of the Aguadilla Facility as of
September 30, 1994. In addition, Dr. Tweddell and Messrs. Ashton and Craker
agreed that, in developing a valuation for the Faulding Subsidiaries, they would
take into consideration (i) the increase in manufacturing activity undertaken by
FPR subsequent to its acquisition of the Aguadilla Facility, thereby increasing
FPR's and FPC's inventory levels; (ii) capital expenditures made by FPR for
facility improvements, which were funded by Faulding; (iii) the implementation
of certain agreements between members of the Faulding Group and the Faulding
Subsidiaries (e.g., the Licensing Agreement between F.H. Faulding and FPC
pursuant to which FPC, commencing in September 1995, would market certain
products manufactured by F.H. Faulding in the United States); (iv) the value of
FMDC's molds and other tooling for production of its proprietary SGV products;
and, to a lesser extent (v) the potential future benefits, approximating
$680,000, realizable by Purepac by acquiring the tax loss carry-forwards of the
Faulding Subsidiaries which might be utilized by Purepac to offset future taxes
payable.
Because the proposed Acquisition Transaction is a transaction between
affiliated parties and because Dr. Tweddell and Mr. Ashton were officers and/or
directors of both Purepac and Faulding, it was determined that Purepac would
request those members of the Purepac Board having no affiliation with Faulding
to act as a special committee of the Purepac Board to review any proposed
acquisition transaction to assure its fairness to the Purepac Stockholders other
than Faulding. Purepac has routinely
8
<PAGE>
<PAGE>
utilized a special committee of independent directors to review all proposed
transactions between Faulding and/or its affiliates and Purepac.
On May 4, 1995, at the request of Purepac's management, David Beretta and
Bruce Tully, the two directors of Purepac who are neither employees of Purepac
nor affiliates of the Faulding Group, attended a meeting in New York with Parker
Duryee and with representatives of Salomon Brothers to discuss the proposed
acquisition transaction and to interview Salomon Brothers in connection with the
proposed engagement of that firm to opine upon the fairness of the proposed
acquisition transaction, from a financial point of view, to Purepac. Salomon
Brothers reviewed with Messrs. Beretta and Tully its knowledge about the
Faulding Group as a result of its prior consultations with Faulding relating to
a potential unconsummated acquisition transaction and related matters. Following
that meeting, Messrs. Beretta and Tully advised Purepac's management that they
were satisfied that Salomon Brothers' prior service to Faulding did not
constitute an impediment to Salomon Brothers' retention by the Purepac Board and
they were in agreement that Salomon Brothers should be retained on behalf of
Purepac. They also confirmed that they were prepared to act as a special
committee (the 'Special Committee') to evaluate the proposed acquisition
transaction from the standpoint of fairness to Purepac.
On May 9, 1995, Dr. Tweddell submitted a written proposal (the 'Acquisition
Proposal') to the Purepac Board which contemplated Purepac's acquisition of the
Faulding Subsidiaries. The Acquisition Proposal did not address the potential
valuation of the Faulding Subsidiaries, but proposed that the form of payment to
Faulding be Purepac Common Stock. The Acquisition Proposal also called for
Purepac to enter into negotiations with Faulding for the purpose of structuring
an acquisition transaction for consideration by the Purepac Board, for the
Special Committee to evaluate the Acquisition Proposal from the standpoint of
fairness to Purepac, and for Salomon Brothers' retention to advise the Purepac
Board and the Special Committee.
The Acquisition Proposal also stated that, should the transaction
contemplated by the Acquisition Proposal ultimately be approved by the Purepac
Board, such transaction be submitted for approval to the Purepac Stockholders as
promptly as practicable.
On May 26, 1995, the Purepac Board unanimously approved and authorized the
actions proposed by Dr. Tweddell in the Acquisition Proposal.
During the following three week period, discussions ensued on several
occasions between representatives of Purepac and Faulding, particularly among
Messrs. Ashton, Craker and Pritchard. These discussions addressed five year
projections of operating results for each of the Faulding Subsidiaries and for
Purepac, and Purepac's ability to finance the operations of the Faulding
Subsidiaries in light of anticipated operating losses of the Faulding
Subsidiaries through at least June 30, 1997. F.H. Faulding's willingness to
provide Purepac with additional funding, and the likelihood of utilizing
Purepac's own credit facilities (approximately $15.0 million of availability)
were discussed briefly as well.
On June 13, 1995, a written report regarding the proposed acquisition
transaction, prepared by Messrs. Ashton and Craker, was distributed to the
Purepac Board. The report addressed:
A general description of the respective businesses of the Faulding
Subsidiaries.
A summary of the proposed acquisition transaction, structured as a
stock-for-stock exchange.
A post-acquisition business strategy for each of the Faulding
Subsidiaries, including goals of achieving greater utilization of the
Aguadilla Facility, providing FPC with a broader range of product
offerings to be sourced from FPR and F.H. Faulding, and
commercializing the products under development by FMDC which, in
part, could be incorporated into injectable products offered by FPC.
A financial analysis of each of the Faulding Subsidiaries, including
five year revenue, capital expenditure and income/loss projections,
indicating expected pre-tax net operating losses of approximately
$4.0 million and $1.7 million to be incurred during the fiscal years
ending June 30, 1996 and 1997 upon revenues of approximately $15.8
million and $29.2 million, respectively, and the likelihood that no
pre-tax net operating income would be recognized prior to the fiscal
year ending June 30, 1998.
9
<PAGE>
<PAGE>
Five year anticipated funding requirements for Purepac, including
financing alternatives as well as the possibility of the need for
additional credit facilities or other sources of capital depending
upon the timing of receipt of FDA approvals of products under
development by Purepac.
Per share earnings projections for Purepac on both a stand-alone
basis and assuming Purepac's acquisition of the Faulding
Subsidiaries, indicating the immediate dilutive effect that
consummation of the Faulding Transaction would have on Purepac's per
share earnings.
On June 20, 1995, the Purepac Board considered the Acquisition Proposal.
All of the members of the Purepac Board participated in these discussions, as
well as representatives of Salomon Brothers. In particular, Mr. Craker reviewed
the financial information which had been provided to the Purepac Board, focusing
on projected earnings, per share earnings dilution and funding requirements, and
sources thereof, to sustain the Faulding Subsidiaries' operations if acquired by
Purepac. Specific funding issues addressed by Mr. Craker related to anticipated
negative cash flow from the combined operations of Purepac and the Faulding
Subsidiaries through June 30, 1998 of approximately $25 million, of which
approximately $20 million would be attributable to the Faulding Subsidiaries.
The Purepac Board recommended that alternatives for financing the cash flow
requirements of the combined operations of Purepac and the Faulding Subsidiaries
be further explored. Financial projections presented by Mr. Craker to the
Purepac Board at this meeting assumed an estimated acquisition valuation of
$30.0 million, for illustrative purposes only and for use in the calculations of
certain financial projections, such as per share earnings.
Salomon Brothers then delivered to the Purepac Board a written presentation
and reviewed with the Purepac Board the overall scope of the Salomon Brothers
engagement. Salomon Brothers reviewed the established alternative valuation
methodologies which would be utilized by Salomon Brothers in connection with the
delivery to the Purepac Board, if an acquisition transaction were agreed to
between Purepac and Faulding, of an opinion as to the fairness to Purepac, from
a financial point of view, of the consideration to be paid by Purepac for the
Faulding Subsidiaries. Also discussed by the members of the Purepac Board were
various valuation methodologies available, including those which Salomon
Brothers proposed to utilize. Salomon Brothers presented to the Purepac Board
certain preliminary financial data relating to Purepac and the Faulding
Subsidiaries based upon Mr. Craker's financial projections and his assumed $30.0
million valuation.
Parker Duryee then made a presentation to the Purepac Board regarding
various legal considerations and timing requirements for implementing the
proposed acquisition transaction. These included, in light of the affiliation
between Purepac and Faulding, the advisability of an independent review and
approval of the terms of the proposed transaction by the Special Committee, the
need for stockholder approval of the transaction under the rules of The Nasdaq
National Market and the advisability of allowing approval or disapproval of the
acquisition transaction to be determined by the vote of the Purepac Stockholders
other than Faulding.
After further discussion among the members of the Purepac Board regarding
the proposed acquisition transaction, the Purepac Board instructed Purepac's
management, Salomon Brothers and Parker Duryee to continue to pursue development
of the terms and structure of the proposed transaction as promptly as possible
along the lines outlined at the meeting with the objective of submitting
definitive terms of the proposed transaction for approval in principle to the
Purepac Board at a Special Meeting, ultimately scheduled for August 9, 1995.
On July 17, 1995, Mr. Pritchard, on behalf of F.H. Faulding, and Mr.
Craker, on behalf of Purepac, met in New York City to review proposed valuations
for the Faulding Subsidiaries. Also participating in those meetings were Parker
Duryee and representatives of Salomon Brothers. During these discussions,
valuation issues were again reviewed with a view towards determining an
acquisition price for the Faulding Subsidiaries. Because Faulding had recently
acquired the Aguadilla Facility and certain product lines now marketed by FPC
for a purchase price based upon the net asset value of the Aguadilla Facility
and its attendant operations, and in view of the fact that FPR's and FPC's
operations constituted the majority of the assets of the Faulding Subsidiaries,
it was determined by Messrs. Pritchard and Craker to base the purchase price of
the Faulding Subsidiaries in substantial part upon their Net Asset Value, then
estimated to be approximately $17.7 million, plus, to a lesser extent, the
10
<PAGE>
<PAGE>
incremental value of a distribution agreement that was to be put into place
between F.H. Faulding and FPC, and the net operating loss tax carry-forwards of
the Faulding Subsidiaries from which Purepac might derive a future tax benefit.
Messrs. Pritchard and Craker agreed to present a proposed purchase price of
$20.0 million to the respective boards of directors of Faulding and Purepac,
together with a concurrent purchase by Faulding of $15.0 million of a new class
of Purepac preferred stock to provide a source of funding for the Faulding
Subsidiaries' post-acquisition operations. It was agreed that the attributes of
the new preferred stock would be based principally on the terms of Purepac's
currently outstanding Class A Preferred Stock, all of which is held by Faulding,
taking into account current interest rates and prevailing conversion premium
levels and dividend rates for recent convertible preferred stock issuances by
unaffiliated parties. Mr. Pritchard expressed the view that, from Faulding's
perspective, its purchase of preferred stock as a funding mechanism was
preferable to a loan by Faulding to Purepac for the Faulding Subsidiaries'
post-acquisition working capital needs, provided the preferred stock paid a
dividend, as under Australian generally accepted accounting principles, the
receipt of such a dividend, if sufficient in amount, would assist F.H. Faulding
to report its investment in Purepac as profitable. Salomon Brothers was
requested to provide Purepac with advice as to suggested dividend rates and
conversion premiums for this new class of preferred stock. Mr. Pritchard also
stated that Faulding was prepared to contribute all sums theretofore advanced to
the Faulding Subsidiaries (then estimated to be approximately $20.0 million) to
their capital upon consummation of an acquisition transaction to eliminate the
need for their future repayment.
On August 4, 1995, a report was delivered to the Purepac Board by Mr.
Moldin, who had become Purepac's Chief Executive Officer on July 17, 1995,
replacing Mr. Ashton. This report summarized the proposed acquisition
transaction, setting forth the proposed purchase price of $20.0 million and the
relationship of such purchase price to the Net Asset Value of the Faulding
Subsidiaries. The report also provided the financial projections for each of
Purepac and the Faulding Subsidiaries, as previously furnished to the Purepac
Board on June 13, 1995. In particular, Mr. Moldin's report addressed the funding
issues related to the proposed business operations of the Faulding Subsidiaries,
earnings forecasts for Purepac and the Faulding Subsidiaries for the ensuing
five fiscal years ending June 30, 2000, and forecasted capital expenditures to
be incurred in connection with the businesses to be acquired. The report also
addressed the availability of financing through Purepac's existing credit
facilities and the rationale for proposing to partly satisfy the need for
additional funding by means of a preferred stock issuance to Faulding to
generate proceeds of $15.0 million. Mr. Moldin's report also set forth a
recommended dividend rate of 4.5% and conversion premium of 8% above the then
market price of Purepac Common Stock for such preferred stock.
On August 9, 1995, the Special Committee met with Messrs. Moldin and Craker
and Parker Duryee to review the proposed acquisition transaction. Specifically
addressed were various operating and financial aspects of the Faulding
Subsidiaries, the proposed purchase price, and the methodology for arriving at
such price. In addition, the Special Committee reviewed with Mr. Craker certain
cash flow and funding requirements of Purepac and the Faulding Subsidiaries and
the terms of the proposed preferred stock issuance. The members of the Special
Committee also confirmed with both Messrs. Moldin and Craker that, as senior
management of the Company, they continue to be in full support of the
transactions proceeding along the lines proposed.
On the evening of August 9, 1995, the Purepac Board met in New York City to
review the final proposal regarding the Acquisition Transaction and the
Preferred Stock Purchase. Participating in the meeting were all of the members
of the Purepac Board, excepting only Mr. Alan McGregor, who was unavailable.
Also participating in the meeting were Parker Duryee and representatives from
Salomon Brothers.
Salomon Brothers, having first delivered a written presentation to the
Purepac Board, then verbally summarized its written presentation which detailed
the several methodologies by which Salomon Brothers valued the Faulding
Subsidiaries for the purposes of its opinion. First noting that Purepac had not
directed Salomon Brothers to use any particular valuation methodology, Salomon
Brothers stated that it had employed a Public Market Valuation Method, a Merger
and Acquisition Transaction Multiple Method and a Discounted Cash Flow Method
for this purpose. These methods resulted in
11
<PAGE>
<PAGE>
valuation ranges of $15.0 to $25.0 million, $30.0 to $40.0 million, and $80.0 to
$110.0 million, respectively. Salomon Brothers, however, advised the Purepac
Board, as discussed under 'Opinion of Financial Advisor' elsewhere herein, that
each of these valuation methodologies had inherent limitations. Salomon Brothers
also presented a breakdown of the number of shares of Purepac Common Stock to be
issued in the Faulding Transaction and the terms of the proposed Class B
Preferred Stock, based upon an assumed closing price of the Purepac Common Stock
on such date of $8.875 per share. Salomon Brothers then formally delivered to
the Purepac Board its written opinion to the effect that, as of such date, the
consideration to be paid by Purepac to Faulding for the Faulding Subsidiaries,
and the consideration to be received by Purepac upon its sale of the Class B
Preferred Stock to Faulding, was fair, from a financial point of view, to
Purepac. See 'The Proposed Faulding Transaction -- Opinion of Financial
Advisor.'
The Special Committee confirmed to the Purepac Board that it had considered
the Faulding Transaction and had determined that the terms of the Faulding
Transaction were fair to Purepac. The Purepac Board thereupon approved the
Faulding Transaction, subject to its approval by the Purepac Stockholders other
than Faulding. The Purepac Board also authorized Mr. Moldin to execute the
Letter of Intent, which had been theretofore prepared by Parker Duryee and
reviewed by F.H. Faulding's in-house counsel.
During the remainder of August and through October 1995, Purepac, through
Parker Duryee, and Faulding, through Reid & Priest LLP, retained by Faulding
subsequent to August 9, 1995 to act as its counsel, prepared and revised drafts
of the Stock Purchase Agreement and the Preferred Stock Purchase Agreement.
In late August, Messrs. Moldin and Craker commenced monitoring the ongoing
financial performance of both Purepac and the Faulding Subsidiaries, and
analyzed their respective financial projections. During late September, a more
detailed review of financial data for the Faulding Subsidiaries and for Purepac
was undertaken by Messrs. Moldin and Craker. Such reviews revealed that, as a
result of continued competitive pricing pressures in the oral generic drug
industry, Purepac's operating revenues continued to reflect a downward trend,
and that delays in obtaining regulatory approvals were disrupting anticipated
market introductions of Purepac's new products, with the likelihood, if such
delays were to continue, of a resultant diminution in anticipated future
revenues and profitability. This downward trend was at variance from a more
optimistic forecast contained in Mr. Moldin's report that was delivered to the
Purepac Board on August 4, 1995. Mr. Moldin also observed that FPC's sales were
not at the levels initially expected, resulting in lower than expected projected
revenues and margins for the quarter ending September 30, 1995. As a consequence
of these factors, Mr. Craker concluded that Purepac's existing credit facilities
of approximately $15.0 million, which were anticipated to be applied in part to
the projected cash flow needs of the Faulding Subsidiaries, could instead be
required in large measure to fund Purepac's operating needs on a stand-alone
basis. Mr. Craker also concluded that unfavorable changes in credit terms with
Purepac's suppliers and customers from those assumed for purposes of the
projections could further limit Purepac's ability to fund the Faulding
Subsidiaries. Mr. Craker noted that any future receipt of new product approvals
from the FDA, with the resultant need to substantially increase inventories of
raw materials to permit the manufacture in volume of such products, could
further exacerbate Purepac's future cash flow needs. In all, Mr. Craker
concluded that the negative cash flow of the combined operations of Purepac and
the Faulding Subsidiaries through June 30, 1998 could be substantially greater
than the earlier estimate of approximately $25.0 million presented to the
Purepac Board on June 20, 1995.
Based upon this updated financial data, and incorporating certain
adjustments to the respective business plans of the Faulding Subsidiaries which
Purepac's management had determined to make as a result of its analysis of their
ongoing operations, Purepac's management prepared revised financial projections
for the Faulding Subsidiaries. In particular, these revised projections, among
other matters, estimated pre-tax net operating losses of $4.4 million and $2.2
million for the fiscal years ending June 30, 1996 and June 30, 1997, upon
estimated revenues of approximately $15.2 million and $28.5 million,
respectively. Consistent with the projections previously presented to the
Purepac Board in the June 13, 1995 report, recognition of pre-tax net operating
income was not expected prior to the fiscal year ending June 30, 1998. However,
anticipated revenues and net operating income levels for that fiscal
12
<PAGE>
<PAGE>
year, as well as for the next two fiscal years, were substantially reduced from
those previously presented to the Purepac Board as a consequence of the more
conservative approach taken in the October 24, 1995 projections with respect to
the anticipated impact during such fiscal years of potential market share
erosion and aggressive competitive pricing. See ' Management's Discussion and
Analysis of Financial Condition and Results of Operations -- Faulding
Subsidiaries -- Overview.'
Purepac's management provided these revised projections for both Purepac
and the Faulding Subsidiaries to Salomon Brothers in early October 1995, and
requested that Salomon Brothers advise the Purepac Board as to the effect, if
any, which these updated financial projections, as well as a downward movement
in the market price of Purepac's Common Stock from August 9, 1995 and general
market conditions, may have upon Salomon Brothers' opinion.
On October 12, 1995, the Special Committee met with Messrs. Moldin and
Craker, as well as Parker Duryee, to review the revised financial projections
for Purepac and the Faulding Subsidiaries and to discuss the bases for the
revisions to the Purepac and Faulding Subsidiaries' projections. Salomon
Brothers, telephonically present at such meeting, confirmed its belief that it
would be able to continue to provide Purepac with a fairness opinion.
On October 24, 1995, a meeting of the Purepac Board was held, at which the
revised financial results of Purepac and the Faulding Subsidiaries were
reviewed. Messrs. Moldin and Craker presented an analysis of such results and
management's proposals for certain modifications in the respective business
plans of Purepac and the Faulding Subsidiaries, which included a restructuring
of Purepac's management and an analysis as to which of Purepac's product
development projects should be pursued most aggressively. Representatives of
Salomon Brothers, also present at the meeting, delivered to the Purepac Board a
written presentation in a format similar to that delivered at the Purepac
Board's August 9, 1995 meeting, which incorporated the revised financial data
and projections of Purepac's management for the Faulding Subsidiaries based upon
Purepac management's revised business plans. Salomon Brothers' presentation
contained a revaluation of the Faulding Subsidiaries for purposes of its opinion
using the same methodologies used in its August 9, 1995 presentation. Salomon
Brothers' revaluation of the Faulding Subsidiaries using the Public Market
valuation methodology did not result in a change in valuation ranges from the
previous $15.0 to $25.0 million range presented at the August 9, 1995 Purepac
Board Meeting. However, Salomon Brothers' revaluation of the Faulding
Subsidiaries utilizing the Merger and Acquisition Multiple and the Discounted
Cash Flow valuation methodologies reduced such ranges by $5.0 million and $15.0
million, respectively, from the ranges presented at the August 9, 1995 Purepac
Board meeting, to $25.0 to $35.0 million and $65.0 to $85.0 million,
respectively. In concluding its presentation, Salomon Brothers confirmed that it
could continue to be able to deliver its fairness opinion after giving effect to
such revaluations.
Salomon Brothers also presented a pro forma combination analysis of Purepac
and the Faulding Subsidiaries for the fiscal years ending June 30, 1995, 1996
and 1997, utilizing the financial projections for Purepac and each of the
Faulding Subsidiaries for the fiscal years 1996 and 1997, which as noted above
were prepared by Purepac's management in early October 1995, and utilizing the
actual results of operations for the fiscal year ended June 30, 1995. Such
analysis, which was presented to the Purepac Board solely for illustrative
purposes, assumed consummation of the Faulding Transaction and reflected, among
other matters, the anticipated contribution of each of Purepac and the Faulding
Subsidiaries to the combined revenues and pre-tax operating income/loss of
Purepac for such fiscal years.
The pro forma results of operations for the fiscal year ended June 30, 1995
are set forth in detail herein under the Section 'Pro Forma Financial
Statements.' The pro forma combination analysis presented by Salomon Brothers
reflected an increasing revenue contribution of the Faulding Subsidiaries over
the years ended June 30, 1996 and 1997, and reflected a significant negative
impact of the Faulding Subsidiaries upon Purepac's pre-tax operating income/loss
for the fiscal year ending June 30, 1996, with a somewhat reduced negative
impact for the fiscal year ending June 30, 1997. In addition, the pro forma
combination analysis reflected a substantial negative impact of the Faulding
Subsidiaries upon Purepac's available cash flow during the fiscal years ending
June 30, 1996 and 1997. Salomon Brothers expressed no opinion as to whether the
projections used by Salomon Brothers in preparing the pro forma combination
analysis were reasonable.
13
<PAGE>
<PAGE>
At the October 24, 1995 meeting, Bruce Tully, an independent director and a
member of the Special Committee, asked Salomon Brothers to prepare a revised
Discounted Cash Flow analysis of the Faulding Subsidiaries utilizing a higher
discount factor for FPR and FPC. Salomon Brothers advised the Special Committee
that, while Salomon Brothers believed the discount factor used in its
presentation was appropriate, it would prepare such an analysis for illustrative
purposes. Subsequent to this meeting, on October 27, 1995, Salomon Brothers
presented this analysis, using a range of discount rates from 33% to 37% for FPR
and FPC and from 30% to 40% for FMDC, as compared to a range of discount rates
from 18% to 22% for FPR and FPC and from 30% to 40% for FMDC used for the
purposes of its October 24, 1995 presentation. The October 27, 1995 discounted
cash flow analysis resulted in a valuation range of $38.6 million to $72.8
million, as compared to the $54.6 million to $99.0 million valuation range
derived from the October 24, 1995 analysis.
Following Salomon Brothers' presentation at the October 24 meeting, both
the Special Committee and the Purepac Board unanimously reaffirmed their
approval of the Faulding Transaction. In the discussion relating to such
re-affirmation, the issue of adjusting Purepac's $20.0 million purchase price
for the Faulding Subsidiaries in view of the near-term diminution of their
respective revenue prospects since August 9, 1995 was addressed. In determining
not to seek a change in the purchase price, the Purepac Board noted that the
$20.0 million purchase price had been primarily linked to the Net Asset Value of
the Faulding Subsidiaries, rather than to their future prospects or to the cash
flows to be derived from their future operations. The Purepac Board noted that
the anticipated negative cash flow attributable to the Faulding Subsidiaries
through June 30, 1998 had not materially changed from the $20 million level
presented to the Purepac Board on June 20, 1995. The Purepac Board also took
note of the fact that, as the purchase price for the Faulding Subsidiaries was
to be paid in shares of Purepac Common Stock, any attempt to renegotiate the
valuation of the Faulding Subsidiaries to a figure of less than $20.0 million
would give rise to the likelihood that Faulding would contend that a current,
and lower ($8.00 compared to $8.875) per share price should also be used in
computing the aggregate number of shares to be issued to Faulding, thus
potentially resulting in a greater number of shares of Purepac Common Stock
being issued to Faulding, with a resultant increase in dilution to Purepac
Stockholders. Further, irrespective of the fact that the revised financial
projections of the Faulding Subsidiaries had resulted in a downward valuation in
two of the three valuation methodologies utilized by Salomon Brothers, the
Purepac Board's economic rationale in consummating the Faulding Transaction was
based in substantial part upon the potential long range benefits to Purepac
resulting from product diversification opportunities and operational
efficiencies, which would not be materially affected by such valuation
reductions.
On October 30, 1995, a teleconference was held among the Special Committee,
Messrs. Moldin and Craker and Parker Duryee to review the terms of both the
Stock Purchase Agreement and the
Preferred Stock Purchase Agreement, at which time the Special Committee approved
the terms thereof.
On November 30, 1995, the Special Committee met in New York City with Mr.
Moldin and Parker Duryee to review the status of the Faulding Transaction and
the most current operating results and financial projections of both Purepac and
the Faulding Subsidiaries.
In December 1995, representatives of Purepac and Faulding and their
respective counsel completed negotiation of the terms of the Stock Purchase
Agreement and the Preferred Stock Purchase Agreement.
On January 23, 1996, the Special Committee, after reviewing the then most
current operating results and financial projections of both Purepac and the
Faulding Subsidiaries, reaffirmed its approval of the Faulding Transaction. Also
on January 23, 1996, the Purepac Board approved the execution and delivery of
the Stock Purchase Agreement and the Preferred Stock Purchase Agreement, both of
which were executed on Purepac's behalf later that day.
14
<PAGE>
<PAGE>
RECOMMENDATION OF THE PUREPAC BOARD; REASONS FOR THE FAULDING TRANSACTION
On August 9, 1995 and January 23, 1996, the Purepac Board, following the
recommendation of the Special Committee, unanimously approved the Faulding
Transaction.
In determining whether or not to approve the Faulding Transaction, the
Purepac Board noted the variety of business operations conducted by the Faulding
Subsidiaries, which primarily focus upon injectable generic drugs and related
products, and the extent to which such businesses could complement and
supplement the business operations of Purepac, as well as provide a greater
diversification of Purepac's product offerings, presently limited to generic
solid oral pharmaceuticals. The Purepac Board also considered that,
collectively, the Faulding Subsidiaries comprised a manufacturing facility for
injectable generic products, a marketing and sales infrastructure for such
products and a medical device development company that could provide value-added
benefits to products of FPC, as well as potential commercialization of its own
products on a stand-alone basis. The Purepac Board noted that the expense and
time required for the construction of an injectable drug facility meeting
regulatory requirements and for the acquisition of the necessary manufacturing
expertise pose significant barriers to entry into this marketplace. The Purepac
Board believed that the Acquisition Transaction provided an opportunity to
substantially overcome such barriers. The Purepac Board also considered the
different end-customer base of the Faulding Subsidiaries, being institutional
sales, as contrasted with Purepac's retail-based sales, and the potential
benefits to Purepac that could be derived from broadening Purepac's access to
institutional purchasers. The Purepac Board also took note of the fact that
since largely the same distribution channels are utilized by Purepac and the
Faulding Subsidiaries to service their respective end customers, there was a
significant likelihood of achieving operating efficiencies from the integration
of their respective administrative, distribution and sales organizations and
efforts.
The Purepac Board also considered the Faulding Transaction as an
opportunity for Purepac to solidify and formalize its position as the base of
F.H. Faulding's generic and related pharmaceutical product technology and
product offerings in the United States. In particular, Purepac's acquisition of
the Faulding Subsidiaries, which are parties to various agreements with F.H.
Faulding providing the Faulding Subsidiaries with United States marketing rights
to certain products developed by F.H. Faulding, would enable Purepac to hold
substantially all of F.H. Faulding's United States generic and injectable
pharmaceutical product interests. The Purepac Board also took into account the
broad recognition of F.H. Faulding in the worldwide pharmaceutical industry and
the opportunity to capitalize on the 'Faulding' name as a result of the
consolidation of all of F.H. Faulding's United States business operations within
Purepac, and by changing Purepac's name to 'Faulding Inc.'
The Salomon Brothers opinion was also taken into consideration by the
Purepac Board in making its determination to approve the Faulding Transaction.
However, as discussed above, the valuation methodologies used by Salomon
Brothers were not the bases for determination of the purchase price to be paid
by Purepac for the Faulding Subsidiaries. Rather, Salomon Brothers' opinion was
primarily utilized by the Purepac Board to confirm that the terms of the
Faulding Transaction, negotiated in substantial part by Messrs. Craker and
Pritchard on behalf of, respectively, Purepac and Faulding, were fair, from a
financial point of view, to Purepac.
The Purepac Board considered the proposed budgets and projected financial
performance of the Faulding Subsidiaries and the funding requirements for
expenditures for their respective businesses and of their anticipated operating
losses through at least June 30, 1997. In particular, the Purepac Board observed
that the Faulding Subsidiaries would require an infusion in excess of $20
million during such period to sustain their respective operations. The Purepac
Board considered these factors in light of Purepac's own revenue projections,
available credit facilities, options available for external financing, and the
projected time frame during which each of these businesses were expected to
generate sufficient cash flow from operations to sustain their respective
operations. The Purepac Board determined that the offer of Faulding to purchase
the Class B Preferred Stock provided Purepac with an immediate source of
financing on terms and conditions which were fair to Purepac and which would
provide Purepac with flexibility in the application of such proceeds to the
Faulding Subsidiaries' business operations or, if required, to Purepac's
existing operations. The Purepac Board also took into account Faulding's
agreement to contribute to capital all indebtedness of the Faulding Subsidiaries
to Faulding.
15
<PAGE>
<PAGE>
The Purepac Board also considered certain potentially negative factors such
as the historical operating losses of FMDC, the limited operating histories of
each of FPR and FPC, and the need for substantial capital to fulfill the
business plans of the Faulding Subsidiaries, all as hereinafter discussed under
'Business of the Faulding Subsidiaries -- Certain Risks Relating to the Faulding
Subsidiaries.' The Purepac Board concluded, however, that notwithstanding these
negative considerations, the acquisition of the Faulding Subsidiaries and the
infusion of $15.0 million of capital in Purepac by Faulding would be in the best
interests of Purepac and the Purepac Stockholders, and would afford Purepac the
possibility of significant growth potential. See 'Background' for additional
factors considered by the Purepac Board.
OPINION OF FINANCIAL ADVISOR
Following Salomon Brothers' attendance at, and participation in a number of
meetings among representatives of Purepac and Faulding at various dates through
the early summer of 1995, as discussed under 'Background,' Salomon Brothers was
formally retained by the Purepac Board on July 31, 1995 to render an opinion to
the Purepac Board that the consideration to be paid by Purepac to Faulding for
the Faulding Subsidiaries, and the consideration to be received by Purepac upon
its sale of the Class B Preferred Stock to Faulding, was fair, from a financial
point of view, to Purepac. Salomon Brothers rendered its opinion to such effect
to the Purepac Board on August 9, 1995, immediately prior to Purepac's execution
of the Letter of Intent.
No limitations were imposed by the Purepac Board upon Salomon Brothers with
respect to the investigations made or the procedures followed by Salomon
Brothers in rendering its opinion. Salomon Brothers did not, and was not
requested by the Purepac Board, to make any recommendations as to the form or
amount of consideration to be paid by Purepac in connection with the Acquisition
Transaction, or the form or amount of consideration to be received by Purepac in
connection with the Preferred Stock Purchase.
On October 24, 1995, and, again, on January 23, 1996, Salomon Brothers, at
the request of the Purepac Board and after reviewing updated operating results
and financial projections of each of Purepac and the Faulding Subsidiaries,
reaffirmed its August 9, 1995 opinion as of such dates.
The full text of Salomon Brothers' opinion, dated January 23, 1996, which
sets forth the assumptions made, general procedures followed, matters considered
and limits on the review undertaken, is attached as Exhibit C to this Proxy
Statement. Salomon Brothers' opinion is directed only to the fairness to
Purepac, from a financial point of view, of the consideration to be paid by
Purepac in connection with the Acquisition Transaction and the consideration to
be received by Purepac in connection with the Preferred Stock Purchase, and does
not constitute a recommendation to any holder of Purepac Common Stock as to how
such holder should vote on the Faulding Transaction. The summary of Salomon
Brothers' opinion set forth below is qualified in its entirety by reference to
the full text of such opinion. Stockholders are urged to read the opinion in its
entirety.
In connection with rendering its opinion, Salomon Brothers reviewed the
Letter of Intent, including the exhibit thereto. Salomon Brothers also reviewed
certain publicly available business and financial information and analyzed
information provided by the managements of both Purepac and Faulding regarding
the Faulding Subsidiaries, which included but was not limited to non-public
financial and operating information. This information included the following:
(i) operating plans and strategies; (ii) historical and projected financial
statements, and plans for growing revenues and profits; (iii) customer bases,
industry trends and competitor analyses; and (iv) description of business
segments.
The information provided by management of, respectively, Purepac and
Faulding was relevant to all analyses conducted by Salomon Brothers, which
included: (i) Public Market Valuation analysis; (ii) Precedent Merger and
Acquisition analysis; and (iii) Discounted Cash Flow analysis. In its review and
analyses and in arriving at its opinion, Salomon Brothers assumed and relied
upon the accuracy and completeness of the information provided to it or publicly
available, and Salomon Brothers did not assume any responsibility for
independent verification of such information or for any independent evaluation,
appraisal or inspection of the assets (including, properties and facilities) or
liabilities of Purepac or the Faulding Subsidiaries.
16
<PAGE>
<PAGE>
With respect to Purepac's and the Faulding Subsidiaries' financial
projections, Salomon Brothers assumed that such projections had been reasonably
prepared on bases reflecting the best currently available estimates and
judgments of the management of Purepac or Faulding, as the case may be, as to
the future financial performance of Purepac or the Faulding Subsidiaries, as the
case may be, and Salomon Brothers expressed no opinion about such forecasts or
the assumptions on which they were based.
Salomon Brothers' opinion is necessarily based upon business, market,
economic and other conditions as they existed on, and could be evaluated as of,
the date of Salomon Brothers' opinion and did not address Purepac's underlying
business decision to effect the Acquisition Transaction or the Preferred Stock
Purchase. Salomon Brothers' opinion did not imply any conclusions as to the
likely trading range for Purepac Common Stock or preferred stock (including the
Class B Preferred Stock to be issued pursuant to the Preferred Stock Purchase)
following the date of Salomon Brothers' opinion, which may vary depending on,
among other factors, changes in interest rates, dividend rates, market
conditions, general economic conditions and other factors that generally
influence the price of securities.
Salomon Brothers' opinion is also based on the assumption that the
convertible preferred stock to be issued by Purepac pursuant to the Preferred
Stock Purchase will bear cumulative dividends at a rate of 4.5% and will be
convertible into shares of Purepac Common Stock at a conversion rate
representing a premium of 8% to the last sale price of Purepac's Common Stock as
of the date of the execution of the Letter of Intent and will not have call
protection greater than three years.
Although Salomon Brothers understood that the purchase price as negotiated
between Purepac and Faulding was arrived at based primarily upon the aggregate
Net Asset Value of the Faulding Subsidiaries, Salomon Brothers utilized three
recognized valuation methodologies unrelated to Net Asset Value in connection
with the issuance of its opinion, being, respectively, a Discounted Cash Flow
analysis, a Public Market Valuation analysis and a Precedent Merger and
Acquisition Transactions analysis.
Salomon Brothers considered all three valuation methods in its opinion but
assigned significantly greater relevance to the Discounted Cash Flow analysis,
due to the lack of current earnings and pure play comparables for the other two
methodologies, as more fully discussed below. A sensitivity matrix for the
Discounted Cash Flow analysis, reflecting a range of discount rates and terminal
EBDIAT multiples, was provided to the Purepac Board as part of Salomon Brothers'
presentations on August 9, 1995 and on October 24, 1995.
DISCOUNTED CASH FLOW ANALYSIS
Using a Discounted Cash Flow ('DCF') methodology, Salomon Brothers valued
the Faulding Subsidiaries by estimating the present value of future unlevered
free cash flows of each of the Faulding Subsidiaries if they were to perform on
a stand-alone basis (without giving effect to the Acquisition Transaction) in
accordance with projections provided by Faulding. Unlevered free cash flow
represents the amount of cash generated and available for principal, interest
and dividend payments after providing for ongoing business operations. For each
of the Faulding Subsidiaries, Salomon Brothers aggregated (x) the present value
of the projected unlevered free cash flow of their businesses over the period
from 1995 to 2000 with (y) the present value of the projected range of terminal
values for such businesses, determined as described below. Terminal value
reflects the estimated value of the subject enterprise which is attributable to
the period beyond the forecasted time horizon. Inherent to the DCF analysis is a
high degree of uncertainty in forecasting by management of future cash flows,
particularly in the fiscal year 2000 upon which the terminal value is based.
A terminal value multiple range of 5.0x to 7.0x was used in the DCF
analysis. The terminal value represents the value of the Faulding Subsidiaries
after the five year period used in the DCF analysis. This value is derived using
a multiple of the unlevered cash flow in the terminal year, in this case fiscal
year 2000. The range of 5.0x to 7.0x unlevered free cash flow represents Salomon
Brothers' assessment of the acquisition value of the Faulding Subsidiaries in
the terminal year, based on the operating and financial characteristics of the
Faulding Subsidiaries, as well as the historical acquisition multiples paid by
acquirors in similar acquisitions. The foregoing was based upon the historical
financial data and
17
<PAGE>
<PAGE>
projections prepared by management of Purepac and the Faulding Subsidiaries,
which indicated that the Faulding Subsidiaries would incur operating losses
through at least fiscal 1997 and would require a maximum infusion of in excess
of $20 million during such five year period to sustain operations, with the last
two years of the forecast period expected to provide significant growth in
unlevered cash flow. Accordingly, the present value of unlevered cash flows of
the Faulding Subsidiaries over the period covered by the DCF analysis is
negative, and the terminal value (based upon the fiscal year 2000 projected cash
flows) represents more than 100% of the present value of the equity determined
by the DCF analysis.
As part of the DCF analysis, Salomon Brothers used a range of discount
rates (representing the opportunity cost of capital, determined by applying the
capital asset pricing model) of 18% to 22% for FPC and FPR and 30% to 40% for
FMDC. In the DCF analysis used for the October 24, 1995 fairness opinion,
Salomon Brothers used a range of discount rates from 18% to 22% for FPR and FPC
to reflect the lower risk of the existing operations at the Aguadilla Facility
and FPC's existing sales contracts. Salomon Brothers used a higher discount rate
range of 30% to 40% for FMDC to reflect the start up nature of this business and
the typical returns required by an investor to fund such a development stage
business. This DCF analysis resulted in a present equity value reference range
of $80.0 million to $110.0 million for the Faulding Subsidiaries using the data
presented on August 9, 1995, as compared with a range of $65.0 million to $85.0
million using the data presented on October 24, 1995.
PUBLIC MARKET VALUATION ANALYSIS
Salomon Brothers was limited in performing a Public Market Valuation
analysis of the Faulding Subsidiaries as Salomon Brothers concluded that
publicly traded companies with closely comparable business, product and
financial characteristics to the Faulding Subsidiaries did not exist. Salomon
Brothers, however, considered the valuation data of eight publicly traded
pharmaceutical companies, Biocraft Laboratories, Inc. ('Biocraft'), Copley
Pharmaceutical, Gensia, Inc. ('Gensia'), Immunex Corporation, IVAX Corp., Marsam
Pharmaceuticals, R.P. Scherer and Watson Pharmaceuticals, with an emphasis being
placed on Gensia and Biocraft as they were deemed to be the most comparable from
both an operating and financial perspective to the Faulding Subsidiaries.
In particular, Salomon Brothers reviewed certain publicly available
financial data of these companies including: latest twelve months ('LTM')
revenues, earnings before depreciation, interest, amortization and taxes
('EBDIAT'), earnings before interest and taxes ('EBIT') and net income; certain
latest quarter balance sheet data including equity market capitalization plus
total debt, preferred stock and minority interests less cash (collectively,
'Firm Value'); analysis of certain indicative ratios including EBDIAT to
revenues, EBIT to revenues, net income to revenues, total debt to book value
capitalization and total debt to market capitalization; analysis of growth over
the past three years of revenue, EBDIAT, EBIT and net income; the ratio of
current stock prices to LTM earnings per share, current fiscal year estimated
earnings per share (as estimated by IBES) and next fiscal year estimated
earnings per share (as estimated by the Institutional Brokers Estimate System
('IBES')); and the ratio of Firm Value to LTM sales, EBDIAT and EBIT. Because
the Faulding Subsidiaries currently lack earnings and cash flow, Salomon
Brothers assigned greater relevance to the respective ratios of Firm Value to
LTM sales in such review.
Due to the lack of current earnings and cash flow of the Faulding
Subsidiaries, Salomon Brothers focused its analysis on the Firm Value/sales
multiple of Gensia, Biocraft and the other comparable companies. Salomon
Brothers applied a Firm Value/sales multiple range of 1.0x to 1.5x, as the high
end of this range is approximately the low end of the publicly-held comparable
company range (1.4x to 6.6x). This low multiple range (as compared to the
comparable companies) was used to reflect the start-up nature of the Faulding
Subsidiaries, in contrast to the ongoing operations of the publicly-traded
comparable companies.
The nominal fiscal 1995 revenues of the Faulding Subsidiaries and the lack
of current earnings pose a potential barrier to deriving a meaningful valuation
under this methodology. Given the existing operations at FPR and the existing
contracts for the sale of products manufactured by FPR, and the start-up nature
of the other Faulding Subsidiaries, Salomon Brothers has used fiscal year 1996
sales for the Faulding Subsidiaries as a more appropriate basis to derive the
equity valuation range.
18
<PAGE>
<PAGE>
This analysis resulted in an equity value reference range for the Faulding
Subsidiaries of $15.0 million to $25.0 million using the data analyzed both on
August 9, 1995 and on October 24, 1995.
Salomon Brothers believes that the Public Market Valuation analysis has
limited applicability to the valuation of the Faulding Subsidiaries given the
inherent constraints arising from the lack of current earnings of the Faulding
Subsidiaries and the lack of pure play comparable businesses, in terms of
operating and financial comparability, to the Faulding Subsidiaries.
PRECEDENT MERGER AND ACQUISITION TRANSACTIONS ANALYSIS
Salomon Brothers also was limited in its ability to perform a Precedent
Merger and Acquisition Transaction analysis of the Faulding Subsidiaries due to
the lack of transactions for which valuation data is publicly available
involving companies which are closely comparable to the Faulding Subsidiaries on
an operating, product and financial basis.
In performing the Precedent Merger and Acquisition Transaction analysis,
Salomon Brothers analyzed fifteen precedent transactions. With respect to
targets comparable to FPR and FPC, such transactions were Schein
Pharmaceuticals/Marsam Pharmaceuticals (1995); Watson Pharmaceuticals Inc./Circa
Pharmaceuticals Inc. (1995); West Co. Inc./Paco Pharmaceutical (1995); NeXagen
Inc./Vestar Inc. (1994); IVAX Corp./Zenith Laboratories (1994); IVAX
Corp./McGraw Inc. (1994); International Basic Resources/In Vitro Diagnostics
Inc. (1993); Bradley Pharmaceuticals Inc./Doak Pharmacal Inc. (1993). With
respect to targets comparable to FMDC, such transactions were Johnson &
Johnson/Mitek Surgical Products (1995); Pfizer Inc./NAMIC U.S.A. (1994);
Retirement Care Associates/Contour Medical Inc. (1994); Tyco International
Ltd./Kendall International, Inc. (1994); Baxter International Inc./Intramed
Laboratories Inc. (1994); Enviromed/Medical Safe TEC Inc. (1993); and Scherer
Healthcare Inc./Marquest Medical (1993) with an emphasis being placed on the
IVAX/McGraw and Schein/Marsam transactions. Salomon Brothers has used the firm
value/sales multiple of the IVAX Corp. acquisition of McGraw Inc. as the most
relevant valuation benchmark. Salomon Brothers also considered Schein
Pharmaceuticals' acquisition of Marsam Pharmaceutical a relevant transaction
from an operating perspective, but significantly less relevant from a financial
perspective, to the Faulding Subsidiaries.
The analysis considered the multiples of Firm Value to EBIT, EBDIAT and
sales; and the multiple of offer price to the target's LTM net income. As in the
case of the Public Market Valuation analysis, the nominal fiscal 1995 revenues
and the lack of current earnings pose a potential barrier to deriving a
meaningful valuation. Given the existing operations at FPR and the existing
contracts for the sale of products manufactured by FPR, and the start-up nature
of the other Faulding businesses, Salomon Brothers has used fiscal year 1996
sales for the Faulding Subsidiaries as a more appropriate basis to derive the
equity valuation range.
This analysis resulted in an equity value reference range for the Faulding
Subsidiaries of $30.0 million to $40.0 million using the data analyzed on August
9, 1995 and a range of $25.0 million to $35.0 million using the data analyzed on
October 24, 1995.
As was the case with the Public Market Valuation analysis, Salomon Brothers
believes that the Precedent Merger and Acquisition Transactions Analysis also
has limited applicability to the valuation of the Faulding Subsidiaries given
the inherent constraints arising from the lack of current earnings of the
Faulding Subsidiaries and the lack of pure play comparable businesses, in terms
of operating and financial comparability, to the Faulding Subsidiaries.
CONVERTIBLE PREFERRED STOCK VALUATION
Using the Black-Scholes model for option pricing, and assuming that the
convertible preferred stock to be issued by Purepac pursuant to the Preferred
Stock Purchase will bear cumulative dividends at a rate of 4.5% of stated value
and will be convertible into shares of Purepac Common Stock at a conversion rate
representing a premium of 8% to the last sale price of Purepac's Common Stock as
of August 9, 1995 (the date of the Letter of Intent for the transaction and the
date of Salomon Brothers' original opinion) and will not have call protection
greater than three years, Salomon Brothers estimated the theoretical value of
such convertible preferred stock. As of August 9, 1995, this analysis resulted
in a
19
<PAGE>
<PAGE>
theoretical value of 109.1% of stated value for the convertible preferred stock,
and, assuming issuance to Faulding at stated value, a theoretical discount of
8.34%. Salomon Brothers reviewed the terms of recent actual public offerings of
convertible debt and equity securities by issuers exhibiting comparable
financial characteristics to Purepac (based upon the rating of such issuer's
debt and equity securities, the nature of its business or the relatively low
conversion premium on the convertible instrument issued). Specifically, Salomon
Brothers reviewed issuances by the following companies: Altera Corp., Alaska Air
Group, Scandinavian Broadcasting, Beazer Homes USA, ICN Pharmaceuticals, AMC
Entertainment, Beverley Enterprises and Delta Air Lines. This analysis resulted
in a theoretical public transaction discount reference range of 3.6% to 11.8%,
with a median theoretical public transaction discount of 8.1%.
Salomon Brothers' preferred stock valuation is based on the value of
publicly-issued convertible securities of companies with comparable capital
structures, offering terms and industry orientation, which did not involve any
affiliated parties. In contrast to the convertible securities used as benchmarks
for valuation, it is noted that the Class B Preferred Stock to be issued by
Purepac in connection with the proposed Faulding Transaction will be privately
negotiated and therefore will neither be publicly listed nor traded on any
exchange.
GENERAL
No company or transaction used in the Public Market Valuation analysis or
the Precedent Merger and Acquisition Transaction analysis summarized above is
identical to Purepac, the Faulding Subsidiaries or the Faulding Transaction
itself. No company or convertible security used in the Convertible Preferred
Stock Valuation analysis summarized above is identical to Purepac or the Class B
Preferred Stock to be issued by Purepac pursuant to the Preferred Stock Purchase
Agreement. The preparation of financial analyses and fairness opinions is a
complex process and is not necessarily susceptible to partial analysis or
summary description. Salomon Brothers believes that its analysis (and the
summary set forth above) must be considered as a whole, and that selecting
portions of such analyses and of the factors considered by Salomon Brothers,
without considering all such analysis and factors, could create an incomplete
view of the processes underlying the analyses conducted by Salomon Brothers and
its opinion. In performing its analyses, Salomon Brothers made numerous
assumptions with respect to industry performance, general business, financial,
market and economic conditions and other matters, many of which are beyond the
control of Purepac or the Faulding Subsidiaries. Any estimates contained in
Salomon Brothers' analysis are not necessarily indicative of actual values or
actual future results, which may be significantly more or less favorable than as
set forth therein. Estimates of values of companies or securities do not purport
to be appraisals or necessarily reflect the prices at which companies may
actually be sold or the prices at which securities may trade at the present time
or any time in the future. Because such estimates are inherently subject to
uncertainty, Salomon Brothers does not assume responsibility for their accuracy.
Salomon Brothers is an internationally recognized investment banking firm
engaged in, among other things, the valuation of businesses and their securities
in connection with mergers and acquisition, restructurings, leveraged buyouts,
negotiated underwritings, competitive biddings, secondary distributions of
listed and unlisted securities, private placements and valuations for estate,
corporate and other purposes. The Purepac Board retained Salomon Brothers based
on Salomon Brothers' expertise in the valuation of companies as well as its
familiarity with Purepac's and the Faulding Subsidiaries' industries.
Pursuant to an engagement letter dated July 31, 1995, Purepac has agreed to
pay Salomon Brothers a fee of $500,000, $100,000 of which was payable upon
execution of the engagement letter, and $400,000 of which is payable upon the
closing of the Faulding Transaction. Purepac also has agreed to reimburse
Salomon Brothers for certain expenses incurred in connection with its engagement
and to indemnify Salomon Brothers and certain related persons against certain
liabilities and expenses relating to or arising out of its engagement, including
certain liabilities under the federal securities laws.
Salomon Brothers has advised Purepac that, in the ordinary course of its
business, Salomon Brothers may actively trade the securities of Purepac and F.H.
Faulding for its own account and for the accounts of customers and, accordingly,
may at any time hold a long or short position in such securities.
20
<PAGE>
<PAGE>
RELATIONSHIPS BETWEEN PUREPAC AND FAULDING; POTENTIAL CONFLICTS OF INTEREST
The Chairman of the Purepac Board, Dr. Edward D. Tweddell, is the Group
Managing Director and Chief Executive Officer of F.H. Faulding, as well as a
director of Faulding, a director of each of the Faulding Subsidiaries and a
director of Faulding Services. Alan G. McGregor, the Chairman of the Board of
F.H. Faulding, serves as a member of the Purepac Board. Michael R.D. Ashton, a
current member of the Purepac Board, is a director and officer of each of the
Faulding Subsidiaries, Faulding and Faulding Services. William R. Griffith, the
Secretary of Purepac, is a director and officer of each of the Faulding
Subsidiaries, Faulding and Faulding Services. In addition, Lee Craker, Purepac's
Chief Financial Officer, and Garth Boehm, Purepac's Vice President -- Quality
Assurance and Quality Control, have each previously held management positions
with affiliates of F.H. Faulding. These interlocking offices and relationships
may be viewed as giving rise to potential conflicts of interest.
Faulding holds 6,839,980 shares of Purepac Common Stock, representing 54.4%
of the currently outstanding Purepac Common Stock. Faulding also holds 834,188
shares of Purepac's Class A Preferred Stock, being all of the currently
outstanding shares of such series, convertible into shares of Purepac Common
Stock at a rate of six shares of Common Stock for each share of Class A
Preferred Stock or an aggregate of 5,005,128 shares of Common Stock if fully
converted, representing, together with Faulding's current ownership of Purepac
Common Stock, a 67.4% equity interest in Purepac. Accordingly, Faulding has, and
will continue to have, the ability to elect all of the members of the Purepac
Board and to control Purepac's management and operations.
Faulding's parent, F.H. Faulding, is a party to several supply, licensing
and research and development agreements with Purepac. In addition, Faulding
Services has entered into agreements with Purepac which require Purepac to act
as a contract manufacturer for, and to provide Faulding Services with certain
technical, distribution and warehousing services with respect to a
pharmaceutical product for which Faulding Services acts as licensee of F.H.
Faulding. Purepac is also party to an agreement with FPC which requires Purepac
to provide certain warehousing, distribution and record keeping services to FPC.
In view of the relationships among Purepac, Faulding, F.H. Faulding and
their respective affiliates, summarized above, the terms of the Faulding
Transaction may be viewed as having been negotiated on a non-arms-length basis.
During the negotiation and execution of the Letter of Intent, Faulding was
represented by F.H. Faulding's in-house legal counsel. After execution of the
Letter of Intent, Faulding retained the law firm of Reid & Priest LLP to act as
its counsel. Purepac's counsel, Parker Duryee, represented Faulding in
connection with its acquisition of the Aguadilla Facility and currently
represents Purepac and the Purepac Board in connection with the Faulding
Transaction. Such firm also currently represents, and in the past has
represented F.H. Faulding and its affiliates, including Faulding, with respect
to certain matters in the United States. William R. Griffith, who, as noted
above, is Secretary of Purepac and a director and officer of each of the
Faulding Subsidiaries, Faulding Services and Faulding, is a member of Parker
Duryee. Such representation may be viewed as giving rise to potential conflicts
of interest.
STOCK PURCHASE AGREEMENT
The following is a summary of all material terms of the Stock Purchase
Agreement. This summary is qualified in its entirety by reference to the Stock
Purchase Agreement, which is attached to this Proxy Statement as Exhibit A and
is incorporated herein by reference.
General. The Stock Purchase Agreement provides that at the Closing, Purepac
will acquire all of the outstanding capital stock of FPR, FPC and FMDC from
Faulding, in exchange for 2,253,521 shares of Purepac Acquisition Stock, which
amount is subject to adjustment based upon changes in the Net Asset Value of the
Faulding Subsidiaries from June 30, 1995 through the Closing Date.
Conversion of Indebtedness. Faulding has agreed to contribute, on or prior
to the Closing Date, all indebtedness of the Faulding Subsidiaries to Faulding
as at the Closing Date to the capital of the Faulding Subsidiaries.
21
<PAGE>
<PAGE>
Representations and Warranties. The Stock Purchase Agreement contains
various representations and warranties of Faulding and Purepac relating to,
among other things: (i) each of the Faulding Subsidiaries' and Purepac's
organization and similar corporate matters, (ii) each of the Faulding
Subsidiaries' and Purepac's capital structure, (iii) the authorization,
execution, delivery, performance and enforceability of the Stock Purchase
Agreement and related documentation, (iv) their respective financial statements
and contractual obligations, and (v) the absence of any governmental or
regulatory authorization, consent or approval to consummate the Acquisition
Transaction (other than those specified in the Stock Purchase Agreement as
conditions to closing). The agreement also contains specific representations and
warranties of Faulding as to the business operations of the Faulding
Subsidiaries, and of Purepac as to the documents and reports filed by Purepac
with the Securities and Exchange Commission (the 'Commission') under the
Securities Act of 1934, as amended (the 'Exchange Act'), and the accuracy of the
information contained therein.
Certain Covenants. Pursuant to the Stock Purchase Agreement, Faulding has
agreed that, during the period from the date of the Stock Purchase Agreement
until the Closing, except as permitted by the Stock Purchase Agreement or
consented to in writing by Purepac, (i) the Faulding Subsidiaries will each
conduct its business in the ordinary and usual course and consistent with past
practice, (ii) Faulding will not cause any of the Faulding Subsidiaries to fail
to use reasonable efforts consistent with past practices to preserve the
business and organization of the Faulding Subsidiaries including the failure to
(a) keep available the services of the present employees and agents of the
Faulding Subsidiaries; (b) complete or maintain all contracts in full force and
effect in accordance with their existing terms, (c) maintain the integrity of
all confidential information of the Faulding Subsidiaries, (d) maintain in full
force and effect existing or comparable insurance policies, and (e) preserve the
goodwill of, and the Faulding Subsidiaries' business and contractual
relationship with, suppliers, customers and others having business relations
with the Faulding Subsidiaries, (iii) Faulding will not cause any of the
Faulding Subsidiaries to sell or transfer any of its material assets or property
except in the usual and ordinary course of business or make any distribution,
whether by dividend or otherwise, to any of its stockholders or employees except
for compensation to employees in the usual and ordinary course of business and
(iv) Faulding will not cause any of the Faulding Subsidiaries to (a) declare any
dividend or distribution, redeem or otherwise acquire any shares of its capital
stock or other securities, (b) issue any shares of its capital stock or other
securities, or (c) make capital expenditures in excess of $100,000 without
Purepac's consent, or agree to do any of the foregoing.
Indemnification. The Stock Purchase Agreement provides that, for a period
of two years after the Closing (or, in the case of liability for taxes, until
the later of the expiration of the applicable statutes of limitation or 60 days
after a final determination of any tax liability), Faulding will indemnify
Purepac, and Purepac will indemnify Faulding, as the case may be, and their
respective officers, directors and agents, and hold it, or each of them,
harmless against all Losses (as defined in the Stock Purchase Agreement) arising
out of or relating to the breach of any representation or warranty of such
indemnifying party contained in the Stock Purchase Agreement or in any
certificate delivered by it pursuant to the Stock Purchase Agreement, once such
Losses exceed $200,000 in the aggregate, but only for such Losses in excess of
$200,000.
Conditions to Consummation of Acquisition Transaction. No Federal or state
regulatory approvals are required to be obtained or regulatory requirements
complied with (other than as relate to the solicitation of proxies pursuant to
this Proxy Statement) in connection with the Acquisition Transaction. The
respective obligations of Purepac and of Faulding to effect the Acquisition
Transaction are subject to satisfaction or waiver of a number of conditions,
including among others: (i) the Stock Purchase Agreement and the transactions
contemplated thereby (including the Acquisition Transaction) shall have been
approved and ratified by at least a majority of the shares of Common Stock voted
with respect to such proposals at the Annual Meeting by the Purepac Stockholders
other than Faulding, and (ii) no preliminary or permanent injunction or other
order shall have been issued and in effect by any court or by any governmental
or regulatory agency, body or authority which prohibits the consummation of the
transactions contemplated by the Stock Purchase Agreement and the Preferred
Stock Purchase Agreement.
22
<PAGE>
<PAGE>
In addition to the conditions set forth above, the obligations of Faulding
to effect the Acquisition Transaction are subject to the following conditions:
(i) Purepac shall have performed and complied in all material respects with all
agreements and conditions contained in the Stock Purchase Agreement to be
complied with by Purepac and all representations and warranties of Purepac
contained in the Stock Purchase Agreement shall be true and correct in all
material respects on and as of the date made and the Closing Date; (ii) Faulding
shall have converted all of the indebtedness of the Faulding Subsidiaries owing
to Faulding into equity in the Faulding Subsidiaries and (iii) the absence of
material adverse changes or events or circumstances which would result in
material adverse changes in the financial position, results of operations,
assets, liabilities or prospects of Purepac.
In addition to the conditions set forth in the first paragraph of this
subsection, the obligations of Purepac to effect the Acquisition Transaction are
subject to the following conditions: (i) Faulding shall have performed and
complied in all material respects with all agreements and conditions contained
in the Stock Purchase Agreement to be complied with by Faulding and all
representations and warranties of Faulding contained in the Stock Purchase
Agreement shall be true and correct in all material respects on and as of the
date made and the Closing Date; (ii) the absence of material adverse changes or
events or circumstances which would result in material adverse changes in the
financial position, results of operations, assets, liabilities or prospects of
the Faulding Subsidiaries, and (iii) the Net Asset Value of the Faulding
Subsidiaries as of the Closing Date shall be no less than $17,000,000.
Termination. The Stock Purchase Agreement may be terminated prior to the
Closing Date: (i) at any time by mutual consent of Purepac and Faulding, (ii) by
either Purepac or Faulding after April 30, 1996, if the Acquisition Transaction
shall not have been consummated on or before such date, or (iii) by either
Purepac or Faulding following the insolvency or bankruptcy of the other or if
any condition to the obligations of such other party under the Stock Purchase
Agreement shall become incapable of fulfillment on or prior to April 30, 1996
and shall not have been waived by the party for whose benefit the condition was
established. No termination fee is payable in the event of termination pursuant
to the foregoing provisions. However, if the Stock Purchase Agreement and the
Preferred Stock Purchase Agreement are terminated as a result of the failure of
the Purepac Stockholders to approve the Faulding Transaction, Faulding will
reimburse Purepac for one-half of Purepac's expenses incurred in connection with
the Faulding Transaction.
In the event of termination of the Stock Purchase Agreement by either
Purepac or Faulding as provided above, there will be no further obligation on
the part of any of the parties to the Stock Purchase Agreement to any other
party unless such termination arises from a willful breach of the Stock Purchase
Agreement or liability to any other party incurred before the date of such
termination.
Amendment and Waiver. At any time prior to the Closing, the party for whose
benefit the condition was established may (i) extend the time for the
performance of any of the obligations or other acts to be performed by any other
party pursuant to the Stock Purchase Agreement; (ii) waive any inaccuracies in
the representations and warranties by the other party contained in the Stock
Purchase Agreement or in any other document delivered pursuant to the Stock
Purchase Agreement; and (iii) waive compliance with any of the agreements of any
other party or conditions precedent to the parties' respective obligations
contained in the Stock Purchase Agreement. The Stock Purchase Agreement may be
amended, or compliance with certain provisions thereof may be waived, at any
time before or after its approval by the Purepac stockholders by the written
agreement of Faulding and Purepac. Purepac will not agree to any such amendment
or waiver undertaken after such approval is obtained, except to the extent that
such amendment or waiver affects non-material provisions of such agreement.
Neither Purepac nor Faulding has any current intention of amending or waiving
any provision of such agreement.
23
<PAGE>
<PAGE>
PREFERRED STOCK PURCHASE AGREEMENT
The Preferred Stock Purchase Agreement, which is attached to this Proxy
Statement as Exhibit B and incorporated herein by reference, contains
representations and warranties of each party thereto as to the authorization,
execution, delivery and enforceability of the Preferred Stock Purchase
Agreement, and representations and warranties of Purepac as to the validity, due
issuance and fully paid and non-assessable nature of the Class B Preferred Stock
and as to the accuracy of period reports filed by Purepac with the Commission
under the Exchange Act. The Preferred Stock Purchase Agreement also contains
indemnification and termination provisions and conditions to closing
substantially similar to those contained in the Stock Purchase Agreement.
CERTAIN TAX CONSEQUENCES OF THE FAULDING TRANSACTION
No gain or loss will be recognized by either Purepac or the Purepac
Stockholders as a result of the Faulding Transaction. EACH PUREPAC STOCKHOLDER
SHOULD CONSULT HIS OR HER TAX ADVISOR AS TO THE SPECIFIC TAX CONSEQUENCES OF THE
ACQUISITION TRANSACTION TO HIM OR HER, INCLUDING THE APPLICATION AND EFFECT OF
FEDERAL, STATE, LOCAL AND OTHER TAX LAWS AND THE POSSIBLE EFFECTS OF CHANGES IN
FEDERAL LAW OR OTHER TAX LAWS.
ABSENCE OF REGULATORY FILINGS AND APPROVALS
The Faulding Transaction is not subject to obtaining any regulatory
approvals or complying with any regulatory filing requirements.
ABSENCE OF APPRAISAL RIGHTS
Holders of Purepac Common Stock will not be entitled to appraisal rights
under applicable Delaware law in connection with the Faulding Transaction.
ACCOUNTING TREATMENT
Faulding, by virtue of its majority equity interest in Purepac, will
continue to indirectly control each of FMDC, FPR and FPC following consummation
of the Faulding Transaction. Accordingly the Acquisition Transaction will be
viewed for accounting purposes as a reorganization of Faulding's interests in
the United States. Consequently, for accounting and financial reporting
purposes, the Acquisition Transaction will be accounted for at historical cost
in a manner similar to a 'pooling of interests.'
EXPENSES
Expenses incurred in connection with the proposed Faulding Transaction,
currently estimated to aggregate approximately $950,000, will be treated as
operating expenses incurred by Purepac during its fiscal year ended June 30,
1996. A substantial portion of such expenses will be so incurred whether or not
the Faulding Transaction is consummated. If the Stock Purchase Agreement and the
Preferred Stock Purchase Agreement are terminated as a result of the failure of
the Purepac Stockholders to approve the Faulding Transaction, Faulding will
reimburse Purepac for one-half of Purepac's expenses incurred in connection with
the Faulding Transaction.
24
<PAGE>
<PAGE>
SELECTED HISTORICAL FINANCIAL DATA OF THE FAULDING SUBSIDIARIES
The selected financial data set forth below has been derived from, and
should be read in conjunction with, the respective Financial Statements of FMDC,
FPR and FPC and related Notes thereto appearing elsewhere in this Proxy
Statement and should be read in conjunction with Management's Discussion and
Analysis of Financial Condition and Results of Operations of the Faulding
Subsidiaries contained herein.
FMDC
<TABLE>
<CAPTION>
THREE MONTHS
ENDED
SEPTEMBER 30, YEAR ENDED JUNE 30,
------------- -------------------------------------------------------------
1995 1994 1995 1994 1993 1992 1991
----- ---- ------ ------ ----------- ----------- -----------
(UNAUDITED) (UNAUDITED) (UNAUDITED) (UNAUDITED)
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C> <C>
Statement of Operations Data:
Net Sales...................... $ 338 $681 $2,455 $1,947 $ 1,183 $ 701 $ 75
Net income (loss).............. (214) 8 (336) (305) (222) (675) (355)
</TABLE>
<TABLE>
<CAPTION>
THREE MONTHS
ENDED YEAR ENDED JUNE 30,
SEPTEMBER 30, ---------------------------------------------------------------
1995 1995 1994 1993 1992 1991
------------- ----- ------ ----- ----- -----
(UNAUDITED) (UNAUDITED) (UNAUDITED)
(UNAUDITED) (IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C>
alance Sheet Data:
Working capital, net of
intercompany balances....... $ 325 $ 423 $ 629 $ 308 $ 399 $ 256
Total assets.................. 2,712 2,848 2,936 2,754 2,969 2,385
Net intercompany balances
payable..................... 4,997 4,929 4,735 4,238 4,212 2,971
Stockholders' (deficiency).... (2,365) (2,151) (1,814) (1,509) (1,287) (612)
</TABLE>
FPR
<TABLE>
<CAPTION>
THREE MONTHS APRIL 7
ENDED (INCEPTION) JANUARY 1 YEAR ENDED DECEMBER 31,
SEPTEMBER 30, TO JUNE 30, TO APRIL 6, -----------------------------------------------
1995 1995 1995(A) 1994(a) 1993(a) 1992(a) 1991(a)
------------- ----------- ----------- ------ -------- ----------- -----------
(UNAUDITED) (UNAUDITED (UNAUDITED)
(UNAUDITED) (IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C> <C>
Statement of Operations
Data:
Net Sales to
unaffiliated
parties(b)...... $ 530 $ 789 $ 717 $1,490 $ 1,840 $-- $--
Net (loss)........ (912) (182) N/A N/A N/A N/A N/A
Costs attributable
to owners'
interest(c)..... N/A N/A 2,804 9,826 14,563 11,070 10,241
</TABLE>
25
<PAGE>
<PAGE>
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
SEPTEMBER 30, JUNE 30, APRIL 6, ---------------------------------------------
1995 1995 1995(a) 1994(a) 1993(a) 1992(a) 1991(a)
------------- ----------- ---------- ------- ------- ------- -------
(UNAUDITED) (UNAUDITED)
(IN THOUSANDS) (UNAUDITED (UNAUDITED)
<S> <C> <C> <C> <C> <C> <C> <C>
Balance Sheet Data:
Working capital, net of
intercompany
balances.............. $ 4,208 $ 3,054 $ 92 $ 393 $13,929 $ 2,741 $ 4,665
Total assets............ 17,508 16,158 12,498 12,715 25,348 12,656 19,107
Net intercompany
balances payable...... 14,663 15,156 N/A N/A N/A N/A N/A
Stockholders'
(deficiency).......... (1,094) (182) N/A N/A N/A N/A N/A
Joint Venture
equity(d)............. N/A N/A 9,538 10,090 23,817 11,013 17,926
</TABLE>
- ------------
(a) Represents operating data of the Aguadilla Facility while under the
ownership of DuPont Merck Pharma or its predecessor.
(b) Excludes intercompany sales to affiliates of FPR or of DuPont Merck Pharma.
(c) Based upon the cost of product supplied from the Aguadilla Facility to
DuPont Merck Pharma's affiliates, net of any income or loss from net sales
to third parties and administrative costs.
(d) Represents net investment in the Aguadilla Facility.
N/A means not applicable
FPC
<TABLE>
<CAPTION>
APRIL 7, 1995
(INCEPTION)
THREE MONTHS ENDED THROUGH JUNE
SEPTEMBER 30, 1995 30, 1995
------------------ ------------
(UNAUDITED)
(IN THOUSANDS)
<S> <C> <C>
Statement of Operations Data:
Net Sales................................................................ $ 538 $ 516
Net (loss)............................................................... (648) (253)
</TABLE>
<TABLE>
<CAPTION>
SEPTEMBER 30, 1995 JUNE 30, 1995
------------------ -------------
(UNAUDITED)
(IN THOUSANDS)
<S> <C> <C>
Balance Sheet Data:
Working capital, net of intercompany balances............................ $ (463) $1,243
Total assets............................................................. 2,482 1,456
Net intercompany balances payable........................................ 3,179 1,549
Stockholders' (deficiency)............................................... (901) (253)
</TABLE>
26
<PAGE>
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS -- FAULDING SUBSIDIARIES
OVERVIEW
FMDC has been primarily engaged in research and development activities
since its inception in 1989 and has experienced operating losses since
inception. FMDC's primary source of revenue, a distribution agreement with
Steris, terminated in the quarter ending December 31, 1995, at which time FPC
succeeded to the license for the products previously marketed thereunder.
FPR was organized to acquire the Aguadilla Facility from DuPont Merck.
Based on actual operating results of FPR for the period from April 7, 1995
through September 30, 1995, and Purepac's interpretation of financial
information of the Aguadilla Facility while under ownership and management of
DuPont Merck, the Aguadilla Facility has, over the last several years, been
running at a net loss, principally due to under-utilization of production
capacity, with production costs consistently exceeding revenue.
FPC is a recently organized company which commenced operations in April
1995. FPC was formed to commence a sales and marketing operation for the
products manufactured by FPR and for certain other products manufactured by F.H.
Faulding, including those previously marketed through FMDC. FPC has experienced
net operating losses from operations since its inception.
Because of the current stages of development of the various Faulding
Subsidiaries, Purepac does not believe that the historical results of operations
of such companies provide a meaningful basis for the evaluation of the future
prospects of the Faulding Subsidiaries. While it is expected that the Faulding
Subsidiaries will continue to generate operating losses through at least the
fiscal year ended June 30, 1997, the results of operations for the quarter ended
September 30, 1995 are not expected to be indicative of anticipated operating
results for the balance of the current fiscal year, as the first quarter results
of FPC do not reflect anticipated revenues, commencing in the second quarter, of
additional sales of products formerly sold by FMDC through Steris nor those
attributable to anticipated sales of additional products produced by F.H.
Faulding in Australia.
Purepac's management anticipates that FPR and FPC, which collectively will
constitute the generic injectable business of the Faulding Subsidiaries, will
incur pre-tax net operating losses of approximately $2.5 to $3.0 million and
approximately $1.0 to $1.5 million for the fiscal years ending June 30, 1996 and
June 30, 1997, on estimated revenues of approximately $15 million and $26
million, respectively.
Purepac's management further anticipates that the Faulding Subsidiaries'
medical device business, conducted by FMDC, will not have any operating revenues
for the fiscal year ending June 30, 1996 and is estimated to incur pre-tax net
operating losses of approximately $1.6 million for such fiscal year. For the
fiscal year ending June 30, 1997, Purepac management anticipates that FMDC will
incur pre-tax net operating losses of approximately $1.1 million upon revenues
of approximately $2.3 million.
The foregoing projected operating results are premised upon the ability of
the Faulding Subsidiaries to develop new products during the two fiscal years
ending June 30, 1997 without undue cost or delay and, of greater import, upon
the Faulding Subsidiaries' receipt of FDA approvals, thereby permitting such new
products to be commercially marketed. As noted elsewhere herein, the receipt and
timing of such regulatory approvals cannot be predicted with any degree of
certainty. Any projection of operating results beyond the fiscal year ending
June 30, 1997 is, at best, conjectural in view of the uncertainty of regulatory
approval and the inability to predict then competitive market conditions. In any
event, Purepac's management does not anticipate that the Faulding Subsidiaries
will achieve profitable operations prior to June 30, 1998, at the earliest.
OPERATIONS OF FMDC
FMDC was organized by F.H. Faulding in 1989 for the purpose of seeking to
develop certain SGV related medical devices for use in conjunction with
injectable pharmaceutical products. FMDC has developed three such drug-dependent
products, none of which is available as yet for commercialization in the United
States. FMDC has received minimal revenues to date from the sale by affiliates
of
27
<PAGE>
<PAGE>
Faulding of products incorporating such drug-dependent devices in Canada and
Portugal. Research for other non-drug-dependent devices, still in the
development stage, is continuing. In the last two fiscal years, FMDC has
expended approximately $1,200,000 in research and development for such devices,
funded entirely by advances from Faulding. Research and development expenses
increased from $504,000 in the fiscal year ended June 30, 1994 to $696,000 in
the fiscal year ended June 30, 1995, and from $124,000 for the quarter ended
September 30, 1994 to $230,000 for the quarter ended September 30, 1995, in each
case as a result of increased personnel costs associated with such activities.
FMDC's net loss increased to $336,000 for the fiscal year ended June 30, 1995
from $306,000 for the fiscal year ended June 30, 1994, and to $214,000 for the
quarter ended September 30, 1995 from net income of $8,000 for the quarter ended
September 30, 1994 primarily as a result of such increased research and
development costs, and to a lesser extent as a result of lower gross margins
resulting from lower sales volumes. To date, research and development efforts by
FMDC have no direct relationship with FMDC's sources of revenue.
Until recently, FMDC received revenues from the sale by Steris of certain
injectable products licensed to FMDC by F.H. Faulding. Revenues from the sales
of such products increased to $2,455,000 during the fiscal year ended June 30,
1995, as compared with $1,947,000 for the prior fiscal year, as a result of
increased unit sales by Steris. Sales for the quarter ended September 30, 1995
were $338,000 as compared to $681,000 in the quarter ended September 30, 1994.
The decrease was attributable to an increase in chargeback allowances allocated
to these products during such quarter and as a result of an inability to satisfy
demand due to a shortage in raw materials. Faulding terminated both the Steris
agreement and FMDC's license for the products marketed thereunder as of December
31, 1995, thereby eliminating FMDC's primary source of operating revenue.
Contemporaneously therewith, F. H. Faulding granted a license for the rights to
such products in the United States to FPC, its newly organized United States
marketing arm. Consequently, the income stream from the sale of such products
will remain with the Faulding Subsidiaries. However, FMDC does not have any
other products currently available for sale. Therefore, FMDC will have no source
of revenue, other than minimal revenues resulting from sales of its drug
dependent devices to F.H. Faulding for markets outside of the United States
until such time as one or more of its products under development is
commercialized in the United States.
OPERATIONS OF FPR
FPR acquired the Aguadilla Facility, along with associated assets and
liabilities, from DuPont Merck on April 7, 1995 for approximately $13.0 million.
The Aguadilla Facility currently has under-utilized manufacturing capacity.
Because the majority of the products manufactured at the Aguadilla Facility
are offered for sale through FPC, with FPR conducting no marketing or sales
efforts of its own, FPR is not operated as a stand-alone business. Products
manufactured at the Aguadilla Facility are transferred to FPC, and FPR
recognizes revenues based upon the transfer prices (at present, essentially
costs of production plus a portion of general overhead expenses) for products.
Sales for the period April 7, 1995 (inception) through September 30, 1995,
including intercompany sales to FPC, totaled $3,913,478, of which $2,594,218
represents sales to FPC. The balance represents sales under manufacturing
agreements with two unaffiliated third parties, respectively, Ohmeda and DuPont
Merck.
At April 7, 1995, FPC had no opening inventory. Consequently, during the
period from April 7, 1995 to September 30, 1995, FPR undertook a major
manufacturing effort to supply finished goods inventory for FPC which, to a
degree, artificially inflated production volume throughout that period.
Consequently, both operating expenses and associated overhead recoveries for the
Aguadilla Facility are not necessarily representative of FPR's on-going
business.
OPERATIONS OF FPC
As FPC is principally a marketing organization, it is not expected that
significant investment in facilities will be required. However, as FPC's product
range is expanded, additional working capital will
28
<PAGE>
<PAGE>
be required to ensure adequate supply of inventory. Consequently, FPC's working
capital needs is expected to correlate with resultant income streams linked to
FDA approvals.
To date, substantially all products marketed and sold by FPC have been
manufactured by FPR and transferred to FPC. In the second quarter of fiscal
1996, FPC commenced marketing its first product under a license from F.H.
Faulding which manufactures such product in Australia. After December 31, 1995,
FPC will commence marketing the products previously marketed by Steris pursuant
to its agreement with FMDC.
Net sales for the period April 7, 1995 (inception) through September 30,
1995 were $1,054,000. However, as a result of FPC being a newly organized sales
and marketing operation, actual sales did not commence until late in May 1995,
once inventory had been produced by FPR for sale by FPC. Consequently, these
revenues represent less than five months of actual sales. However, included in
such revenues were certain significant initial orders placed by pharmaceutical
wholesalers, which are not expected to be repeated on a regular basis.
Accordingly, the level of net sales for the period of April 7, 1995 through
September 30, 1995, cannot be viewed as indicative of future revenues.
Similarly, the chargeback allowance level at June 30, 1995 of $561,448 was
unusually low as a result of the limited sales efforts to such date. Typically,
it is several months before chargeback claims of wholesalers are received. The
chargeback allowance level at September 30, 1995 therefore reflects an increase
to $941,720.
Operating expenses for the period, April 7, 1995 to September 30, 1995
totaled $1,056,244, or 100.3% of net sales. Because, as noted above, sales were
generated during only a portion of the period, while operating expenses,
including certain non-recurring expenses associated with the establishment of a
sales and marketing force, were incurred throughout the entire period, the level
of operating expenses as a percentage of sales for such period is not
necessarily indicative of future levels.
LIQUIDITY AND CAPITAL RESOURCES
Funding for FMDC's operations has historically been provided by revenues
generated through the agreement with Steris, with any shortfall in funding
requirements having been met through intercompany loans from Faulding. As a
result of the termination of the agreement with Steris, and the transfer of the
licenses to the products sold thereunder to FPC, FMDC will not have any
significant revenues from operations after December 31, 1995 to fund its
development costs. No provision has been made or is anticipated which would
result in FMDC receiving any funds from FPC to finance FMDC's operations. Total
intercompany loans and advances to FMDC from Faulding as of September 30, 1995
were $4,996,616.
Funding requirements for FPR not satisfied by revenues generated by its
third party contract manufacturing agreements have been provided from April 7,
1995 through September 30, 1995 by day-to-day cash advances from Faulding. To
date, FPR has supplied product to FPC in exchange for intercompany debt,
aggregating $2,595,127 at September 30, 1995. Therefore, such sales have not
provided FPR with any cash proceeds for use in FPR's operations. This is
expected to continue until the Closing Date. Future capital expenditures by FPR
will be partially dependent upon and related to the commercialization of some of
the technologies being developed by FMDC. Total intercompany loans and advances
to FPR from Faulding as of September 30, 1995, including an initial advance of
$12,442,998 to finance the acquisition of the Aguadilla Facility, were
$17,258,248.
Funding of FPC's day-to-day operating funds to date was provided
principally by Faulding. In addition, FPR supplied inventory for FPC in exchange
for intercompany debt of FPC. On-going funding requirements for FPC are expected
to increase to the extent that FPC experiences an increase in sales, with
corresponding increased needs in working capital. This is expected to be
partially offset by the net cash flow from sales by FPC of products currently
licensed by FMDC from F.H. Faulding and sold pursuant to the agreement with
Steris. Total intercompany loans and advances to FPC from Faulding as of
September 30, 1995 were $493,691.
Total intercompany loans and advances to the Faulding Subsidiaries from
Faulding as of September 30, 1995 were $22,748,555. All such intercompany loans,
as well as any further loans or
29
<PAGE>
<PAGE>
advances through the Closing Date will be contributed to the capital of the
Faulding Subsidiaries upon consummation of the Faulding Transaction.
Assuming consummation of the Faulding Transaction, each of the Faulding
Subsidiaries will be required to look to Purepac for any working capital
shortfalls, whether to defray operating expenses or capital expenditures, as it
is not anticipated that the Faulding Subsidiaries will generate adequate
revenues to finance their combined operating expenses until at least 1998.
Although it is anticipated that the $15.0 million to be received by Purepac from
the Preferred Stock Purchase will be used in substantial part for this purpose,
additional funding is expected to be required. In such event, Purepac will be
required to utilize funds available under its then existing credit facilities or
from cash flow from operations to finance any shortfalls. As of September 30,
1995, Purepac had approximately $12 million of available borrowings under its
existing credit facilities. The use of Purepac's credit facilities and other
sources of capital would diminish funding available to Purepac to sustain or
expand its current business operations. Purepac's operations and results of
operations are subject to many of the same risks identified for the Faulding
Subsidiaries, such as uncertainty and variability of financial results,
competition, dependence on product development and the timing of regulatory
approvals permitting the introduction of new products. It is expected that
Purepac will need to utilize some or all of its existing credit facilities to
fund its own operations. Consequently, there can be no assurance that Purepac's
operating results will be sufficient to permit Purepac to adequately fund the
Faulding Subsidiaries, or that satisfying such financing obligations will not
adversely effect Purepac's ongoing business operations or its ability to finance
its current long range objectives. Accordingly, Purepac may be forced to seek
additional credit facilities or to seek additional funding from sales of its
securities or from other sources. There can be no assurance that such financing
will be available when required, if at all, or will be available upon terms
Purepac may deem commercially reasonable. See 'Management's Discussion and
Analysis of Financial Condition and Results of
Operations -- Purepac -- Liquidity and Capital Resources.'
PROPOSAL TO CHANGE PUREPAC'S NAME
BACKGROUND
Pursuant to the terms of the Faulding Transaction, Purepac is to be
granted, on the Closing Date, a worldwide royalty-free license to use the name
'Faulding' in connection with its business and to allow the Faulding
Subsidiaries to continue to conduct their respective businesses using the
'Faulding' name after the Faulding Transaction. Such license may be terminated
by Faulding on three years prior notice at any time after Faulding no longer
holds in excess of 50% of the outstanding Common Stock of Purepac on a fully
diluted basis. Purepac's operating subsidiary, Purepac Pharmaceutical Co., will
nevertheless continue to operate under such name.
Purepac's decision to acquire the Faulding Subsidiaries was based in part
on the broad recognition in the worldwide pharmaceutical industry associated
with F.H. Faulding and the opportunity to capitalize on that name as a result of
the consolidation of F.H. Faulding's United States generic pharmaceutical and
related business operations within the existing Purepac corporate organization.
See 'The Proposed Faulding Transaction -- Recommendation of the Purepac Board;
Reasons for the Faulding Transaction.' Accordingly, the Purepac Board determined
that the change of Purepac's name to Faulding Inc. following consummation of the
Faulding Transaction would best reflect such consolidation and associate the
company as a whole with the various Faulding businesses to be conducted in the
United States.
If the proposed amendment to Purepac's Certificate of Incorporation to
effectuate the Name Change is approved by the Purepac stockholders, such change
will be implemented as soon as practicable after the Closing Date of the
Faulding Transaction. Purepac will concurrently change the trading symbol under
which the Purepac Common Stock is traded on The Nasdaq National Market from
'PURE' to 'FAUL.'
If the Faulding Transaction is not approved, the Name Change will not be
implemented even if approved by the Purepac Stockholders.
30
<PAGE>
<PAGE>
BOARD RECOMMENDATION
The affirmative vote of the holders of a majority of all outstanding shares
of Purepac Common Stock is required for approval of the proposal to amend the
Purepac's Certificate of Incorporation to effectuate the Name Change. THE BOARD
OF DIRECTORS RECOMMENDS THAT THE PUREPAC STOCKHOLDERS VOTE FOR THIS PROPOSAL.
PROPOSAL TO INCREASE CAPITALIZATION
RECOMMENDED INCREASE IN AUTHORIZED COMMON STOCK
The Purepac Board has approved an amendment to Purepac's Certificate of
Incorporation to increase the number of authorized shares of Purepac Common
Stock from 25,000,000 to 35,000,000. The Company's Board believes such action to
be in the best interest of the Company so as to make additional shares available
for future employment benefit programs, possible acquisitions and financings and
other corporate purposes. The additional shares may be issued from time to time
as the Purepac Board may determine without further action by the Purepac
Stockholders.
With the exception of the issuance of Purepac Common Stock upon the
exercise of options and the vesting of stock awards granted or to be granted
under Purepac's 1991 Restricted Stock Incentive Plan or 1994 Stock Option Plan,
the issuance of the Purepac Acquisition Stock pursuant to the Stock Purchase
Agreement and the reservation of Common Stock upon possible conversions of Class
B Preferred Stock, no additional issuances of shares of Purepac Common Stock is
presently contemplated nor does Purepac currently have any agreements,
arrangements or understandings with respect to any possible acquisitions or
financings.
Holders of Purepac Common Stock do not currently possess, nor upon the
adoption of the proposed amendment will they acquire, preemptive rights which
would entitle such persons, as a matter of right, to subscribe for the purchase
of any securities of Purepac.
CURRENTLY AUTHORIZED CAPITAL STOCK
The Company's Certificate of Incorporation, as amended (the 'Certificate of
Incorporation'), currently authorizes the issuance of 25,000,000 shares of
Common Stock, $.01 par value. At January 24, 1996, there were 12,581,223 shares
of Common Stock issued and outstanding. The Company has reserved an additional
5,005,128 shares of Common Stock for issuance upon the conversion of outstanding
shares of Class A Preferred Stock and 1,000,000 and 311,625 shares of Common
Stock for issuance upon the exercise of options or rights to purchase shares of
Common Stock pursuant, respectively, to the Company's 1994 Stock Option Plan and
its 1991 Restricted Stock Incentive Plan.
Pursuant to the Stock Purchase Agreement, the Company has agreed to deliver
to Faulding approximately 2,253,521 shares of Common Stock, subject to
adjustment. If such transaction were to have closed on September 30, 1995, such
number of shares would have been adjusted to 2,321,621 shares. Furthermore, an
additional 1,564,950 shares of Common Stock will be required to be reserved for
issuance upon future conversions, if any, of the Class B Preferred Stock
proposed to be issued to Faulding under the Preferred Stock Purchase Agreement.
If these transactions are all consummated, the authorized shares of Common Stock
available for future issuances would total 2,215,453 shares.
DESCRIPTION OF CAPITAL STOCK
The Certificate also authorizes 834,188 shares of Class A Preferred Stock,
$.01 par value, all of which shares are presently issued and outstanding and
owned by Faulding, and 1,000,000 shares of 'blank check' preferred stock (the
'Undesignated Preferred Stock'), none of which is presently issued and
outstanding.
COMMON STOCK
The holders of Purepac Common Stock are entitled to one vote for each share
held of record on all matters to be voted on by stockholders. There is no
cumulative voting with respect to the election of
31
<PAGE>
<PAGE>
directors, with the result that the holders of more than 50% of the shares voted
for the election of directors can elect all of the directors. The holders of
Purepac Common Stock are entitled to receive dividends when, as and if declared
by the Board of Directors out of funds legally available therefor. In the event
of liquidation, dissolution or winding up of Purepac, the holders of Purepac
Common Stock are entitled to share ratably in all assets remaining available for
distribution to them after payment of liabilities and after provision has been
made for each class of stock having preference over the Purepac Common Stock.
Holders of shares of Purepac Common Stock, as such, have no conversion,
preemptive or other subscription rights. All of the outstanding shares of
Purepac Common Stock are, and the shares of Purepac Common Stock issuable on
consummation of the Faulding Transaction, when delivered in accordance with the
terms of the Stock Purchase Agreement, will be, fully paid and nonassessable.
PREFERRED STOCK
Class A Preferred Stock
In 1987, Purepac issued and sold to Faulding 834,188 shares of Class A
Preferred Stock at $29.34 per share, or $23,133,223, net of expenses of
$1,341,853. The Class A Preferred Stock does not have any voting rights, except
as required by the General Corporation Law of Delaware. These shares provide for
a cumulative dividend of 8.5% per annum, which dividend accrues until such time
as Purepac shall have profits, surpluses or other funds legally available for
payment of dividends. Dividends accrue on each share of Class A Preferred Stock
on a daily basis at 8.5% per annum, payable quarterly, on the liquidation value
of the Class A Preferred Stock. If any accrued dividends, for any reason, are
not paid, then such dividend is considered in arrears and, until paid, continues
to be accrued on the liquidation value plus dividends in arrears.
Each share of Class A Preferred Stock may be converted, at the election of
the holder, into six shares of Common Stock. At January 24, 1996, 5,005,128
shares of Common Stock were reserved for issuance under the terms of the Class A
Preferred Stock. In the event of any liquidation, dissolution or winding up of
Purepac, the holders of Class A Preferred Stock shall be entitled to be paid out
of the assets of Purepac available for distribution to its stockholders, whether
from capital, surplus or earnings, an amount in cash equal to the sum of $29.34
per share plus all accrued and unpaid dividends.
On or after December 1, 1997, Purepac may, at its election redeem any or
all shares of Class A Preferred Stock. For each share of Class A Preferred Stock
redeemed, Purepac shall be obligated to pay a redemption price of $29.34 per
share plus any accrued and unpaid dividends.
Class B Preferred Stock
The Board of Directors of Purepac, by resolution, has authorized the
designation of a Class B Preferred Stock, consisting of 150,000 shares, which is
proposed to be purchased by Faulding on the Closing Date. The Class B Preferred
Stock, if and when designated, will be charged against the Undesignated
Preferred Stock, discussed below.
The rights of the holders of Class B Preferred Stock will be similar, but
not identical, to those of the holders of Class A Preferred Stock. The Class B
Preferred Stock will accrue dividends at the rate of 4.5% per annum, payable on
a quarterly basis and will have a liquidation preference of $100 per share, plus
the amount of any accrued but unpaid dividends. The Class B Preferred Stock will
not have any voting rights, except as required by the General Corporation Law of
Delaware, and will be convertible at the option of the holder after the first
anniversary of issuance, at the ratio of 10.433 for one, into an aggregate of
1,564,950 shares of Purepac Common Stock.
On or after the third anniversary of issuance, the Class B Preferred Stock
is subject to redemption by Purepac at its option at a redemption price equal to
the liquidation value of the Class B Preferred Stock at the date of redemption,
plus accrued and unpaid dividends, if any.
See 'The Proposed Faulding Transaction -- The Preferred Stock Purchase' for
a discussion of the impact upon the rights of the Purepac Stockholders.
32
<PAGE>
<PAGE>
'Blank Check' Preferred Stock
The Certificate authorizes the issuance of up to 1,000,000 shares of
Undesignated Preferred Stock with such designation, rights and preferences as
may be determined from time to time by the Purepac Board. Accordingly, the
Purepac Board is empowered, without stockholder approval, to issue Undesignated
Preferred Stock with dividend, liquidation, conversion, voting or other rights
which could adversely affect the voting power or other rights of the holders of
Purepac Common Stock. Purepac has no current intention to issue any shares of
Undesignated Preferred Stock other than the Class B Preferred Stock.
REQUIRED VOTE
The affirmative vote of the holders of a majority of all the outstanding
shares of Purepac Common Stock is required for approval of this proposal.
Faulding has indicated its intent to vote in favor of this proposal.
Accordingly, it is a virtual certainty that this proposal will be approved at
the meeting. THE PUREPAC BOARD UNANIMOUSLY RECOMMENDS THAT THE PUREPAC
STOCKHOLDERS VOTE FOR THIS PROPOSAL.
ELECTION OF DIRECTORS
INFORMATION CONCERNING NOMINEES
Pursuant to a resolution adopted by the Purepac Board in accordance with
Purepac's Bylaws, the number of directors to be elected at the Annual Meeting
has been fixed at five. Michael R.D. Ashton, a current director of Purepac has
indicated his intention not to stand for re-election. The shares represented by
the proxies will be voted in favor of the election as directors of the persons
named below unless authority to do so is withheld. The directors elected will
hold office for a term of one year or until their respective successors are duly
elected and qualify. If any nominee is not a candidate for election at the
Annual Meeting, an event which the Purepac Board does not anticipate, the
proxies will be voted for a substitute nominee as well as for the other persons
named below.
<TABLE>
<CAPTION>
PUREPAC STOCK
BENEFICIALLY
OWNED AS OF
NAME OFFICE(S) SINCE AGE JAN. 24, 1996
- -------------------------- ---------------------------------------------- ----- --- -------------
<S> <C> <C> <C> <C>
Edward D. Tweddell........ Director/Chairman 1990 55 -0-(1)
Alan G. McGregor.......... Director 1988 59 -0-(1)
David Beretta............. Director 1989 67 -0-
Bruce C. Tully............ Director 1989 46 -0-
Richard F. Moldin......... President, Chief Executive Officer, 1995 48 -0-(2)
Acting Chief Operating Officer, Director
</TABLE>
- ------------
(1) Mr. McGregor and Dr. Tweddell are directors of F.H. Faulding, the parent of
Faulding, the principal stockholder of Purepac. See 'Principal Stockholders
of Purepac' and 'Compensation Committee Interlocks and Insider
Participation.'
(2) Excludes 150,000 shares issuable upon the exercise of stock option awards,
not presently exercisable, that have been made to Mr. Moldin under the
Company's 1994 Stock Option Plan. See 'Compensation of Executive Officers'.
------------------------
Edward D. Tweddell, M.D., was elected a director in November 1990 and was
subsequently elected Chairman of the Purepac Board. He joined F.H. Faulding as
Managing Director of its Faulding Pharmaceuticals Division in September 1988. He
was elected to the Board of Directors of F.H. Faulding in March 1989 and served
as Executive Director of the Faulding Pharma Group from 1990 to November 1993
when he was appointed Group Managing Director and Chief Executive Officer of
F.H. Faulding. From July 1987, until joining F.H. Faulding, he held the position
of Chairman and Chief Executive Officer of Pharmol Pacific Ltd., an Australian
biotechnology company. Prior thereto and from April
33
<PAGE>
<PAGE>
1986, he was President and Chief Executive Officer of Homecare Japan, LTD. Dr.
Tweddell, who holds a Bachelor of Science degree in addition to an honors degree
in Medicine, spent his early career in medical practice and, in 1976, joined the
multinational pharmaceutical company, Pfizer International Inc. ('Pfizer'),
where he held a number of senior management positions.
Alan G. McGregor, a director of Purepac since June 1988, is Chairman of
F.H. Faulding. Mr. McGregor is also a director of James Hardie Industries Ltd.,
Burns, Philip & Co. Ltd. and other companies. He has served as a partner in two
major Adelaide, South Australia law firms and was a Crown Prosecutor with the
South Australian Crown Solicitor's Office.
David Beretta, a director of Purepac since April 1989, is President of
Executive Consulting Inc., a business consulting firm in Jamestown, Rhode
Island. Mr. Beretta is, and since April 1991 has been, Vice Chairman and
President of Amtrol Inc., a concern engaged in the manufacture of products used
in flow control, storage, heating and other treatment of fluids in the water
systems market and selected sectors of the heating, ventilating and air
conditioning market in West Warwick, Rhode Island. Until 1982, he was Chairman
of the Board of Uniroyal, Inc. and remained a director until 1987. He is also a
director of Chartel Power Systems Inc.
Bruce Tully, a director of Purepac since April 1989, has been a Managing
Director of BT Securities Corporation, a subsidiary of Bankers Trust New York
Corporation in New York, New York, since September 1989. Prior thereto and from
October 1986, he was Managing Director of Bankers Trust Company and for four
years prior thereto, was a Vice President thereof.
Richard F. Moldin was appointed President and Chief Executive Officer of
Purepac and President of Purepac Pharmaceutical Co. on July 17, 1995 and was
appointed to serve as a director and acting Chief Operating Officer of the
Company on July 24, 1995 upon Robert H. Bur's resignation from such positions.
Prior to joining the Company and from October 1994 he served as Managing
Director, Australia & New Zealand for Wellcome Australia Limited. From May 1993
until his appointment as Managing Director, he was Divisional Manager, Primary
Manufacturing, for Wellcome Foundation Limited, U.K. Prior thereto and from
September 1979, he served in various executive positions at Burroughs Wellcome
Co., U.S.A., including from October 1991 to February 1993 as Vice President,
Logistics & Primary Manufacturing.
INFORMATION CONCERNING THE PUREPAC BOARD
During Purepac's fiscal year ended June 30, 1995, the Purepac Board held
two meetings. All directors were in attendance at such meetings.
The Purepac Board's Audit Committee is charged with the review of the
activities of Purepac's independent auditors, including, but not limited to, the
review of fees, services and scope of audit. During the fiscal year ended June
30, 1995, Messrs. Beretta, Tully and Michael R.D. Ashton served as the members
of the Audit Committee, with Mr. Tully serving as its Chairman. The Audit
Committee met one time during the fiscal year ended June 30, 1995, with all
members in attendance.
The Compensation Committee of the Purepac Board is responsible for
establishing, approving and administering the policies which govern annual
executive salary levels and increases, incentive payments, the award of stock
grants under Purepac's 1991 Restricted Stock Incentive Plan and the award of
stock options under its 1994 Stock Option Plan. The Compensation Committee is
comprised of Messrs. Beretta, Tweddell and McGregor and met one time during the
fiscal year ended June 30, 1995, with all members in attendance.
Purepac does not have a nominating committee charged with the search for,
and recommendation to the Purepac Board, of potential candidates for Purepac
Board membership. This function is performed by the Purepac Board as a whole.
David Beretta and Bruce Tully each receives $15,000 per annum for his
services as a director of Purepac. None of the other directors of Purepac
receives any cash compensation for his services as such.
34
<PAGE>
<PAGE>
SECTION 16(A) REPORTING DELINQUENCIES
Section 16(a) of the Exchange Act requires the Company's officers and
directors, and persons who own more than 10% of a registered class of the
Company's equity securities, to file reports of ownership and changes in
ownership ('Reports') with the Commission. Officers, directors and greater than
10% stockholders are required by the Commission's regulations to furnish the
Company with copies of all such reports.
Based solely on its review of the copies of such reports received by it, or
written representations from certain reporting persons that no reports were
required for those persons, the Company believes that, during the fiscal year
ended June 30, 1995 all filing requirements applicable to its officers,
directors and greater than 10% stockholders were complied with, except that Mr.
Bur made a late filing of a Report, involving one transaction relating to a
change in beneficial ownership of the Company's securities.
RATIFICATION OF SELECTION OF INDEPENDENT AUDITORS
Unless otherwise instructed, the persons named in the enclosed proxy intend
to vote the same in favor of the approval of the selection by Purepac's Board of
Deloitte & Touche LLP to serve as the Company's independent auditors for the
fiscal year ending June 30, 1996. That firm, an affiliate of which is also F.H.
Faulding's principal independent auditor, has reported to the Company that none
of its members has any direct financial interest or material indirect financial
interest in the Company or any of its subsidiaries, nor has any member of such
firm had any such connection during the past three years.
Deloitte & Touche LLP served as the Company's principal independent auditor
for the fiscal year ended June 30, 1995. A representative from Deloitte & Touche
LLP is expected to attend the Annual Meeting and will be afforded the
opportunity to make a statement or respond to appropriate questions from
stockholders or both.
It is expected that representatives of Deloitte & Touche LLP will be
present at the Annual Meeting and will be available to respond to questions.
They will be given an opportunity to make a statement at the Annual Meeting if
they so desire.
PRICE RANGES OF PUREPAC COMMON STOCK
Purepac's Common Stock is traded on The Nasdaq National Market under the
trading symbol PURE. The following table sets forth the range of high and low
closing sales prices of the Company's Common Stock on The Nasdaq National
Market.
<TABLE>
<CAPTION>
FOR THE QUARTER ENDED: HIGH LOW
- ---------------------------------------------------------------------------------- ------- -------
<S> <C> <C>
Fiscal 1994
September 30, 1993........................................................... $20.500 $ 8.625
December 31, 1993............................................................ 25.000 15.000
March 31, 1994............................................................... 17.000 8.500
June 30, 1994................................................................ 10.500 7.000
Fiscal 1995
September 30, 1994........................................................... $14.250 $ 8.000
December 31, 1994............................................................ 16.250 10.125
March 31, 1995............................................................... 11.625 8.750
June 30, 1995................................................................ 11.375 8.375
Fiscal 1996
September 30, 1995........................................................... $10.875 $ 7.750
December 31, 1995............................................................ 8.750 5.125
</TABLE>
On August 8, 1995, (the last trading day prior to the public announcement
of the execution of the Letter of Intent), the closing price of Purepac Common
Stock was $8.875 per share. Purepac's Class A Preferred Stock is not publicly
traded. On January 23, 1996, the closing price of Purepac Common Stock was
$6.125 per share. Purepac Stockholders are urged to obtain current market
quotations.
35
<PAGE>
<PAGE>
SELECTED FINANCIAL DATA OF PUREPAC
The selected financial data set forth below has been derived from, and
should be read in conjunction with, the Purepac Financial Statements and related
Notes thereto appearing elsewhere in this Proxy Statement and should be read in
conjunction with Management's Discussion and Analysis of Financial Condition and
Results of Operations of Purepac contained herein.
<TABLE>
<CAPTION>
SEPTEMBER 30, YEAR ENDED JUNE 30,
------------------------ -------------------------------------------
1995 1994 1995 1994 1993 1992 1991
---------- ----------- ------- ------- ------- ------- -------
(UNAUDITED) (UNAUDITED)
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<S> <C> <C> <C> <C> <C> <C> <C>
Statement of Operations Data:
Net sales..................................... $14,167 $16,876 $61,146 $70,005 $70,508 $64,531 $52,279
Income (loss) before preferred stock
dividends................................... (1,076) (25) (847) 8,447(a) 9,160 14,979 4,866
Preferred stock dividends..................... 520 520 2,080 2,080 2,080 2,081 2,237
Net income (loss), available for Common
Stock....................................... (1,596) (545) (2,927) 6,367(a) 7,080 12,776(b) 5,985(c)
Net income (loss) per common share, primary... (.13) (.04) ( .23) .51 .57 1.05 .54
</TABLE>
- ------------
(a) Net income available for common stock for the year ended June 30, 1994
included the cumulative effect of a change in accounting for income taxes
of $4,149.
(b) Net income available for common stock for the year ended June 30, 1992
included the cumulative effect, on prior years, of a change in the method
of accounting for income taxes of $122.
(c) Net income available for common stock for the year ended June 30, 1991
included an extraordinary item reduction of income taxes due to carry
forward of prior year operating losses of $3,356.
<TABLE>
<CAPTION>
YEAR ENDED JUNE 30,
SEPTEMBER 30, ---------------------------------------------------
1995 1995 1994 1993 1992 1991
----------------- ------- ------- ------- ------- -------
(UNAUDITED)
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C>
Balance Sheet Data:
Working capital........................ $20,605 $21,811 $24,221 $23,150 $20,460 $12,072
Total assets........................... 64,440 64,929 67,267 63,017 52,269 35,247
Long-term debt......................... -- -- -- -- -- --
Stockholders' equity................... 51,065 52,557 54,860 48,060 39,699 24,927
</TABLE>
36
<PAGE>
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS -- PUREPAC
RESULTS OF OPERATIONS
THREE MONTHS ENDED SEPTEMBER 30, 1995
COMPARED WITH THE THREE MONTHS ENDED SEPTEMBER 30, 1994
Net sales for the current three month period was $14,167,000 compared with
$16,876,000 for the corresponding 1994 period. The 16% decrease reflects lower
sales of certain mature products including nifedipine products which accounted
for 8% of net sales in the current quarter compared with 11% for the
corresponding 1994 quarter. The decrease in net sales is primarily due to
declines in selling prices and, to a lesser degree, volume reductions of some
products as a result of competitive pressure, and the absence of newly approved
product introductions during such period.
Gross profit for the current period was $2,512,000 compared with $4,198,000
for the corresponding 1994 period. Gross profit as a percent of net sales for
the current period was 18% compared with 25% for the 1994 period. The decline
was attributable to both the reduced sales and to lower selling prices for
nifedipine and several other products. Decreasing gross profits, as well as net
sales, can be expected to continue until such time as Purepac receives FDA
approvals for new products.
Selling, general and administrative expense for the current period of
$2,255,000 decreased from the corresponding prior period expense of $2,471,000
by $216,000 (9%). The expense as a percent of net sales was 16% compared with
15% for the 1994 period. The decrease in expense was primarily due to lower
personnel expenses.
Research and development expense for the current period remained relatively
constant at $1,951,000 compared with $1,765,000 for the corresponding 1994
period. The expense as a percent of net sales was 14% compared with 10% for the
1994 period. The increase of $186,000 (11%) primarily reflects timing
differences.
The net loss before preferred stock dividends for the current three month
period was $1,076,000 compared with a net loss before preferred stock dividends
of $25,000 for the corresponding 1994 period.
The first quarter result was adversely affected by strong pricing pressures
within the oral generic pharmaceutical industry and some unexpected delays in
new product regulatory approvals which did not allow the Company to offset those
pressures, even though expense levels generally did not increase.
YEAR ENDED JUNE 30, 1995
COMPARED WITH THE YEAR ENDED JUNE 30, 1994
Net sales for the current year ended June 30, 1995 were $61,146,000
compared with $70,005,000 for the prior year ended June 30, 1994. The decrease
reflects lower sales of certain mature products, including nifedipine, primarily
due to declines in selling prices and, to a lesser degree, volume reductions of
some products as a result of competitive pressure, partially offset by increased
sales of several new products. The nifedipine products accounted for 12% of net
sales for the current year compared with 13% for the prior year.
Gross profit for the current year was $14,671,000 compared with $22,834,000
for the prior year, a decline of $8,163,000 (36%). The gross profit as a percent
of net sales for the year ended June 30, 1995 was 24% compared with 33% for the
prior year ended June 30, 1994. The decline was attributable primarily to lower
selling prices due to increased competition and to a lesser extent to higher raw
material costs.
Selling, general and administrative expenses for the year ended June 30,
1995 were $9,817,000 compared with $9,409,000 for the prior year ended June 30,
1994, an increase of $408,000, or 4%. The expenses as a percent of net sales was
16% compared with 13% for the prior year. The increase of $408,000 is primarily
due to higher personnel expenses.
Research and development expenses for the current year remained relatively
constant at $6,741,000 compared with the prior year expenses of $6,797,000. The
expenses as a percent of net sales for the year
37
<PAGE>
<PAGE>
ended June 30, 1995 was 11% compared with 10% for the year ended June 30, 1994.
The steady level of expense reflects a continuing commitment to new product
development.
Other expenses of $63,000 for the current year ended June 30, 1995,
included interest expense of $105,000 partially offset by interest income of
$42,000. The prior year's other income of $273,000 included interest income of
$102,000 and income of $200,000 from the sale of Purepac's Poroplastic'r'
technology to F.H. Faulding, partially offset by interest expense of $29,000.
The interest income decline was primarily due to the reduction of cash available
for investment. The interest expense for both years includes the revolving
credit agreement fees.
The effective income tax (benefit) rate for the year ended June 30, 1995,
was (57%) compared with 38% for the year ended June 30, 1994 before the
cumulative effect of a change in accounting for income taxes. The current year
tax rate includes a $325,000 benefit related to a reversal of prior years' tax
provisions resulting from a favorable resolution of completed income tax
examinations.
Net loss for the current year before preferred stock dividends was $847,000
compared with net income before preferred stock dividends for the prior year of
$4,298,000.
YEAR ENDED JUNE 30, 1994
COMPARED WITH THE YEAR ENDED JUNE 30, 1993
Net sales for the year ended June 30, 1994 were $70,005,000 compared with
$70,508,000 for the prior year. The decrease reflects a decline in nifedipine
selling prices, partially offset by increased sales of certain mature products
and the introduction of three new products. The three new products were
carbidopa levodopa, alprazolam and naproxen. Nifedipine accounted for 13% of net
sales for the current year compared with 30% for the prior year.
Gross profit for the year ended June 30, 1994 was $22,834,000 compared with
$29,277,000 for the prior year, a decline of $6,443,000, or 22%. The gross
profit as a percent of net sales for the year ended June 30, 1994 was 33%
compared with 42% for the prior year ended June 30, 1993. The decline was
primarily attributable to nifedipine price reductions resulting from increased
competition.
Selling, general and administrative expenses for the year ended June 30,
1994 of $9,409,000 declined from the prior year expense of $9,858,000 by
$449,000, or 5%. The expenses as a percent of net sales for the year ended June
30, 1994 was 13% compared with 14% for the prior year ended June 30, 1993. The
decrease is attributable to reductions in advertising, travel and entertainment
expenses.
Research and development expenses for the year ended June 30, 1994 were
$6,797,000 compared with $5,944,000 for the prior year ended June 30, 1993. The
expenses as a percent of net sales were 10% compared with 8% for the prior year.
The increase of $853,000, or 14%, reflects the continuing commitment to new
product development.
Other income of $273,000 for the year ended June 30, 1994, included
interest income of $102,000 and income of $200,000 from the sale of Purepac's
Poroplastic'r' technology to F.H. Faulding, partially offset by interest expense
of $29,000. The prior year's other income of $301,000 included interest income
of $331,000 less interest expense of $30,000. The interest income decline was
primarily due to the reduction of cash available for investment. The interest
expense, for both years, included the revolving credit agreement fees.
The effective income tax rate for the year ended June 30, 1994, before the
cumulative effect of a change in accounting for income taxes, was 38% compared
with 34% in the prior year. The rate increase is attributable to the prior year
having the benefit of approximately $936,000 for the utilization of net
operating loss carryforwards in accordance with Statement of Financial
Accounting Standards No. 96, 'Accounting for Income Taxes' ('SFAS 96'). This was
partially offset by a lower effective state tax rate in the current year due to
a favorable mix of income by state. In accordance with Statement of Financial
Accounting Standards No. 109, 'Accounting for Income Taxes:' ('SFAS 109'), in
current and subsequent years, the income tax expense provision will not include
the benefit of recognizing available loss carryforwards to the extent they have
already been recognized as a deferred tax asset when such benefits are utilized
to reduce taxes payable. (Refer to Note 14 of the Notes to Consolidated
Financial Statements).
38
<PAGE>
<PAGE>
Net income available for common stock for the year ended June 30, 1994
included the cumulative effect of a change in accounting for income taxes of
$4,149,000 ($.33 per primary share and $.24 per share on a fully diluted basis)
as a result of the adoption of SFAS 109. Net income before preferred stock
dividends was $4,298,000 for the current year compared with $9,160,000 for the
prior year.
FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES
The Company had $743,000 in cash and cash equivalents at September 30,
1995, compared with $1,156,000 in cash and cash equivalents at June 30, 1995,
and compared with $3,154,000 at June 30, 1994. The decrease in the current three
month period of $413,000 resulted primarily from cash used for operating
activities of $990,000, investments in property, plant and equipment of $423,000
offset by $1,000,000 borrowed from a bank. The decrease for the year ended June
30, 1995 of $1,998,000 resulted primarily from cash used for investments in
property, plant and equipment of $2,954,000 and payments for preferred dividends
of $2,080,000, offset by $2,000,000 borrowed from a bank and $1,036,000 of cash
provided from operating activities.
A comparison of the balance sheet accounts at September 30, 1995 to the
June 30, 1995 balances shows the following to be noteworthy:
Inventory decreased by $999,000 in response to lower sales volumes.
Other current assets increased by $1,329,000 primarily due to the
recording of a federal income tax receivable based on the Company
carrying back the current period's net operating loss.
The accrued preferred dividend, payable to Faulding of $520,095 for the
three month period ended September 30, 1995 was subsequently paid on October 2,
1995.
In comparing the balance sheet accounts at June 30, 1995 to the June 30,
1994 balances, the following are noteworthy:
Net accounts receivable decreased by $1,270,000 as a result of lower
sales volumes and a $502,000 increase in the net reserves for
doubtful accounts and sales allowances, as described in the
following.
Included in the reserves for doubtful accounts and sales allowances
is the allowance for sales returns, allowances and discounts of
$1,935,000 at June 30, 1995 compared with $1,365,000 at June 30,
1994, an increase of $570,000. This increase is primarily due to
increases of $416,000 in the provision for credits owed to direct
source buying groups and $173,000 in the provision for
returns/allowances. The increase in the provision for such
allowances had an adverse effect on net sales and operations with no
effect on cash flows.
Inventory decreased by $1,358,000 due to lower sales volumes and in
part to the discontinuance of certain mature products.
Other current assets increased by $1,301,000 primarily due to the
recording of a $1,129,000 federal income tax refund receivable as a
result of the Company carrying back its current year's net operating
loss.
Net property, plant and equipment increased by $898,000 reflecting
the investment in the modified-release manufacturing suite and
additions to the manufacturing facilities.
Accounts payable decreased by $2,207,000 due to both timing
differences in the purchase of materials and the lower inventory
level.
As a result of the issuance of the Class B Preferred Stock to Faulding,
Purepac will be required to pay an annual dividend of $675,000 to Faulding with
respect to such shares until such time, if ever that such shares are converted
or redeemed. The annual dividend of $2,080,000 payable with respect to the
currently outstanding Class A Preferred Stock, all of which is held by Faulding,
will be payable until such time, if ever that such shares are converted or
redeemed.
In October 1995, the Company made the decision to restructure certain
aspects of its business. This restructuring was considered necessary to make the
Company more competitive in the oral generic pharmaceutical industry. Costs
associated with this restructuring, including severance payments, will be
39
<PAGE>
<PAGE>
incurred beginning in the second fiscal quarter and are expected to total less
than $1 million. This restructuring will better position the Company to
integrate the Faulding Subsidiaries.
The proposed Faulding Transaction is expected to cause Purepac to incur
approximately $950,000 of expenses relating to such transaction. If the Faulding
Transaction is not consummated due to the failure of the Purepac Stockholders to
approve such transaction, Faulding will reimburse Purepac for one-half of the
expenses incurred by Purepac.
Purepac believes that its current cash resources, anticipated operating
cash flows and funds available under a revolving credit and loan arrangement
with a bank will be sufficient to fund Purepac's working capital needs for the
next 24 months. Depending upon the timing of Purepac's cash flow requirements,
which is highly dependent upon the unpredictable timing of the receipt of FDA
product approvals, the future cash flow needs of Purepac could exceed the
available credit under Purepac's existing credit facilities. As of September 30,
1995, Purepac had approximately $12.0 million of available borrowings under its
existing credit facilities. In addition, it is not anticipated that the Faulding
Subsidiaries will generate adequate revenues to finance their combined operating
expenses until at least 1998. Although it is anticipated that the $15.0 million
to be received by Purepac from the Preferred Stock Purchase will be used in
substantial part for this purpose, additional funding is likely to be required.
The use of Purepac's credit facilities and other sources of capital to finance
any shortfalls in the cash flow needs of the Faulding Subsidiaries would
diminish funding available to Purepac to sustain or expand its current business
operations. Consequently, there can be no assurance that Purepac's operating
results will be sufficient to permit Purepac to adequately fund the Faulding
Subsidiaries, or that satisfying such financing obligations will not adversely
effect Purepac's ongoing business operations or its ability to finance its
current long range objectives. Accordingly, Purepac may be forced to seek
additional credit facilities or to seek additional funding from sales of its
securities or from other sources. Purepac anticipates that it would be able to
increase its credit facilities or obtain financing from other sources, should it
require additional cash flow to support the commercialization of new products
following the receipt of FDA approval therefor. However, there can be no
assurance that such financing will be available when required, if at all, or
will be available upon terms Purepac may deem commercially reasonable.
As at June 30, 1995, the Company has committed to expansion of its
granulation and oven capacity within the Elizabeth facility. Total costs are
expected to be $1,600,000. Management regularly reviews its overall facility
requirements for the business, taking into consideration future capacity,
compliance and regulatory requirements necessary within this industry, including
production and product development capabilities. Funding for these and other
expenditures which may be approved by management or by the Purepac Board is
expected to be funded from either operating profits or further draw down from
Purepac's borrowing facility.
NEW ACCOUNTING PRONOUNCEMENTS
In March 1995, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standard No. 121 'Accounting For The Impairment Of
Long-Lived Assets' ('SFAS 121') which requires that long-lived assets be
reviewed for impairment whenever events or changes in circumstance indicate that
the carrying amount of an asset may not be recoverable. To determine a loss, if
any, to be recognized, the book value of the asset would be compared to the
market value or expected future cash flow value. The Company is required to
adopt SFAS 121 for the fiscal years beginning after December 15, 1995 (fiscal
year ended June 30, 1997 for the Company), although earlier implementation is
permitted. The Company is evaluating when it will adopt SFAS 121 and
anticipates, based upon information currently available, that it will not have a
material impact on its results of operations and financial position.
In October 1995, the Financial Accounting Standards Board issued Statement
of Financial Accounting Standard No. 123 'Accounting For Stock Based
Compensation' ('SFAS 123') which requires that an employer's financial
statements include expanded disclosure regarding stock-based employee
compensation arrangements. The Company is evaluating the requirements of SFAS
123, which must be adopted by fiscal year 1997, and currently believes that SFAS
123 will not have a material impact upon its results of operations or financial
condition.
40
<PAGE>
<PAGE>
UNKNOWN EFFECT OF RECENT MEDICAL STUDY
In August 1995, the National Heart, Lung and Blood Institute issued a
warning regarding large doses of the short-acting form of nifedipine. In the
fiscal year ended June 30, 1995 and the three months ended September 30, 1995,
sales of nifedipine products accounted for approximately 12% and 8%,
respectively, of the Company's sales. Not all of the Company's nifedipine
products are of the dosage which was the subject of the warning. In addition,
the results and conclusions of the studies upon which such warning was based
have been challenged by some members of the pharmaceutical and medical
community. Accordingly, management is currently unable to determine the effects,
if any, that such warning or that the findings of the reports upon which such
warning was issued, will have upon the Company's levels of sales of nifedipine
products.
PRO FORMA FINANCIAL STATEMENTS
The unaudited pro forma statements of operations consolidate the statements
of operations of the Faulding Subsidiaries for the year ended June 30, 1995 and
the three month period ended September 30, 1995 with the consolidated statements
of operations of Purepac for the year ended June 30, 1995 and the three month
period ended September 30, 1995, respectively; however such statements do not
include dividends which would have been accrued with respect to the Class B
Preferred Stock during such fiscal periods, if such shares had been issued and
outstanding during such periods. The statement of operations of the Faulding
Subsidiaries for the year ended June 30, 1995 includes the operations of FMDC
for the full fiscal year and the operations of each of FPR and FPC for the
period April 7, 1995 (inception) through June 30, 1995.
Pro forma per share data are based on the average number of shares of
Purepac Common Stock that would have been outstanding had the Acquisition
Transaction occurred at the beginning of the earliest period presented. The
number of shares of Purepac Common Stock for which the pro forma effect has been
provided (2,321,261 shares) is based on the September 30, 1995 Net Asset Value
of the Faulding Subsidiaries. The actual number of shares of Purepac Common
Stock issued will be based on the Faulding Subsidiaries' Net Asset Value on the
Closing Date. The difference between the pro forma number of shares of Purepac
Common Stock provided as at September 30, 1995 and the actual number of shares
at the Closing Date is not expected to be material, or have a material impact
upon the pro forma presentation presented.
The pro forma balance sheet reflects the contribution by Faulding to the
capital of the respective Faulding Subsidiaries of all indebtedness of the
Faulding Subsidiaries to Faulding, aggregating $22,748,555 at September 30,
1995.
The unaudited pro forma statements of operations may not be indicative of
the results that actually would have been achieved if the Faulding Transaction
had been in effect as of the date and for the periods indicated, and is not
expected to be indicative of the results which may be obtained in the future. In
particular, the statement of operations data for the period ended June 30, 1995
include less than three months of operations of FPR and FPC, which period, in
the case of FPR, was the first three months in which FPR owned the Aguadilla
Facility, and which, in the case of FPC, was the first three months of
operations of a newly organized business.
The unaudited pro forma statements of operations should be read in
conjunction with the Financial Statements of the Faulding Subsidiaries and the
Consolidated Financial Statements of Purepac contained elsewhere herein.
41
<PAGE>
<PAGE>
PRO FORMA STATEMENT OF OPERATIONS DATA (UNAUDITED)
FOR THE YEAR ENDED JUNE 30, 1995
<TABLE>
<CAPTION>
FAULDING
FMDC FPC FPR ELIMINATIONS SUBSIDIARIES PUREPAC
------ ----- ------ ------------- ------------ -------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<S> <C> <C> <C> <C> <C> <C>
Net sales................................................... $2,455 $ 516 $1,960 $(1,171) $3,760 $61,146
Cost of sales............................................... 1,956 350 1,954 (1,171) 3,089 46,476
------ ----- ------ ------------- ------ -------
Gross profit................................................ 499 165 5 -- 669 14,671
Selling, general & administration........................... -- 389 -- -- 389 9,817
Research & development...................................... 696 -- -- -- 696 6,741
------ ----- ------ ------------- ------ -------
Income (loss) from operations............................... (197) (223) 5 -- (415) (1,888)
Other (expense), net........................................ (139) -- (187) -- (326) (63)
Benefit/(provision) for income taxes........................ -- (30) -- -- (30) 1,104
------ ----- ------ ------------- ------ -------
(Loss) before preferred stock dividends..................... (336) (253) (182) -- (771) (847)
------ ----- ------ ------------- ------ -------
Preferred stock dividends................................... -- -- -- -- -- 2,080
------ ----- ------ ------------- ------ -------
(Loss) available for common share........................... $ (336) $(253) $ (182) -- $ (771) $(2,927)
------ ----- ------ ------------- ------ -------
------ ----- ------ ------------- ------ -------
Net (loss) per common share, primary........................ ($.23)
-------
-------
Weighted average number of common shares outstanding........ 12,539
<CAPTION>
PRO FORMA
CONSOLIDATED
------------
<S> <C>
Net sales................................................... $ 64,906
Cost of sales............................................... 49,565
------------
Gross profit................................................ 15,340
Selling, general & administration........................... 10,206
Research & development...................................... 7,437
------------
Income (loss) from operations............................... (2,303)
Other (expense), net........................................ (389)
Benefit/(provision) for income taxes........................ 1,074
------------
(Loss) before preferred stock dividends..................... (1,618)
------------
Preferred stock dividends................................... 2,080
------------
(Loss) available for common share........................... $ (3,698)
------------
------------
Net (loss) per common share, primary........................ ($.25)
------------
------------
Weighted average number of common shares outstanding........ 14,860
</TABLE>
PRO FORMA STATEMENT OF OPERATIONS DATA (UNAUDITED)
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 1995
<TABLE>
<CAPTION>
ELIMINATIONS/ FAULDING
FMDC FPC FPR ADJUSTMENTS SUBSIDIARIES PUREPAC
----- ----- ------ ------------- ------------ -------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<S> <C> <C> <C> <C> <C> <C>
Net sales................................................... $338 $ 538 $1,954 $(1,424) $ 1,405 $14,167
Cost of sales............................................... 290 518 2,690 (1,424) 2,073 11,655
----- ----- ------ ------------- ------------ -------
Gross profit................................................ 48 20 (736) -- (668) 2,512
Selling, general & administration........................... -- 618 7 -- 625 2,255
Research & development...................................... 229 50 -- -- 279 1,951
----- ----- ------ ------------- ------------ -------
(Loss) from operations...................................... (182 ) (648) (743) -- (1,573) (1,694)
Other (expense), net........................................ (32 ) -- (169) -- (201) (41)
Benefit for income taxes.................................... -- -- -- -- -- 658
----- ----- ------ ------------- ------------ -------
(Loss) before preferred stock dividends..................... (214 ) (648) (912) -- (1,773) (1,076)
----- ----- ------ ------------- ------------ -------
Preferred stock dividends................................... -- -- -- -- -- 520
----- ----- ------ ------------- ------------ -------
(Loss) available for common shares.......................... $(214) $(648) $ (912) -- $ (1,773) $(1,596)
----- ----- ------ ------------- ------------ -------
----- ----- ------ ------------- ------------ -------
Net (loss) per common share, primary........................ ($.13)
-------
-------
Weighted average number of common shares outstanding........ 12,581
<CAPTION>
PRO FORMA
CONSOLIDATED
------------
<S> <C>
Net sales................................................... $ 15,572
Cost of sales............................................... 13,728
------------
Gross profit................................................ 1,844
Selling, general & administration........................... 2,880
Research & development...................................... 2,230
------------
(Loss) from operations...................................... (3,266)
Other (expense), net........................................ (241)
Benefit for income taxes.................................... 658
------------
(Loss) before preferred stock dividends..................... (2,849)
------------
Preferred stock dividends................................... 520
------------
(Loss) available for common shares.......................... $ (3,369)
------------
------------
Net (loss) per common share, primary........................ ($.23)
------------
------------
Weighted average number of common shares outstanding........ 14,902
</TABLE>
42
<PAGE>
<PAGE>
The unaudited pro forma balance sheet combines the balance sheet of the
Faulding Subsidiaries at September 30, 1995 with the consolidated balance sheet
of Purepac at September 30, 1995. The pro forma balance sheet also reflects the
receipt of $15,000,000 of cash proceeds from the Preferred Stock Purchase, and
the deduction of expenses of the Faulding Transaction, estimated to be $950,000.
PRO FORMA BALANCE SHEET (UNAUDITED)
AT SEPTEMBER 30, 1995
<TABLE>
<CAPTION>
ELIMINATIONS/ FAULDING
FMDC FPC FPR ADJUSTMENTS SUBSIDIARIES PUREPAC
------ ------ ------- ------------- ------------ -------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C>
ASSETS
Current assets:
Cash...................................... $ 18 $ 165 $ (58) $ -- $ 125 $ 743
Accounts receivable -- net................ 337 433 488 -- 1,258 9,756
Inventory................................. -- 1,787 2,035 -- 3,822 16,833
Due from affiliates....................... -- -- 2,595 (2,595) -- --
Other current assets...................... 50 42 491 -- 583 3,135
Deferred income taxes..................... -- -- -- -- -- 3,513
------ ------ ------- ------------- ------------ -------
Total current assets...................... 405 2,427 5,551 (2,595) 5,788 33,980
Property, plant & equipment -- net........ 1,951 56 11,956 -- 13,963 26,509
Other assets.............................. 357 -- -- -- 357 3,226
Deferred income taxes..................... -- -- -- -- -- 724
------ ------ ------- ------------- ------------ -------
Total assets.......................... $2,712 $2,482 $17,508 $ (2,595) $ 20,108 $64,439
------ ------ ------- ------------- ------------ -------
------ ------ ------- ------------- ------------ -------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable to affiliates............ $ -- $2,685 $ -- $ (2,595) $ 90 $ 91
Intercompany payables to Faulding......... 4,997 494 17,258 (22,749) -- --
Loan payable -- bank...................... -- -- -- -- -- 3,000
Accounts payable.......................... -- -- 705 -- 705 5,494
Accrued expenses.......................... 80 205 639 -- 923 4,270
Accrued income taxes...................... -- -- -- -- -- --
Accrued preferred dividends............... -- -- -- -- -- 520
------ ------ ------- ------------- ------------ -------
Total current liabilities................. 5,076 3,383 18,602 (25,343) 1,718 13,375
------ ------ ------- ------------- ------------ -------
Deferred income taxes..................... -- -- -- -- -- --
Commitments and contingencies
Stockholders' equity:
Class A preferred......................... -- -- -- -- -- 8
Series B preferred........................ -- -- -- -- -- --
Common stock.............................. -- -- -- -- -- 126
Paid in capital........................... -- -- -- 22,749 22,749 24,388
Stockholder's equity (deficit)............ (2,365) (901) (1,094) -- (4,360) 26,543
------ ------ ------- ------------- ------------ -------
Total stockholders equity (deficit)....... (2,365) (901) (1,094) 22,749 18,389 51,065
------ ------ ------- ------------- ------------ -------
Total liabilities & stockholders'
equity.............................. $2,712 $2,482 $17,508 ($ 2,595) $ 20,108 $64,439
------ ------ ------- ------------- ------------ -------
------ ------ ------- ------------- ------------ -------
<CAPTION>
EFFECT OF
FAULDING PRO FORMA
TRANSACTION CONSOLIDATED
----------- ------------
<S> <C> <C>
ASSETS
Current assets:
Cash...................................... $14,050 $ 14,918
Accounts receivable -- net................ -- 11,014
Inventory................................. -- 20,655
Due from affiliates....................... -- --
Other current assets...................... -- 3,718
Deferred income taxes..................... -- 3,513
----------- ------------
Total current assets...................... 14,050 53,818
Property, plant & equipment -- net........ -- 40,472
Other assets.............................. -- 3,583
Deferred income taxes..................... -- 724
----------- ------------
Total assets.......................... $14,050 $ 98,597
----------- ------------
----------- ------------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable to affiliates............ $-- $ 181
Intercompany payables to Faulding......... -- --
Loan payable -- bank...................... -- 3,000
Accounts payable.......................... -- 6,199
Accrued expenses.......................... -- 5,193
Accrued income taxes...................... -- --
Accrued preferred dividends............... -- 520
----------- ------------
Total current liabilities................. -- 15,093
----------- ------------
Deferred income taxes..................... -- --
Commitments and contingencies
Stockholders' equity:
Class A preferred......................... -- 8
Series B preferred........................ 15,000 15,000
Common stock.............................. 23 149
Paid in capital........................... (23) 47,114
Stockholder's equity (deficit)............ (950) 21,233
----------- ------------
Total stockholders equity (deficit)....... 14,050 83,504
----------- ------------
Total liabilities & stockholders'
equity.............................. $14,050 $ 98,597
----------- ------------
----------- ------------
</TABLE>
43
<PAGE>
<PAGE>
NOTES TO PRO FORMA FINANCIAL STATEMENTS
1. BASIS OF PRESENTATION
The pro forma combined balance sheet at September 30, 1995, and pro forma
combined statements of operations for the year ended June 30, 1995 and for the
three months ended September 30, 1995 have been prepared based upon the
historical results of (a) the Faulding Subsidiaries and (b) Purepac as if the
Acquisition Transaction had been consummated at the beginning of the fiscal
periods presented and as if the Preferred Stock Purchase had been consummated on
September 30, 1995. Accordingly, no accrued dividends are reflected with respect
to the Class B Preferred Stock for the fiscal year ended June 30, 1995 or the
three months ended September 30, 1995. Purepac has a fiscal year ended June 30,
1995. The statements of operations for the Faulding Subsidiaries for the year
ended June 30, 1995 include (a) the operations of FMDC for the fiscal year ended
June 30, 1995 and (b) the operations of each of FPC and FPR for the period from
April 7, 1995 (inception) through June 30, 1995. The pro forma data are
presented for information purposes only and do not give effect to any financial
effects that may occur due to the integration of existing operations of the
companies. Accordingly, the pro forma data are not necessarily indicative of the
operating results or financial position that would have occurred if the
transaction actually had been consummated at the date indicated, nor necessarily
indicative of future operating results or financial position.
2. ELIMINATIONS/ADJUSTMENTS AND EFFECT OF FAULDING TRANSACTION
The cash and stockholders' equity of the consolidated company has been
adjusted as follows:
Cash -- to present the proceeds of the issuance of the Class B
Preferred Stock of $15,000,000 and the disbursements for estimated expenses
incurred in relation to the transaction of $950,000.
Intercompany Payables to Faulding -- As a result of the Acquisition
Transaction, all indebtedness of the Faulding Subsidiaries to Faulding
will, on or prior to the Closing Date, be contributed by Faulding to the
capital of the respective Faulding Subsidiaries.
Stockholders' Equity -- to present the issuance of 150,000 shares of
Class B Preferred Stock to Faulding for an aggregate purchase price of
$15,000,000 in cash, the acquisition by Purepac of all of the common stock
of the Faulding Subsidiaries in exchange for 2,321,261 shares of Purepac
Common Stock (based upon the Net Asset Value of the Faulding Subsidiaries
as of September 30, 1995) and the recording of the disbursements for
estimated expenditures incurred in relation to the transaction. The actual
number of shares of Purepac Common Stock to be issued pursuant to the
transaction may be adjusted at the closing date of the transaction.
The net adjustments to stockholder's equity are as follows (in thousands):
<TABLE>
<CAPTION>
Class B Preferred Stock:
<S> <C>
Issuance of 150,000 shares of Class B Preferred Stock.................... $15,000
-------
-------
Common Stock and Paid in Capital:
Issuance of 2,321,261 shares of Purepac Common Stock..................... $ 23
-------
-------
Retained Earnings:
Expenses Incurred........................................................ (950)
-------
-------
</TABLE>
In combining the financial accounts of the Faulding Subsidiaries, sales by
FPR to FPC are eliminated along with the respective accounts receivable and
accounts payable on the subsidiary balance sheets.
3. PREFERRED STOCK DIVIDEND
Dividends on the Class B Preferred Stock have not been accrued in the Pro
Forma Statements of Operations because such statements were prepared on the
basis that the proceeds of the sale of the Class B Preferred Stock were not
available to offset the working capital needs of Purepac or the Faulding
Subsidiaries during such periods. Similarly, such statements and the Pro Forma
Balance Sheet
44
<PAGE>
<PAGE>
do not reflect the effect on other items, such as interest expense, which might
have resulted if the proceeds of the sale of the Class B Preferred Stock were
available to satisfy such working capital needs during these periods.
4. ACCOUNTING TREATMENT
Faulding, by virtue of its majority equity interest in Purepac, will
continue to indirectly control each of FMDC, FPR and FPC following consummation
of the Faulding Transaction. Accordingly the Acquisition Transaction will be
viewed for accounting purposes as a reorganization of Faulding's interests in
the United States. Consequently, for accounting and financial reporting
purposes, the Acquisition Transaction will be accounted for at historical cost
in a manner similar to a 'pooling of interests.'
5. PRO FORMA PER SHARE DATA
Pro forma per share data is based on the average number of shares of
Purepac Common Stock that would have been outstanding had the Acquisition
Transaction occurred at the beginning of the earliest period presented. The
number of shares of Purepac common stock for which the pro forma effect has been
provided is based on the September 30, 1995 Net Asset Value of the Faulding
Subsidiaries. The actual number of shares of Purepac Common Stock issued will be
based on the Faulding Subsidiaries' Net Asset Value on the Closing Date. The
difference between the pro forma number of shares of Purepac Common Stock
provided as at September 30, 1995 and the actual number of shares at the Closing
Date is not expected to be material, or have a material impact upon the pro
forma presentation presented. The pro forma per share data is not necessarily
indicative of the results which would actually have been attained if the
Faulding Transaction had been consummated at the beginning of the period
indicated. In particular, the pro forma statement of operations for the period
ended June 30, 1995 includes only the period from April 7, 1995 (inception)
through June 30, 1995 of FPC and FPR.
45
<PAGE>
<PAGE>
BUSINESS OF THE FAULDING SUBSIDIARIES
CERTAIN RISKS RELATING TO THE FAULDING SUBSIDIARIES
The business operations of the Faulding Subsidiaries involve certain
elements of risk including, but not limited to, the factors discussed below.
Limited Operating History; Prior Losses from Operations. FPC is a recently
organized company which commenced operations in April 1995. FPC was formed
following FPR's acquisition of the Aguadilla Facility to commence a new sales
and marketing operation for the products manufactured by FPR and for certain
other products manufactured by F.H. Faulding for which FPC has acquired United
States marketing rights. For the period of its inception through June 30, 1995,
FPC experienced a net pre-tax loss of approximately $223,000, upon net sales of
approximately $516,000. For the three months ended September 30, 1995, FPC
experienced a net pre-tax loss of approximately $648,000 upon net sales of
approximately $538,000.
FMDC has had net operating losses since its inception in 1989 and expects
such losses to increase in the near term as its sole existing source of sales
revenue is scheduled to terminate December 31, 1995. This revenue stream was
generated from sales of two products by an agreement between FMDC and Steris.
Commencing on January 1, 1996, the marketing rights to such products will be
transferred to FPC. FMDC expects to continue its research and development
efforts and therefore continue to incur losses from operations in fiscal 1996.
There can be no assurance that FMDC will be able to generate income from
operations prior to at least June 30, 1998, if at all.
FPR is a recently organized company formed to acquire the Aguadilla
Facility from DuPont Merck. Historically, the products manufactured at such
facility were marketed and sold primarily through DuPont Merck. Based on actual
operating results of FPR for the period from April 7, 1995 to September 30,
1995, and Purepac's interpretation of financial information of the Aguadilla
Facility while under ownership and management of DuPont Merck, the Aguadilla
Facility has, over the last several years, been running at a loss, principally
due to under-utilization of production capacity at the site, and therefore
revenues have been less than manufacturing costs. Over time, this deficiency has
been magnified by reduced selling prices of some of the finished products
produced at the Aguadilla Facility. For the three months ended September 30,
1995, FPR experienced a net pre-tax loss of approximately $912,000. For the
Aguadilla Facility to return to a profitable situation, additional products will
need to be developed and be manufactured at the Aguadilla Facility to enable
sufficient overhead expenses to be recovered. There can be no assurance that the
Aguadilla Facility will be able to generate sufficient revenues to cover its
expenses in the future or that continued erosion of prices for the products
manufactured at the Aguadilla Facility will not cause such deficiency to
increase in the future.
Dependence Upon the Continued Availability of Funding for Operations. The
business operations of the Faulding Subsidiaries are likely to require
significant additional capital infusions or other sources of financing to fund
their day to day operations and to meet their capital expenditure requirements.
While the Preferred Stock Purchase will provide Purepac with net proceeds of
$15,000,000 for the purpose, in part, of providing such financing, to some
extent such financing requirements will need to be satisfied by Purepac's cash
flow from operations or its existing credit facilities. Purepac's operations and
results of operations are subject to many of the same risks identified for the
Faulding Subsidiaries, such as uncertainty and variability of financial results,
competition and dependence on product development. It is likely that Purepac
will be required to use some or all of the available credit under its existing
credit facilities to fund its own operations. Therefore, there can be no
assurance that Purepac's results of operations will be sufficient to permit
Purepac to adequately provide the Faulding Subsidiaries with the requisite
financing, or that satisfying such financing obligations will not adversely
affect Purepac's ongoing business operations or its ability to finance its
current long range objectives. Accordingly, Purepac may be forced to seek
additional credit facilities or obtain additional funding from sales of its
securities or from other sources. There can be no assurance that such financing
will be available when required, if at all. See 'Management's Discussion and
Analysis of Financial Condition and Results of
Operations -- Purepac -- Liquidity and Capital Resources.'
Uncertainty of and Variability of Future Financial Results. The Faulding
Subsidiaries expect to have quarter-to-quarter and year-to-year fluctuations in
revenues, expenses and losses, some of which could
46
<PAGE>
<PAGE>
be significant. Future profitability, which is not expected prior to at least
June 30, 1998, will depend on, among other things, a combination of one or more
of the following factors: (i) the Faulding Subsidiaries' ability to successfully
complete the development of new products, the timing of receipt of regulatory
approvals of such product and the ability to successfully commercialize such
products; (ii) competing technological and market developments and the timing of
new product introductions by competitors; (iii) manufacturing costs associated
with its various products and potential products; and (iv) continued compliance
with government regulations regarding the manufacture and distribution of
pharmaceutical products. Revenues and gross profit derived from generic
pharmaceutical products tend to follow a pattern based on regulatory and
competitive factors unique to the generic pharmaceutical industry. As patents
for brand name products and related exclusivity periods mandated by regulatory
authorities expire, the first generic manufacturer to receive regulatory
approval for generic equivalents of such products is usually able to achieve
relatively high revenues and gross profit. As other generic manufacturers
receive regulatory approvals on competing products, prices and revenues
typically decline. In addition, competition in the United States generic
pharmaceutical market continues to intensify as the pharmaceutical industry
adjusts to increased pressures to contain health care costs. Brand name
companies are increasingly selling their products into the generic market
directly by acquiring or forming strategic alliances with generic pharmaceutical
companies. No regulatory approvals are required for a brand name manufacturer to
sell directly or through a third party to the generic market, nor do such
manufacturers face any other significant barriers to entry into such market.
Dependency On Product Development. The Faulding Subsidiaries' future
success is largely dependent upon their ability to develop, manufacture and
market commercially viable new medical devices, pharmaceutical products and
generic versions of off-patent pharmaceutical products. Generally, in order to
be marketed commercially, products must be developed and tested. In addition,
generic products must be proven to be bioequivalent to the name brand
counterpart or be granted a waiver by the United States Food and Drug
Administration (the 'FDA') from the need to demonstrate bioequivalence.
Injectable products, such as those currently produced by FPR and sold by FPC,
are, in most cases, granted such a waiver. Each of these steps, as well as the
process taken as a whole, involves significant periods of time and expense.
There can be no assurance that any products presently under development, if and
when fully developed and tested, will perform in accordance with expectations,
that necessary regulatory approvals will be obtained in a timely manner, if at
all, or that any of such products can be successfully and profitably produced
and marketed.
Competition and Technological Change. The markets in which the Faulding
Subsidiaries do business are highly competitive and subject to rapid
technological change. Competitors include major pharmaceutical companies, many
of which have considerably greater financial, technical, clinical, marketing and
other resources and experience than the Faulding Subsidiaries. The markets in
which the Faulding Subsidiaries compete and intend to compete are undergoing,
and are expected to continue to undergo, rapid and significant technological
change, and the Faulding Subsidiaries expect competition to intensify as
technological advances in such fields are made. There can be no assurance that
developments by others will not render the products or technologies of the
Faulding Subsidiaries obsolete or uncompetitive.
Governmental Regulation. The Faulding Subsidiaries' operations are subject
to extensive regulation by the FDA, the Drug Enforcement Agency and by state and
local governmental authorities, which regulate the testing, approval,
manufacture, labeling, marketing and sale of pharmaceutical products. The
Faulding Subsidiaries devote significant time, effort and expense addressing the
extensive government regulations applicable to their businesses, and in general,
the trend is towards more stringent regulation. The process of obtaining
regulatory approval is rigorous, time consuming and costly. There can be no
assurance that the Faulding Subsidiaries will obtain necessary approvals on a
timely basis, if at all. Delays in receiving regulatory approvals would
adversely affect the Faulding Subsidiaries' ability to market products
commercially. Product approvals by the FDA may be withdrawn if compliance with
regulatory standards is not maintained or if problems relating to the products
are experienced after initial approval. Failure of the Faulding Subsidiaries (or
by any of their component source suppliers) to continue to comply with
governmental regulations regarding the manufacture, storage and distribution of
pharmaceutical products, such as the FDA's Current Good Manufacturing Practices,
could result in delays or interruption of the manufacturing or distribution
operations of the
47
<PAGE>
<PAGE>
Faulding Subsidiaries' businesses, which could have a material adverse effect on
the businesses of such companies.
Uncertainty Regarding Patents and Proprietary Technology. FMDC's success
will be dependent in part on its ability to obtain patent protection for its
products, maintain trade secret protection and operate without infringing the
proprietary rights of others. FMDC has obtained or is the exclusive licensee
under U.S. patents relating to its devices. FMDC has filed, and intends to file,
applications for additional patents covering both products and processes as
appropriate. There can be no assurance that any patent applications filed by,
assigned to, or licensed to FMDC will be granted, that FMDC will develop
additional products that are patentable or that any patents issued to or
licensed by FMDC will provide FMDC with any competitive advantages or adequate
protection for inventions. Moreover, no assurance can be given that any patents
issued to FMDC or licensed by FMDC will not be challenged, invalidated or
circumvented by others.
There can be no assurance that issued patents, or patents that may issue,
will provide protection against competitive products or otherwise be
commercially valuable. The defense and prosecution of patent claims is both
costly and time consuming. An adverse outcome could result in significant
liabilities to third parties, require disputed rights to be licensed from third
parties or require the Faulding Subsidiaries to cease selling or developing
certain products.
The Faulding Subsidiaries also rely on trade secrets and proprietary
know-how, which they seek to protect in part by confidentiality agreements with
their respective collaborators, employees and consultants. There can be no
assurance that these agreements will not be breached, that the Faulding
Subsidiaries will have adequate remedies for any such breach or that the
Faulding Subsidiaries' trade secrets will not otherwise become known or be
independently developed by competitors.
FMDC
FMDC, formerly DBL Inc., was organized in 1989 to design, develop and
commercialize injectable related disposable devices and injectable drug delivery
system devices. These devices are designed to enhance the speed and safety of
injectable drug delivery. While FMDC has developed and/or acquired the exclusive
license in the United States to commercialize three drug dependent devices and
intravenous delivery systems, such products as yet are not commercially
available in the United States. While two of such products, which incorporate
proprietary devices with shell glass vials pre-filled with an injectable generic
drug, have received FDA marketing approval, additional drug-specific approvals
for these products are required before sales of these devices filled with a drug
can be made. The exclusive rights to such products outside of the United States
have been licensed by FMDC to F.H. Faulding pursuant to an agreement dated
January 23, 1996. Such agreement provides F.H. Faulding the right to sub-license
such technology on a product-by-product basis to its affiliates. In accordance
with such agreement, affiliates of F.H. Faulding currently market products
utilizing the drug dependent technology in Canada and Portugal. F.H. Faulding
and its affiliates are required to purchase the devices from FMDC. To date,
revenues received by FMDC as a result of such sales have been minimal.
FMDC does not currently have any facilities for the production of any of
such products, however certain of such products are currently manufactured for
FMDC by third parties on a contract manufacturing basis.
FMDC intends to focus its marketing and sales efforts towards four distinct
U.S. healthcare market segments -- hospitals, ambulatory care, long term care
and home health services. These segments have been selected because they
represent the majority of the injectable drug use in the United States.
FPR
FPR was organized to acquire the Aguadilla Facility, which is a small
volume parenteral product and oral liquid pharmaceutical manufacturing facility
located in Aguadilla, Puerto Rico from DuPont Merck. The Aguadilla Facility,
which was acquired in April 1995, manufactures ampules and vials of 2 ml to 30
ml containing six generic pharmaceutical products in injectable form, Tridil'r',
Intropin'r', Bretylol'r', acetylcysteine, metoclopramide and amikacin. In
addition to acquiring the Aguadilla Facility, FPR acquired the intellectual
property rights, including the United States trademarks for Tridil'r' and
48
<PAGE>
<PAGE>
Intropin'r', and the rights to market and sell in the United States the majority
of such products manufactured at the Aguadilla Facility. The Aguadilla Facility
also acts as a contract manufacturer for unrelated pharmaceutical companies.
The Aguadilla Facility was originally constructed in 1975, and had been
operated by DuPont Merck (and its predecessor in interest) since 1986. In March
1995, FPR agreed to acquire the Aguadilla Facility and United States marketing
rights to products manufactured at the Facility (with the exception of
Brevibloc'r' and cimetidine, which are marketed in the United States by Ohmeda
and DuPont Merck, respectively), as well as the intellectual property rights
relating to the manufacture of such products, including United States Trademarks
for Tridil'r' and Intropin'r'. FPR paid approximately $13.0 million for the
Aguadilla Facility and the intellectual property rights described above and,
subsequently, through advances by Faulding, has provided additional funding for
capital expenditures and expansion of FPR's operations.
The Aguadilla Facility is comprised of seven buildings, comprising
approximately 68,000 square feet. One of such buildings is used for the
production of parenteral products, another contains an oral liquid filling
facility, another is used for packaging and quality testing laboratories, yet
another one houses administrative offices, while the remaining three buildings
are for warehousing and storage. The oral liquid filling facility was newly
constructed in 1990, and its equipment has yet to be used on a commercial basis.
Faulding, however, does not intend to utilize the oral liquid filling facility.
The Aguadilla Facility is leased from the Port Authority of the
Commonwealth of Puerto Rico pursuant to a lease expiring in 2020. The Aguadilla
Facility employs approximately 116 full time persons, 26 of whom are
administrative and managerial personnel and 90 of whom are in manufacturing and
production. FPR believes the Aguadilla Facility is in material compliance with
applicable FDA regulations and the U.S. Drug Enforcement Agency requirements for
the handling of Schedule II and Schedule III narcotics.
The products manufactured at the Aguadilla Facility were previously
marketed by DuPont Merck, including its Endo Laboratories Division, and by other
unaffiliated parties pursuant to its manufacturing agreements. The Aguadilla
Facility had not previously maintained, and currently does not maintain an
independent sales or marketing staff for the distribution of its products.
Accordingly, when the Aguadilla Facility was acquired by FPR in April 1995,
Faulding organized a new sales and marketing business, FPC, for the purpose of
marketing the products manufactured at the Aguadilla Facility in the United
States. See 'Business of the Faulding Subsidiaries -- FPC.' Contemporaneously
with its acquisition of the Aguadilla Facility, FPR entered into manufacturing
and supply agreements with DuPont Merck pursuant to which FPR agreed to supply
the products currently manufactured at the Aguadilla Facility (with the
exception of Brevibloc) to DuPont Merck for sales principally outside of the
United States for a three year period. In addition, FPR assumed DuPont Merck's
contractual obligation to manufacture Brevibloc for Ohmeda, for sale in the
United States and various foreign countries.
Raw materials utilized in the manufacture of products at FPR, such as
pharmaceutical chemicals and packaging components are purchased by FPR from a
variety of sources. FPR believes that alternative sources of supply are
available for each of such raw materials and components should any current
source become unavailable.
FPR, in conjunction with FPC, competes with other manufacturers and
marketers of generic injectable pharmaceutical products in their efforts to
become the first to develop a generic form of a brand name product for which the
patent has expired. Generally, being the first to develop and bring to market a
generic form of a pharmaceutical product affords the developer a competitive
advantage, at least in the short term, over later entries into the market. To
the extent that FPR acts and desires to act in the future as the manufacturer of
pharmaceutical products on behalf of unaffiliated third parties as a contract
manufacturer, FPR may face competition from other manufacturers of injectable
pharmaceutical products seeking such opportunities.
49
<PAGE>
<PAGE>
FPC
FPC, originally organized as Faulding Hospital Products, Inc., was recently
established to perform United States sales and marketing activities for the
products produced by FPR at the Aguadilla Facility and for certain of F.H.
Faulding's products, including oncological disease treatment products
manufactured at F.H. Faulding's Mulgrave, Australia facility. Products currently
marketed and sold by FPC are injectable pharmaceutical products. Additional
forms of products, however, such as oral solids, may be sold by FPC in the
future, particularly if such products contain the same drug as may then be
contained in an injectable product sold by FPC or would otherwise be
complementary to FPC's then current product portfolio.
FPC currently markets and sells eight products in the United States,
consisting of six generic injectable products manufactured by FPR, and
cytarabine and mitomycin, both generic oncology drugs manufactured by F.H.
Faulding. FPC acquired, after December 31, 1995, the right to market in the
United States two additional oncology drugs, vincristine and vinblastine,
manufactured by F.H. Faulding at Mulgrave, which products are currently marketed
by Steris. In addition, as a result of the Licensing Agreement between FPC and
F.H. Faulding, FPC may gain the marketing rights to additional injectable
products, including certain in the oncological disease treatment area, currently
under development by F.H. Faulding or which may be developed by F.H. Faulding in
the future. The Licensing Agreement with F.H. Faulding provides for FPC and F.H.
Faulding to meet on an ongoing basis to discuss proposed and existing product
development activities and the potential viability of the marketing and sale of
such products in the United States. The Licensing Agreement also provides FPC
with a right of first refusal to market, on an exclusive basis in the United
States, any such injectable product developed by F.H. Faulding. The purchase
price to be paid by FPC to F.H. Faulding for any such injectable product is to
be determined on a product by product basis, predicated upon pricing mechanisms
which take into consideration factors such as production costs and market prices
for such products.
FPC's sales and marketing efforts are targeted at hospital buying groups,
HMO's and other managed care and institutional purchasers of injectable
pharmaceutical products, such as clinics and nursing homes, through six full
time salespersons. FPC's products are currently sold to approximately 240 end
customers. Product is delivered to such customers, primarily through diverse
wholesalers. FPC's headquarters consist of approximately 1,100 square feet of
office space in Dana Point, California which it occupies pursuant to a one year
lease expiring in April 1996.
FPC competes primarily with many large generic pharmaceutical
manufacturers, including Abbott Laboratories, and with other generic drug
suppliers, such as Gensia, some of which are associated with major
pharmaceutical companies which also market oral solid generic products or
branded products. In addition to pricing policies and practices, breadth of
product lines and strength in a given therapeutic category are also competitive
factors.
BUSINESS OF PUREPAC
INTRODUCTION
The Company was incorporated in Delaware on September 2, 1982. On November
2, 1992, the Company's name was changed from Moleculon, Inc. to Purepac, Inc.
The Company, through Purepac Pharmaceutical Co. ('Purepac Pharmaceutical'),
a wholly-owned subsidiary, is primarily engaged in the development, manufacture
and sale of generic oral drug products. As used herein, all references to the
Company are deemed to include Purepac Pharmaceutical, unless the context
indicates to the contrary.
A generic drug contains active drug substances and is the therapeutic
equivalent of a brand name drug for which patent protection, granted by the
United States Patent Office and/or exclusivity granted by the FDA, has expired.
Accordingly, a generic drug is marketed under its chemical name or under a brand
name promoted by its generic manufacturer. While subject to the same government
standards as its brand name equivalent, a generic drug is usually marketed at a
substantially lower price.
Sales of generic drugs have increased significantly in recent years, due in
substantial part to greater awareness and acceptance of generic drugs by
physicians, pharmacists and the general public. Among
50
<PAGE>
<PAGE>
the factors contributing to such increased awareness and acceptance have been
the enactment and modification of laws in most states permitting (or in some
instances requiring) physicians or pharmacists to substitute generic drugs for
brand name drugs, and the publication by the FDA of a list of therapeutically
equivalent drugs which provides physicians and pharmacists with the approved
sources of generic drug alternatives for each drug product. In addition, since
generic drugs are typically sold at prices substantially below those of brand
name drugs, the prescribing of generic drugs has been encouraged and, in some
instances, required by various government agencies and by private health
insurers as a cost-saving measure in the purchase of, or reimbursement for, drug
products.
PRODUCTS
The Company markets both prescription drugs and non-prescription drugs,
also called over-the-counter ('OTC'), in oral solid (tablet and capsule), oral
liquid and topical dosage forms. In accordance with FDA requirements, each
dosage strength and form of a generic drug is considered a separate drug
product. Consequently, classification of the Company's generic drug products and
their number can be generally summarized as follows: antibiotic and
anti-infective drugs (6); cardiovascular drugs (30); anti-inflammatories (12);
analgesics (10); anti-depressants and tranquilizers (34); and all others (16).
Sales of generic prescription drug products equaled 99% of the Company's
revenue for the years ended June 30, 1995 and 1994, compared with 98% for the
year ended June 30, 1993. The sale of OTC drugs accounted for the balance of the
Company's revenue in each of such years. A majority of the Company's products is
sold under its 'Purepac' label and the balance is sold under private label
agreements with certain pharmaceutical distributors.
Nifedipine, the generic version of Pfizer's 'PROCARDIA' cardiovascular
product, accounted for 12%, 13%, and 30% of the Company's generic prescription
drug product revenue for its years ended June 30, 1995, 1994 and 1993,
respectively and 8% for the three months ended September 30, 1995. In 1992 and
later years, additional companies received approval from the FDA to sell
nifedipine and entered the market. It is typical in the generic drug industry
for the first companies selling a new generic product initially to have a
relatively high profit margin, which then decreases as selling prices decline
when more companies enter the market. Consequently, such competition has
continued to erode the Company's gross profit from nifedipine sales, thereby
adversely impacting the Company's net income. In August 1995, the National
Heart, Lung and Blood Institute issued a warning regarding large doses of the
short-acting form of nifedipine. Not all of the Company's nifedipine products
are of the dosage which was the subject of the warning. In addition, the results
and conclusions of the studies upon which such warning was based have been
challenged by some members of the pharmaceutical and medical community.
Accordingly, management is currently unable to determine the effects, if any,
that such warning or that the findings of the reports upon which such warning
was issued, will have upon the Company's levels of sales of nifedipine products.
NEW PRODUCT DEVELOPMENT
Research and development expenses for the years ended June 30, 1995, 1994
and 1993 amounted to $6,741,000, $6,797,000, and $5,944,000, respectively.
During the year ended June 30, 1995, the Company's new product development
program remained focused on AB-rated (substitutable) generic equivalents to a
number of immediate-release and modified-release solid oral prescription
products. As of November 30, 1995, the Company had 19 immediate-release and
modified-release solid oral prescription products in various stages of product
development. Of those, five are in biostudy, one has completed the final
formulation development phase and is awaiting test batch manufacture; six are in
the formulation development stage; four are in the induction phase and three are
undergoing feasibility assessment. No assurances can be given as to the date of
introduction into the marketplace of such products or the extent to which any of
such introductions would generate significant revenues for the Company.
During its fiscal year ended June 30, 1995, the Company received FDA
approval for three new immediate-release generic drug products; gemfibrozil
tablets, metoprolol tartrate tablets and naproxen sodium tablets. During its
1995 fiscal year, the Company also filed two new ANDAs and, at June 30,
51
<PAGE>
<PAGE>
1995, had five ANDAs pending approval. No assurance can be given as to the
receipt or timing of ANDA approvals and the commercial significance of any
products so approved. The proposed acquisition of the Faulding Subsidiaries
would also add four products awaiting FDA approval. See 'Businesses of the
Faulding Subsidiaries.'
MARKETING AND CUSTOMERS
The Company markets its products primarily through a sales force of 11
employees.
The Company's customers include drug wholesalers, national and regional
retail drugstore chains and drug distributors. At June 30, 1995, the Company had
approximately 150 customers. For the fiscal year ended June 30, 1995, Walgreens
and Bergen Brunswig each accounted for 10% or more of sales. The Company
believes that the loss of either or both of these customers, neither of which
has any affiliation with the Company or any other member of the Faulding Group,
could have a material impact on the Company's financial position, operations and
cash flow. For the year ended June 30, 1994, Walgreens and McKesson Drugs each
accounted for 10% or more of sales. No customer accounted for 10% of the
Company's sales in the year ended June 30, 1993.
The backlog of firm orders at June 30, 1995 was $1,050,000, compared with
$3,904,000 at June 30, 1994, and $6,830,000 at June 30, 1993. The Company does
not believe that its backlog is material to an understanding of its historical
and prospective operations since annual fluctuations are primarily attributable
to unpredictable timing differences in the receipt of product orders. The
Company anticipates that it will fill all of its June 30, 1995 backlog during
its year ending June 30, 1996. Seasonality is not a factor in the Company's
business.
MANUFACTURING AND SOURCES OF SUPPLY
The Company manufactures and packages more than 90% of its products
(measured as a percentage of revenue) in its own manufacturing facilities. The
balance of the Company's products are manufactured to its specifications by a
number of outside contractors. Alternative contract manufacturing sources are
available.
Raw materials essential to the conduct of the Company's business are
pharmaceutical chemicals and packaging components which the Company purchases in
bulk from a variety of sources. Historically, the Company has not experienced
any significant difficulty in obtaining the raw materials it requires. If raw
materials from a current supplier were to become unavailable, approval for a
replacement supplier would have to be sought from the FDA. The FDA approval
process could cause a delay of six months or longer in the manufacture of a
product so impacted.
ENVIRONMENTAL MATTERS
The Company's operations require it to comply with a broad variety of laws,
statutes and regulations which are intended to protect both the environment and
the industrial workplace including, among others, the Federal Clean Water Act,
Clean Air Act, Resources Conservation and Recovery Act, Emergency Planning and
Community Right to Know Act, Comprehensive Environmental Response, Compensation
and Liability Act and the Occupational and Safety Health Act, as well as their
state and local equivalents, if any.
The Company believes that it is currently in substantial compliance with
all federal, state and local environmental laws and regulations applicable to
its business as now conducted.
During the years ended June 30, 1995, 1994 and 1993, the Company expended
$30,000, $15,000 and $579,000, respectively, for environmental control equipment
in connection with the expansion of its manufacturing facilities. Capital
expenditures for environmental control equipment for the year ending June 30,
1996 are estimated to be less than $100,000.
52
<PAGE>
<PAGE>
COMPETITION
The Company competes with a number of other significant generic
pharmaceutical companies in a highly competitive and fragmented segment of the
health-care industry. In addition, many of the brand name companies with
substantially greater financial resources for research, development and
marketing are entering the generic market.
Principal competitive factors in the generic drug market include regulatory
compliance, price, customer service (including prompt fulfillment of orders) and
the ability to introduce generic versions of brand name drugs promptly after the
date of patent expiration granted by the United States Patent Office and/or
exclusivity granted by the FDA.
GOVERNMENT REGULATION
Pharmaceutical manufacturers are subject to extensive regulation by the FDA
and other government agencies and authorities. Various federal laws and
regulations govern the testing, manufacturing, safety, labeling, packaging,
storage, pricing, advertising and promotion of the Company's generic drug
products. Failure to comply with such laws and regulations may result in the
imposition of fines, recall and/or seizure of products, suspension of
manufacturing and FDA refusal to approve new drug applications.
REGULATORY APPROVAL PROCESS
The Company's product line primarily consists of generic drug products
which contain the same active ingredient as the innovator (brand name) product.
The dosage form, route of administration and strength must be the same as the
innovator's product which was previously approved by the FDA under a full New
Drug Application ('NDA') and includes the results of clinical trials that
demonstrate safety and efficacy.
Each generic drug product is subject to prior FDA approval through the
submission of an ANDA or an AADA (Abbreviated Antibiotic Drug Application). An
ANDA or AADA must contain essentially the same information as a full NDA, with
the exception of safety and efficacy data. Since a generic drug product contains
the same active ingredient in the same amount as the innovator product, it is
assumed to have the same safety and efficacy profile. Among other matters
addressed in the FDA review process, a generic product must be bioequivalent to
the innovator product referenced in the application. This means that the drug
product must demonstrate the same rate and extent of systemic absorption. An
in-vivo bioavailability study is conducted in healthy human subjects to meet
this requirement. In addition, the generic product must meet appropriate
in-vitro (dissolution) criteria. Quality Control testing is conducted to ensure
that the product meets compendia (United States Pharmacopeia) standards and
in-house specifications, as applicable.
RECENT TRENDS IN FDA PROCEDURES
The FDA has placed greater emphasis on the filing by all generic drug
product manufacturers, including the Company, of complete ANDAs and has
enunciated its position that it will not accept any application that does not
contain all necessary information as specified in the FDA's current guidelines.
In addition, the FDA has imposed more stringent requirements on various aspects
of the product development process, the need for development of new procedures
and increased documentation, all of which potentially extend the time to file
ANDAs.
Another major component of the FDA's review process, applicable to all
generic drug manufacturers, is the product specific pre-approval inspection in
which the FDA focuses on the development of the drug product, the manufacture of
exhibit batches and the applicant's capability to manufacture that product in
accordance with the methods and specifications defined in the ANDA. This manner
of inspection may also potentially lengthen the approval time for ANDAs.
53
<PAGE>
<PAGE>
GOOD MANUFACTURING PRACTICES
As a manufacturer of pharmaceutical products, the Company is also subject
to current Goods Manufacturing Practices ('cGMP') standards promulgated by the
FDA. Failure to comply with such standards may result in, among other actions,
the suspension of production and possibly the seizure of non-complying products.
THE MEDICAID PRUDENT PHARMACEUTICAL PURCHASING ACT OF 1991
This legislation, which became effective January 1, 1991, requires all
generic pharmaceutical manufacturers to pay a rebate, equal to 10% of the
manufacturer's average net selling price, for each prescription of its products
reimbursed by the states under Medicaid. As of January 1, 1994, the rebate
percent increased to 11%.
PROPOSED HEALTH CARE REGULATION
Numerous proposals for health-care regulation and reform have recently been
proposed at both the federal and state levels. These proposals, generally, seek
to reduce the cost of health care and increase its availability and efficiency.
It cannot be determined at this time which, if any, of such proposals will be
enacted and, to the extent enacted, what effect such proposals will have on the
price, distribution and marketing of pharmaceutical products, including those of
the Company.
EMPLOYEES
At September 30, 1995, the Company employed 320 full-time employees. Of
these, 38 were executive and administrative personnel. Personnel primarily
engaged in research, product development and regulatory activities totaled 70.
Marketing and sales personnel totaled 25. Production and distribution personnel
totaled 135, while quality assurance and quality control personnel totaled 52.
Collective bargaining agreements between the Company and Locals 575 and 815 of
the International Brotherhood of Teamsters expiring in January 1997 and January
1996, respectively, covered 110 employees as of September 30, 1995. The Company
has not experienced a material work stoppage in the past five years and believes
that its current labor relations are satisfactory.
PROPERTIES
The Company's executive offices, as well as research, production, principal
warehouse and distribution facilities, are housed in a 245,000 square foot
facility with two adjoining acres of parking space in Elizabeth, New Jersey. In
addition, the Company leases a 13,000 square foot distribution center in Sparks,
Nevada and a 38,000 square foot warehouse and office building in Linden, NJ.
The Company believes that its facilities will be sufficient to satisfy its
anticipated needs for the proximate future.
LITIGATION
On December 20, 1994, an action was commenced against the Company and two
officers of the Company in the United States District Court for the District of
New Jersey entitled Dechter vs. Purepac, Inc., Robert H. Bur and Russell J.
Reardon, 94 Civ. 6195. The complaint, which purported to be a class action on
behalf of purchasers of Purepac, Inc. common stock, asserted, among other
things, violations of Section 10(b) of the Securities Exchange Act of 1934 and
certain common law claims.
The Company believed the allegations in the Complaint to be entirely
without merit, and filed a motion to dismiss the Complaint in March 1995. A
hearing before the Court was held on the Company's motion to dismiss on Monday,
September 11, 1995. At that hearing, the Court granted the Company's motion, and
dismissed the Complaint in its entirety, finding that the Complaint failed to
allege any actual violation of the U.S. securities laws on the part of Purepac,
Inc. or its senior executives.
Pursuant to the court's decision, the plaintiffs had the opportunity to
consider filing a motion with the court for permission to submit a proposed
amended complaint to address the deficiencies that led to
54
<PAGE>
<PAGE>
the court's dismissal of the current action. The plaintiffs elected not to file
such a motion, thereby terminating such litigation.
On or about June 9, 1995, an action was commenced against the Company in
the United States District Court for the District of Delaware entitled Merck &
Co., Inc. v. Purepac Pharmaceutical Co. Case No. 95-495. The Complaint alleges
that the Company's recent submission of an ANDA to the FDA for approval of
generic drug product developed by the Company which would be the Company's
generic version of a branded drug manufactured by Merck constituted an act of
infringement on certain patents owned by Merck with respect to such product as
listed in the FDA's Orange Book of Approved Drug Products with Therapeutic
Equivalence Evaluations (15th ed. 1995).
The Complaint alleges that the Company has represented and certified to the
FDA that its proposed generic product is 'bioequivalent' to Merck's branded
product, and that by virtue of this representation, Purepac would be able to
rely on Merck's safety and efficacy data for such product rather than having to
conduct its own safety and efficacy studies for submission to the FDA. The
Complaint further alleges that Purepac has informed Merck that its proposed
generic drug product will not infringe on the listed patents owned by Merck with
respect to Merck's product on the grounds that the Company's generic product
does not contain all of the elements of the claims of the listed Merck patents
with respect to Merck's products. In the Complaint, Merck disputes the Company's
assertion of non-infringement, and seeks, among other things, (a) a judgment
that the Company's proposed generic product is covered by Merck's patents, (b)
an order delaying any FDA approval of the Company's ANDA until the expiration of
Merck's patents, (c) an order enjoining the Company from the commercial
manufacture or sale of any product that infringes on Merck's patents with
respect to Merck's product, and (d) alternatively, an order requiring the
Company to make further disclosure to the FDA regarding the bioequivalence of
its proposed product. Further, the Complaint also seeks money damages in an
unspecified amount in the event that the Company manufactures, uses or sells any
product found to infringe Merck's patents.
The Company is involved in litigation incidental to the conduct of its
business, in addition to the above matters, and does not believe that the
ultimate adverse resolutions of any, or all, thereof would have a material
adverse effect on its financial position, results of operations or cash flows.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
During the year ended June 30, 1995, Purepac paid F.H. Faulding $734,000
for merchandise purchases and $918,000 for research and development services.
Purepac paid Faulding Services $225,000 for business development consultancy
services pursuant to a consultancy agreement described below. During the year
ended June 30, 1995, F.H. Faulding paid Purepac $1,919,000 for materials and
services related to research and development projects.
During the year ended June 30, 1994, Purepac paid F.H. Faulding $2,536,000
for merchandise purchases, $1,007,000 for research and development services and
paid Faulding Services $127,000 for business development consultancy services.
Purepac also paid Faulding Services $623,000 for engineering and consulting
services related to the construction of a manufacturing suite to accommodate
modified-release pharmaceutical products.
During the year ended June 30, 1994, F.H. Faulding paid Purepac $486,000
for materials and services related to research and development projects and
$200,000 for acquisition of Purepac's Poroplastic'r' technology.
Included in other assets at June 30, 1995 and 1994 is $2,903,000 paid by
Purepac to F.H. Faulding in June 1992 to acquire the proprietary technology,
including the scientific information and expertise, processes and procedures,
for the manufacture and sale of the generic version of certain modified-release
pharmaceutical products. The acquired technology is restricted to use on an
exclusive basis, in the United States of America and its territories. Purepac
plans to amortize the cost of acquiring the technology over its then-estimated
useful life.
Purepac also entered into an agreement with F.H. Faulding as of December 5,
1992, pursuant to which Purepac agreed to provide services to F.H. Faulding for
the tableting of pellets and micropellets
55
<PAGE>
<PAGE>
on a time and materials basis. During the year ended June 30, 1995, no related
services were provided by Purepac to Faulding.
In addition, Purepac and F.H. Faulding entered into a three-year agreement,
also dated as of December 5, 1992, which is automatically renewable for
successive two-year periods, pursuant to which F.H. Faulding granted Purepac a
non-exclusive license to import, distribute and market a modified release
erythromycin product in the United States.
On January 1, 1993, Purepac and Faulding Services entered into a consulting
agreement which terminates on December 31, 1995, pursuant to which Purepac
retained Faulding Services to serve as a business development consultant and
advisor on a non-exclusive basis.
On August 1, 1993, Purepac entered into a ten year agreement with Faulding
Services to manufacture a specific product utilizing Faulding Services'
technology, processes and manufacturing methods. The parties amended this
agreement in December 1994 to resolve certain inconsistencies between it and a
supply and distribution agreement (the 'Distribution Agreement') that Faulding
Services had executed contemporaneously therewith, pursuant to which Faulding
Services had granted to an unrelated third party the exclusive right, in the
United States and its territories, to distribute the product manufactured by
Purepac. In addition, on June 27, 1995 the Company and Faulding Services entered
into a Services Agreement pursuant to which Purepac agreed to provide certain
services, on Faulding Services' behalf, that Faulding Services had committed to
provide, or arranged to provide, under the Distribution Agreement. Under these
three related agreements with Faulding Services, Purepac's obligation to provide
manufacturing services commences upon Faulding Services' obtaining, at its sole
cost, the necessary approvals from the appropriate regulatory authorities to
permit the sale of the product.
On March 15, 1995, Purepac and F.H. Faulding entered into a three-year
non-exclusive license agreement for Purepac to import and distribute a certain
modified delayed release doxycycline product in the United States, in exchange
for $70,000 and ongoing purchase payments for the product, as set forth in the
agreement.
Purepac and F.H. Faulding entered into two agreements as of June 26, 1995.
In one, Faulding granted to Purepac an exclusive ten-year license to utilize
certain technology to complete development of a modified release product and to
manufacture and sell such product in the United States in exchange for (a)
Purepac's reimbursement to F.H. Faulding of all of its costs in connection with
the development of the technology up until the transfer of the technology to
Purepac, (b) a technology transfer fee of $250,000, and (c) certain royalty
payments set forth in the agreement.
The other agreement entered into as of June 26, 1995 is a ten-year
Co-development, Supply and Licensing Agreement whereby F.H. Faulding agrees to
develop and deliver a certain component pellet of a sustained-release product
for Purepac's use in Purepac's development, manufacture and distribution of such
product in the United States. Under this agreement, F.H. Faulding will supply
Purepac with pellets at a price set forth in the agreement. If the parties later
concur that Purepac should manufacture the pellets, F.H. Faulding has agreed to
grant Purepac an exclusive license to the pellet technology for the remainder of
the term of the agreement (currently proposed as a ten-year term with successive
automatic two-year renewal terms). In such case, Purepac will pay F.H. Faulding
a technology transfer fee of $250,000 and ongoing royalty payments as set forth
in the agreement.
As of June 26, 1995, Purepac also entered into a one-year Services
Agreement with FPC for Purepac to provide certain customer support, warehousing,
information/accounting functions and quality assurance services. In addition,
FPC will pay Purepac for any direct costs that Purepac incurs in providing such
services.
Purepac believes that the terms of the foregoing agreements are at least as
favorable as those it could have obtained in comparable nonaffiliated third
party transactions.
56
<PAGE>
<PAGE>
PERFORMANCE GRAPH
Set forth below is a line graph comparing the cumulative stockholder return
on the Company's Common Stock against the cumulative total return of the NASDAQ
Industrial Index and the NASDAQ Pharmaceutical Index for the Company's fiscal
years ended June 30, 1995, June 30, 1994, June 30, 1993, June 30, 1992, and June
30, 1991, respectively.
COMPARISON OF FIVE YEAR CUMULATIVE TOTAL RETURN*
AMONG PUREPAC, INC.,
THE NASDAQ UNITED STATES INDEX AND THE NASDAQ
PHARMACEUTICAL INDEX
[PERFORMANCE GRAPH]
<TABLE>
<CAPTION>
6/90 6/91 6/92 6/93 6/94 6/95
---- ---- ---- ---- ---- ----
<S> <C> <C> <C> <C> <C> <C>
Purepac, Inc. 100 405 1038 705 610 762
NASDAQ United States 100 106 127 160 162 215
NASDAQ Pharmaceutical 100 159 199 176 146 196
</TABLE>
- -----------
* $100 Invested on 11/30/89 in Stock or Index
57
<PAGE>
<PAGE>
EXECUTIVE OFFICERS OF PUREPAC
Set forth below is certain information with respect to Purepac's executive
officers.
Richard F. Moldin, age 48, was appointed President and Chief Executive
Officer of the Company and President of Purepac on July 17, 1995 and was
appointed to serve as a director and acting Chief Operating Officer of the
Company on July 24, 1995 upon Robert H. Bur's resignation from such positions.
See 'Election of Directors -- Information Concerning Nominees' for additional
biographical information with respect to Mr. Moldin.
Lee H. Craker, age 40, was appointed Chief Financial Officer of the Company
on May 26, 1995. Mr. Craker has held various positions with F. H. Faulding, or
certain of its affiliates, dating from his initial employment by F.H. Faulding
in 1973. From May 1985 to May 1990 he served as Finance and Administration
Manager of David Bull Laboratories Pty. Ltd., a wholly owned subsidiary of F.H.
Faulding. From May 1990 to June 1994, he was Finance and Administration Manager
of the Faulding Pharma Group and from July 1994 until joining the Company in May
1995, he was Finance and Administration Manager of Faulding Services.
Garth Boehm, Ph.D., age 45, joined the Company as Vice
President -- Scientific Affairs in April 1990 and was elected Executive Vice
President in October 1991. He was Deputy Research Director of Faulding
Pharmaceuticals, a division of F.H. Faulding, from July 1989 to April 1990. From
1985 to June 1989, he held senior management positions at Enterovax Limited, a
joint venture of F.H. Faulding, the University of Adelaide and the Australian
Industry Development Corporation. Prior thereto and from 1981, he was
Development Scientist of the R&D Division of F.H. Faulding.
The executive officers and directors of Purepac prior to the consummation
of the Faulding Transaction will continue as such after such consummation.
COMPENSATION OF EXECUTIVE OFFICERS
SUMMARY COMPENSATION
Set forth below is the aggregate compensation for services rendered in all
capacities to the Company during its fiscal years ended June 30, 1995, 1994 and
1993 by each of its executive officers who served as executive officers on June
30, 1995 and whose compensation exceeded $100,000 during its fiscal year ended
June 30, 1995:
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
ANNUAL COMPENSATION
-----------------------------------
NAME AND FISCAL OTHER ANNUAL
PRINCIPAL POSITION YEAR SALARY BONUS COMPENSATION
- ------------------------------------------------------------------- ------ -------- ------- ------------
<S> <C> <C> <C> <C>
Michael R.D. Ashton(1) ............................................ 1995 (1) (1) (2)
Chief Executive Officer and President 1994 (1) (1) (2)
1993 (1) (1) (2)
Robert H. Bur(3) .................................................. 1995 $222,153 $ 0 (2)
Chief Operating Officer 1994 $195,356 $60,120 (2)
1993 $148,000 $48,000 (2)
Garth Boehm ....................................................... 1995 $160,814 $ 7,450 (2)
Executive Vice President 1994 $156,344 $29,930 (2)
1993 $143,108 $35,000 (2)
Russell J. Reardon(4) ............................................. 1995 $135,992 $ 6,650 (2)
Vice President of Administration 1994 $128,214 $34,020 (2)
1993 $120,002 $35,000 (2)
</TABLE>
- ------------
(1) Michael R.D. Ashton served as President and Chief Executive Officer of the
Company from January 25, 1995 until his resignation, effective July 17,
1995. Mr. Ashton previously served from April 1989 to January 1, 1993, as
Chief Executive Officer of the Company. During the fiscal year ended June
30, 1995 and the six-month period ended January 1, 1993, Mr. Ashton, who
also served
(footnotes continued on next page)
58
<PAGE>
<PAGE>
(footnotes continued from previous page)
as Chairman and Chief Executive Officer of Faulding Services, Faulding and
FMDC, was compensated by Faulding Services. Purepac and Faulding Services
are parties to a Consulting Agreement pursuant to which Faulding Services
renders business consultancy services, including the services of Mr. Ashton,
to Purepac. See 'Certain Relationships and Related Transactions.'
(2) Such amounts for each of the named executive officers listed in the Summary
Compensation Table are less than 10% of the total annual salary and bonus
reported for each such executive officer.
(3) Robert H. Bur served as the Company's president and CEO until his
resignation from such offices in January 1995. He resigned his position of
Chief Operating Officer of the Company on July 24, 1995.
(4) Mr. Reardon resigned on October 11, 1995.
STOCK OPTIONS AND BONUS PLANS
The Company's 1994 Stock Option Plan (the '1994 Plan') was adopted by the
Purepac Board on August 16, 1994 and by a majority in interest of the
stockholders of the Company on October 18, 1994. The 1994 Plan provides for the
granting of up to 1,000,000 options which are intended to qualify either as
incentive stock options ('Incentive Stock Options') within the meaning of
Section 422 of the Internal Revenue Code of 1986 or as options which are not
intended to meet the requirements of such section ('Nonstatutory Stock
Options'). The total number of shares of Purepac Common Stock reserved for
issuance under the 1994 Plan is 1,000,000. Options to purchase shares may be
granted under the 1994 Plan to persons who, in the case of Incentive Stock
Options, are employees (including officers) of the Company, or, in the case of
Nonstatutory Stock Options, are employees (including officers) or non-employee
directors of the Company.
The 1994 Plan is administered by a committee appointed by the Board of
Directors, which has discretionary authority, subject to certain restrictions,
to determine the number of shares issued pursuant to Incentive Stock Options and
Nonstatutory Stock Options and the individuals to whom, the time at which, and
the exercise price for which options will be granted.
The exercise price of all Incentive Stock Options granted under the 1994
Plan must be at least equal to the fair market value of such shares on the date
of the grant or, in the case of Incentive Stock Options granted to the holder of
more than ten percent of Purepac's Common Stock, at least 110% of the fair
market value of such shares on the date of the grant. The maximum exercise
period for which Incentive Stock Options may be granted is ten years from the
date of grant (five years in the case of an individual owning more than 10% of
the Purepac's Common Stock). The aggregated fair market value (determined at the
date of the option grant) of shares with respect to which Incentive Stock
Options are exercisable for the first time by the holder of the options during
any calendar year shall not exceed $100,000.
None of the executive officers of the Company named in the Summary
Compensation Table holds options to purchase shares of Purepac's Common Stock.
Upon commencing employment as the Company's Chief Executive Officer and
President, Richard F. Moldin, who currently is also the acting Chief Operating
Officer of the Company, a director of the Company, and President of Purepac
Pharmaceutical Co., was granted an Incentive Stock Option under the 1994 Plan to
purchase 49,382 shares of the Company's Common Stock and non-statutory stock
options to acquire 100,618 shares of Purepac Common Stock in each case
exercisable at $10.125 per share. His option is not currently exercisable.
1991 RESTRICTED STOCK INCENTIVE PLAN
The Company's 1991 Restricted Stock Incentive Plan (the '1991 Plan') was
adopted by the Board of Directors on November 25, 1991 and ratified by a
majority in interest of the stockholders of the Company on October 21, 1992. The
stated intent of the 1991 Plan is to induce persons of outstanding ability and
potential to join and remain with the Company and to enable key employees, who
make substantial contribution to the Company, to acquire proprietary equity
interests in the Company.
59
<PAGE>
<PAGE>
The Board of Directors chooses the Committee, whose members are ineligible
to receive stock awards under the 1991 Plan, to administer the Plan. The
Committee determines the employees to whom awards of Common Stock will be
granted and the amount, size and terms of each such award.
A total of 465,000 shares of Purepac Common Stock were reserved for
issuance under the 1991 Plan, of which aggregate grants of 275,000 and 50,000
were awarded in November 1991 and March 1993, respectively, at the respective
values of $8.125 and $13.8125, being the respective market value thereof on the
date of the grant. During the year ended June 30, 1995, due to two resignations,
grants totaling 10,500 shares were terminated. During the year ended June 30,
1995, the Company issued 71,125 shares of Common Stock to employees pursuant to
the 1991 Plan.
AGREEMENTS WITH OFFICERS
Michael R.D. Ashton had served as President and Chief Executive Officer of
Purepac from April 1989 to January 1993 and from January 1995 to July 1995. Mr.
Ashton has entered into a consulting agreement with Purepac and F.H. Faulding
pursuant to which Mr. Ashton will provide certain consulting services to such
companies. Pursuant to such agreement, Purepac has paid an aggregate of $150,000
of the compensation payable to Mr. Ashton. All other compensation under such
agreement is the responsibility of affiliates of F.H. Faulding.
On July 24, 1995 the Company entered into an agreement with Robert H. Bur,
the Company's Chief Operating Officer, under which the Company has agreed to pay
Mr. Bur severance equal to approximately one year's salary, plus his accrued
vacation, in twelve monthly payments. The Company has also agreed to continue
Mr. Bur's medical and dental plan coverage for a period ending on the earlier of
twelve months after the date of the agreement or Mr. Bur's enrollment in another
medical plan, and to permit Mr. Bur to have continued use of a Company car until
October 24, 1995.
PENSION PLAN
The Company maintains a defined benefit pension plan, fully paid for by the
Company, for the benefit of eligible employees. All non-union employees become
eligible for participation in the pension plan on January 1 or July 1, as
applicable, following completion of one year of service. 159 persons were
participants in the pension plan as of June 30, 1995.
A participant in the Company's pension plan will receive retirement income
based on .91% of his final average annual compensation, defined in the pension
plan as including salary, bonuses, overtime and commissions, plus .52% of his
final average annual compensation in excess of Social Security covered
compensation, multiplied by years of credited service up to 35 years. Years of
service for benefit accrual purposes are only after January 1, 1976. Final
average compensation is defined in the pension plan as the average of a
participant's total compensation received during the highest paid five
consecutive plan years during the last 10 consecutive plan years immediately
prior to retirement. A participant is 100% vested in his accrued pension benefit
after five years of service as defined in the plan. The vested benefit of many
participants employed prior to October 31, 1989, are provided through both the
Purepac Plan and the Solvay Group Pension Plan, the predecessor company's plan.
60
<PAGE>
<PAGE>
The following table indicates the estimated annual plan benefits payable
upon retirement as of June 30, 1995 at age sixty-five after fifteen, twenty,
twenty-five, thirty and thirty-five years of credited service to the Company:
PENSION PLAN TABLE
<TABLE>
<CAPTION>
BENEFIT AT YEARS OF SERVICE
AVERAGE ---------------------------------------------------
COMPENSATION 15 20 25 30 35
- ----------------------------------------------------------- ------- ------- ------- ------- -------
<S> <C> <C> <C> <C> <C>
$125,000.................................................. $24,916 $33,222 $41,527 $49,832 $58,138
150,000.................................................. 30,279 40,372 50,464 60,557 70,650
175,000.................................................. 30,279 40,372 50,464 60,557 70,650
200,000.................................................. 30,279 40,372 50,464 60,557 70,650
225,000.................................................. 30,279 40,372 50,464 60,557 70,650
250,000.................................................. 30,279 40,372 50,464 60,557 70,650
300,000.................................................. 30,279 40,372 50,464 60,557 70,650
350,000.................................................. 30,279 40,372 50.464 60,557 70,650
400,000.................................................. 30,279 40,372 50,464 60,557 70,650
450,000.................................................. 30,279 40,372 50,464 60,557 70,650
500,000.................................................. 30,279 40,372 50,464 60,557 70,650
</TABLE>
At June 30, 1995, the credited years of service under the pension plan for
Messrs. Ashton, Bur and Reardon were five, fifteen and four, respectively. Dr.
Boehm is not a participant in the pension plan.
SAVINGS PLAN
The Company has a savings plan, implemented as of January 1, 1990, covering
all non-union employees of the Company and its subsidiaries. Under the savings
plan, employees may defer up to 15% of their salary, to a maximum of $9,240 per
annum. The Company makes an annual matching contribution equal to 50% of an
employee's contribution, not exceeding 6% of the employee's salary. Matching
contributions are vested at the rate of 20% per annum commencing upon one year's
participation in the savings plan. All vested amounts in a participant's
account, including earnings, may be distributed only following hardship,
retirement, death, permanent or total disability or termination of employment.
For the three-year period ended June 30, 1995, the Company had contributed
an aggregate of $628,367 to the savings plan (net of forfeitures of non-vested
amounts), for the respective accounts of 153 participants. Of such $628,367, an
aggregate of $35,250 has been credited to the accounts of all current executive
officers as a group, being $14,798, $6,847, and $13,605 for the respective
accounts of Mr. Bur, Dr. Boehm and Mr. Reardon.
COMPENSATION COMMITTEE REPORT ON EXECUTIVE COMPENSATION
GENERAL COMPENSATION POLICIES
The Company's Compensation Committee (the 'Committee') is responsible for
establishing, approving and administering the policies which govern annual
executive salary levels, increases/adjustments, incentive payments the award of
stock grants under the Company's 1991 Restricted Stock Incentive Plan and the
award of stock options under the Company's 1994 Stock Option Plan. The Committee
is composed of three members, all of whom are non-employee directors. See
'Compensation Committee Interlocks and Insider Participation.'
In setting salary levels, providing incentives and granting stock and
option incentives, the objectives of the Committee are to encourage profitable
growth of the Company in a mutuality of interest between the Company's
executives and stockholders and to balance competitive pay with the Company's
overall performance. Specifically, the Committee attempts to provide levels of
compensation to the President/Chief Executive Officer and the Company's other
executive officers which reflect the contribution of such executives to the
Company's growth in sales, earnings and market share, the
61
<PAGE>
<PAGE>
development of stockholder value as reflected in the increase in the Company's
stock price and the implementation of corporate strategies consistent with the
growth of the Company.
Growth in earnings is a significant factor in determining compensation. In
addition, contribution to the development of new product opportunities, the
progress of bioavailability and other studies and of development activities
required to bring products to market and the successful marketing of the
Company's primary products are evaluated in setting compensation policy. As
well, to assure the Company's ability to attract, motivate and retain talented
executives, the Committee attempts to keep the Company's levels of executive
compensation competitive with that of other health care companies of comparable
size and performance.
PRESIDENT/CHIEF EXECUTIVE OFFICER AND EXECUTIVE OFFICERS COMPENSATION
The Company's executive compensation program consists of three key
components: base salary, a cash incentive scheme and long term incentives
through the awards of restricted stock grants and stock options. The incentive
payments have two performance components: (a) a financial budget achievement
target based on net profit before taxes and (b) achievement of specific
job-related objectives. The underlying principle for the design and
implementation of the Company's incentive scheme is based on the concept that
the Company commit in advance to predetermined annual levels of performance.
Actual results achieved are measured against that commitment.
The Company's long term incentives to date have been in the form of
restricted stock and stock option grants. The object of this program has been to
advance the longer term interest of the Company and its stockholders. Equity
compensation is an important element of the performance-based compensation of
the executive officers and helps to ensure that management's interests remain
closely aligned with those of the Company's stockholders. The Committee is of
the view that restricted stock awards and stock option grants provide the
Company's key employees an opportunity for increased equity ownership and help
to create an incentive to remain with the Company for the long term, since the
grants vest over a four to six year period.
Prior to the last six months of the fiscal year ended June 30, 1995, the
compensation of the Company's President and Chief Executive Officer has
reflected the Committee's assessment of the Company's overall financial
performance and of his leadership in strengthening the position of the Company.
Robert H. Bur was President and Chief Executive Officer of the Company until his
resignation from such positions in January 1995. He remained as the Company's
Chief Operating Officer until July 24, 1995.
Mr. Bur's compensation package for the fiscal year ended June 30, 1995 was
established in July 1994. He was granted a base salary of $215,000. He was also
awarded a cash incentive award of $60,120 in September 1994 in respect of work
he had performed for the fiscal year ended June 30, 1994. Mr. Bur's leadership
contribution to the implementation of the Company's programs during the fiscal
year ended June 30, 1994 was the primary criterion used in determining his
compensation package.
In January 1995, Michael R.D. Ashton was appointed President and Chief
Executive Officer of the Company. His yearly salary as President of Faulding
Services had already been established by the directors of Faulding and was not
altered upon his acceptance of his additional responsibilities as President and
CEO of the Company. During the period from his appointment in January 1995
through the end of 1995, Faulding Services paid Mr. Ashton's compensation.
Purepac and Faulding Services are parties to a Consulting Agreement dated
January 1, 1993 pursuant to which Faulding Services provides consulting services
to Purepac, including, among other services, the services of Mr. Ashton.
On July 17, 1995, the Company appointed Richard F. Moldin as President and
Chief Executive Officer of the Company. It is contemplated that his continued
compensation will reflect the performance-based factors used by the Company in
previous financial years.
$1,000,000 LIMIT ON TAX DEDUCTIBLE COMPENSATION
As part of the Omnibus Budget Reconciliation Act passed by Congress in
1993, a new limit has been created for the deductibility of compensation paid to
certain officers. These officers are the Chief
62
<PAGE>
<PAGE>
Executive Officer and the next four most highly compensated officers in office
at the end of the year. Compensation paid to these officers in excess of
$1,000,000, that is not performance-based, cannot be claimed by the Company as a
tax deduction.
It is the Committee's intention to continue to utilize performance-based
compensation. Accordingly, these regulations should not impact the compensation
paid by the Company to its officers.
<TABLE>
<S> <C>
Edward D. Tweddell Members of the Compensation
Alan G. McGregor Committee
David Beretta August 10, 1995
</TABLE>
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
Dr. Tweddell is Group Managing Director and Chief Executive Officer and a
director of F.H. Faulding. He is also a director of Faulding, FPR, FPC, FMDC and
Faulding Services. Faulding owns approximately 54.4% of Purepac's Common Stock,
plus preferred stock convertible into additional shares of Purepac's Common
Stock. Alan G. McGregor is Chairman of the Board and a director of F.H.
Faulding. See 'Principal Stockholders of Purepac' and 'Certain Relationships and
Related Transactions.'
PRINCIPAL STOCKHOLDERS OF PUREPAC
The following table sets forth certain information regarding shares of the
Company's outstanding Purepac Common Stock beneficially owned on January 24,
1996, (i) by each person who is known by the Company to beneficially own or
exercise voting or dispositive control over more than 5% of Purepac's Common
Stock, and (ii) by each of the Company's Directors, and (iii) by all executive
officers and Directors of the Company as a group:
<TABLE>
<CAPTION>
NAME OF NUMBER OF SHARES PERCENTAGE
BENEFICIAL OWNER BENEFICIALLY OWNED OF CLASS
- ----------------------------------------------------------------------- ------------------ ----------
<S> <C> <C>
Faulding Holdings Inc. ................................................ 11,845,108(1) 67.4%(1)
529 Fifth Avenue
8th Floor
New York, New York 10017
All executive officers and directors as a group 5,250(2) *
(9 persons)..........................................................
</TABLE>
- ------------
(1) Includes 5,005,128 shares issuable upon conversion of 834,188 shares of the
Company's Class A Preferred Stock.
(2) Mr. McGregor is Chairman and a director, and Dr. Tweddell is Group Managing
Director, Chief Executive Officer and a director, respectively, of F.H.
Faulding. Dr. Tweddell is also a director of Faulding, FPR, FPC and FMDC.
Each of Dr. Tweddell and Mr. McGregor, however, disclaims any beneficial
interest in or voting or dispositive control over the shares of Purepac's
Common Stock owned by Faulding. Does not include 150,000 shares issuable to
Mr. Moldin upon the exercise of options, not presently exercisable, granted
under the 1994 Stock Option Plan. Faulding disclaims any beneficial interest
in or voting or dispositive control over any such shares.
* Equals a percentage less than 1% of the outstanding shares of the Company's
stock.
STOCKHOLDER PROPOSALS
Stockholders' proposals intended to be presented at the Company's 1996
Annual Meeting of Stockholders pursuant to the provisions of Rule 14a-8,
promulgated under the Exchange Act, must be received at the Company's offices
not later than June 17, 1996, for inclusion in the Company's Proxy Statement and
form of proxy relating to that meeting.
63
<PAGE>
<PAGE>
[THIS PAGE INTENTIONALLY LEFT BLANK]
<PAGE>
<PAGE>
FINANCIAL STATEMENTS
<TABLE>
<S> <C>
Financial Statements of the Faulding Subsidiaries
Faulding Medical Device Co., for the years ended June 30, 1995 and 1994............................... F-2
Faulding Medical Device Co., for the three months ended September 30, 1995 and 1994 (unaudited)....... F-9
Faulding Pharmaceutical Co., for the period from April 7, 1995 (date of inception) through June 30,
1995................................................................................................. F-14
Faulding Pharmaceutical Co. for the three months ended September 30, 1995 (unaudited)................. F-21
Faulding Puerto Rico, Inc., for the period April 7, 1995 (date of inception) to June 30, 1995......... F-26
Faulding Puerto Rico, Inc. for the three months ended September 30, 1995 (unaudited).................. F-34
Aguadilla Branch Operations of DuPont Merck Pharma for the period from January 1, 1995 through April
6, 1995 (unaudited).................................................................................. F-39
Aguadilla Branch Operations of DuPont Merck Pharma for the years ended December 31, 1994 and 1993..... F-44
Financial Statements of Purepac, Inc.
For the years ended June 30, 1995 and 1994....................................................... F-53
For the three months ended September 30, 1995 (unaudited)........................................ F-72
</TABLE>
F-1
<PAGE>
<PAGE>
FAULDING MEDICAL DEVICE CO.
FINANCIAL STATEMENTS
FOR THE YEARS ENDED JUNE 30, 1995 AND 1994,
AND
INDEPENDENT AUDITORS' REPORT
F-2
<PAGE>
<PAGE>
INDEPENDENT AUDITORS' REPORT
To the Stockholder of
FAULDING MEDICAL DEVICE CO.
We have audited the accompanying balance sheets of Faulding Medical Device
Co. (the 'Company') as of June 30, 1995 and 1994, and the related statements of
operations and deficit and cash flows for the years then ended. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform an audit to obtain
reasonable assurance whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, such financial statements present fairly, in all material
respects, the financial position of the Company at June 30, 1995 and 1994 and
the results of its operations and cash flows for the years then ended in
accordance with generally accepted accounting principles.
DELOITTE & TOUCHE LLP
Parsippany, New Jersey
August 9, 1995
F-3
<PAGE>
<PAGE>
FAULDING MEDICAL DEVICE CO.
BALANCE SHEETS
JUNE 30, 1995 AND 1994
<TABLE>
<CAPTION>
1995 1994
----------- -----------
<S> <C> <C>
ASSETS
Current assets:
Cash........................................................................... $ 49,736 $ 34,514
Accounts receivable -- trade................................................... 437,535 606,042
Prepaid expenses............................................................... 6,049 4,038
----------- -----------
Total current assets...................................................... 493,320 644,594
Property, plant and equipment (Note 3).............................................. 1,988,276 2,099,641
Patents and trademarks (Note 7)..................................................... 366,390 191,973
----------- -----------
Total assets.............................................................. $ 2,847,986 $ 2,936,208
----------- -----------
----------- -----------
LIABILITIES AND STOCKHOLDER'S DEFICIENCY
Current liabilities:
Accounts payable and accrued charges........................................... $ 69,962 $ 16,100
Due to a related company (Note 7).............................................. 4,928,602 4,734,512
----------- -----------
Total current liabilities................................................. 4,998,564 4,750,612
----------- -----------
Stockholder's deficiency:
Common stock -- authorized, an unlimited number of common shares, issued and
paid, 100 common shares....................................................... 100 100
Accumulated deficit............................................................ (2,150,678) (1,814,504)
----------- -----------
Total stockholder's deficiency............................................ (2,150,578) (1,814,404)
----------- -----------
Total liabilities and stockholder's deficiency...................................... $ 2,847,986 $ 2,936,208
----------- -----------
----------- -----------
</TABLE>
See Notes to Financial Statements.
F-4
<PAGE>
<PAGE>
FAULDING MEDICAL DEVICE CO.
STATEMENTS OF OPERATIONS AND DEFICIT
FOR THE YEARS ENDED JUNE 30, 1995 AND 1994
<TABLE>
<CAPTION>
1995 1994
---------- ----------
<S> <C> <C>
Sales................................................................................. $2,454,709 $1,947,084
Cost of goods sold.................................................................... 1,664,015 1,363,799
---------- ----------
Gross margin.......................................................................... 790,694 583,285
Research and development expenses..................................................... 696,081 503,524
Management fees (Note 7).............................................................. 138,798 123,467
Depreciation and amortization......................................................... 291,989 261,552
---------- ----------
Net loss.............................................................................. 336,174 305,258
Accumulated deficit, beginning of year................................................ 1,814,504 1,509,246
---------- ----------
Accumulated deficit, end of year...................................................... $2,150,678 $1,814,504
---------- ----------
---------- ----------
Loss per common share................................................................. $ 3,362 $ 3,053
---------- ----------
---------- ----------
</TABLE>
See Notes to Financial Statements.
F-5
<PAGE>
<PAGE>
FAULDING MEDICAL DEVICE CO.
STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED JUNE 30, 1995 AND 1994
<TABLE>
<CAPTION>
1995 1994
--------- ---------
<S> <C> <C>
Cash flows from operating activities:
Net loss........................................................................... $(336,174) $(305,258)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization................................................. 291,989 261,552
Write-off of accounts receivable -- other..................................... -- 46,361
Changes in operating assets and liabilities:
Decrease (increase) in accounts receivable -- trade........................... 168,507 (352,557)
Increase in prepaid expenses.................................................. (2,011) (2,430)
Increase (decrease) in accounts payable and accrued charges................... 53,862 (9,050)
--------- ---------
Net cash provided by (used in) operating activities...................... 176,173 (361,382)
--------- ---------
Cash flows from investing activities:
Purchase of property, plant and equipment.......................................... (161,424) (131,931)
Purchase of patents and trademarks................................................. (193,617) --
--------- ---------
Net cash used in investing activities.................................... (355,041) (131,931)
--------- ---------
Cash flows from financing activity:
Net increase in amount due to a related company.................................... 194,090 496,722
--------- ---------
Net cash provided by financing activity.................................. 194,090 496,722
--------- ---------
Net increase in cash.................................................................... 15,222 3,409
Cash balance, beginning of year......................................................... 34,514 31,105
--------- ---------
Cash balance, end of year............................................................... $ 49,736 $ 34,514
--------- ---------
--------- ---------
</TABLE>
See Notes to Financial Statements.
F-6
<PAGE>
<PAGE>
FAULDING MEDICAL DEVICE CO.
NOTES TO FINANCIAL STATEMENTS
YEARS ENDED JUNE 30, 1995 AND 1994
1. DESCRIPTION OF BUSINESS
Faulding Medical Device Co. (the 'Company'), a Delaware corporation
qualified in the state of Arizona, was incorporated on May 9, 1989 and is a
wholly-owned subsidiary of Faulding Holdings Inc. ('Faulding'), which is a
wholly-owned subsidiary of F.H. Faulding & Co. Limited ('F.H. Faulding'). As of
July 26, 1995, the Company changed its name from DBL Inc. to Faulding Medical
Device Co. The Company's principal business is to design, develop and
commercialize injectable related disposable devices and injectable drug delivery
system devices. These devices are designed to enhance the speed and safety of
injectable drug delivery. While the Company has developed and/or acquire the
exclusive license in the United States to commercialize three drug dependent
devices and intravenous delivery systems, such products as yet are not
commercially available in the United States. While two of such products, which
incorporate proprietary devices with shell glass vials pre-filled with an
injectable generic drug, have received FDA marketing approval, additional
drug-specific approvals for these products are required before sales of these
devices filled with a drug can be made. The exclusive rights to such products
outside of the United States have been licensed by the Company to F. H. Faulding
pursuant to an agreement dated July 1, 1995. Such agreement provides F. H.
Faulding the right to sub-license such technology on a product-by-product basis
to its affiliates. In accordance with such agreement, affiliates of F. H.
Faulding currently market products utilizing the drug dependent technology in
Canada and Portugal, F. H. Faulding and its affiliates are required to purchase
the devices from the Company.
2. ACCOUNTING POLICIES
The financial statements have been prepared in accordance with generally
accepted accounting principles in the United States and include the following
significant accounting policies.
Property, Plant and Equipment -- Property, plant and equipment are stated
at cost less accumulated depreciation and are depreciated using the declining
balance method over the estimated useful lives as follows:
<TABLE>
<S> <C>
Computer equipment................................................................ 4 years
Plant equipment................................................................... 10 years
Furniture and fixtures............................................................ 5 years
</TABLE>
Patents and Trademarks -- Patents and trademarks are stated at cost and are
amortized over a ten-year period.
Income Taxes -- The Company utilizes the provisions of Statement of
Financial Accounting Standard No. 109, 'Accounting for income taxes' ('SFAS
109'). SFAS 109 requires the Company to compute deferred income taxes based on
the difference between the financial statement and tax basis of assets and
liabilities using enacted tax rates in effect in the years in which the
differences are expected to reverse.
Revenue Recognition -- Sales are recorded upon shipments of products to
customer.
3. PROPERTY, PLANT AND EQUIPMENT
<TABLE>
<CAPTION>
1995 1994
---------- ----------
<S> <C> <C>
Computer equipment................................................ $ 34,848 $ 15,312
Plant equipment................................................... 2,818,248 2,676,360
Furniture and fixtures............................................ 1,891 1,891
---------- ----------
2,854,987 2,693,563
Accumulated depreciation.......................................... 866,711 593,922
---------- ----------
$1,988,276 $2,099,641
---------- ----------
---------- ----------
</TABLE>
F-7
<PAGE>
<PAGE>
FAULDING MEDICAL DEVICE CO.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
YEARS ENDED JUNE 30, 1995 AND 1994
4. PATENTS AND TRADEMARKS
<TABLE>
<CAPTION>
1995 1994
-------- --------
<S> <C> <C>
Cost.................................................................. $385,590 $191,973
Accumulated depreciation.............................................. 19,200 --
-------- --------
$366,390 $191,973
-------- --------
-------- --------
</TABLE>
5. INCOME TAXES
The Company has recorded a deferred tax asset of approximately $657,000 and
$520,000 at June 30, 1995 and 1994, respectively, which primarily reflects the
net tax effect of temporary differences between the carrying amount of property,
plant and equipment for financial reporting purposes and the amounts used for
income tax purposes. A full valuation allowance has been recorded against such
amounts as the Company cannot currently demonstrate the ability to recognize
such asset.
The Company has net operating losses available as carryforwards to reduce
future Federal income taxes. State tax losses are also available as carry
forwards. At June 30, 1995, for Federal tax purposes, the net operating loss
carry forward amounted to $2,507,000 and $2,692,000 for state which expire
through 2008. The future utilization of the net operating loss carryforwards by
the Company is subject to limitation under provisions of the Internal Revenue
Code.
6. LEASE COMMITMENTS
The Company has operating leases expiring in 1998. Minimum annual rental
commitment for the next three years is as follows:
<TABLE>
<S> <C>
1996............................................................................... $29,520
1997............................................................................... 13,320
1998............................................................................... 3,960
-------
$46,800
-------
-------
</TABLE>
7. RELATED PARTY TRANSACTIONS
During the year, the following transactions occurred with F.H. Faulding and
its entities:
<TABLE>
<CAPTION>
1995 1994
---------- ----------
<S> <C> <C>
Purchase of goods................................................. $1,554,967 $1,253,426
Consulting fees................................................... 40,654 59,174
Management fees................................................... 138,798 123,467
</TABLE>
As of June 30, 1995, the outstanding payable balance to Faulding was
$4,928,602.
8. SEGMENT INFORMATION
The Company's sales for each of the two years ended June 30, 1995 were
generated by the sale of certain anti-cancer products pursuant to an agreement
with Steris Inc. Management does not believe significant credit risk related to
Steris Inc. exists at June 30, 1995. The accounts receivable balance from Steris
Inc. amounted to $423,605 as of June 30, 1995.
F-8
<PAGE>
<PAGE>
FAULDING MEDICAL DEVICE CO.
FINANCIAL STATEMENTS (UNAUDITED)
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 1995 AND 1994
F-9
<PAGE>
<PAGE>
FAULDING MEDICAL DEVICE CO.
BALANCE SHEET (UNAUDITED)
AS OF SEPTEMBER 30, 1995
<TABLE>
<CAPTION>
ASSETS
<S> <C>
Current assets
Cash.......................................................................................... $ 17,476
Accounts receivable -- trade.................................................................. 336,920
Prepaid expenses.............................................................................. 50,238
-----------
Total current assets..................................................................... 404,634
Property, plant and equipment...................................................................... 1,950,716
Patents and trademarks............................................................................. 356,789
-----------
Total assets........................................................................ $ 2,712,139
-----------
-----------
LIABILITIES AND STOCKHOLDER'S DEFICIENCY
Current liabilities
Accounts payable and accrued charges.......................................................... $ 79,959
Due to a related company...................................................................... 4,996,616
-----------
Total current liabilities................................................................ $ 5,076,575
-----------
Stockholder's deficiency
Common stock
Authorized -- an unlimited number of common shares.......................................
Issued paid -- 100 common shares......................................................... 100
Accumulated deficit........................................................................... (2,364,536)
-----------
Total stockholder's deficiency...................................................... (2,364,436)
-----------
Total liabilities and stockholder's deficiency...................................... $ 2,712,139
-----------
-----------
</TABLE>
See Notes to Financial Statements.
F-10
<PAGE>
<PAGE>
FAULDING MEDICAL DEVICE CO.
STATEMENTS OF OPERATIONS AND DEFICIT
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 1995 AND 1994
<TABLE>
<CAPTION>
THREE MONTHS ENDED
SEPTEMBER 30,
--------------------------
1995 1994
----------- -----------
(UNAUDITED)
<S> <C> <C>
Sales............................................................................... $ 337,985 $ 681,029
Cost of goods sold.................................................................. 219,690 469,153
----------- -----------
Gross margin........................................................................ 118,295 211,876
Research and Development expenses................................................... 229,695 123,941
Management fees..................................................................... 32,000 34,000
Depreciation and amortization....................................................... 70,458 45,750
----------- -----------
Net loss....................................................................... (213,858) 8,185
Accumulated deficit, beginning of period............................................ 2,150,678 1,814,504
----------- -----------
Accumulated deficit, end of period.................................................. $(2,364,536) $(1,806,319)
----------- -----------
----------- -----------
(Loss)/income per common share...................................................... $ (2,139) $ 82
----------- -----------
----------- -----------
</TABLE>
See Notes to Financial Statements.
F-11
<PAGE>
<PAGE>
FAULDING MEDICAL DEVICE CO.
STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 1995 AND 1994
<TABLE>
<CAPTION>
THREE MONTHS ENDED
SEPTEMBER 30,
----------------------
1995 1994
--------- ---------
(UNAUDITED)
<S> <C> <C>
Cash flows from operating activities
Net loss........................................................................... $(213,858) $ 8,185
Adjustments to reconcile net loss to net cash provided by operating activities.....
Depreciation and amortization...................................................... 47,161 45,750
Changes in operating assets and liabilities
Decrease in accounts receivable -- trade...................................... 100,615 256,886
Increase in prepaid expenses.................................................. (44,189)
Increase in accounts payable and accrued charges.............................. 9,997 36,800
--------- ---------
Net cash provided by (used in) operating activities................................ (100,274) 347,621
--------- ---------
Cash flows from investing activities
Purchase of property, plant and equipment..........................................
Purchase of patents and trademarks................................................. -- --
--------- ---------
Net cash (used in) investing activities............................................ -- --
--------- ---------
Cash flows from financing activity
Net increase (decrease) in amount due to a related company......................... 68,014 (328,860)
Net cash provided by (used in) financing activity.................................. 68,014 (328,860)
--------- ---------
Net increase (decrease) in cash......................................................... (32,260) 18,761
Cash balance, beginning of period....................................................... 49,736 34,514
--------- ---------
Cash balance, end of period............................................................. $ 17,476 $ 52,275
--------- ---------
--------- ---------
</TABLE>
See Notes to Financial Statements.
F-12
<PAGE>
<PAGE>
FAULDING MEDICAL DEVICE CO.
NOTES TO FINANCIAL STATEMENTS (UNAUDITED)
The notes to the financial statements of the Faulding Medical Device Co.
for the years ended June 30, 1995 and 1994 contain information pertinent to the
accompanying financial statements. There has been no material change in the
information contained in such footnotes. The balance sheet at September 30, 1995
and the related statements of operations and deficit and cash flows for the
three months ended September 30, 1995 and September 30, 1994, have not been
audited.
In the opinion of management, all adjustments (consisting only of normal
recurring entries) necessary for a fair presentation of such financial results
have been included.
BASIS OF PRESENTATION
The financial statements have been prepared in accordance with general
accepted accounting principles.
INCOME TAXES
The Company utilizes the provisions of Statement Financial Accounting
Standard No. 109 'Accounting for income taxes' ('SFAS 109'). SFAS 109 requires
the Company to compute deferred income taxes based on the difference between the
financial statement and tax basis of assets and liabilities using tax rates in
effect in the years in which the differences are expected to reverse.
The Company has recorded a deferred tax asset of approximately $690,000 at
September 30, 1995, which primarily reflects the net tax effect of temporary
differences between the carrying amount of property, plant and equipment for
financial reporting purposes and the amounts used for income tax purposes. A
full valuation allowance has been recorded against such amounts as the Company
cannot currently demonstrate the ability to recognize such asset.
The Company has net operating losses available as carry forwards to reduce
future federal income taxes. State tax losses are also available as carry
forwards. At September 30, 1995, for federal tax purposes, the net operating
loss carry forward amounted to $2,607,000 and $2,792,000 for state which expire
through 2008. The future utilization of the net operating loss carry forwards by
the Company is subject to limitation under provisions of the Internal Revenue
Code.
F-13
<PAGE>
<PAGE>
FAULDING PHARMACEUTICAL CO.
FINANCIAL STATEMENTS
FOR THE PERIOD FROM APRIL 7, 1995 (DATE OF INCEPTION)
THROUGH JUNE 30, 1995
AND
INDEPENDENT AUDITORS' REPORT
F-14
<PAGE>
<PAGE>
INDEPENDENT AUDITORS' REPORT
To the Board of Directors and Stockholders
OF FAULDING PHARMACEUTICAL CO.
We have audited the accompanying balance sheet of Faulding Pharmaceutical
Co. (the 'Company') as of June 30, 1995, and the related statement of operations
and of cash flows for the period from April 7, 1995 (date of inception) to June
30, 1995. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audit.
We conducted our audit in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statement. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audit provides a reasonable basis for our opinion.
In our opinion, such financial statements present fairly, in all material
respects, the financial position of Faulding Pharmaceutical Co. as of June 30,
1995, and the results of its operations and its cash flows for the period April
7, 1995 (date of inception) to June 30, 1995 in conformity with generally
accepted accounting principles.
DELOITTE & TOUCHE LLP
Parsippany, New Jersey
August 16, 1995
F-15
<PAGE>
<PAGE>
FAULDING PHARMACEUTICAL CO.
BALANCE SHEET
JUNE 30, 1995
<TABLE>
<CAPTION>
ASSETS
<S> <C>
Current assets
Cash........................................................................................... $ 18,451
Accounts receivable (net of allowance for chargebacks of $561,448) (Note 3).................... 543,314
Inventory (Note 1)............................................................................. 832,894
Prepaids....................................................................................... 7,104
----------
Total current assets...................................................................... 1,401,763
Furniture, fixtures, and equipment (Note 1)......................................................... 53,970
----------
Total Assets........................................................................................ $1,455,733
----------
----------
LIABILITIES & STOCKHOLDER'S DEFICIENCY
Liabilities:
Accounts payable............................................................................... $ 81,793
Accrued expenses............................................................................... 47,185
Accrued income taxes (Note 5).................................................................. 30,000
Due to affiliated companies (Note 2)........................................................... 1,549,460
----------
Total current liabilities................................................................. 1,708,438
----------
Stockholder's Deficiency:
Common stock -- authorized 200 shares with no par value; 100 shares issued and outstanding at
assigned value.................................................................................... 100
Accumulated deficit................................................................................. (252,805)
----------
Total stockholder's deficiency............................................................ (252,705)
----------
Total liabilities and stockholder's deficiency............................................ $1,455,733
----------
----------
</TABLE>
See Notes to Financial Statements.
F-16
<PAGE>
<PAGE>
FAULDING PHARMACEUTICAL CO.
STATEMENT OF OPERATIONS
PERIOD FROM APRIL 7, 1995 (DATE OF INCEPTION) THROUGH JUNE 30, 1995
<TABLE>
<S> <C>
Net sales (Note 3)................................................................................... $ 515,834
Cost of sales........................................................................................ 350,413
---------
Gross profit.................................................................................... 165,421
---------
Expenses:
Distribution expenses........................................................................... 14,517
Administrative expenses......................................................................... 20,215
Sales and marketing expenses.................................................................... 353,494
---------
Total expenses............................................................................. 388,226
---------
Loss before provision for income taxes............................................................... (222,805)
Provision for income taxes (Note 5).................................................................. (30,000)
---------
Net loss............................................................................................. $(252,805)
---------
---------
</TABLE>
See Notes to Financial Statements.
F-17
<PAGE>
<PAGE>
FAULDING PHARMACEUTICAL CO.
STATEMENT OF CASH FLOWS
PERIOD FROM APRIL 7, 1995 (DATE OF INCEPTION) THROUGH JUNE 30, 1995
<TABLE>
<S> <C>
Net loss............................................................................................ $ (252,805)
Changes in operating assets and liabilities:
Increase in accounts receivable................................................................ (543,314)
Increase in inventory.......................................................................... (832,894)
Increase in prepaids........................................................................... (7,104)
Increase in accounts payable................................................................... 81,793
Increase in accrued income taxes............................................................... 30,000
Increase in accrued expenses................................................................... 47,185
Increase in due to affiliates.................................................................. 1,549,460
----------
Net cash provided by operating activities................................................. 72,321
----------
Investing activities:
Capital expenditures........................................................................... (53,970)
----------
Net cash used in investing activities..................................................... (53,970)
----------
Financing activities:
Proceeds from issuance of common stock......................................................... 100
----------
Net cash provided by financing activities...................................................... 100
----------
Net increase in cash................................................................................ 18,451
Cash, beginning of period........................................................................... --
----------
Cash, end of period................................................................................. $ 18,451
----------
----------
</TABLE>
See Notes to Financial Statements.
F-18
<PAGE>
<PAGE>
FAULDING PHARMACEUTICAL CO.
NOTES TO FINANCIAL STATEMENTS
PERIOD ENDED JUNE 30, 1995
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization -- Faulding Pharmaceutical Co. (the 'Company') began
operations on April 7, 1995 and is a wholly-owned subsidiary of Faulding
Holdings Inc. ('Faulding') which is a wholly-owned subsidiary of F.H. Faulding &
Co. Limited (the 'Parent'). The Company's principal business is to act as
liaison between certain Faulding operating companies and North American
suppliers and customers in the sales and marketing of generic injectibles in the
pharmaceutical industry.
Effective July 25, 1995, the Company changed its name from Faulding
Hospital Products, Inc. to Faulding Pharmaceutical Co.
Revenue Recognition -- Sales revenue, net of an allowance for chargebacks,
is recognized upon shipment of the Company's product.
Inventory -- Inventory is comprised of finished goods only and is stated at
the lower of cost (first-in, first out) or market.
Furniture, Fixtures and Equipment -- Property and equipment are stated at
cost. Depreciation is computed using the straight-line method over the estimated
useful lives as follows:
<TABLE>
<S> <C>
Computer equipment...................................................... 4 years
Office equipment........................................................ 7 years
Furniture and fixtures.................................................. 10 years
</TABLE>
In accordance with the depreciation policy followed by the Parent, assets
purchased in the third and fourth quarter of a fiscal year begin being
depreciated in the first quarter of the subsequent fiscal year. As such, no
depreciation expense has been recorded for the period from April 7, 1995 (date
of inception) through June 30, 1995.
Income Taxes -- The Company utilizes the provisions of Statement of
Financial Accounting Standards No. 109, 'Accounting for Income Taxes' ('SFAS
109'). SFAS 109 requires the Company to compute deferred income taxes based on
the difference between the financial statement and tax basis of assets and
liabilities using enacted tax rates in expected to apply the years in which the
differences are expected to reverse.
2. RELATED PARTY TRANSACTIONS
The Company purchased $1,170,942 of finished goods inventory from Faulding
Puerto Rico, Inc., an affiliate of the Company.
The Company also received cash in the amount of $368,993 to fund initial
operations from Faulding Inc., an affiliate of the Company.
The following balances were due to affiliates at June 30, 1995:
<TABLE>
<S> <C>
Faulding Puerto Rico, Inc............................................. $1,170,942
Faulding Inc.......................................................... 368,993
Purepac Pharmaceutical Co............................................. 9,525
----------
Due to affiliates..................................................... $1,549,460
----------
----------
</TABLE>
3. CHARGEBACK ALLOWANCE
The Company has recorded an allowance for the effect of customer
chargebacks to sales and accounts receivable in the amount of $561,448. This
reserve is based upon management's best estimate of the amounts that will be
charged back to the Company for the difference between the wholesale invoiced
price and the contract price with an individual customer.
F-19
<PAGE>
<PAGE>
FAULDING PHARMACEUTICAL CO.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
PERIOD ENDED JUNE 30, 1995
4. LEASES
The Company is obligated under a non-cancelable operating lease for office
space expiring in fiscal 1996. Total rental expense for this lease was $4,238
for the period from April 7, 1995 (date of inception) through June 30, 1995.
Future minimum commitments under this operating lease at June 30, 1995 are
$17,100 in the year ended June 30, 1996.
5. PROVISION FOR INCOME TAXES
Faulding files a consolidated Federal income tax return. As Faulding is in
a taxable loss situation, no Federal income tax provision has been recorded.
There is no sharing agreement in existence between Faulding and the Company. The
tax provision booked by the Company relates to state taxes to be paid due to
temporary differences between book and taxable income at an effective rate of
8%.
The Company has recorded a deferred tax asset of approximately $228,000
which primarily reflects the net tax effect of temporary differences between the
carrying amount of the allowance for chargebacks for financial reporting
purposes and the amounts used for income tax purposes. A full valuation
allowance has been recorded against such amount as the Company cannot currently
demonstrate the ability to recognize such asset.
F-20
<PAGE>
<PAGE>
FAULDING PHARMACEUTICAL CO.
FINANCIAL STATEMENTS (UNAUDITED)
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 1995
F-21
<PAGE>
<PAGE>
FAULDING PHARMACEUTICAL CO.
BALANCE SHEET (UNAUDITED)
AS OF SEPTEMBER 30, 1995
<TABLE>
<S> <C>
ASSETS
Current assets
Cash........................................................................................... $ 165,107
Accounts receivable, net of allowance for chargebacks of $941,720.............................. 432,732
Inventory...................................................................................... 1,786,809
Prepaids....................................................................................... 42,212
----------
Total current assets...................................................................... 2,426,860
Furniture, fixtures & equipment -- net.............................................................. 55,512
----------
Total assets........................................................................................ $2,482,372
----------
----------
LIABILITIES & STOCKHOLDER'S DEFICIENCY
Current liabilities:
Accounts payable & accrued expenses............................................................ $ 204,632
Due to affiliated companies.................................................................... 3,178,503
----------
Total current liabilities................................................................. 3,383,135
----------
Stockholder's Deficiency
Common stock -- authorized 200 shares with no par value 100 shares issued and outstanding at
assigned value.................................................................................... 100
Accumulated deficit................................................................................. (900,863)
----------
Total stockholder's deficiency................................................................. (900,763)
----------
Total liabilities & stockholder's deficiency.............................................. $2,482,372
----------
----------
</TABLE>
See Notes to Financial Statements.
F-22
<PAGE>
<PAGE>
FAULDING PHARMACEUTICAL CO.
STATEMENT OF OPERATIONS (UNAUDITED)
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 1995
<TABLE>
<S> <C>
Net sales............................................................................................ $ 537,667
Cost of sales........................................................................................ 517,707
---------
Gross margin......................................................................................... 19,960
Selling, general & administrative costs.............................................................. 617,632
Research & Development............................................................................... 50,386
---------
Net loss............................................................................................. $(648,058)
---------
---------
</TABLE>
See Notes to Financial Statements.
F-23
<PAGE>
<PAGE>
FAULDING PHARMACEUTICAL CO.
STATEMENT OF CASH FLOWS (UNAUDITED)
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 1995
<TABLE>
<S> <C>
Operating Activities:
Net loss............................................................................................ $ (648,058)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization.................................................................. 2,415
Changes in operating assets & liabilities:
Decrease in accounts receivable................................................................ 110,582
Increase in inventory.......................................................................... (953,915)
Increase in prepaids........................................................................... (35,108)
Increase in accounts payable and accrued expenses.............................................. 75,654
Decrease in accrued income taxes............................................................... (30,000)
Increase in due to affiliates.................................................................. 1,629,043
----------
Net cash provided by operating activities........................................................... 150,613
Investing activities:
Capital expenditures................................................................................ (3,957)
----------
Net cash (used in) investing activities............................................................. (3,957)
----------
Net increase in cash................................................................................ 146,656
Cash, beginning of period........................................................................... 18,451
----------
Cash, end of period................................................................................. $ 165,107
----------
----------
</TABLE>
See Notes to Financial Statements.
F-24
<PAGE>
<PAGE>
FAULDING PHARMACEUTICAL CO.
NOTES TO FINANCIAL STATEMENTS
The notes to the financial statements of the Faulding Pharmaceutical Co.
for the period April 7, 1995 (inception) through June 30, 1995 contains
information pertinent to the accompanying financial statements. There has been
no material change in the information contained in such footnotes. The balance
sheet at September 30, 1995 and the related statements of operations and deficit
and cash flows for the three months ended September 30, 1995, have not been
audited.
In the opinion of management, all adjustments (consisting only of normal
recurring entries) necessary for a fair presentation of such financial results
have been included.
CHARGEBACK ALLOWANCE
At September 30, 1995, the Company has recorded an allowance for the effect
of customer chargebacks to sales and accounts receivable in the amount of
$941,720. This reserve is based upon management's best estimate of the amounts
that will be charged back to the Company for the difference between the
wholesale invoiced price and the contract price with an individual customer.
PROVISION FOR INCOME TAXES
The Company utilizes the provisions of Statement of Financial Accounting
Standards No. 109, 'Accounting for Income Taxes' ('SFAS 109'). SFAS 109 requires
the Company to compute deferred income taxes based on the difference between the
financial statement and tax basis of assets and liabilities using enacted tax
rates in expected to apply the years in which the differences are expect to
reverse.
Faulding files a consolidated Federal income tax return. As Faulding is in
a taxable loss situation, no Federal income tax provision has been recorded.
There is no sharing agreement in existence between Faulding and the Company.
The Company has recorded a deferred tax asset of approximately $300,000
which primarily reflects the net tax effect of temporary differences between the
carrying amount of the allowance for chargebacks for financial reporting
purposes and the amounts used for income tax purposes. A full valuation
allowance has been recorded against such amounts as the Company cannot currently
demonstrate the ability to recognize such asset.
F-25
<PAGE>
<PAGE>
FAULDING PUERTO RICO, INC.
FINANCIAL STATEMENTS
FOR THE PERIOD FROM APRIL 7, 1995 (DATE OF INCEPTION) TO JUNE 30, 1995
AND
INDEPENDENT AUDITORS' REPORT
F-26
<PAGE>
<PAGE>
INDEPENDENT AUDITORS' REPORT
To the Board of Directors and Stockholder
of FAULDING PUERTO RICO, INC.
We have audited the accompanying balance sheet of Faulding Puerto Rico,
Inc. as of June 30, 1995, and the related statements of operations and deficit
and of cash flows for the period from April 7, 1995 (date of inception) through
June 30, 1995. These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
financial statements based on our audit.
We conducted our audit in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audit provides a reasonable basis for our opinion.
In our opinion, such financial statements present fairly, in all material
respects, the financial position of Faulding Puerto Rico, Inc. as of June 30,
1995, and the results of its operations and its cash flows for the period then
ended in conformity with generally accepted accounting principles.
DELOITTE & TOUCHE LLP
Parsippany, New Jersey
August 1, 1995
F-27
<PAGE>
<PAGE>
FAULDING PUERTO RICO, INC.
BALANCE SHEET
JUNE 30, 1995
<TABLE>
<S> <C>
ASSETS
Current assets:
Cash.......................................................................................... $ 503
Accounts receivable:
Affiliates (Note 5)...................................................................... 1,170,942
Trade and other.......................................................................... 414,804
Inventories (Note 3).......................................................................... 2,173,177
Prepaid expenses.............................................................................. 478,965
-----------
Total current assets................................................................ 4,238,391
Property, plant and equipment -- net (Note 4)...................................................... 11,919,289
-----------
Total.......................................................................... $16,157,680
-----------
-----------
LIABILITIES AND STOCKHOLDER'S DEFICIENCY
Current liabilities:
Note payable to affiliate (Notes 2 and 5)..................................................... $12,442,998
Accounts payable -- affiliates (Notes 2 and 5)................................................ 2,713,293
Other accounts payable and accrued liabilities................................................ 1,183,489
-----------
Total current liabilities........................................................... 16,339,780
-----------
Stockholder's deficiency:
Common stock -- authorized 200 shares with no par value; 10 shares issued and outstanding..... 100
Deficit....................................................................................... (182,200)
-----------
Total stockholder's deficiency...................................................... (182,100)
-----------
Total.......................................................................... $16,157,680
-----------
-----------
</TABLE>
See Notes to Financial Statements.
F-28
<PAGE>
<PAGE>
FAULDING PUERTO RICO, INC.
STATEMENT OF OPERATIONS AND DEFICIT
PERIOD FROM APRIL 7, 1995 (DATE OF INCEPTION) THROUGH JUNE 30, 1995
<TABLE>
<S> <C>
Net sales:
Affiliates (Note 5)............................................................................ $1,170,942
Trade.......................................................................................... 788,687
----------
Total net sales...................................................................... 1,954,233
----------
Cost and expenses:
Cost of sales.................................................................................. 1,959,629
Interest expense............................................................................... 187,596
----------
Total costs and expenses............................................................. 2,141,829
----------
Net loss and deficit at June 30, 1995............................................................... $ (182,200)
----------
----------
</TABLE>
See Notes to Financial Statements.
F-29
<PAGE>
<PAGE>
FAULDING PUERTO RICO, INC.
STATEMENT OF CASH FLOWS
PERIOD FROM APRIL 7, 1995 (DATE OF INCEPTION) THROUGH JUNE 30, 1995
<TABLE>
<S> <C>
Cash flows from operating activities:
Net loss...................................................................................... $ (182,200)
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization............................................................ 153,038
Changes in operating assets and liabilities:
Increase in:
Accounts receivable -- affiliates................................................... (1,170,942)
Accounts receivable -- trade and other.............................................. (200,884)
Inventories......................................................................... (986,577)
Prepaid expenses.................................................................... (65,942)
Increase in:
Accounts payable -- affiliates...................................................... 2,186,484
Other accounts payable and accrued liabilities...................................... 415,320
-----------
Net cash provided by operating activities...................................... 148,297
Cash flows used in investing activities:
Capital expenditures.......................................................................... (147,894)
Cash flows from financing activities:
Issuance of common stock...................................................................... 100
-----------
Net increase in cash and cash balance at June 30, 1995............................................. $ 503
-----------
-----------
</TABLE>
See Notes to Financial Statements.
F-30
<PAGE>
<PAGE>
FAULDING PUERTO RICO, INC.
NOTES TO FINANCIAL STATEMENTS
PERIOD FROM APRIL 7, 1995 (DATE OF INCEPTION) THROUGH JUNE 30, 1995
1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization -- Faulding Puerto Rico, Inc. (the 'Company') is a
wholly-owned subsidiary of Faulding Holdings Inc. ('Faulding') which in turn is
a wholly-owned subsidiary of F. H. Faulding & Co. Limited, a major Australian
pharmaceutical company. The Company, which was organized under the laws of
Delaware, is engaged in manufacturing pharmaceutical products in Aguadilla,
Puerto Rico and commenced operations on April 7, 1995, upon completing the
acquisition described in Note 2.
Revenue recognition -- Sales revenue is recognized upon shipment of the
Company's products.
Inventory -- Inventories are stated at the lower of cost (first-in,
first-out basis) or market. Cost includes direct labor and materials and an
appropriate amount for fixed and variable overhead.
Property, plant and equipment -- Property, plant and equipment are recorded
at cost. Depreciation and amortization is provided using the straight-line
method over the following estimated useful lives:
<TABLE>
<S> <C>
Leasehold improvements.......................................................... 25 years
Machinery and equipment......................................................... 15 years
Furniture, fixtures and other................................................... 4 - 10 years
</TABLE>
Accounting for income taxes -- The Company accounts for income taxes under
the provisions of Statement of Financial Accounting Standards No. 109,
Accounting for Income Taxes. This statement requires an asset and liability
approach for financial accounting and reporting for income taxes.
2. BUSINESS ACQUISITION
On April 7, 1995, the Company completed the acquisition of the parenteral
pharmaceutical products and related assets of DuPont Merck Pharma, a
manufacturer of pharmaceutical products in Aguadilla, Puerto Rico for an
aggregate purchase price of $12,969,807. The acquisition was accounted for by
the purchase method of accounting. Accordingly, the purchase price was allocated
to assets acquired and liabilities assumed based on their market values at the
date of acquisition.
The following is a summary of management's best estimate of the fair market
value of the acquired assets and liabilities on the date of the acquisition:
<TABLE>
<S> <C>
Assest acquired:
Accounts receivable....................................................... $ 213,920
Inventories............................................................... 1,186,600
Other assets.............................................................. 413,023
Fixed assets.............................................................. 11,924,433
-----------
Total assets acquired.......................................................... 13,737,976
Liabilities assumed:
Accounts payable and accrued liabilities.................................. 768,169
-----------
Total net assets acquired...................................................... $12,969,807
-----------
-----------
</TABLE>
A portion of the cost of the acquisition was paid by an affiliated company
and charged to the Company through a demand loan payable of $12,442,998, bearing
interest at 6.63%. The remaining cost of the acquisition amounting to $526,809
was paid by an affiliated company and charged to the Company through an
intercompany account. These noncash transactions were excluded from the
statement of cash flows.
F-31
<PAGE>
<PAGE>
FAULDING PUERTO RICO, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
PERIOD FROM APRIL 7, 1995 (DATE OF INCEPTION) THROUGH JUNE 30, 1995
3. INVENTORIES
Inventories at June 30, 1995 consisted of:
<TABLE>
<S> <C>
Raw materials................................................................... $1,265,097
Work in process................................................................. 786,195
Finished goods.................................................................. 121,885
----------
Total...................................................................... $2,173,177
----------
----------
</TABLE>
4. PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment at June 30, 1995 consisted of:
<TABLE>
<S> <C>
Leasehold improvements......................................................... $ 4,789,734
Machinery and equipment........................................................ 5,901,037
Furniture, fixtures and other.................................................. 231,528
Construction in progress....................................................... 1,150,028
-----------
Total..................................................................... 12,072,327
Less accumulated depreciation and amortization................................. 153,038
-----------
Property, plant and equipment -- net........................................... $11,919,289
-----------
-----------
</TABLE>
5. TRANSACTIONS WITH AFFILIATES
The Company had sales during the period to an affiliated company, Faulding
Pharmaceutical Co., of $1,170,942 of which no amount had been collected as of
June 30, 1995.
The Company has a demand note payable to Faulding at June 30, 1995 of
$12,442,998 related to the acquisition described in Note 1. The note bears
interest at 6.63%.
The Company has other amounts due to Faulding of $2,713,293 for additional
costs related to the initial acquisition, interest on the demand note payable
and amounts received to fund initial operations.
6. INCOME TAXES
The Company has requested a partial tax exemption from the Puerto Rico
government under the 1987 Puerto Rico Tax Incentives Act. Such grant would
provide for a 90% tax exemption from industrial development income and property
tax and a 60% exemption from municipal license tax for a period of fifteen (15)
years. In the opinion of management, the tax exemption decree should be approved
by the government during the current fiscal year. The Company's Puerto Rico
effective income tax rate would be 4.5%.
The Company has recorded a deferred tax asset of approximately $7,000 at
June 30, 1995, which reflects the net tax effect of temporary differences
between the carrying amount of certain items for financial reporting purposes
and the amounts used for income tax purposes. A full valuation allowance has
been recorded against such amount as the Company cannot currently demonstrate
the ability to recognize such asset.
The Company's income attributable to the Puerto Rico operations is included
in the consolidated return of the parent company.
F-32
<PAGE>
<PAGE>
FAULDING PUERTO RICO, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
PERIOD FROM APRIL 7, 1995 (DATE OF INCEPTION) THROUGH JUNE 30, 1995
7. COMMITMENTS
The Company leases its manufacturing facilities, office equipment and
vehicles under operating leases which expire through 2020. Future minimum lease
payments are as follows:
<TABLE>
<CAPTION>
YEAR ENDING
JUNE 30, AMOUNT
- ----------- ----------
<S> <C>
1996 ......................................................................... $ 301,000
1997 ......................................................................... 262,000
1998 ......................................................................... 232,000
1999 ......................................................................... 180,000
2000 ......................................................................... 178,000
Thereafter............................................................................. 3,564,000
----------
$4,717,000
----------
----------
</TABLE>
Rent expense for the period ended June 30, 1995 was $85,348.
8. SAVINGS PLAN
The Company has a savings and investment plan which allows employees to
defer up to 10% of their salary, with the Company matching 50% of each
employee's contribution not exceeding 6% of an employee's salary. The Company's
contribution charged to operations for the period ended June 30, 1995 was
$13,853.
9. SUPPLEMENTAL CASH FLOWS INFORMATION
There were no interest or income tax payments for the period ended June 30,
1995. Refer to Note 2 for certain noncash transactions excluded from the
statement of cash flows.
10. SEGMENT INFORMATION
The Company operates in one business segment, i.e. the manufacture and sale
of pharmaceutical products. For the period from April 7, 1995 (date of
inception) through June 30, 1995, two customers each accounted for approximately
60% and 34% of sales. Sales to the two customers were $1,171,000 and $662,000,
respectively.
F-33
<PAGE>
<PAGE>
FAULDING PUERTO RICO, INC.
FINANCIAL STATEMENTS (UNAUDITED)
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 1995
F-34
<PAGE>
<PAGE>
FAULDING PUERTO RICO, INC.
BALANCE SHEET (UNAUDITED)
AS OF SEPTEMBER 30, 1995
<TABLE>
<S> <C>
ASSETS
Current assets:
Cash.......................................................................................... $ (57,887)
Accounts receivable:
Affiliates............................................................................... 2,595,127
Trade and other.......................................................................... 487,982
Inventory..................................................................................... 2,035,427
Other current assets.......................................................................... 491,040
-----------
Total current assets................................................................ 5,551,689
Property, plant & equipment -- net............................................................ 11,956,723
-----------
Total assets........................................................................ $17,508,412
-----------
LIABILITIES & EQUITY
Current liabilities:
Note payable to affiliates.................................................................... $12,442,998
Accounts payable affiliates................................................................... 4,815,250
Other accounts payable, accrued liabilities................................................... 1,343,986
-----------
Total current liabilities........................................................... 18,602,234
-----------
Stockholder's deficiency
Common Stock -- authorized 200 shares with no par value; 10 shares
issued and outstanding...................................................................... 100
Deficit....................................................................................... (1,093,922)
-----------
Total stockholder's deficit................................................................... (1,093,822)
-----------
Total liabilities & stockholder's deficit..................................................... $17,508,412
-----------
-----------
</TABLE>
See Notes to Financial Statements.
F-35
<PAGE>
<PAGE>
FAULDING PUERTO RICO, INC.
STATEMENT OF OPERATIONS AND DEFICIT (UNAUDITED)
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 1995
<TABLE>
<S> <C>
Net Sales
Affiliates.................................................................................... $ 1,424,185
Trade......................................................................................... 529,664
-----------
Total net sales.......................................................................... 1,953,849
Cost of sales...................................................................................... 2,689,885
-----------
Gross margin....................................................................................... (736,036)
Selling, general & administrative expenses......................................................... 6,943
-----------
Loss from operations............................................................................... (742,979)
Other expense...................................................................................... 168,743
-----------
Net loss........................................................................................... (911,722)
Accumulated deficit, beginning of period........................................................... (182,200)
-----------
Accumulated deficit, end of period................................................................. $(1,093,922)
-----------
-----------
</TABLE>
See Notes to Financial Statements.
F-36
<PAGE>
<PAGE>
FAULDING PUERTO RICO, INC.
STATEMENT OF CASH FLOWS (UNAUDITED)
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 1995
<TABLE>
<S> <C>
Cash flows from operating activities:
Net loss...................................................................................... $ (911,722)
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization............................................................ 162,441
Changes in operating assets & liabilities:
Increase in accounts receivable -- affiliates....................................... (1,424,185)
Increase in accounts receivable -- trade & other.................................... (73,178)
Decrease in inventory............................................................... 137,750
Increase in prepaid expenses........................................................ (12,075)
Increase in accounts payable -- affiliates.......................................... 2,101,967
Increase in accounts payable and accrued liabilities................................ 160,497
-----------
Net cash provided by operating activities...................................... 141,495
Cash flows used in investing activities:
Capital expenditures.......................................................................... (199,865)
-----------
Net decrease in cash.......................................................................... (58,370)
Cash balance at the beginning of the period................................................... 503
-----------
Cash balance at the end of the period......................................................... $ (57,887)
-----------
-----------
</TABLE>
See Notes to Financial Statements.
F-37
<PAGE>
<PAGE>
FAULDING PUERTO RICO, INC.
NOTES TO FINANCIAL STATEMENTS (UNAUDITED)
The notes to the financial statements of the Faulding Puerto Rico, Inc. for
the period April 7, 1995 (inception) through September 30, 1995 contains
information pertinent to the accompanying financial statements. There has been
no material change in the information contained in such footnotes. The balance
sheet at September 30, 1995 and the related statements of operations and deficit
and cash flows for the three months ended September 30, 1995, have not been
audited.
In the opinion of management, all adjustments (consisting only of normal
recurring entries) necessary for a fair presentation of such financial results
have been included.
INVENTORIES
Inventories at September 30, 1995 consisted of:
<TABLE>
<S> <C>
Raw materials................................................................... $1,180,548
Work in process................................................................. 732,754
Finished goods.................................................................. 122,125
----------
Total................................................................. $2,035,427
----------
----------
</TABLE>
INCOME TAXES
The Company accounts for income taxes under the provisions of Statement of
Financial Accounting Standards No. 109, Accounting for Income Taxes. This
statement requires an asset and liability approach for financial accounting and
reporting for income taxes.
The Company has requested a partial tax exemption from the Puerto Rico
government under the 1987 Puerto Rico Tax Incentives Act. Such grant would
provide for a 90% tax exemption from industrial development income and property
tax and a 60% exemption from municipal license tax for a period of fifteen (15)
years. In the opinion of management, the tax exemption decree should be approved
by the government during the current fiscal year. The Company's Puerto Rico
effective income tax rate would be 4.5%.
The Company's income attributable to the Puerto Rico operations is included
in the consolidated return of the parent company.
F-38
<PAGE>
<PAGE>
AGUADILLA BRANCH OPERATIONS
OF DUPONT MERCK PHARMA
FINANCIAL STATEMENTS (UNAUDITED)
FOR THE PERIOD FROM JANUARY 1, 1995 THROUGH APRIL 6, 1995
F-39
<PAGE>
<PAGE>
AGUADILLA BRANCH OPERATIONS OF DUPONT MERCK PHARMA
STATEMENTS OF ASSETS AND LIABILITIES AND JOINT VENTURE EQUITY (UNAUDITED)
APRIL 6, 1995
<TABLE>
<S> <C>
ASSETS
Current Assets:
Cash.......................................................................................... $ 252,404
Accounts receivable, trade.................................................................... 759,899
Inventories................................................................................... 1,602,700
Other current assets.......................................................................... 436,764
-----------
Total current assets..................................................................... 3,051,767
Property, plant and equipment, Net................................................................. 9,446,526
-----------
Total............................................................................... $12,498,293
-----------
-----------
LIABILITIES AND JOINT VENTURE EQUITY
Current Liabilities:
Accounts payable.............................................................................. $ 261,781
Accrued liabilities........................................................................... 2,698,081
-----------
Total current liabilities................................................................ 2,959,862
Joint venture equity in Aguadilla operations....................................................... 9,538,431
-----------
Total............................................................................... $12,498,293
-----------
-----------
</TABLE>
See Notes to Financial Statements.
F-40
<PAGE>
<PAGE>
AGUADILLA BRANCH OPERATIONS OF DUPONT MERCK PHARMA
STATEMENTS OF NET COST ATTRIBUTABLE TO OWNERS' INTEREST (UNAUDITED)
PERIOD FROM JANUARY 1, 1995 THROUGH APRIL 6, 1995
<TABLE>
<S> <C>
Costs of goods sold to third parties and/or transferred to affiliates............................... $3,378,522
Other operating expenses............................................................................ 141,861
----------
Total.......................................................................................... 3,520,383
Revenues -- sales to third parties.................................................................. (716,774)
----------
Net cost attributable to owners' interest........................................................... (2,803,609)
Joint venture equity, beginning of year............................................................. 10,089,504
Cash settlements and transfers -- net............................................................... 2,252,536
----------
Joint venture equity, end of year................................................................... $9,538,431
----------
----------
</TABLE>
See Notes to Financial Statements.
F-41
<PAGE>
<PAGE>
AGUADILLA BRANCH OPERATIONS OF DUPONT MERCK PHARMA
STATEMENTS OF CASH FLOWS (UNAUDITED)
PERIOD FROM JANUARY 1, 1995 THROUGH APRIL 6, 1995
<TABLE>
<S> <C>
Cash flows from operating activities:
Net cost attributable to owners' interest.................................................... $ (2,803,609)
Depreciation and amortization................................................................ 318,583
Increase (decrease) in cash from:
Accounts receivable..................................................................... (183,512)
Inventories............................................................................. (13,819)
Other current assets.................................................................... 3,130
Accounts payable........................................................................ 24,899
Accrued liabilities..................................................................... 309,136
------------
Net cash used in operating activities.............................................. (2,345,192)
Cash flows from investing activities --
Purchase of property, plant and equipment.................................................... (68,509)
Cash flows from financing activities --
Cash settlements and transfers -- net........................................................ 2,252,536
------------
Decrease in cash and cash equivalents............................................................. (161,165)
Cash and cash equivalents, beginning of year...................................................... 413,569
------------
Cash and cash equivalents, end of year............................................................ $ 252,404
------------
------------
</TABLE>
See Notes to Financial Statements.
F-42
<PAGE>
<PAGE>
AGUADILLA BRANCH OPERATIONS OF DUPONT MERCK PHARMA
NOTES TO FINANCIAL STATEMENTS (UNAUDITED)
PERIOD FROM JANUARY 1, 1995 THROUGH APRIL 6, 1995
The notes to the financial statements of the Aguadilla Branch Operations of
Dupont Merck Pharma for the years ended December 31, 1994 and 1993 contain
information pertinent to the accompanying financial statements. There has been
no material change in the information contained in such footnotes. The balance
sheet at April 6, 1995 and the related statements of net cost attributable to
owners' interest and cash flows for the period from January 1, 1995 through
April 6, 1995 have not been audited.
The accrued liability for the cost of the pension plan and postretirement
benefits other than pensions was not assumed by Faulding Puerto Rico, Inc. when
the Aguadilla Plant was acquired on April 7, 1995.
In the opinion of management, all adjustments (consisting only of normal
recurring entries) necessary for a fair presentation of such financial results
have been included.
Basis of Presentation -- The accompanying financial statements have been
prepared from the separate accounting records maintained by the Aguadilla
Operations of the Partnership and may not necessarily be indicative of the
conditions that would have existed if the Plant had been operated as an
unaffiliated company. Amounts collected in excess of cost of products
transferred to related parties were classified as increases in joint venture
equity and amounts distributed to partners were reflected as net cash
settlements or transfers in the accompanying financial statements. These
financial statements are intended to present the statements of assets and
liabilities and joint venture equity and statements of net cost attributable to
owners' interest and cash flows of the business of the Aguadilla Operations of
the Partnership acquired by Faulding Puerto Rico, Inc. on April 7, 1995.
Income taxes -- As a partnership operating in Puerto Rico, the Partnership
is subject to Puerto Rico income taxes in a manner similar to a corporation.
However, in December 1992 the Puerto Rico Government granted the Partnership a
tax ruling whereby income from the Partnership's operations will accrue directly
to the partners for tax purposes. Therefore, the Partnership will not be subject
to income taxes, but its partners will include their participation in the
Partnership's profits in their individual tax returns. Accordingly, no provision
for income taxes has been reflected in the accompanying financial statements.
Inventory at April 6, 1995 consisted of:
<TABLE>
<S> <C>
Raw materials......................................................... $1,072,486
Work in process....................................................... 509,537
Finished goods........................................................ 20,677
----------
Total............................................................ $1,602,700
----------
----------
</TABLE>
F-43
<PAGE>
<PAGE>
AGUADILLA BRANCH OPERATIONS
OF DUPONT MERCK PHARMA
FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 1994 AND 1993
AND
INDEPENDENT AUDITORS' REPORT
F-44
<PAGE>
<PAGE>
INDEPENDENT AUDITORS' REPORT
DUPONT MERCK PHARMA
We have audited the accompanying statements of assets and liabilities and
joint venture equity of the Aguadilla Branch Operations of DuPont Merck Pharma
(the 'Plant') as of December 31, 1994 and 1993, and the related statements of
net cost attributable to owners' interest and of cash flows for the years then
ended. These financial statements are the responsibility of the Plant's
management. Our responsibility is to express an opinion on these financial
statements based on our audit.
We conducted our audit in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audit provides a reasonable basis for our opinion.
As discussed in Note 1, the accompanying financial statements have been
prepared from the separate records maintained by the Plant and may not
necessarily be indicative of the conditions that would have existed with respect
to the results of operations if the Plant had been operated as an unaffiliated
company.
In our opinion, such financial statements present fairly, in all material
respects, the statements of assets and liabilities and joint venture equity of
Aguadilla Branch Operations of DuPont Merck Pharma at December 31, 1994 and
1993, and the related net cost attributable to owners' interest and the cash
flows for the years then ended in conformity with generally accepted accounting
principles.
DELOITTE & TOUCHE LLP
Parsippany, New Jersey
August 25, 1995
F-45
<PAGE>
<PAGE>
AGUADILLA BRANCH OPERATIONS OF DUPONT MERCK PHARMA
STATEMENTS OF ASSETS AND LIABILITIES AND JOINT VENTURE EQUITY
DECEMBER 31, 1994 AND 1993
<TABLE>
<CAPTION>
1994 1993
----------- -----------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents..................................................... $ 413,569 $13,384,395
Accounts receivable, trade.................................................... 576,387 449,155
Inventories (Note 2).......................................................... 1,588,881 1,148,981
Other current assets.......................................................... 439,894 477,222
----------- -----------
Total current assets..................................................... 3,018,731 15,459,753
Property, plant and equipment, net (Note 3)........................................ 9,696,600 9,888,612
----------- -----------
Total............................................................... $12,715,331 $25,348,365
----------- -----------
----------- -----------
LIABILITIES AND JOINT VENTURE EQUITY
Current liabilities:
Accounts payable.............................................................. $ 236,882 $ 258,526
Accrued liabilities (Note 4).................................................. 2,388,945 1,272,942
----------- -----------
Total current liabilities................................................ 2,625,827 1,531,468
Joint venture equity............................................................... 10,089,504 23,816,897
----------- -----------
Total............................................................... $12,715,331 $25,348,365
----------- -----------
----------- -----------
</TABLE>
See Notes to Financial Statements.
F-46
<PAGE>
<PAGE>
AGUADILLA BRANCH OPERATIONS OF DUPONT MERCK PHARMA
STATEMENTS OF NET COST ATTRIBUTABLE TO OWNERS' INTEREST
YEARS ENDED DECEMBER 31, 1994 AND 1993
<TABLE>
<CAPTION>
1994 1993
----------- -----------
<S> <C> <C>
Costs of goods sold to third parties and/or transferred to affiliates.............. $10,224,109 $11,089,667
Other operating expenses........................................................... 1,281,134 380,661
Property impairment (Note 3)....................................................... 5,000,000
----------- -----------
Total.................................................................... 11,505,243 16,470,328
----------- -----------
Revenues
Sales to third parties........................................................ (1,490,414) (1,840,498)
Interest income............................................................... (188,514) (66,778)
----------- -----------
Total.................................................................... (1,678,928) (1,907,276)
----------- -----------
Net cost attributable to owners' interest.......................................... (9,826,315) (14,563,052)
Joint venture equity, beginning of year............................................ 23,816,897 16,604,767
Cash settlements and transfers -- net.............................................. (3,901,078) 21,775,182
----------- -----------
Joint venture equity, end of year.................................................. $10,089,504 $23,816,897
----------- -----------
----------- -----------
</TABLE>
See Notes to Financial Statements.
F-47
<PAGE>
<PAGE>
AGUADILLA BRANCH OPERATIONS OF DUPONT MERCK PHARMA
STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 1994 AND 1993
<TABLE>
<CAPTION>
1994 1993
------------ ------------
<S> <C> <C>
Cash flows from operating activities:
Net cost attributable to owners' interest.................................... $ (9,826,315) $(14,563,052)
Depreciation and amortization................................................ 1,174,623 969,123
Property impairment (Note 3)................................................. 5,000,000
Increase (decrease) in cash from:
Accounts receivable.......................................................... (127,232) (447,789)
Inventories.................................................................. (439,900) 879,759
Other current assets......................................................... 37,328 (31,943)
Accounts payable............................................................. (21,644) (263,133)
Accrued liabilities.......................................................... 1,116,003 240,349
------------ ------------
Net cash used in operating activities................................... (8,087,137) (8,216,686)
------------ ------------
Cash flows from investing activities
Purchase of property, plant and equipment.................................... (982,611) (2,082,940)
Cash flows from financing activities
Cash settlements and transfers -- net........................................ (3,901,078) 21,775,182
------------ ------------
Increase (decrease) in cash and cash equivalents.................................. (12,970,826) 11,475,556
Cash and cash equivalents, beginning of year...................................... 13,384,395 1,908,839
------------ ------------
Cash and cash equivalents, end of year............................................ $ 413,569 $ 13,384,395
------------ ------------
------------ ------------
</TABLE>
See Notes to Financial Statements.
F-48
<PAGE>
<PAGE>
AGUADILLA BRANCH OPERATIONS OF DUPONT MERCK PHARMA
NOTES TO FINANCIAL STATEMENTS
YEARS ENDED DECEMBER 31, 1994 AND 1993
1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization -- DuPont Merck Pharma (the 'Partnership') is a joint venture
between wholly-owned subsidiaries of E.I. DuPont de Nemours and Company
('DuPont') and Merck and Co., Inc. ('Merck') formed as of January 1, 1991. The
Partnership is engaged in the manufacture and sale of pharmaceutical products,
radiopharmaceutical products and other related product lines and has production
facilities in Manati, Aguadilla and Caguas, Puerto Rico. The Partnership
agreements, as amended (the 'Agreements') primarily comprise the Master
Agreement dated October 15, 1990, the Partnership Agreement dated January 1,
1991 and the Asset Contribution Agreement dated January 1, 1991.
The Aguadilla Plant primarily exists to provide certain products to the
partnership for sale and distribution outside of Puerto Rico. Technology rights,
product rights and other services have been provided to the Plant by the joint
venture partners. No cost associated with the use of these rights or these other
services provided to the Plant have been reflected in the accompanying
statements.
Basis of Presentation -- The accompanying financial statements have been
prepared from the separate accounting records maintained by the Aguadilla
Operations of the Partnership and may not necessarily be indicative of the
conditions that would have existed if the Plant had been operated as an
unaffiliated company. Amounts collected from related parties and amounts
distributed to partners are reflected as cash settlements and transfers -- net
in the accompanying financial statements. These financial statements are
intended to present the statements of assets and liabilities and joint venture
equity and statements of net cost attributable to owners' interest and cash
flows of the business of the Aguadilla Operations of the Partnership acquired by
Faulding Puerto Rico, Inc. on April 7, 1995.
Income taxes -- As a partnership operating in Puerto Rico, the Partnership
is subject to Puerto Rico income taxes in a manner similar to a corporation.
However, in December 1992 the Puerto Rico Government granted the Partnership a
tax ruling whereby income from the Partnership's operations accrues directly to
the partners for tax purposes. Therefore, the Partnership is not subject to
income taxes, but its partners include their participation in the Partnership's
profits in their individual tax returns. Accordingly, no provision for income
taxes has been reflected in the accompanying financial statements.
Cash equivalents -- The Partnership considers highly liquid investments
with original maturities at the time of purchase of three months or less to be
cash equivalents. Cash equivalents consist of time deposits with institutions
with strong credit ratings. The carrying amount of cash and cash equivalents is
a reasonable estimate of its fair value.
Inventories -- Inventories are valued at cost or market, whichever is
lower. Cost is determined on the average cost method.
Property, plant and equipment -- Property, plant and equipment contributed
by DuPont and Merck are carried at their net basis as of January 1, 1991 and are
depreciated over the estimated useful lives of the assets, using the
straight-line method. Major additions are capitalized and depreciated over the
estimated useful lives of the assets using the straight-line method. Maintenance
and repairs are expensed when incurred.
F-49
<PAGE>
<PAGE>
AGUADILLA BRANCH OPERATIONS OF DUPONT MERCK PHARMA
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
YEARS ENDED DECEMBER 31, 1994 AND 1993
2. INVENTORIES
Inventories at December 31, 1994 and 1993 consisted of:
<TABLE>
<CAPTION>
1994 1993
---------- ----------
<S> <C> <C>
Raw materials..................................................... $1,039,090 $1,019,847
Work in progress.................................................. 548,266 120,037
Finished goods.................................................... 1,525 9,097
---------- ----------
Total........................................................ $1,588,881 $1,148,981
---------- ----------
---------- ----------
</TABLE>
3. PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment at December 31, 1994 and 1993 consisted of:
<TABLE>
<CAPTION>
1994 1993
----------- -----------
<S> <C> <C>
Leasehold improvements......................................... $ 6,556,465 $ 6,048,539
Machinery and equipment........................................ 9,770,079 7,322,957
Furniture, fixtures and other.................................. 752,230 674,534
Construction in progress....................................... 1,159,099 3,209,232
----------- -----------
Total..................................................... 18,237,873 17,255,262
Accumulated depreciation and amortization...................... (3,541,273) (2,366,650)
Reserve for property impairment................................ (5,000,000) (5,000,000)
----------- -----------
Property, plant and equipment -- net........................... $ 9,696,600 $ 9,888,612
----------- -----------
----------- -----------
</TABLE>
In 1993, as a result of excess capacity for the manufacture of injectables
based on current market projections, a decision was made to sell the Aguadilla
Plant. In the fourth quarter of 1993, as part of the partnership's restructuring
plan, a reserve of $5,000,000 was established to reflect the net realizable
value of the Plant.
4. ACCRUED LIABILITIES
Accrued liabilities at December 31, 1994 and 1993 consisted of:
<TABLE>
<CAPTION>
1994 1993
---------- ----------
<S> <C> <C>
Pension plan (Note 5)............................................. $ 724,695 $ 308,160
Postretirement benefits other than pensions (Note 5).............. 1,083,022 405,236
Vacation.......................................................... 188,819 136,504
Sick-leave........................................................ 190,039 209,223
Other............................................................. 202,370 213,819
---------- ----------
Total........................................................ $2,388,945 $1,272,942
---------- ----------
---------- ----------
</TABLE>
5. RETIREMENT PLANS
Pension coverage for the Aguadilla Plan employees of the Partnership is
provided through a noncontributory defined benefit pension and retirement plan
(the 'Plan'). Benefits under the Plan are based principally on years of service
and employees' pay near retirement. The Partnership's funding policy is
consistent with the requirements of federal and Puerto Rico tax laws and
regulations. The Aguadilla Plant components of net pension costs, present value
of accumulated plan benefits and net assets available for the payment of such
benefits are not presented because such information is not determined by plant
but rather at the Partnership level. Retirement plan costs are allocated based
on the number of participants at each location.
F-50
<PAGE>
<PAGE>
AGUADILLA BRANCH OPERATIONS OF DUPONT MERCK PHARMA
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
YEARS ENDED DECEMBER 31, 1994 AND 1993
Net pension costs allocated to the Aguadilla Plant for the year ended
December 31, 1994 and 1993 were $600,796 (including $307,396 related to an early
retirement option) and $204,135, respectively.
In addition to providing pension benefits, the Partnership provides
medical, dental and life insurance benefits for certain pensioners and
beneficiaries. Substantially all of the employees of the Partnership who are
eligible to retire under the pension plan, and provided they reach retirement
age while working for the partnership, may become eligible for these benefits.
No disbursements for providing these benefits were made during 1994.
The Aguadilla Plant's components of net postretirement benefit costs and
accrued postretirement benefit costs are not presented because such information
is not determined by plant but rather at the Partnership level. These costs are
allocated based on the number of employees at each location. Net postretirement
benefit costs allocated to the Aguadilla Plant for the years ended December 31,
1994 and 1993 were $677,786 (includes $439,106 related to an early retirement
option) and $131,536, respectively.
During the year ended December 31, 1994, the Partnership offered its
employees a voluntary early retirement option which resulted in a charge to
other operating expenses by the Aguadilla Plant of $746,502.
6. COMMITMENTS
DuPont Merck Pharma has an operating lease for the Aguadilla facilities.
Such agreement is with the Puerto Rico Land Authority and expires in 2010.
Future minimum lease payments are as follows:
<TABLE>
<CAPTION>
YEAR
- ------------------------------------------------------------
<S> <C>
1995........................................................ 180,000
1996........................................................ 180,000
1997........................................................ 180,000
1998........................................................ 180,000
1999........................................................ 180,000
Thereafter.................................................. 1,980,000
----------
$2,880,000
----------
----------
</TABLE>
Rent expense for the years ended December 31, 1993 and 1994 amounted to
$158,274 and $157,467, respectively.
7. SALE OF AGUADILLA PLANT FACILITIES
On April 7, 1995, Faulding Puerto Rico, Inc. acquired from the Partnership
the Aguadilla Plant assets and certain intellectual property rights and certain
marketing rights relating to products manufactured at the facility and assumed
certain liabilities of the Plant for an amount approximately equal to the net
book value of the acquired assets and assumed liabilities at the date of sale.
The Aguadilla Plant manufactures ampules, syringes and vials containing
pharmaceutical products in injectable form, including Tridil'r', Intropin'r',
acetylcysteine, metoclopramide and amikacin.
F-51
<PAGE>
<PAGE>
AGUADILLA BRANCH OPERATIONS OF DUPONT MERCK PHARMA
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
YEARS ENDED DECEMBER 31, 1994 AND 1993
In connection with the sale of the Aguadilla Plant facilities, the
following assets and liabilities, which appear in the accompanying financial
statements and related notes, were excluded from the sale and were not acquired
or assumed by Faulding Puerto Rico, Inc.:
Cash and cash equivalents
Accounts receivable -- except for accounts receivable due from Faulding, Inc.
Accrued liabilities:
Pension plan
Postretirement benefits other than pensions
Other
All liabilities not assumed by Faulding Puerto Rico, Inc. were retained by,
and remain the responsibility of, DuPont Merck Pharma.
8. SUPPLEMENTAL CASH FLOWS INFORMATION
There were no interest or income tax payments during the year ended
December 31, 1994 and 1993.
F-52
<PAGE>
<PAGE>
PUREPAC, INC.
FINANCIAL STATEMENTS
FOR THE YEARS ENDED JUNE 30, 1995 AND 1994
F-53
<PAGE>
<PAGE>
INDEPENDENT AUDITORS' REPORT
To the Board of Directors and Shareholders
of PUREPAC, INC.:
We have audited the accompanying consolidated balance sheets of Purepac,
Inc. and subsidiary as of June 30, 1995 and 1994 and the related consolidated
statements of operations, stockholders' equity, and cash flows for each of the
three years in the period ended June 30, 1995. These financial statements are
the responsibility of the Company's management. Our responsibility is to express
an opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, such consolidated financial statements present fairly, in
all material respects, the financial position of Purepac, Inc. and its
subsidiary at June 30, 1995 and 1994, and the results of their operations and
their cash flows for each of the three years in the period ended June 30, 1995
in conformity with generally accepted accounting principles.
As discussed in Note 14 to the financial statements, the Company changed
its method of accounting for income taxes effective July 1, 1993, to conform
with Statement of Financial Accounting Standards No. 109.
DELOITTE & TOUCHE LLP
Parsippany, New Jersey
August 16, 1995
F-54
<PAGE>
<PAGE>
PUREPAC, INC.
CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
JUNE 30,
--------------------------
1995 1994
----------- -----------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents..................................................... $ 1,156,109 $ 3,153,844
Accounts receivable, trade (less reserves for doubtful accounts and sales
allowances of $2,054,000 and $1,552,000 at June 30, 1995, and 1994,
respectively)................................................................ 9,702,889 10,973,351
Inventory (Note 3)............................................................ 17,831,934 19,189,435
Due from affiliated companies (Note 5)........................................ 172,689 --
Other current assets.......................................................... 1,806,231 504,766
Deferred income taxes (Note 14)............................................... 3,513,038 2,806,000
----------- -----------
Total current assets..................................................... 34,182,890 36,627,396
----------- -----------
Property, plant and equipment, net (Note 4)........................................ 26,603,069 25,705,262
Other assets (Note 5).............................................................. 3,229,140 3,241,644
Deferred income taxes (Note 14).................................................... 914,346 1,693,000
----------- -----------
Total Assets............................................................. $64,929,445 $67,267,302
----------- -----------
----------- -----------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable.............................................................. $ 4,843,679 $ 7,051,025
Due to affiliated companies (Note 5).......................................... -- 119,593
Loan payable to bank (Note 7)................................................. 2,000,000 --
Accrued expenses (Note 6)..................................................... 5,008,267 4,411,866
Accrued income taxes (Note 14)................................................ -- 304,241
Accrued preferred dividends (Note 11)......................................... 520,095 520,095
----------- -----------
Total current liabilities................................................ 12,372,041 12,406,820
----------- -----------
Commitments and contingencies (Note 12)............................................ -- --
----------- -----------
Stockholders' equity (Notes 8, 9, 10 and 11):
Class A convertible preferred stock; par value $.01, authorized 1,834,188
shares; issued and outstanding 834,188 (liquidation value $24,995,171)....... 8,342 8,342
Common stock; par value $.01, authorized 25,000,000 shares; issued and outstanding
12,581,223 and 12,510,098 at June 30, 1995 and 1994, respectively................ 125,812 125,101
Capital in excess of par value..................................................... 24,804,252 26,261,185
Retained earnings.................................................................. 27,618,998 28,465,854
----------- -----------
Total stockholders' equity............................................... 52,557,404 54,860,482
----------- -----------
Total Liabilities and Stockholders' Equity............................... $64,929,445 $67,267,302
----------- -----------
----------- -----------
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
F-55
<PAGE>
<PAGE>
PUREPAC, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
YEAR ENDED JUNE 30,
-----------------------------------------
1995 1994 1993
----------- ----------- -----------
<S> <C> <C> <C>
Net sales........................................................... $61,146,088 $70,004,673 $70,507,655
Cost of sales....................................................... 46,475,507 47,170,793 41,230,869
----------- ----------- -----------
Gross profit........................................................ 14,670,581 22,833,880 29,276,786
----------- ----------- -----------
Expenses:
Selling, general and administrative............................ 9,817,278 9,409,492 9,858,130
Research and development....................................... 6,741,066 6,796,967 5,943,651
----------- ----------- -----------
Total expenses...................................................... 16,558,344 16,206,459 15,801,781
----------- ----------- -----------
Income (loss) from operations....................................... (1,887,763) 6,627,421 13,475,005
----------- ----------- -----------
Other income (expense), net......................................... (63,093) 272,695 301,043
----------- ----------- -----------
Income (loss) before income taxes................................... (1,950,856) 6,900,116 13,776,048
Provision (benefit) for income taxes (Note 14)...................... (1,104,000) 2,602,000 4,616,000
----------- ----------- -----------
Income (loss) before preferred stock dividends...................... (846,856) 4,298,116 9,160,048
Preferred stock dividends........................................... 2,080,380 2,080,380 2,080,380
----------- ----------- -----------
Income (loss) before cumulative effect of a change in accounting for
income taxes...................................................... (2,927,236) 2,217,736 7,079,668
Cumulative effect of a change in accounting for income taxes (Note
14)............................................................... -- 4,149,000 --
----------- ----------- -----------
Net income (loss), available for common stock....................... $(2,927,236) $ 6,366,736 $ 7,079,668
----------- ----------- -----------
----------- ----------- -----------
Primary earnings per common share (Note 2)
Income (loss) before cumulative effect of a change in
accounting for income taxes.................................. $(.23) $.18 $.57
Cumulative effect of a change in accounting for income taxes
(Note 14).................................................... -- .33 --
Net income (loss).............................................. $(.23) $.51 $.57
Weighted average number of common shares outstanding................ 12,538,537 12,468,184 12,417,536
----------- ----------- -----------
Earnings per share assuming full dilution (Note 2):
Income before cumulative effect of a change in accounting for
income taxes................................................. $.24 $.52
Cumulative effect of a change in accounting for income taxes
(Note 14).................................................... .24 --
Net income..................................................... $.48 $.52
Weighted average number of fully diluted shares..................... 17,558,610 17,520,852
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
F-56
<PAGE>
<PAGE>
PUREPAC, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
<TABLE>
<CAPTION>
COMMON STOCK CLASS A PREFERRED
(NOTE 10) STOCK (NOTE 11) CAPITAL IN RETAINED
---------------------- ----------------- EXCESS OF EARNINGS
SHARES AMOUNT SHARES AMOUNT PAR VALUE (DEFICIT) TOTAL
---------- -------- ------- ------ ----------- ----------- -----------
<S> <C> <C> <C> <C> <C> <C> <C>
Balance, June 30, 1992.......... 12,400,848 $124,008 834,188 $8,342 $28,708,065 $10,858,690 $39,699,105
---------- -------- ------- ------ ----------- ----------- -----------
Exercise of stock options (Note
8)............................ 27,000 270 -- -- 48,668 -- 48,938
Class A preferred stock dividend
(Note 11)..................... -- -- -- -- (2,080,380) -- (2,080,380)
Stock grant amortization........ -- -- -- -- 360,546 -- 360,546
Reduction of income tax
liability from exercise of
warrants (Note 10)............ -- -- -- -- 872,185 -- 872,185
Net income...................... -- -- -- -- -- 9,160,048 9,160,048
---------- -------- ------- ------ ----------- ----------- -----------
Balance, June 30, 1993.......... 12,427,848 124,278 834,188 8,342 27,909,084 20,018,738 48,060,442
---------- -------- ------- ------ ----------- ----------- -----------
Common stock issued pursuant to
stock grant plan (Note 9)..... 82,250 823 -- -- (823) -- --
Class A preferred stock dividend
(Note 11)..................... -- -- -- -- (2,080,380) -- (2,080,380)
Stock grant amortization........ -- -- -- -- 371,126 -- 371,126
Reduction of income tax
liability from exercise of
stock options (Note 8)........ -- -- -- -- 62,178 -- 62,178
Net income...................... -- -- -- -- -- 8,447,116 8,447,116
---------- -------- ------- ------ ----------- ----------- -----------
Balance, June 30, 1994.......... 12,510,098 125,101 834,188 8,342 26,261,185 28,465,854 54,860,482
---------- -------- ------- ------ ----------- ----------- -----------
Common stock issued pursuant to
stock grant plan (Note 9)..... 71,125 711 -- -- (711) -- --
Class A preferred stock dividend
(Note 11)..................... -- -- -- -- (2,080,380) -- (2,080,380)
Stock grant amortization........ -- -- -- -- 366,304 -- 366,304
Reduction of income tax
liability from issuance of
stock pursuant to stock grant
plan (Note 9)................. -- -- -- -- 257,854 -- 257,854
Net income (loss)............... -- -- -- -- -- (846,856) (846,856)
---------- -------- ------- ------ ----------- ----------- -----------
Balance, June 30, 1995.......... 12,581,223 $125,812 834,188 $8,342 $24,804,252 $27,618,998 $52,557,404
---------- -------- ------- ------ ----------- ----------- -----------
---------- -------- ------- ------ ----------- ----------- -----------
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
F-57
<PAGE>
<PAGE>
PUREPAC, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
YEAR ENDED JUNE 30,
-----------------------------------------
1995 1994 1993
----------- ----------- -----------
<S> <C> <C> <C>
Cash flows from operating activities:
Net income (loss), avaliable for common stock............................... $(2,927,236) $ 6,366,736 $ 7,079,668
Adjustments to reconcile net income (loss) to net cash provided by (used
for) operating activities:
Depreciation and amortization.......................................... 2,068,534 1,864,240 1,574,657
Compensation expense -- stock grants................................... 366,304 371,126 360,546
Provision for deferred taxes (including cumulative effect of accounting
change).............................................................. -- (2,834,000) --
Deferred income tax, asset............................................. 71,616 -- 951,000
Increase (decrease) in cash from:
Accounts receivable, trade........................................ 1,270,462 (667,572) (4,052,069)
Inventory......................................................... 1,357,501 (4,272,320) (2,427,164)
Other current assets.............................................. (172,465) (231,541) 67,712
Other assets...................................................... -- -- 183,484
Accounts payable.................................................. (2,207,346) 107,575 3,781,413
Accrued expenses.................................................. 596,401 (1,062,799) (698,839)
Accrued income taxes.............................................. (1,175,387) (1,065,560) (257,000)
Due to/from affiliates............................................ (292,282) (314,075) 446,245
----------- ----------- -----------
Total adjustments............................................ 1,883,338 (8,104,926) (70,015)
----------- ----------- -----------
Net cash provided by (used for) operating activities............................. (1,043,898) (1,738,190) 7,009,653
----------- ----------- -----------
Cash flows from investing activities:
Purchases of property, plant and equipment.................................. (2,953,837) (5,747,689) (7,429,619)
----------- ----------- -----------
Net cash provided by (used for) investing activities............................. (2,953,837) (5,747,689) (7,429,619)
----------- ----------- -----------
Cash flows from financing activities:
Proceeds from issuance of common stock...................................... -- -- 48,938
Borrowings from bank........................................................ 2,000,000 -- --
----------- ----------- -----------
Net cash provided by (used for) financing activities............................. 2,000,000 -- 48,938
----------- ----------- -----------
Increase (decrease) in cash and cash equivalents................................. $(1,997,735) $(7,485,879) $ (371,028)
----------- ----------- -----------
----------- ----------- -----------
Cash and cash equivalents, beginning of year..................................... 3,153,844 10,639,723 11,010,751
----------- ----------- -----------
Cash and cash equivalents, end of year........................................... $ 1,156,109 $ 3,153,844 $10,639,723
----------- ----------- -----------
----------- ----------- -----------
Supplemental disclosure of cash flow information:
Cash paid during the year for:
Interest............................................................... $ 77,299 $ 29,253 $ 25,768
Income taxes........................................................... $ 89,289 $ 2,355,000 $ 3,922,000
----------- ----------- -----------
</TABLE>
The accompanying notes are an integral part of these financial statements.
F-58
<PAGE>
<PAGE>
PUREPAC, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. ORGANIZATION AND BUSINESS
At June 30, 1995, 1994 and 1993, 54%, 55% and 55%, respectively, of the
outstanding common stock of Purepac, Inc. (the 'Company') was owned by Faulding
Holdings Inc. ('Holdings'), a wholly-owned subsidiary of F. H. Faulding & Co.
Limited ('Faulding'), a major Australian pharmaceutical company.
On November 2, 1992, the Company changed its name from Moleculon, Inc. to
Purepac, Inc.
2. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
PRINCIPLES OF CONSOLIDATION
The consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiary, Purepac Pharmaceutical Co. ('Purepac'). All
intercompany accounts and transactions have been eliminated.
REVENUE RECOGNITION
Sales revenue is recognized upon shipment of the Company's products.
CASH AND CASH EQUIVALENTS
Cash and cash equivalents consist of cash, certificates of deposit and
commercial paper having original maturities of three months or less.
INVENTORY
Inventory is stated at the lower of cost (first-in, first-out) or market.
PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment is recorded at cost. Depreciation and
amortization is computed using the straight-line method over the following
estimated useful lives:
<TABLE>
<S> <C>
Building and improvements....................................... 30 years
Machinery and equipment......................................... 4-10 years
Furniture and fixtures.......................................... 7-10 years
Leasehold improvements.......................................... remaining term of lease
</TABLE>
TRADEMARKS
Trademarks, included in other assets, are amortized over 40 years using the
straight-line method, consist of the following:
<TABLE>
<CAPTION>
JUNE 30, JUNE 30,
1995 1994
-------- --------
<S> <C> <C>
Cost.................................................................. $500,000 $500,000
Accumulated amortization.............................................. 195,000 183,000
-------- --------
Net book value........................................................ $305,000 $317,000
-------- --------
-------- --------
</TABLE>
F-59
<PAGE>
<PAGE>
PUREPAC, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
RESEARCH AND DEVELOPMENT COSTS
Research and development costs, including charges for such services
provided by Faulding, are charged to operations as incurred and represent the
Company's independent research and development efforts.
RECLASSIFICATIONS
Certain amounts in the 1994 and 1993 statements of operations and
statements of cash flows have been reclassified to conform with the 1995
presentation.
EARNINGS PER COMMON SHARE
Primary earnings per common share is calculated by (i) dividing income
before cumulative effect of a change in accounting for income taxes less
preferred dividends by the weighted average number of common shares outstanding
during the year and (ii) by dividing the cumulative effect of a change in
accounting for income taxes, if any, by such average number of common shares.
Common stock equivalents are excluded as the effect is either not material or
anti-dilutive. Earnings per share, assuming full dilution (principally from
convertible preferred shares), is also presented for the years ended June 30,
1994 and 1993 and is based on the assumption that all contingently issuable
shares were outstanding from the beginning of the year to the extent dilution
results. For the current year ended June 30, 1995, fully diluted earnings per
share is not presented as the effect would be anti-dilutive.
SUPPLEMENTAL CASH FLOW INFORMATION
During the year ended June 30, 1995, the Company recognized a tax benefit
when the Company issued 82,250 shares of common stock to employees pursuant to
the Company's 1991 Restricted Stock Incentive Plan. This transaction provided
the Company a tax benefit equal to the fair market value of the stock on the
date of issuance. For financial reporting purposes, the tax benefit was recorded
as a reduction of the deferred tax asset to the extent previously provided and
the remainder of the benefit was recorded as additional capital in excess of par
value. It is not reflected in the current tax provision.
During the year ended June 30, 1994, the Company recognized a tax benefit
when a holder of nonstatutory stock options purchased 14,000 shares of common
stock at $1.81 per share. This transaction provided the Company a tax benefit to
the extent that the fair market value of the stock issued on the exercise date
exceeded the option price. For financial reporting purposes, this benefit was
recorded as additional capital in excess of par value and is not reflected in
the current tax provision.
During the year ended June 30, 1993, the Company recognized a tax benefit
when a holder of warrants purchased 300,000 shares of common stock at an average
price of $5.17 per share. This transaction provided the Company a tax benefit to
the extent that the fair market value of the stock issued on the exercise date
exceeded the warrant price. For financial reporting purposes, this benefit was
recorded as additional capital in excess of par value and is not reflected in
the current tax provision.
3. INVENTORY
<TABLE>
<CAPTION>
JUNE 30, JUNE 30,
1995 1994
----------- -----------
<S> <C> <C>
Raw materials.................................................. $ 4,813,344 $ 7,734,277
Work-in-process................................................ 5,327,342 3,676,862
Finished goods................................................. 7,691,248 7,778,296
----------- -----------
Total..................................................... $17,831,934 $19,189,435
----------- -----------
----------- -----------
</TABLE>
F-60
<PAGE>
<PAGE>
PUREPAC, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
4. PROPERTY, PLANT AND EQUIPMENT
<TABLE>
<CAPTION>
JUNE 30, JUNE 30,
1995 1994
----------- -----------
<S> <C> <C>
Land..................................................................... $ 2,198,968 $ 2,198,968
Buildings and improvements............................................... 13,020,845 12,592,250
Machinery and equipment.................................................. 13,995,485 13,304,732
Construction in progress................................................. 6,157,784 4,342,695
----------- -----------
Total cost.......................................................... 35,373,082 32,438,645
Less accumulated depreciation and amortization........................... (8,770,013) (6,733,383)
----------- -----------
Net book value...................................................... $26,603,069 $25,705,262
----------- -----------
----------- -----------
</TABLE>
5. RELATED-PARTY TRANSACTIONS
During the years ended June 30, 1995, 1994 and 1993, the Company paid
Faulding $734,000, $2,536,000 and $2,006,000, respectively, for merchandise
purchases (pursuant to agreements to market erythromycin and doxycycline, both
described herein), $918,000, $1,007,000 and $458,000, respectively, for research
and development services and paid Faulding Services Inc. (formerly Faulding
Inc.) $225,000, $127,000 and $100,000, respectively, for business development
services (pursuant to an agreement with Faulding Services Inc., described
herein). Faulding Services Inc. is a 100% owned subsidiary of Holdings.
Additionally, during the years ended June 30, 1995 and 1994, the Company
was reimbursed $1,919,000 and $486,000, respectively, by Faulding for materials
and services related to research and development projects and $200,000 during
the year ended June 30, 1994 for the sale to Faulding of the Company's
Poroplastic' technology.
During the year ended June 30, 1994, the Company paid Faulding Services
Inc. $623,000 for engineering and consulting services related to the
construction of a manufacturing suite to accommodate the modified-release
technology.
During the year ended June 30, 1993, the Company paid Faulding $194,000 for
engineering and consulting services related to the construction of the
manufacturing suite and a $250,000 transfer fee, both to accommodate the
modified-release technology.
Included in other assets at June 30, 1995 and 1994 is $2,903,000 paid by
the Company to Faulding in June 1992 to acquire the proprietary technology,
including the scientific information and expertise, processes and procedures,
for the manufacture and sale of the generic version of certain modified-release
pharmaceutical products. The acquired technology is restricted to use, on an
exclusive basis, in the United States of America and its territories.
Amounts due from (due to) affiliated companies are payable on demand and
were as follows as of:
<TABLE>
<CAPTION>
JUNE 30, 1995 JUNE 30, 1994
------------- -------------
<S> <C> <C>
Faulding........................................................ $ 200,007 $(123,455)
Holdings........................................................ 9,677 3,000
Faulding Services Inc........................................... (36,995) 862
------------- -------------
$ 172,689 $(119,593)
------------- -------------
------------- -------------
</TABLE>
Purepac entered into an agreement with Faulding as of December 5, 1992,
pursuant to which Purepac agreed to provide services to Faulding for the
tableting of pellets and micropellets on a time and materials basis. During the
year ended June 30, 1995, no related services were provided by Purepac to
Faulding.
F-61
<PAGE>
<PAGE>
PUREPAC, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
In addition, Purepac and Faulding entered into a three-year agreement, also
dated as of December 5, 1992, which is automatically renewable for successive
two-year periods, pursuant to which Faulding granted Purepac a non-exclusive
license to import, distribute and market an erythromycin product in the United
States and the Latin American Countries, subject to certain minimum purchase
requirements.
On January 1, 1993, Purepac and Faulding Services Inc. entered into a
consulting agreement, which terminates on December 31, 1995, pursuant to which
Purepac retained Faulding Services Inc. to serve as a business development
consultant and advisor on a non-exclusive basis.
On August 1, 1993, Purepac entered into a ten-year agreement with Faulding
Services Inc. to manufacture a specific product utilizing Faulding Services Inc.
technology, processes and manufacturing methods. Faulding Services Inc., at its
sole cost, shall seek all necessary approvals and/or registrations from the
appropriate regulatory authority to enable the sale of the product and, upon
such approval, Purepac's obligation to provide manufacturing services will
commence. The parties amended this agreement in December 1994 to resolve certain
inconsistencies between this agreement and an agreement with an unrelated third
party, to distribute the product manufactured by Purepac. On June 27, 1995 the
Company and Faulding Services Inc. entered into a Services Agreement pursuant to
which Purepac agreed to provide certain services on Faulding Services Inc.'s
behalf that Faulding Services Inc. had agreed to provide under the agreement
with the third party.
On March 15, 1995 Purepac and Faulding entered into a three-year
non-exclusive license agreement for Purepac to import and distribute
doxycycline, a delayed-release product, in the United States in exchange for
certain payments to Faulding for its supply of the product to Purepac.
Purepac and Faulding entered into two agreements as of June 26, 1995. One
is a licensing agreement pursuant to which Faulding granted to Purepac an
exclusive ten-year license to utilize certain technology to complete the
development of a modified-release product and manufacture and sell the product
in the United States. Relating to the product development, Purepac paid to
Faulding most of the technology licensing fees prior to June 30, 1994 (expensed
as research and development costs) with a projection of approximately $600,000
still to be paid as incurred. In addition, Purepac will be obligated to pay
royalties related to net sales of the product.
The second agreement dated as of June 26, 1995 is a ten-year
Co-development, Supply and Licensing Agreement whereby Faulding will develop and
deliver a certain component pellet of a modified-release product for Purepac's
use in developing, manufacturing and distributing such product in the United
States. Faulding will supply Purepac with pellets at a price set forth in the
agreement. If the parties later concur that Purepac will manufacture the
pellets, Faulding will grant Purepac an exclusive license to the pellet
technology for the remainder of the term of the agreement in consideration of a
technology transfer fee of $250,000 and ongoing royalty payments.
As of June 26, 1995, Purepac entered into a one-year Services Agreement
with Faulding Pharmaceutical Co., a wholly owned subsidiary of Holdings, for
Purepac to provide certain customer support, warehousing, accounting and quality
assurance services.
The Company believes that the terms of the foregoing agreements are at
least as favorable as those it could have obtained in comparable nonaffiliated
third party transactions.
F-62
<PAGE>
<PAGE>
PUREPAC, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
6. ACCRUED EXPENSES
<TABLE>
<CAPTION>
JUNE 30, JUNE 30,
1995 1994
---------- ----------
<S> <C> <C>
Advertising and promotion programs.......................................... $1,320,489 $1,164,038
Medicaid rebate............................................................. 519,947 654,639
Professional fees........................................................... 825,205 644,279
Compensation and payroll taxes.............................................. 1,299,511 1,024,798
All other................................................................... 1,043,115 924,112
---------- ----------
Total.................................................................. $5,008,267 $4,411,866
---------- ----------
---------- ----------
</TABLE>
7. LONG-TERM DEBT
On May 24, 1990, the Company entered into an uncollateralized financing
agreement with a commercial bank, which agreement was amended on May 24, 1992.
The agreement permits the Company to borrow up to $10,000,000, of which a
maximum of $5,000,000 may be borrowed under a term loan facility. Borrowings
under the term loan facility mature five years from the date of the borrowing.
The difference between the total financing agreement of $10,000,000 and any
borrowings under the term loan facility may be utilized as revolving debt. The
Company is required to meet certain financial covenants, including a minimum
debt-to-equity ratio and a minimum aggregate net asset amount.
In August 1994, the aforementioned agreement was further amended to permit
the Company to borrow up to $15,000,000.
At June 30, 1995, the Company had an outstanding loan from the bank of
$2,000,000 at an interest rate of 6.64% per annum. Due to the short-term nature
of this debt and related interest rates, the Company believes that the recorded
amount is a reasonable estimate of fair value for the outstanding loan. At June
30, 1995, there were no outstanding letters of credit.
At June 30, 1994, the Company had no outstanding borrowings from the bank
and had an outstanding standby letter of credit of $250,000 for an alcohol
drawback bond.
8. STOCK OPTIONS
1994 STOCK OPTION PLAN
On October 18, 1994, the shareholders approved the 1994 Stock Option Plan
(the '1994 Plan') which provides for issuance of up to 1,000,000 options to
acquire shares of the Company's authorized common stock. The options are
intended to qualify as Incentive Stock Options (statutory options) as defined by
the Internal Revenue Code or as Nonstatutory Stock Options.
Under the 1994 Plan, the Incentive Stock Options may be granted to key
employees of the Company or a subsidiary of the Company and the Nonstatutory
Stock Options may be granted to any key employee, officer, non-employee director
or consultant to the Company or a subsidiary of the Company, with the exception
that Nonstatutory Stock Options may not be granted to a holder of more than 10%
of the total voting power of the Company.
The exercise price of all Incentive Stock Options must be at least equal to
the fair market value of such shares on the date of grant. The exercise price of
all Nonstatutory Stock Options granted under the 1994 Plan shall be determined
by the Board of Directors of the Company at the time of grant. No option granted
shall be exercisable after the expiration of ten (10) years from the date of
grant.
During the year ended June 30, 1995, the Company awarded two employees
33,000 Incentive Stock Options exercisable at $9.25 per share. In July 1995,
4,600 of those options were exercisable.
F-63
<PAGE>
<PAGE>
PUREPAC, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
On July 17, 1995 the Company granted Richard Moldin, the Chief Executive
Officer and President of the Company, options to purchase 150,000 shares, of
which 49,382 were Incentive Stock Options and 100,618 were Nonstatutory Stock
Options, all at $10.125 per share. None of the options are currently
exercisable.
INCENTIVE STOCK OPTIONS, TERMINATED YEAR ENDED JUNE 30, 1993
The Company had a Stock Option Plan which was terminated in accordance with
its own provisions on September 1, 1992. Under this plan, incentive stock
options were granted to key employees of the Company at not less than fair
market value as determined by the Board of Directors on the date of the grant.
Nonstatutory options were granted at not less than 50% of the fair market value,
as determined by the Board of Directors on the date of grant.
During the year ended June 30, 1993, an employee exercised options to
purchase 7,000 shares of common stock. This was the last remaining exercisable
incentive stock option. The net proceeds from the 7,000 share transaction
amounted to $12,688.
Information on incentive stock option activity under the Stock Option Plan
is as follows:
<TABLE>
<CAPTION>
EXERCISE
NUMBER OF PRICE
SHARES PER SHARE
--------- ---------
<S> <C> <C>
Outstanding at June 30, 1991.......................................... 10,000 $1.81
---------
Exercised............................................................. (3,000) 1.81
---------
Outstanding at June 30, 1992.......................................... 7,000 1.81
---------
Exercised............................................................. (7,000) 1.81
---------
Outstanding at June 30, 1993, Final................................... -0-
---------
---------
</TABLE>
NON-QUALIFIED STOCK OPTIONS, TERMINATED YEAR ENDED JUNE 30, 1993
On January 19, 1988, the Board of Directors granted five-year non-qualified
stock options to a then director to purchase 30,000 shares of common stock at
the fair market value of $1.8125 per share. These options were exercisable at
the rate of 25% per year commencing one year from the date of grant and expiring
five years from the date of grant. During the year ended June 30, 1992, the
former director exercised options to purchase 10,000 shares of common stock.
During the year ended June 30, 1993, the former director exercised the balance
of his options and purchased 20,000 shares of common stock. This was the last
remaining exercisable non-qualified stock option. The net proceeds from the
20,000 shares amounted to $36,250.
9. RESTRICTED STOCK INCENTIVE PLAN
The shareholders approved the Company's 1991 Restricted Stock Incentive
Plan (the 'Plan') for key employees of the Company. The Board of Directors have
allotted 465,000 shares for the stock grant plan.
On November 25, 1991, the Company awarded grants aggregating 275,000 shares
of the Company's common stock to 15 employees. Such grants were valued at $8.125
per share, being the market value thereof on the date of grant. During the year
ended June 30, 1993, due to two resignations, grants totaling 20,000 shares were
terminated. During the year ended June 30, 1994, due to one resignation, grants
totaling 20,000 shares were terminated. During the year ended June 30, 1995, due
to two resignations, grants totaling 10,500 shares were terminated.
On March 5, 1993, the Company awarded grants aggregating 50,000 shares of
the Company's common stock to six employees. Such grants were valued at $13.8125
per share, being the market value
F-64
<PAGE>
<PAGE>
PUREPAC, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
thereof on the date of grant. During the year ended June 30, 1994, due to one
resignation, grants totaling 7,500 shares were terminated.
During the year ended June 30, 1995, the Company issued 71,125 shares of
common stock to employees pursuant to the Plan. As a result of the issuance of
these shares, the Company will have an income tax deduction of $759,063 in the
year ending June 30, 1996. The deduction will result in a reduction in taxes
payable of approximately $288,000. In the same year, for financial reporting
purposes, the tax benefit will be recorded as a reduction of the deferred tax
asset to the extent previously provided and the remainder of the benefit will be
recorded as additional capital in excess of par value. It will not be reflected
in the reported earnings or the earnings per share calculations.
During the year ended June 30, 1994, the Company issued 82,250 shares of
common stock to employees pursuant to the Plan. As a result of the issuance of
these shares, the Company had an income tax deduction of $1,346,844 in the year
ended June 30, 1995. The deduction resulted in a reduction in taxes payable of
approximately $512,000. In that year, for financial reporting purposes, the tax
benefit was recorded as a reduction of the deferred tax asset to the extent
previously provided and the remainder of the benefit was recorded as additional
capital in excess of par value. It was not reflected in the reported earnings or
the earnings per share calculations.
Information on the Restricted Stock Incentive Plan activity is as follows:
<TABLE>
<CAPTION>
NUMBER OF GRANTS AWARDED, BY DATE
------------------------------------
NOVEMBER 25, 1991 MARCH 5, 1993
----------------- -------------
<S> <C> <C>
Outstanding at June 30, 1992..................................... 275,000
-----------------
Terminated.................................................. (20,000)
Grants awarded.............................................. -- 50,000
----------------- -------------
Outstanding at June 30, 1993..................................... 255,000 50,000
----------------- -------------
Terminated.................................................. (20,000) (7,500)
Shares Issued............................................... (82,250) --
----------------- -------------
Outstanding at June 30, 1994..................................... 152,750 42,500
----------------- -------------
Terminated.................................................. (10,500) --
Shares Issued............................................... (56,250) (14,875)
----------------- -------------
Outstanding at June 30, 1995..................................... 86,000 27,625
----------------- -------------
----------------- -------------
</TABLE>
10. COMMON STOCK AND WARRANTS
On February 1, 1987, the Company granted to Allen & Company Incorporated
five-year warrants to purchase an aggregate of 400,000 shares of common stock of
which 200,000 were exercisable at $4.00 per share (Series A Warrants) and
200,000 at $10.00 per share (Series B Warrants). Pursuant to a written agreement
entered into in January 1992, the Series B Warrants originally issued to
purchase 200,000 shares at $10.00 per share were amended to purchase 100,000
shares at $7.50 per share. In addition, the amendment extended the expiration
date of exercise of both series of warrants from February 1, 1992 to a period of
90 days commencing on the effective date of the related Form S-3 Registration
Statement. The Form S-3 and related prospectus became effective on April 24,
1992 and, during the year ended June 30, 1992, the warrants were exercised to
purchase 300,000 shares of common stock. The gross proceeds from this
transaction amounted to $1,550,000.
During the year ended June 30, 1993, the Company issued in aggregate 27,000
shares of common stock upon exercises of both incentive stock options and
non-qualified stock options discussed in Note 8. The net proceeds from these
transactions amounted to $48,938.
F-65
<PAGE>
<PAGE>
PUREPAC, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
During the year ended June 30, 1994, the Company issued in aggregate 82,250
shares of common stock to employees, pursuant to the Company's 1991 Restricted
Stock Incentive Plan discussed in Note 9. The Company received no proceeds from
this transaction.
During the year ended June 30, 1995, the Company issued in aggregate 71,125
shares of common stock to employees, pursuant to the Company's 1991 Restricted
Stock Incentive Plan discussed in Note 9. The Company received no proceeds from
this transaction.
11. PREFERRED STOCK
The authorized but unissued preferred stock may be issued from time to
time, in one or more series, by the Board of Directors.
In 1987, the Company issued and sold to Holdings 834,188 shares of the
Class A preferred stock at $29.34 per share, or $23,133,223, net of expenses of
$1,341,853. These shares provide for a cumulative dividend of 8.5% per annum,
which dividend accrues until such time as the Company shall have profits,
surpluses or other funds legally available for payment of dividends. Dividends
accrue on each share of Class A preferred stock on a daily basis at 8.5% per
annum of liquidation value and are payable quarterly on the first days of
January, April, July and October, beginning in January 1988. If any accrued
dividends, for any reason, are not paid on these days, then such dividend shall
be considered in arrears and, until paid, shall continue to be accrued on the
liquidation value (purchase price less dividends paid) plus dividends in
arrears.
During the years ended June 30, 1995, 1994 and 1993, all current year
preferred dividends totaling $2,080,380, each year were paid. The quarterly
dividend of $520,095 was declared and accrued at June 30, 1995 and subsequently
paid on July 3, 1995.
Each share of Class A preferred stock may be converted, at the election of
the holder, into six shares of common stock. At June 30, 1995, 5,005,128 shares
of common stock were reserved for issuance under the terms of the Class A
preferred stock.
In the event of any liquidation, dissolution or winding up of the Company,
the holders of Class A preferred stock shall be entitled to be paid out of the
assets of the Company available for distribution to its stockholders, whether
from capital, surplus or earnings, amounts in cash equal to the sum of $29.34
per share plus all accrued and unpaid dividends.
On or after December 1, 1997, the Company may, at its election, redeem any
or all shares of Class A preferred stock. For each share of Class A preferred
stock redeemed, the Company shall be obligated to pay a redemption price of
$29.34 per share plus any accrued and unpaid dividends.
12. COMMITMENTS AND CONTINGENCIES
LEASES
The Company leases certain of its equipment and property under operating
leases which provide for monthly lease payments and, in certain instances,
provide options to purchase the property at fair market value. For the years
ended June 30, 1995, 1994 and 1993, total rental expense for operating leases
amounted to $427,000, $315,000 and $341,000, respectively. The following is a
schedule of future minimum rental payments under such operating leases:
<TABLE>
<CAPTION>
FISCAL YEAR ENDING JUNE 30,
- ---------------------------
<S> <C> <C>
1996 ......................................................... $362,000
1997 ......................................................... 297,000
1998 ......................................................... 209,000
1999 ......................................................... 34,000
2000 ......................................................... 0
</TABLE>
F-66
<PAGE>
<PAGE>
PUREPAC, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
In prior years, the Company had a contingent liability associated with a
property lease it had previously occupied in Cambridge, Massachusetts. During
the year ended June 30, 1995, this property was purchased by the tenant, thereby
extinguishing that contingent liability.
LITIGATION
Purepac, Inc. announced on January 4, 1995 that it had been named as a
defendant in a lawsuit filed in the United States District Court for the
District of New Jersey entitled Dechter vs. Purepac, Inc., Robert H. Bur and
Russell J. Reardon, 94 Civ. 6195. The complaint, which purported to be a class
action on behalf of purchasers of Purepac, Inc. common stock, challenged the
timeliness of the Company's prior public disclosure concerning compliance by its
wholly-owned subsidiary, Purepac Pharmaceutical Co., with current Good
Manufacturing Practices and the receipt by that subsidiary of a warning letter
from the U.S. Food and Drug Administration ('FDA'). The lawsuit asserted, among
other things, violations of Section 10(b) of the Securities Exchange Act of 1934
and certain common law claims.
The Company believed the allegations in the complaint to be entirely
without merit, and filed a motion to dismiss the complaint in March 1995. A
hearing before the court was held on the Company's motion to dismiss on Monday,
September 11, 1995. At that hearing, the court granted the Company's motion, and
dismissed the complaint in its entirety, finding that the complaint failed to
allege any actual violation of the U.S. securities laws on the part of Purepac,
Inc. or its senior executives.
The court's dismissal of the complaint technically ends the case. Pursuant
to the court's decision, the plaintiffs have the opportunity to consider filing
a motion with the court for permission to submit a proposed amended complaint to
address the deficiencies that led to the court's dismissal of the current
action. If this occurs, the Company will have the opportunity to oppose such a
motion, and intends to do so vigorously.
On or about June 9, 1995, an action was commenced against the Company in
the United States District Court for the District of Delaware entitled Merck &
Co., Inc. v. Purepac Pharmaceutical Co. Case No. 95-495. The complaint alleges
that the Company's recent submission of an Abbreviated New Drug Application
('ANDA') to the FDA for approval of a generic drug product developed by the
Company which would be the Company's generic version of a branded drug
manufactured by Merck constituted an act of infringement on certain patents
owned by Merck with respect to such product as listed in the FDA's Orange Book
of Approved Drug Products with Therapeutic Equivalence Evaluations (15th ed.
1995).
The complaint alleges that the Company has represented and certified to the
FDA that its proposed generic product is 'bioequivalent' to Merck's branded
product, and that by virtue of this representation, Purepac would be able to
rely on Merck's safety and efficacy data for such product rather than having to
conduct its own safety and efficacy studies for submission to the FDA. The
complaint further alleges that Purepac has informed Merck that its proposed
generic drug product will not infringe on the listed patents owned by Merck with
respect to Merck's product on the grounds that the Company's generic product
does not contain all of the elements of the claims of the listed Merck patents
with respect to Merck's products. In the complaint, Merck disputes the Company's
assertion of non-infringement, and seeks, among other things, (a) a judgment
that the Company's proposed generic product is covered by Merck's patent, (b) an
order delaying any FDA approval of the Company's ANDA until the expiration of
Merck's patents, (c) an order enjoining the Company from the commercial
manufacture or sale of any product that infringes on Merck's patents with
respect to Merck's product, and (d) alternatively, an order requiring the
Company to make further disclosure to the FDA regarding the bioequivalence of
its proposed product. Further, the complaint also seeks money damages in an
unspecified amount in the event that the Company manufactures, uses or sells any
product found to infringe Merck's patents.
F-67
<PAGE>
<PAGE>
PUREPAC, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The Company is involved in litigation incidental to the conduct of its
business, in addition to the above matters, and does not believe that the
ultimate adverse resolutions of any, or all, thereof would have a material
adverse effect on its financial position, results of operations or cash flows.
13. EMPLOYEE BENEFIT PLANS
In January 1990, the Company adopted a defined benefit pension plan (the
'Plan'). The Plan covers employees who have one year or more of credited service
and whose employment is not governed by a collective bargaining agreement. Net
periodic pension cost is comprised of the components listed below, as determined
using the projected unit credit actuarial cost method. The Company's funding
policy is to make annual contributions to the Plan in such amounts necessary to
fund benefits provided under the Plan on the basis of information furnished by
the Company's actuary.
<TABLE>
<CAPTION>
YEAR ENDED JUNE 30,
--------------------------------
1995 1994 1993
-------- -------- --------
<S> <C> <C> <C>
Net Periodic Pension Cost
Service cost for benefits earned during the period...................... $298,412 $327,922 $234,223
Interest cost on projected benefit obligation........................... 151,444 118,241 82,294
Return on plan assets................................................... (87,570) (63,115) (34,228)
Amortization of prior service cost...................................... 18,423 26,737 26,737
Amortization of actuarial loss.......................................... 561 33,037 11,918
-------- -------- --------
Total.............................................................. $381,270 $442,822 $320,944
-------- -------- --------
-------- -------- --------
</TABLE>
<TABLE>
<CAPTION>
JUNE 30, JUNE 30,
1995 1994
----------- -----------
<S> <C> <C>
Funded Status and Obligations of the Plan
Actuarial present value of accumulated benefit obligations..................... $ 1,080,476 $ 965,302
Vested benefits included in above.............................................. $ 962,519 $ 828,390
----------- -----------
Projected benefit obligation................................................... $ 2,342,912 $ 2,265,250
Plan assets at fair value...................................................... (1,446,850) (1,056,776)
Unrecognized prior service cost................................................ (158,606) (293,504)
Unrecognized net gain (loss)................................................... (198,720) (610,429)
----------- -----------
Accrued pension obligation................................................ $ 538,736 $ 304,541
----------- -----------
----------- -----------
</TABLE>
The discount rate used in determining the projected benefit obligations was
8% at June 30, 1995, an increase of 1.5% from June 30, 1994. The rate of
increase in future compensation levels used in the determination was 5.5% and
4.5% for June 30, 1995 and 1994, respectively. The expected long-term rate of
return on the Plan's assets used in determining pension cost was 8% for both
years.
The Company also has a 401(K) savings and investment plan established
January 1, 1990, which allows employees to defer up to 15% of their salary, with
the Company matching 25% of employees' contributions not exceeding 5% of their
salary. The plan was amended, effective January 1, 1991, to increase the Company
match from 25% to 50% of the first 5% of employees' contribution and, effective
July 1, 1991, to increase the Company matching contribution to 50% of each
employee's contribution not exceeding 6% of an employee's salary. The Company's
contribution charged to operations for the years ended June 30, 1995, 1994 and
1993 was $222,000, $197,000 and $183,000, respectively.
14. INCOME TAXES
The Company adopted Statement of Financial Accounting Standard No. 109,
'Accounting for Income Taxes' ('SFAS 109'), effective July 1, 1993. This
statement supersedes Statement of Financial Accounting Standard No. 96,
'Accounting for Income Taxes' ('SFAS 96'). The cumulative effect of
F-68
<PAGE>
<PAGE>
PUREPAC, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
adopting SFAS 109 on the Company's financial statements for the year ended June
30, 1994, was to increase income by $4,149,000 ($.33 per primary common share
and $.24 per share on a fully diluted basis) with a corresponding increase in
the deferred tax asset.
Deferred income tax assets, both current and non-current, reflect the net
tax effects of (a) temporary differences between the carrying amounts of assets
and liabilities for financial reporting purposes and the amounts used for income
tax purposes, and (b) operating loss and tax credit carryforwards.
In current and subsequent years, the income tax expense provision will not
include the benefit of recognizing available loss carryforwards to the extent
they have already been recognized as a deferred tax asset. Instead, there will
be a reduction in the deferred tax asset when such benefits are utilized to
reduce taxes payable.
The decrease in the current year's deferred tax assets resulted primarily
from the recognition of tax deductible items in the current year.
Net deferred tax assets consisted of the following as of:
<TABLE>
<CAPTION>
JUNE 30, JUNE 30,
1995 1994
---------- ----------
<S> <C> <C>
Current Deferred Tax Asset:
Reserve for doubtful accounts.................................................... $ 779,000 $ 589,000
Reserve for inventory obsolescence............................................... 509,000 623,000
Sundry accruals.................................................................. 557,000 656,000
Stock grant amortization......................................................... -- 97,000
Federal operating loss carryforwards............................................. 1,021,000 533,000
Federal tax credit carryforwards................................................. 707,000 404,000
State operating loss carryforwards............................................... 198,000 --
---------- ----------
3,771,000 2,902,000
---------- ----------
Current Deferred Tax Liability:
Stock grant amortization......................................................... 158,000 --
Prepaids......................................................................... 96,000 77,000
Property, plant and equipment.................................................... 4,000 19,000
---------- ----------
258,000 96,000
---------- ----------
Net Current Deferred Tax Asset........................................................ $3,513,000 $2,806,000
---------- ----------
---------- ----------
Non-Current Deferred Tax Asset:
Stock grant amortization......................................................... $ 392,000 $ 252,000
Federal operating loss carryforwards............................................. 3,416,000 3,904,000
Federal tax credit carryforwards................................................. -- 303,000
---------- ----------
3,808,000 4,459,000
---------- ----------
Non-Current Deferred Tax Liability:
Property, plant and equipment.................................................... 2,609,000 2,591,000
License amortization............................................................. 285,000 175,000
---------- ----------
2,894,000 2,766,000
---------- ----------
Net Non-Current Deferred Tax Asset.................................................... $ 914,000 $1,693,000
---------- ----------
---------- ----------
</TABLE>
F-69
<PAGE>
<PAGE>
PUREPAC, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The provision for income taxes was comprised of the following:
<TABLE>
<CAPTION>
YEAR ENDED JUNE 30,
---------------------------------------
1995 1994 1993
----------- ---------- ----------
<S> <C> <C> <C>
Current
Federal................................................. $(1,026,000) $1,047,000 $2,580,000
State................................................... (150,000) 366,000 1,085,000
----------- ---------- ----------
(1,176,000) 1,413,000 3,665,000
Deferred
Federal................................................. 61,000 1,149,000 951,000
State................................................... 11,000 40,000 --
----------- ---------- ----------
Total provision (benefit).......................... $(1,104,000) $2,602,000 $4,616,000
----------- ---------- ----------
----------- ---------- ----------
</TABLE>
The current year's provision for income taxes includes a $325,000 benefit
related to a reversal of prior years tax provisions resulting from completed
income tax examinations.
The Company has net operating losses and tax credits available as
carryforwards to reduce future federal income taxes. State tax losses are also
available as carryforwards. At June 30, 1995, for federal tax purposes, the net
operating loss and tax credit carryforwards amounted to $13,048,000 and
$707,000, respectively; they expire through 2003. The future utilization of the
net operating loss carryforwards by the Company is subject to limitation under
provisions of the Internal Revenue Code. In addition, the Company will carryback
its current year's federal net operating loss and recover approximately
$1,000,000 of federal income tax.
A reconciliation of the statutory federal rate to the effective tax rate is
as follows:
<TABLE>
<CAPTION>
YEAR ENDED JUNE 30,
------------------------
1995 1994 1993
---- ---- ----
<S> <C> <C> <C>
Statutory federal rate....................................................... (34 %) 34 % 34 %
State taxes net of federal benefit........................................... (4 ) 4 6
Benefit of utilizing net operating loss carryforwards........................ -- -- (7)
Reversal of prior year provisions............................................ (17 ) -- --
Other........................................................................ (2) -- 1
---- ---- ----
Effective tax rate...................................................... (57 %) 38 % 34 %
---- ---- ----
---- ---- ----
</TABLE>
15. SEGMENT INFORMATION
The Company operates in one business segment, i.e., the manufacture and
sale of generic pharmaceutical products. For the year ended June 30, 1995, three
customers each accounted for approximately 13%, 11% and 10% of sales. Sales to
the three customers were $7.8 million, $6.9 million and $6.3 million,
respectively. For the year ended June 30, 1994, two customers each accounted for
approximately 12% and 11% of sales. Sales to the two customers were $8.3 million
and $8.1 million, respectively. For the fiscal year ended June 30, 1993, one
customer with sales of $7.1 million accounted for 10% of sales.
16. SUBSEQUENT EVENTS
On August 10, 1995, the Company announced its intent to (a) execute a Stock
Purchase Agreement with its majority stockholder, Holdings, providing for
Holdings to exchange all of the capital stock of each of Faulding Puerto Rico,
Inc., a Delaware corporation ('FPR'), Faulding Pharmaceutical Co., a Delaware
corporation ('FPC'), and Faulding Medical Device Co., a Delaware corporation
('FMDC'), each a wholly-owned subsidiary of Holdings (collectively, the
'Acquired Companies'), for 2,253,521 shares of the Company's Common Stock,
subject to adjustment as a result of changes in the net asset
F-70
<PAGE>
<PAGE>
PUREPAC, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
value of the Acquired Companies from June 30, 1995 through the closing date
('Share Exchange'), and (b) execute a Preferred Stock Purchase Agreement
providing for Holdings to purchase on the closing date of the Share Exchange for
an aggregate purchase price of $15 million, 150,000 shares of a newly designated
Class B Preferred Stock, which shall accrue dividends at the rate of 4.5% per
annum, have a liquidation preference of $100 per share, plus the amount of any
accrued but unpaid dividends, and shall be convertible after the first
anniversary of issuance, at the ratio of 10.433 for one, into shares of Purepac
Common Stock.
Faulding Puerto Rico, Inc. was organized to acquire a small volume
parenteral product and oral liquid pharmaceutical product manufacturing facility
located in Aguadilla, Puerto Rico (the 'Facility') from the DuPont Merck
Pharmaceutical Company and DuPont Merck Pharma. The Facility, which was acquired
in April 1995, manufactures ampules, syringes and vials of 2 ml to 30 ml
containing six generic pharmaceutical products in injectable form, Tridil'r',
Intropin'r', Bretylol'r', acetylcysteine, metoclopramide and amikacin. In
addition to acquiring the Facility, FPR acquired the intellectual property
rights, including the United States trademarks for Tridil'r' and Intropin'r',
and the rights to market and sell the majority of such products in the United
States. The Facility also acts as a contract manufacturer for two unrelated
pharmaceutical companies.
Faulding Pharmaceutical Co., originally organized as Faulding Hospital
Products, Inc., was recently established to perform the United States sales and
marketing activities for the products produced by FPR at its Aguadilla facility
and for certain of Faulding's products manufactured at its Mulgrave, Victoria,
Australia manufacturing facility, including certain of its anti-cancer products.
The products currently marketed and sold by FPC are injectable pharmaceutical
products, however, additional forms of products, including oral solids, may be
sold by FPC in the future, particularly if such products are complementary with
FPC's injectable product portfolio.
Faulding Medical Device Co., originally organized as DBL Inc., was
established to design, develop, manufacture and market injectable related
disposable devices and drug delivery system devices. The devices are designed to
enhance either the speed, safety, or sterility of injectable drug delivery.
While FMDC has developed and/or acquired the exclusive license in the United
States to several of such products, to date none of such products is
commercially available in the United States and only one of such products has
received FDA marketing approval. However, additional drug-specific approvals are
required from the FDA for this product before the medical device, pre-filled
with a drug, can be sold.
The proposed transactions described above are subject to a number of
conditions, including, without limitation, the approval of the Company's
non-Holdings stockholders and other conditions to closing. It is currently
anticipated that the closing will occur on or about December 31, 1995.
F-71
<PAGE>
<PAGE>
PUREPAC, INC.
FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 1995
(UNAUDITED)
F-72
<PAGE>
<PAGE>
PUREPAC, INC.
CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
SEPTEMBER 30, JUNE 30,
1995 1995
------------- -----------
(UNAUDITED)
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents..................................................... $ 743,113 $ 1,156,109
Accounts receivable........................................................... 9,756,128 9,702,889
Inventory (Note 3)............................................................ 16,832,640 17,831,934
Due from affiliated companies................................................. -- 172,689
Other current assets.......................................................... 3,135,075 1,806,231
Deferred income taxes (Note 5)................................................ 3,513,038 3,513,038
------------- -----------
Total current assets..................................................... 33,979,994 34,182,890
------------- -----------
Property, plant and equipment, net................................................. 26,509,150 26,603,069
Other assets....................................................................... 3,226,014 3,229,140
Deferred income taxes (Note 5)..................................................... 724,346 914,346
------------- -----------
Total assets............................................................. $64,439,504 $64,929,445
------------- -----------
------------- -----------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable.............................................................. $ 5,493,784 $ 4,843,679
Due to affiliated companies................................................... 91,145 --
Loan payable to bank.......................................................... 3,000,000 2,000,000
Accrued expenses.............................................................. 4,269,699 5,008,267
Accrued preferred dividends................................................... 520,095 520,095
------------- -----------
Total current liabilities................................................ 13,374,723 12,372,041
------------- -----------
Stockholders' equity (Note 4)
Class A convertible preferred stock; par value $.01, authorized 1,834,188
shares; issued and outstanding 834,188 (liquidation value $24,995,171)....... 8,342 8,342
Common stock; par value $.01, authorized 25,000,000 shares; issued and
outstanding 12,581,223 at September 30, 1995 and June 30, 1995,
respectively................................................................. 125,812 125,812
Capital in excess of par value................................................ 24,387,800 24,804,252
Retained earnings............................................................. 26,542,827 27,618,998
------------- -----------
Total stockholders' equity............................................... 51,064,781 52,557,404
------------- -----------
Total liabilities and stockholders' equity............................... $64,439,504 $64,929,445
------------- -----------
------------- -----------
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
F-73
<PAGE>
<PAGE>
PUREPAC, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
SEPTEMBER 30,
--------------------------
1995 1994
----------- -----------
<S> <C> <C>
Net sales.......................................................................... $14,166,712 $16,876,313
Cost of sales...................................................................... 11,654,559 12,678,729
----------- -----------
Gross profit....................................................................... 2,512,153 4,197,584
----------- -----------
Expenses:
Selling, general and administrative........................................... 2,255,102 2,471,463
Research and development...................................................... 1,950,591 1,764,533
----------- -----------
Total expenses........................................................... 4,205,693 4,235,996
----------- -----------
Income (loss) from operations...................................................... (1,693,540) (38,412)
----------- -----------
Other income (expense), net........................................................ (40,631) (393)
----------- -----------
Income (loss) before income taxes.................................................. (1,734,171) (38,805)
Provision (benefit) for income taxes (Note 5)...................................... (658,000) (14,000)
----------- -----------
Income (loss) before preferred stock dividends..................................... (1,076,171) (24,805)
Preferred stock dividends.......................................................... 520,095 520,095
----------- -----------
Net income (loss), available for common stock...................................... $(1,596,266) $ (544,900)
----------- -----------
----------- -----------
Primary earnings per common share (Note 2):
Net income (loss)............................................................. $(.13) $(.04)
----------- -----------
Weighted average number of common shares outstanding............................... 12,581,223 12,510,098
----------- -----------
Earnings per share, assuming full dilution (Note 2)................................
----------- -----------
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
F-74
<PAGE>
<PAGE>
PUREPAC, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
SEPTEMBER 30,
--------------------------
1995 1994
----------- -----------
<S> <C> <C>
Cash flows from operating activities:
Net income (loss), available for common stock....................................... $(1,596,266) $ (544,900)
Adjustments to reconcile net income (loss) to net cash provided by (used for)
operating activities:
Depreciation and amortization.................................................. 519,543 520,404
Compensation expense -- stock grants........................................... 66,946 96,316
Deferred income tax, asset..................................................... 190,000 247,947
Increase (decrease) in cash from:
Accounts receivable....................................................... (53,239) (1,112,878)
Inventory................................................................. 999,294 575,816
Other current assets...................................................... (444,147) (447,407)
Accounts payable.......................................................... 650,105 (518,350)
Accrued expenses.......................................................... (738,568) (569,294)
Accrued income taxes...................................................... (848,000) 57,403
Due to/from affiliates.................................................... 263,834 (24,834)
----------- -----------
Total adjustments.................................................... 605,768 (1,174,877)
----------- -----------
Net cash provided by (used for) operating activities................................ (990,498) (1,719,777)
----------- -----------
Cash flows from investing activities:
Purchases of property, plant and equipment.......................................... (422,498) (725,325)
----------- -----------
Net cash provided by (used for) investing activities................................ (422,498) (725,325)
----------- -----------
Cash flows from financing activities:
Borrowings from bank................................................................ 1,000,000 --
----------- -----------
Net cash provided by (used for) financing activities................................ 1,000,000 --
----------- -----------
Increase (decrease) in cash and cash equivalents.................................... $ (412,996) $(2,445,102)
----------- -----------
----------- -----------
Cash and cash equivalents, beginning of period...................................... 1,156,109 3,153,844
----------- -----------
Cash and cash equivalents, end of period............................................ $ 743,113 $ 708,742
----------- -----------
----------- -----------
Supplemental disclosure of cash flow information:
Cash paid during the period for:
Interest.................................................................. $ 54,332 $ 6,764
Income taxes.............................................................. $ -- $ --
----------- -----------
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
F-75
<PAGE>
<PAGE>
PUREPAC, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Notes to the Financial Statements included in Purepac, Inc.'s (the
'Company') Form 10-K for the year ended June 30, 1995 contain information
pertinent to the accompanying financial statements. There has been no material
change in the information contained in such footnotes except as set forth below.
The Consolidated Balance Sheet at September 30, 1995, the Consolidated
Statements of Operations for the three months ended September 30, 1995 and 1994
and the Consolidated Statements of Cash Flows for the three months ended
September 30, 1995 and 1994 have not been audited.
In the opinion of management, all adjustments (consisting only of normal
recurring entries) necessary for a fair presentation of such financial results
have been included.
1. CONSOLIDATION
The consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiary, Purepac Pharmaceutical Co. ('Purepac').
2. EARNINGS PER COMMON SHARE
Primary earnings per common share is calculated by (i) dividing income
before the cumulative effect of a change in accounting for income taxes less
preferred dividends by the weighted average number of common shares outstanding
during the period and (ii) by dividing the cumulative effect of a change in
accounting for income taxes, if any, by such average number of common shares.
Common stock equivalents are excluded as the effect is either not material or
anti-dilutive. Earnings per share assuming full dilution is not presented as the
effect would be anti-dilutive.
3. INVENTORY
<TABLE>
<CAPTION>
SEPTEMBER 30, JUNE 30,
1995 1995
------------- -----------
<S> <C> <C>
Raw materials............................................................ $ 6,889,121 $ 4,813,344
Work-in-process.......................................................... 3,515,696 5,327,342
Finished goods........................................................... 6,427,823 7,691,248
------------- -----------
Total............................................................... $16,832,640 $17,831,934
------------- -----------
------------- -----------
</TABLE>
4. CAPITAL STOCK
During the quarter ended September 30, 1995, no additional shares were
issued.
A reconciliation of the change in total stockholders' equity is as follows:
<TABLE>
<CAPTION>
PAR VALUE
OF
COMMON AND CAPITAL IN TOTAL
PREFERRED EXCESS OF RETAINED STOCKHOLDERS'
STOCK PAR VALUE EARNINGS EQUITY
----------- ----------- ----------- -------------
<S> <C> <C> <C> <C>
Balance, June 30, 1995..................... $ 134,154 $24,804,252 $27,618,998 $ 52,557,404
Class A preferred stock dividend........... (520,095) (520,095)
Stock grant amortization................... 66,946 66,946
Reduction of income tax liability from
issuance of stock grants................. 36,697 36,697
Net income (loss).......................... (1,076,171) (1,076,171)
----------- ----------- ----------- -------------
Balance, September 30, 1995................ $ 134,154 $24,387,800 $26,542,827 $ 51,064,781
----------- ----------- ----------- -------------
----------- ----------- ----------- -------------
</TABLE>
F-76
<PAGE>
<PAGE>
PUREPAC, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(UNAUDITED)
5. ACCOUNTING FOR INCOME TAXES
The Company adopted Statement of Financial Accounting Standard No. 109
('SFAS 109'), 'Accounting for Income Taxes,' effective July 1, 1993. Beginning
with the adoption of SFAS 109, the income tax expense provision will not include
the benefit of recognizing available loss carryforwards to the extent they have
already been recognized as a deferred tax asset. Instead, there will be a
reduction in the deferred tax asset when such benefits are utilized to reduce
taxes payable.
Deferred income tax assets, both current and non-current, reflect the net
tax effects of (a) temporary differences between the carrying amounts of assets
and liabilities for financial reporting purposes and the amounts used for income
tax purposes, and (b) operating loss and tax credit carryforwards.
The provision (benefit) for income tax expense was comprised of the
following:
<TABLE>
<CAPTION>
THREE MONTHS ENDED
SEPTEMBER 30,
---------------------
1995 1994
--------- --------
<S> <C> <C>
Current
Federal................................................................... $(533,000) $ (6,000)
State..................................................................... (63,000) (2,000)
--------- --------
(596,000) (8,000)
Deferred
Federal................................................................... (24,000) (5,000)
State..................................................................... (38,000) (1,000)
--------- --------
Total provision (benefit)............................................ $(658,000) $(14,000)
--------- --------
--------- --------
</TABLE>
------------------------
The Company has net operating losses and tax credits available as
carryforwards to reduce future payments of federal income taxes. State tax
losses are also available as carryforwards. At September 30, 1995, for federal
tax purposes, the net operating loss and tax credit carryforwards amounted to
$13,048,000 and $707,000, respectively; they expire through 2003. The future
utilization of the net operating loss carryforwards is subject to limitation
under provisions of the Internal Revenue Code.
6. LEGAL PROCEEDINGS
On September 11, 1995, the United States District Court for the District of
New Jersey granted the Company's motion to dismiss the complaint filed against
the Company and certain of its senior executives in a lawsuit entitled Dechter
vs. Purepac, Inc., Robert H. Bur and Russell J. Reardon, 94 Civ. 6195. The
complaint, which purported to be a class action on behalf of purchasers of
Purepac, Inc. common stock, asserted, among other things, violations of Section
10(b) of the Securities Exchange Act of 1934 and certain common law claims. At
that hearing, the court dismissed the complaint in its entirety, finding that
the complaint failed to allege any actual violation of the U.S. Securities laws
on the part of Purepac, Inc. or its senior executives. Pursuant to the court's
decision, the plaintiffs had the opportunity to consider filing a motion with
the court for permission to submit a proposed amended complaint to address the
deficiencies that led to the court's dismissal of the current action. The
plaintiffs elected not to file such a motion, thereby terminating such
litigation.
F-77
<PAGE>
<PAGE>
[THIS PAGE INTENTIONALLY LEFT BLANK]
<PAGE>
<PAGE>
EXHIBIT A
STOCK PURCHASE AGREEMENT
STOCK PURCHASE AGREEMENT, dated as of January 23, 1996, between Faulding
Holdings Inc., a Delaware corporation (the 'Seller'), and Purepac, Inc., a
Delaware corporation (the 'Buyer').
WITNESSETH
WHEREAS, the Seller is the owner of (i) all of the issued and outstanding
shares (the 'FPR Shares') of the common stock of Faulding Puerto Rico, Inc., a
Delaware corporation ('FPR'), representing all of the issued and outstanding
capital stock of FPR, (ii) all of the issued and outstanding shares (the 'FPC
Shares') of the common stock of Faulding Pharmaceutical Co., a Delaware
corporation ('FPC'), representing all of the issued and outstanding capital
stock of FPC, and (iii) all of the issued and outstanding shares (the 'FMDC
Shares') of the common stock of Faulding Medical Device Co., a Delaware
corporation ('FMDC'), representing all of the issued and outstanding capital
stock of FMDC, and wishes to transfer the ownership of FPR, FPC and FMDC (the
'Acquired Companies') to the Buyer in a transaction qualifying as a tax-free
reorganization, as contemplated by Section 368 of the Internal Revenue Code of
1986, as amended;
WHEREAS, to accomplish the foregoing, the Seller wishes to exchange all of
the FPR Shares, FPC Shares and FMDC Shares (collectively, the 'Shares') for
newly issued shares of capital stock of the Buyer, on the terms and conditions
and for the consideration described below in this Agreement; and
WHEREAS, simultaneously with the execution of this Agreement, the Seller
and the Buyer are executing and delivering an agreement (the 'Preferred Stock
Purchase Agreement'), providing, among other things, for the purchase by the
Seller of shares of a new class of convertible preferred stock of the Buyer
having an aggregate liquidation/redemption preference of $15,000,000, and
convertible into shares of Common Stock of the Buyer, for a purchase price of
$15,000,000 in cash, all as set forth in such Preferred Stock Purchase
Agreement;
NOW, THEREFORE, in consideration of the mutual promises, covenants,
representations and warranties made herein and of the mutual benefits to be
derived herefrom, the parties hereto agree as follows:
I
PURCHASE AND SALE OF THE SHARES
1.1 Purchase and Sale of the Shares. Subject to the terms and conditions
hereof, the Seller will sell all of the Shares to the Buyer and the Buyer will
purchase all of the Shares from the Seller in consideration for the delivery to
the Seller at the Closing of 2,253,521 shares of Common Stock, $.01 par value,
of the Buyer, such number of shares of Common Stock being subject to adjustment
in accordance with Section 1.4 hereof (the 'Purepac Stock').
1.2 Closing. The closing of the sale and purchase of the Shares (the
'Closing') shall take place at the offices of Parker Duryee Rosoff & Haft, a
professional corporation, 529 Fifth Avenue, New York, New York 10017, at 1:00
p.m. on February 29, 1996, or such other time and date as the parties may agree
to in writing (the 'Closing Date').
At the Closing:
(a) the Seller will deliver to the Buyer, free and clear of all liens,
claims, charges and encumbrances, certificates representing all of the
Shares duly endorsed for transfer to the Buyer or accompanied by stock
powers or other instruments of transfer duly executed for transfer to the
Buyer, and accompanied by all requisite stock transfer stamps;
(b) the Buyer will deliver to the Seller, free and clear of all liens,
claims, charges and encumbrances, a certificate representing 2,253,521
shares of Purepac Stock (subject to the provisions of Section 1.4)
registered in the name of the Seller;
A-1
<PAGE>
<PAGE>
(c) the Seller will deliver to the Buyer the Estimated Closing Balance
Sheet, as hereinafter defined; and
(d) the Buyer and the Seller shall each deliver to the other those
items required to be delivered pursuant to Article VII hereof.
1.3 Preparation of Closing Balance Sheets.
(a) The Seller shall prepare an estimated balance sheet (the 'Estimated
Closing Balance Sheet') of the Acquired Companies as at February 29, 1996 in
accordance with generally accepted accounting principles consistently applied in
accordance with the past practices of the Acquired Companies ('GAAP'), which
Estimated Closing Balance Sheet shall be based upon the January 31, 1996 balance
sheets of the Acquired Companies as adjusted to give effect to estimated changes
therein and adjustments thereto through February 29, 1996. At the Closing, the
Seller shall deliver the Estimated Closing Balance Sheet to the Buyer and
provide the Buyer with a calculation of the estimated Net Asset Value of the
Acquired Companies as at February 29, 1996 (the 'Estimated Net Asset Value').
(b) On or prior to April 15, 1996, the Seller shall deliver to the Buyer a
balance sheet of the Acquired Companies as at February 29, 1996 (the 'Actual
Closing Balance Sheet') together with a calculation of the Net Asset Value as at
February 29, 1996 (the 'Audited Net Asset Value'). The calculation of the
Audited Net Asset Value shall be audited by Deloitte & Touche LLP (the
'Accountants'), and shall be accompanied by a report from the Accountants
stating that the Audited Net Asset Value presents fairly in all material
respects the Net Asset Value of the Acquired Companies at February 29, 1996. The
determination of the Audited Net Asset Value as so reported on by the
Accountants shall be conclusive and binding on the parties. The costs of the
audit will be borne by the Buyer.
(c) For the purposes of this Agreement, 'Net Asset Value' shall mean the
value of the tangible assets of the Acquired Companies plus the book value of
the patents and trademarks of such companies, less all liabilities of the
Acquired Companies other than intercompany debt owed to Faulding or F. H.
Faulding & Co. Limited, all as determined in accordance with GAAP as of the
relevant date. Any changes in Net Asset Value arising from costs associated with
patents and trademarks incurred prior to June 30, 1995, but which were not
reflected on the balance sheets of the Acquired Companies as at June 30, 1995,
shall be excluded from the calculation of Net Asset Value.
1.4 Adjustments to Purchase Price. In the event that the Estimated Net
Asset Value is less than $17,878,028, the number of shares of Purepac Stock set
forth in Section 1(b) delivered by the Buyer to the Seller at the Closing shall
be reduced by such whole number of shares (rounded down to the nearest whole
number of shares) as shall equal (x) the amount of the shortfall divided by (y)
8.875. In the event the Estimated Net Asset Value is greater than $17,878,028,
the number of shares of Purepac Stock to be delivered by the Buyer to the Seller
pursuant to Section 1(b) shall be increased by such number of whole additional
shares (rounded down to the nearest whole number of shares) of Purepac Stock as
shall equal (x) the amount of such excess divided by (y) 8.875. Upon the
determination by the Accountants of the Audited Net Asset Value, (i) if the
Audited Net Asset Value exceeds the Estimated Net Asset Value, then the Buyer
shall, within three business days, deliver to the Seller certificates
representing such number of additional shares of Purepac Stock as shall equal
(x) the amount of such excess divided by (y) 8.875, or (ii) if the Audited Net
Asset Value is less than the Estimated Net Asset Value, then the Seller shall,
within three business days, surrender to the Buyer a certificate representing
such number of whole shares (rounded down to the nearest whole share) of Purepac
Stock as shall equal (x) the amount of such shortfall divided by (y) 8.875,
together with a stock power duly endorsed for transfer of such number of shares
to the Buyer.
A-2
<PAGE>
<PAGE>
II
REPRESENTATIONS AND WARRANTIES OF THE SELLER
AS TO THE AGREEMENT AND THE SHARES
The Seller represents and warrants to the Buyer as follows with the
knowledge and understanding that the Buyer is relying materially on such
representations and warranties.
2.1 Organization and Standing. The Seller is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware.
The Seller has all requisite corporate power to carry on its business as it is
now being conducted.
2.2 Capitalization; Title to Shares. The authorized capital stock of each
of the Acquired Companies, the number of shares of capital stock which are
issued and outstanding and the par value thereof are as set forth in Section 2.2
of the Seller's Disclosure Schedule. All of such shares of capital stock that
are issued and outstanding are duly authorized, validly issued and outstanding,
fully paid and nonassessable, and owned of record and beneficially by the Seller
free and clear of all liens, claims, charges and encumbrances, and were not
issued in violation of the preemptive rights of any person. Upon the closing of
the transactions contemplated hereby, the Buyer will acquire title to the
Shares, free and clear of all liens, claims, charges and encumbrances. There are
no subscriptions, options, warrants, rights or calls or other commitments or
agreements to which the Seller or any of the Acquired Companies is a party or by
which any of them is bound, calling for any issuance, transfer, sale or other
disposition of any class of securities of any of the Acquired Companies. There
are no outstanding securities convertible or exchangeable, actually or
contingently, into shares of capital stock or any other securities of any of the
Acquired Companies.
2.3 Authority. The Seller has the full power and authority to execute this
Agreement and each other agreement to be executed by the Seller in connection
with the transactions contemplated hereby, and this Agreement constitutes, and
all such other agreements will constitute, when executed and delivered by the
Seller in accordance herewith, the valid and binding obligations of the Seller,
enforceable in accordance with their respective terms, subject to general
principles of equity and bankruptcy or other laws relating to or affecting the
rights of creditors generally. The execution and delivery of this Agreement and
the agreements contemplated hereby, and the performance of the Seller's
obligations hereunder and thereunder have been duly authorized by the Board of
Directors of the Seller, and ratified by the sole stockholder of the Seller,
F.H. Faulding & Co. Limited, an Australian corporation ('FHF').
2.4 Acquisition of Purepac Stock for Investment. The Seller is acquiring
the Purepac Stock for investment purposes, with no present intention to
distribute or liquidate such stock or to transfer such stock in violation of
applicable securities laws, including without limitation the Securities Act of
1933, as amended (the 'Act').
2.5 No Conflicts, etc. The execution and delivery of this Agreement and the
consummation of the transactions contemplated hereby will not conflict with or
result in any violation of or default under any provision of the certificate of
incorporation or by-laws of the Seller or of any of the Acquired Companies, or
any mortgage, indenture, lease, stockholders' agreement or other agreement,
instrument, applicable law or license applicable to the Seller or any of the
Acquired Companies or any of the properties of the Acquired Companies.
2.6 Governmental Approvals. No license, permit, franchise, approval, order
or consent of, and no registration, declaration or filing with, any federal,
state or local, or any foreign governmental authority is required on the part of
the Seller or any of the Acquired Companies in connection with the execution and
delivery of this Agreement or the consummation of the transactions contemplated
hereby, the failure of which to obtain would have a material adverse effect upon
the financial condition, properties, assets, liabilities or business of any of
the Acquired Companies. Except as set forth in Section 2.6 of the Seller's
Disclosure Schedule, no consent of any third party is required to be obtained by
the Seller or any of the Acquired Companies in connection with the execution,
delivery and performance of this Agreement or the consummation of the
transactions contemplated hereby, the failure of which to obtain would have a
material adverse effect upon the financial condition, properties, assets,
liabilities or business of any of the Acquired Companies.
A-3
<PAGE>
<PAGE>
2.7 Brokers. Neither the Seller, FPR, FPC nor FMDC has made any agreement
or taken any action with any person or taken any action which would cause any
person to be entitled to any agent's, broker's or finder's fee or commission in
connection with the transactions contemplated by this Agreement.
2.8 Disclosure Schedule Complete. The Seller shall promptly supplement the
Seller's Disclosure Schedule if events occur prior to the Closing Date that
would have been required to be disclosed had they existed at the time of
executing this Agreement. The Seller's Disclosure Schedule, as supplemented
prior to the Closing, will contain a true, correct and complete list and
description of all items required to be set forth therein. The Seller's
Disclosure Schedule is expressly incorporated herein by reference.
Notwithstanding the foregoing, any such supplement to the Seller's Disclosure
Schedule following the date hereof shall not in any way affect the Buyer's right
not to consummate the transactions contemplated hereby as set forth in Article
VIII hereof.
2.9 No Omissions or Untrue Statements. None of the information relating to
any of the Acquired Companies or the Seller supplied in writing or to be
supplied in writing by any of the Acquired Companies or the Seller specifically
for inclusion in the Proxy Statement (as defined in Section 7.6) to be
distributed to the Buyer's stockholders in connection with the Stockholders'
Meeting (as defined in Section 7.5), at the respective times that the Proxy
Statement is filed with the Securities and Exchange Commission (the
'Commission'), first mailed to the Buyer's stockholders and the Stockholders'
Meeting takes place, as the case may be, contains or will contain any untrue
statement of a material fact or omits or will omit to state a material fact
required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not
misleading. The Buyer shall give notice to the Seller in advance of the dates of
such filing, mailing and meeting sufficient to permit the Seller to give notice
to the Buyer of any change in facts or circumstances which would result in any
such statement or omission.
III
REPRESENTATIONS AND WARRANTIES OF THE SELLER
AS TO FPR
The Seller represents and warrants to the Buyer as follows with the
knowledge and understanding that the Buyer is relying materially on such
representations and warranties. To the extent that the representations and
warranties set forth in this Article III relate to facts and circumstances prior
to April 7, 1995, such representations and warranties are made to the knowledge
of the Seller, based solely on the representations and warranties made to the
Seller contained in the Purchase and Sale Agreement dated March 10, 1995 among
FPR, The DuPont Merck Pharmaceutical Company and DuPont Merck Pharma (the
'DuPont Acquisition Agreement'), a copy of which has been provided to the Buyer.
3.1 Organization and Standing. FPR is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware. FPR has
all requisite corporate power to carry on its business as it is now being
conducted and is duly qualified to do business as a foreign corporation and is
in good standing in each jurisdiction where such qualification is necessary
under applicable law except where the failure to qualify (individually or in the
aggregate) does not have any material adverse effect on the business of FPR. The
copies of the Certificate of Incorporation and by-laws of FPR (certified by the
Secretary of FPR), as amended to date, delivered to the Buyer, are true and
complete copies of these documents as now in effect. FPR does not own any
capital stock in any other corporation, business trust or similar entity. The
minute books of FPR are accurate in all material respects.
3.2 Properties. FPR has good and marketable title to all of the assets and
properties reflected on the balance sheet included in the FPR Financial
Statements (as hereinafter defined), or thereafter acquired, in each case free
and clear of any liens, claims or encumbrances. Any lease of material real or
personal property to which FPR is a party is a valid, binding and enforceable
obligation of FPR, and, to the knowledge of the Seller, the other parties
thereto in accordance with its terms. FPR is not in material default in the
performance of any material provision thereunder. The use thereof by FPR of the
real property leased by it does not materially violate any local zoning or
similar land use laws.
A-4
<PAGE>
<PAGE>
3.3 Financial Statements. Section 3.3 of the Seller's Disclosure Schedule
contains (i) balance sheets of the Facility acquired by FPR from DuPont Merck
Pharma as of December 31, 1993, September 30, 1994, and December 31, 1994, (ii)
the balance sheet of FPR as of September 30, 1995 and the related statement of
operations for the three months then ended (collectively with the foregoing
'Unaudited Financial Statements') and (iii) the balance sheet of FPR as of June
30, 1995 and the related statement of operations, statement of cash flows and
statement of stockholders' equity of FPR for the period beginning April 7, 1995
and ending June 30, 1995, together with the report of Deloitte & Touche LLP
thereon (the 'Audited FPR Financial Statements', and together with the Unaudited
Financial Statements, the 'FPR Financial Statements'). The FPR Financial
Statements, including the notes thereto, present fairly, in all material
respects, the financial position and results of operations of FPR as of the
dates and periods indicated, prepared in accordance with generally accepted
accounting principles consistently applied ('GAAP'). Without limiting the
generality of the foregoing, (i) except as set forth in Section 3.3 of the
Seller's Disclosure Schedule, to the knowledge of the Seller, there is no basis
for any assertion against FPR as of the date of said balance sheets of any
material debt, liability or obligation of any nature not fully reflected or
reserved against in such balance sheets or in the notes thereto; and (ii) there
are no assets of FPR the value of which (in the reasonable judgment of FPR) are
materially overstated in said balance sheets. Except as disclosed therein or in
Section 3.3 of the Seller's Disclosure Schedule or as incurred in the ordinary
course of business since the date of the most recent balance sheet, FPR does not
have any known material contingent liabilities (including liabilities for
taxes).
3.4 Accounts Receivable; Inventories. The accounts receivable of FPR on the
latest balance sheet contained in the FPR Financial Statements (except those
collected since such date) and such additional accounts receivable as are
reflected in Section 3.4 of the Seller's Disclosure Schedule (which sets forth
the accounts receivable on the books of FPR as of September 30, 1995 and an
aging schedule (to the nearest month) of such receivables) have been generated
in the ordinary course of business and reflect a bona fide obligation for the
payment of goods or services provided by FPR. The inventories reflected on the
latest balance sheet contained in the FPR Financial Statements and those
inventories owned by FPR on the date hereof are in good, merchantable and usable
condition and include no obsolete or discontinued items, or items which have
failed quality testing, in each case except to the extent reserved against on
such balance sheet.
3.5 Absence of Certain Changes or Events. Except as set forth in Section
3.5 of the Seller's Disclosure Schedule, since Septmber 30, 1995 there has not
been:
(i) any material adverse change in the financial condition,
properties, assets, liabilities or business of FPR;
(ii) any material damage, destruction or loss of any material
properties of FPR, whether or not covered by insurance;
(iii) any material adverse change in the manner in which the business
of FPR has been conducted;
(iv) any material adverse change in the treatment and protection of
trade secrets or other confidential information of FPR;
(v) any material change in the business or contractual relationship of
FPR with any employee, customer or supplier which might reasonably be
expected to materially and adversely affect the business of FPR;
(vi) declared, set aside, made or paid any dividend with respect to
its capital stock or otherwise purchased or redeemed any shares of its
capital stock;
(vii) incurred, prepaid, forgiven or cancelled any indebtedness other
than in the ordinary course of business;
(viii) acquired or disposed of any assets, or entered into any
agreement or arrangement of any nature except in the ordinary course of
business; and
(ix) any agreement by FPR, whether written or oral, to do any of the
foregoing.
A-5
<PAGE>
<PAGE>
3.6 Taxes.
(a) For purposes of this Agreement, (1) 'Tax' (and, with correlative
meaning, 'Taxes') shall mean any federal, state, local or foreign income,
alternative or add-on minimum, business, employment, franchise, occupancy,
payroll, property, sales, transfer, use, value added, withholding or other tax,
levy, impost, fee, imposition, assessment or similar charge together with any
related addition to tax, interest, penalty or fine thereon; and (2) 'Returns'
shall mean all returns (including, without limitation, information returns and
other material information), reports and forms relating to Taxes.
(b) FPR has duly filed all Returns required to be filed by it. All such
Returns were, when filed, and to the knowledge of the Seller are, accurate and
complete in all material respects and were prepared in conformity with
applicable laws and regulations in all material respects. FPR has paid or, if
not yet due, will pay in full or has adequately reserved against all Taxes
otherwise assessed against it through the Closing Date.
(c) FPR is not a party to any pending action or proceeding by any
governmental authority for the assessment of any Tax, and no claim for
assessment or collection of any Tax related to FPR has been asserted against FPR
that has not been paid. No Return of FPR is currently under audit by the
Internal Revenue Service or any other governmental authority. There are no Tax
liens upon the assets (other than the lien of property taxes not yet due and
payable) of FPR. There is no valid basis, to the knowledge of the Seller, for
any assessment, deficiency, notice, 30-day letter or similar intention to assess
any Tax to be issued to FPR by any governmental authority.
(d) All Taxes which FPR is required to collect or withhold have been duly
and timely collected and withheld and have been set aside in accounts for such
purposes, or to the extent required when due, have been duly and timely paid to
the proper governmental authority.
(e) FPR has submitted to the Commonwealth of Puerto Rico an application for
an industrial tax exemption, a copy of which, and copies of all responses and
correspondence relating thereto, have been provided in full to the Buyer.
3.7 Contracts Listed; No Default. Section 3.7 of the Seller's Disclosure
Schedule contains a complete and correct list as of the date hereof of all
agreements, contracts and commitments of the following types, written or oral,
to which FPR is a party or by which FPR or any of its properties is bound as of
the date hereof: (i) mortgages, indentures, security agreements, letters of
credit, loan agreements and other agreements, guarantees and instruments
relating to the borrowing of money or extension of credit; (ii) employment,
consulting, severance and agency agreements; (iii) collective bargaining
agreements; (iv) bonus, profit-sharing, compensation, stock option, stock
purchase, pension, severance, retirement, deferred compensation or other plans,
trusts or funds for the benefit of employees, officers, agents or directors
(whether or not legally binding); (v) sales agency, manufacturer's
representative or distributorship agreements; (vi) agreements, orders or
commitments for the purchase of raw materials, supplies or finished products
exceeding $100,000; (vii) agreements, orders or commitments for the sale of its
products exceeding $100,000; (viii) licenses of Intellectual Property (as
hereinafter defined), transfer of technology or know how and other intellectual
property rights; (ix) confidentiality agreements (including agreements binding
any of FPR's employees and their respective former employers); (x) agreements or
commitments for capital expenditures in excess of $20,000 for any single project
(it being warranted that all undisclosed agreements or commitments for capital
projects do not exceed $20,000 in the aggregate for all projects); (xi)
brokerage or finder's agreements; (xii) stockholders' agreements and any
agreements restricting the transfer of any of the FPR Shares; and (xiii) joint
venture and partnership agreements; (xiv) leases for real and personal property;
and other agreements, contracts and commitments which in any case involve
payments or receipts of more than $100,000. The Seller has made available to the
Buyer complete and correct copies of all such written agreements, contracts and
commitments, together with all amendments thereto, and provided accurate
descriptions of all oral agreements listed in Section 3.7 of the Seller's
Disclosure Schedule. All agreements, contracts and commitments of the type
described in this Section 3.7 are in full force and effect in accordance with
their respective terms and there does not exist thereunder as of the date hereof
any default by FPR or to the Seller's knowledge, any other party thereto, or
event or condition which, after notice or lapse of time or both, would
constitute a default thereunder on the part of FPR or, to the Seller's
knowledge, any other party thereto.
A-6
<PAGE>
<PAGE>
3.8 Litigation. There is no judicial or administrative action, suit,
proceeding or investigation pending or, to the Seller's knowledge, threatened
which affects or could affect materially FPR or result in any liability on the
part of FPR in excess of $25,000 in the aggregate, or which involves or could
involve the validity of this Agreement or any agreement or instrument executed
or to be executed in connection herewith or of any action taken or to be taken
in connection therewith. The Seller has delivered or made available to the Buyer
in accordance with the terms of this Agreement copies of the files of FPR
containing all information with respect to (i) customer complaints relating to
product performance since January 1, 1989, (ii) recalls of products or
notifications therefor by any Governmental Authority or voluntarily by FPR since
January 1, 1989, and (iii) claims made or threatened which FPR has put in the
hands of its insurance carriers since January 1, 1989 relating to personal or
other injuries or other damages resulting from the production, manufacture, sale
or use of any products produced, manufactured or sold by FPR.
3.9 Compliance with Laws and Regulations. FPR is in compliance, in all
material respects, with all laws, rules, regulations, orders and requirements
(federal, state and local and foreign) applicable to it in all jurisdictions
where its business is conducted or to which it is subject, including, without
limitation, all applicable civil rights and equal opportunity employment laws
and regulations, and all federal, antitrust, antimonopoly and fair trade
practice laws, except where the failure to comply would not have a material
adverse effect upon FPR. The Seller knows of no assertion by any party that FPR
is in violation in any material respect of any such laws, rules, regulations,
orders, restrictions or requirements with respect to its operations and no
notice in that regard has been received by FPR.
3.10 Governmental Licenses, Permits, Etc. FPR has all material governmental
licenses, permits, authorizations and approvals necessary for the conduct of its
business as currently conducted ('FPR Licenses and Permits'). Section 3.10 of
the Seller's Disclosure Schedule includes a list of all FPR Licenses and
Permits. All FPR Licenses and Permits are in full force and effect, and no
proceedings for the suspension or cancellation of any thereof is pending or
threatened. Specifically identified in Section 3.10 of the Seller's Disclosure
Schedule is a complete list of all Approved New Drug Applications ('ANDAS') and
all Abbreviated Antibiotic Applications filed with the United States Food and
Drug Administration (the 'FDA'), and any similar filings with any agency or
department of any foreign government which regulates the production or sale of
pharmaceutical products, as well as all pending applications and amendments
thereto in connection with obtaining any of such registrations, approvals or
authorizations. Except as disclosed in Section 3.10 of the Seller's Disclosure
Schedule, all applications and amendments previously filed by FPR in connection
with receiving such FPR Licenses and Permits were correct at the time such
applications were granted and made in accordance and substantial compliance with
all applicable rules, regulations and instructions for the filing of the same.
Access to all applications previously made or pending, including all related
files, correspondence, notes and telephone logs (as well as all written reports
known to FPR relating to field trials, clinical studies or laboratory testing
relating to its products or products being developed by it) in connection
therewith, all of which documents are maintained at FPR's principal office, has
been provided to the Buyer. Following the Closing, the Seller shall assist the
Buyer in obtaining the continuation or transfer of such permits, licenses,
franchises, orders, registrations or other approvals as may be required by the
transaction contemplated hereby. Neither the execution and delivery of this
Agreement, nor the consummation of the transactions contemplated hereby will
result in the revocation, cancellation or suspension of any of the FPR Licenses
and Permits.
3.11 Environmental Compliance.
(a) Except as set forth in Section 3.11 of the Seller's Disclosure
Schedule, the business, operations, property and assets of FPR (and, to the
knowledge of the Seller, the business of any subtenant or licensee which is
occupying or has occupied any space on any premises of FPR, the activities of
which could result in any material adverse liability to FPR) have been and are
in compliance in all material respects with all, and are not in material
violation of any, applicable federal, state and local or foreign laws, rules and
regulations, including but not limited to the Comprehensive Environmental
Response Compensation and Liability Act of 1980, as amended, including the 1986
Amendments thereto, the Superfunds Amendments and Reauthorization Act ('CERCLA')
and the Resource Conservation and
A-7
<PAGE>
<PAGE>
Recovery Act ('RCRA'), as well as any other laws, rules or regulations relating
to environmental protection or hazardous or toxic waste (collectively, the
'Environmental Laws').
(b) Except as set forth in Section 3.11 of the Seller's Disclosure
Schedule, no suit, action, claim, proceeding, nor investigation, review or
inquiry by any court or federal, state, county, municipal or local governmental
department, commission, board, bureau, agency or instrumentality, domestic or
foreign (all of the foregoing collectively referred to as 'Governmental Entity')
concerning any material violation of any Environmental Laws by FPR is pending
or, to the knowledge of the Seller, threatened in writing, including but not
limited to matters relating to environmental protection or hazardous or toxic
waste. The Seller does not know of any reasonable basis or ground for any such
suit, claim, investigation, inquiry or proceeding.
3.12 Insurance. FPR is covered by insurance policies, or renewals thereof,
as identified and described in Section 3.12 of the Seller's Disclosure Schedule.
The Seller will maintain such insurance (other than insurance relating to
liability of officers and directors) up to and including June 30, 1996. FPR has
not received written notice from any insurer or agent of such insurer that
improvements or expenditures are required to be made in order to continue such
insurance in effect and, so far as known to the Seller, no such improvements or
expenditures are required (other than premium payments). There is no liability
under any insurance policy in the nature of a retroactive rate adjustment or
loss sharing or similar arrangement except as set forth in Section 3.12 of the
Seller's Disclosure Schedule.
3.13 Condition of Assets. The equipment, fixtures and other personal
property of FPR are in good operating condition and repair (ordinary wear and
tear excepted) for the conduct of the business of FPR as now being conducted.
3.14 Employees, Labor Matters, etc.
(a) Section 3.14 of the Seller's Disclosure Schedule contains a complete
and correct list of the names of all directors, officers and salaried employees
of FPR as of October 17, 1995. There is no payment of salary or other deferred
cash compensation for services that has not been paid for more than 30 days past
the date on which such payment would ordinarily be made in the ordinary course
of business that is owed by FPR to any of its directors, officers, employees,
trustees, agents, brokers, representatives or other personnel, current and
former, or any beneficiaries, dependents or survivors of the foregoing, in an
amount in excess of $10,000 in the aggregate (including, without limitation,
expense reimbursement and severance payments), in accordance with the terms of
their respective employment arrangements or under their employment, severance or
agency agreements, if any.
(b) Except as set forth in Section 3.14 of the Seller's Disclosure
Schedule, none of the employees of FPR is represented by any labor union or
collective bargaining unit and the Seller is not aware of any organizational
efforts taking place with respect to such representation of its employees.
3.15 Employee Agreements.
(a) For purposes of this Agreement, the following definitions apply:
(i) 'ERISA' means the Employee Retirement Income Security Act of 1974,
as amended, and any regulations promulgated thereunder.
(ii) 'Multi-employer Plan' means a plan, as defined in ERISA Section
3(37), to which FPR or any Related Entity (as hereinafter defined)
contributes or is required to contribute.
(iii) 'Employee Plan' means any plan described in Section 3(3) of
ERISA (other than a Multi-employer Plan) to which FPR or any Related Entity
contributes, sponsors, maintains or otherwise is bound to with regard to
any benefits on behalf of the employees of FPR.
(iv) 'Employee Pension Plan' means any Employee Plan described in
Section 3(2) of ERISA.
(v) 'Employee Welfare Plan' means any Employee Plan other than an
Employee Pension Plan.
(vi) 'Compensation Arrangement' means any plan or compensation
arrangement other than an Employee Plan, whether written or unwritten, to
which FPR is subject to liability, which provides to employees of FPR,
former employees, officers, directors or stockholders of FPR any
A-8
<PAGE>
<PAGE>
material compensation or other material benefits, whether deferred or not,
in excess of base salary or wages, including, but not limited to, any bonus
or incentive plan, stock rights plan, deferred compensation arrangement,
life insurance, stock purchase plan, severance pay plan and any other
employee fringe benefit plan.
(vii) 'Related Entity' means any entity which is a member of a
controlled group of corporations which includes FPR or the Buyer, as
applicable, or which is under common control with FPR or the Buyer, as
applicable, as set forth in Sections 414(b), (c), (m) and (o) of the Code.
(b) Section 3.15 of the Seller's Disclosure Schedule lists, all (1) written
employment agreements and collective bargaining agreements to which FPR is a
party; (2) material Compensation Arrangements; (3) Employee Welfare Plans,
Employee Pension Plans and consulting agreements under which FPR or any Related
Entity has or may have any material monetary obligations to employees of FPR, or
consultants of FPR or their beneficiaries or legal representatives or under
which any such persons may have any rights against FPR. FPR has previously made
available to the Buyer true and complete copies of all of the foregoing
employment contracts, collective bargaining agreements, Employee Plans and
Compensation Arrangements, including descriptions of any material unwritten
contracts, agreements, Compensation Arrangements or Employee Plans, as amended
to date. In addition, with respect to any Employee Plan which continues after
the Closing Date, FPR has previously delivered or made available to the Buyer
(1) any related trust agreements, master trust agreements, annuity contracts or
insurance contracts; (2) certified copies of all Board of Directors' resolutions
adopting such plans and trust documents and amendments thereto; (3) current
investment management agreements; (4) custodial agreements; (5) fiduciary
liability insurance policies; (6) indemnification agreements; (7) the most
recent determination letter issued by the Internal Revenue Service with respect
to the qualification of any Employee Plan under the provisions of Section 401(a)
of the Code; (8) copies of all 'advisory opinion letters', 'private letter
rulings' and 'no action letters' that were issued by any governmental or quasi-
governmental agency with respect to any Employee Plan; (9) Annual Reports (Form
5500 Series) and Schedules A and B thereto for the last plan year; (10) all
actuarial reports prepared for the last plan year; (11) all certified financial
statements for the last plan year; and (12) all current Summary Plan
Descriptions, Summaries of Material Modifications and Summary Annual Reports.
(c) Except as otherwise disclosed in Section 3.15 of the Seller's
Disclosure Schedule:
(i) No Employee Pension Plan is subject to Title IV of ERISA.
(ii) Each Employee Plan and Compensation Arrangement, to the knowledge
of the Seller, currently substantially complies and has substantially
complied in the past, both as to form and operation, with its terms and
with the applicable provisions of ERISA, the Age Discrimination in
Employment Act and all other applicable Federal or State or foreign laws,
rules and regulations. Each Employee Plan and Compensation Arrangement has
been administered to date in substantial compliance with the requirements
of ERISA and the Code, and FPR has substantially complied with all
reporting and disclosure requirements by any governmental agency.
(iii) With respect to any Multi-employer Plan, neither FPR nor any
Related Entity is required to make any contribution thereto.
(iv) FPR has complied in all material respects with the continuation
coverage requirements, as defined in Section 4980B(f) of the Code.
(v) There are no actions, suits or claims pending (other than routine
claims for benefits) or, to the knowledge of the Seller, which could
reasonably be expected to be asserted against any Employee Plan or
Compensation Arrangement or the assets of any such Plan. No civil or
criminal action brought pursuant to the Code or ERISA with respect to any
Employee Plan or Compensation Arrangement is pending or, to the knowledge
of the Seller, threatened against any fiduciary which is a Related Entity
or employee thereof. None of the Employee Plans or Compensation
Arrangements, or any fiduciary of any Employee Plan or Compensation
Arrangement which is a Related Entity or employee thereof, to the knowledge
of the Seller, currently is the subject of any audit, investigation or
examination by any governmental or quasi-governmental agency, nor is FPR
aware of the existence of any facts that would lead it to believe that any
such audit, investigation or examination is pending or threatened.
A-9
<PAGE>
<PAGE>
(vi) FPR does not sponsor, maintain or contribute to any Employee Plan
or Compensation Arrangement that provides retiree medical or retiree life
insurance coverage to former employees of FPR other than any such benefits
described under Section 4980B of the Code or Part 6 of Title I of ERISA.
(vii) With respect to each Employee Plan:
(A) each Employee Pension Plan has received a favorable
determination letter (or is the subject of an outstanding request for
such a letter) with regard thereto or is based on a prototype plan which
has received a favorable determination letter;
(B) to the knowledge of the Seller, neither FPR nor any Related
Entity has, with respect to any Employee Plan, engaged in a prohibited
transaction, as such term is defined in Code Section 4975 or ERISA
Section 406, which would subject FPR or the Buyer to any taxes,
penalties or other liabilities resulting from prohibited transactions
under Code Section 4975 or under ERISA Sections 409 or 502(i);
(C) to the knowledge of the Seller, no event has occurred and no
condition exists that would subject FPR or the Buyer to any tax under
Code Sections 4971, 4972, 4976, 4977 or 4979 or a fine under ERISA
Section 502(c);
(D) all insurance premiums, including PBGC premiums, required to be
paid on or prior to the Closing Date with regard to each Employee Plan
have been or will be paid; and
(E) FPR and each Related Entity has or will have, as of the Closing
Date, made all contributions or payments to or under such Employee Plans
required by law or by the terms of such Plans or any contract or
agreements to have been made by the Closing Date. To the knowledge of
the Seller, as of the date of this Agreement, the aggregate current
value of all vested accrued benefit obligations under all Employee
Pension Plans does not exceed the aggregate current value of all assets
of such plans allocable to such vested accrued benefit obligations.
3.16 Business Locations. FPR does not own or lease any real or personal
property in any state or country except as set forth in Section 3.16 of the
Seller's Disclosure Schedule.
3.17 Intellectual Property. Section 3.17 of the Seller's Disclosure
Schedule lists all of the Intellectual Property (as hereinafter defined) used by
FPR which constitutes a material patent, trade name, trademark, service mark,
copyright or application for any of the foregoing. Intellectual Property means
all of FPR's right, title and interest in and to all patents, trade names,
assumed names, trademarks, service marks, proprietary technology, processes and
rights, proprietary names, copyrights (including any registration and pending
applications for any such registration for any of them) together with all the
goodwill relating thereto, and all other intellectual property of FPR. Other
than as disclosed in Section 3.17 of the Seller's Disclosure Schedule, FPR has
not any licenses granted by or to it or other agreements to which it is a party,
relating in whole or in part to any Intellectual Property, whether owned by it
or otherwise. All of the patents, trademark registrations and copyrights listed
in Section 3.17 of the Seller's Disclosure Schedule as owned by FPR are to the
knowledge of the Seller valid and in full force and effect. To the knowledge of
the Seller, FPR is not infringing upon, or otherwise violating, the rights of
any third party with respect to any Intellectual Property. Except as otherwise
set forth in Section 3.17 of the Seller's Disclosure Schedule, no proceedings
have been instituted against or claims in writing received by FPR, nor to the
knowledge of the Seller are any proceedings threatened alleging any such
violation.
3.18 Bank Accounts. Section 3.18 of the Seller's Disclosure Schedule
contains a correct and complete list of each bank and financial institution in
which FPR maintains an account or a safe deposit box, the account numbers of
such accounts and the names of the authorized signatories for each such account.
3.19 Selling Materials and Policies. The Seller has delivered to the Buyer
copies of all current catalogs and brochures relating to products manufactured
and or sold by FPR and the pricing structure for volume and promotional
discounts relating to such products.
A-10
<PAGE>
<PAGE>
3.20 Warranties. Section 3.20 of the Seller's Disclosure Schedule sets
forth a true and complete list of the forms of all express warranties and
guaranties made by FPR to third parties with respect to any products sold or
leased, or services rendered. No product or service of FPR has, at any time,
been subject to any voluntary or governmental recall and the Seller knows of no
presently existing circumstances that would constitute a valid basis therefor.
3.21 Customers and Suppliers. Neither the Seller nor FPR has reason to
believe that, either as a result of the transactions contemplated hereby or for
any other reason (exclusive of expiration of a contract upon the passage of
time), any present material customer or supplier of FPR will not continue to
conduct business with FPR after the Closing Date in substantially the same
manner as it has conducted business with FPR in the past.
IV
REPRESENTATIONS AND WARRANTIES OF THE SELLER
AS TO FPC
The Seller represents and warrants to the Buyer as follows with the
knowledge and understanding that the Buyer is relying materially on such
representations and warranties.
4.1 Organization and Standing. FPC is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware. FPC has
all requisite corporate power to carry on its business as it is now being
conducted and is duly qualified to do business as a foreign corporation and is
in good standing in each jurisdiction where such qualification is necessary
under applicable law except where the failure to qualify (individually or in the
aggregate) does not have any material adverse effect on the business of FPC. The
copies of the Certificate of Incorporation and by-laws of FPC (certified by the
Secretary of FPC), as amended to date, delivered to the Buyer, are true and
complete copies of these documents as now in effect. FPC does not own any
capital stock in any other corporation, business trust or similar entity. The
minute books of FPC are accurate in all material respects.
4.2 Properties. FPC has good and marketable title to all of the assets and
properties reflected on the balance sheet included in the Financial Statements
(as hereinafter defined), or thereafter acquired, in each case free and clear of
any liens, claims or encumbrances. Any lease of material, real or personal
property to which FPC is a party is a valid, binding and enforceable obligation
of FPC, and, to the knowledge of the Seller, the other parties thereto in
accordance with its terms. FPC is not in material default in the performance of
any material provision thereunder. The use thereof by FPC of the real property
leased by it does not materially violate any local zoning or similar land use
laws.
4.3 Financial Statements. Section 4.3 of the Seller's Disclosure Schedule
contains (i) the balance sheet of FPC as of June 30, 1995 and the related
statement of operations, statement of cash flows and statement of stockholders'
equity of FPC for the period beginning April 7, 1995 and ending June 30, 1995
together with the report of Deloitte & Touche LLP thereon (the 'FPC Audited
Financial Statements') and the balance sheet of FPC as of September 30, 1995 and
the related statement of operations, statement of cash flows and statement of
stockholders' equity of FPC for the three month period ending September 30, 1995
(together with the Audited Financial Statements, the 'FPC Financial
Statements'). The FPC Audited Financial Statements have been examined, audited
and reported upon by Deloitte & Touche LLP without qualification. The FPC
Financial Statements, including the notes thereto, present fairly, in all
material respects, the financial position and results of operations of FPC as of
the dates and periods indicated, prepared in accordance with GAAP. Without
limiting the generality of the foregoing, to the knowledge of the Seller (i)
there is no basis for any assertion against FPC as of the date of said balance
sheet of any material debt, liability or obligation of any nature not fully
reflected or reserved against in such balance sheet or in the notes thereto; and
(ii) there are no assets of FPC the value of which (in the reasonable judgment
of FPC) are materially overstated in said balance sheet. Except as disclosed
therein or in Section 4.3 of the Seller's Disclosure Schedule or as incurred in
the ordinary course of business since the date of the balance sheet, FPC does
not have any known material contingent liabilities (including liabilities for
taxes).
4.4 Accounts Receivable; Inventories. The accounts receivable of FPC on the
balance sheet contained in the FPC Financial Statements (except those collected
since such date) and such additional
A-11
<PAGE>
<PAGE>
accounts receivable as are reflected in Section 4.4 of the Seller's Disclosure
Schedule (which sets forth the accounts receivable on the books of FPC as of
September 30, 1995 and an aging schedule (to the nearest month) of such
receivables) have been generated in the ordinary course of business and reflect
a bona fide obligation for the payment of goods or services provided by FPC. The
inventories reflected on the balance sheet contained in the FPC Financial
Statements and those inventories owned by FPC on the date hereof are in good,
merchantable and usable condition and have been reflected on such balance sheet
at the transfer price from FPR, or, if acquired from a third party, at the
purchase price paid to such third party, in each case in accordance with GAAP,
and include no obsolete or discontinued items, or items which have failed
quality testing, in each case except to the extent reserved against on such
balance sheet.
4.5 Absence of Certain Changes or Events. Since September 30, 1995 there
has not been:
(i) any material adverse change in the financial condition,
properties, assets, liabilities or business of FPC;
(ii) any material damage, destruction or loss of any material
properties of FPC, whether or not covered by insurance;
(iii) any material adverse change in the manner in which the business
of FPC has been conducted;
(iv) any material adverse change in the treatment and protection of
trade secrets or other confidential information of FPC;
(v) any material change in the business or contractual relationship of
FPC with any employee, customer or supplier which might reasonably be
expected to materially and adversely affect the business of FPC;
(vi) declared, set aside, made or paid any dividend with respect to
its capital stock or otherwise purchased or redeemed any shares of its
capital stock;
(vii) incurred, prepaid, forgiven or cancelled any indebtedness other
than in the ordinary course of business;
(viii) acquired or disposed of any assets, or entered into any
agreement or arrangement of any nature except in the ordinary course of
business; and
(ix) any agreement by FPC, whether written or oral, to do any of the
foregoing.
4.6 Taxes.
(a) FPC has duly filed all Returns required to be filed by it. All such
Returns were, when filed, and to the knowledge of the Seller are, accurate and
complete in all material respects and were prepared in conformity with
applicable laws and regulations in all material respects. FPC has paid or, if
not yet due, will pay in full or has adequately reserved against all Taxes
otherwise assessed against it through the Closing Date.
(b) FPC is not a party to any pending action or proceeding by any
governmental authority for the assessment of any Tax, and no claim for
assessment or collection of any Tax related to FPC has been asserted against FPC
that has not been paid. No Return of FPC is currently under audit by the
Internal Revenue Service or any other governmental authority. There are no Tax
liens upon the assets (other than the lien of property taxes not yet due and
payable) of FPC. There is no valid basis, to the knowledge of the Seller, for
any assessment, deficiency, notice, 30-day letter or similar intention to assess
any Tax to be issued to FPC by any governmental authority.
(c) All Taxes which FPC is required to collect or withhold have been duly
and timely collected and withheld and have been set aside in accounts for such
purposes, or to the extent required when due, have been duly and timely paid to
the proper governmental authority.
4.7 Contracts Listed; No Default. Section 4.7 of the Seller's Disclosure
Schedule contains a complete and correct list as of the date hereof of all
agreements, contracts and commitments of the following types, written or oral,
to which FPC is a party or by which FPC or any of its properties is bound as of
the date hereof: (i) mortgages, indentures, security agreements, letters of
credit, loan agreements and other agreements, guarantees and instruments
relating to the borrowing of money or extension of
A-12
<PAGE>
<PAGE>
credit; (ii) employment, consulting, severance and agency agreements; (iii)
collective bargaining agreements; (iv) bonus, profit-sharing, compensation,
stock option, stock purchase, pension, severance, retirement, deferred
compensation or other plans, trusts or funds for the benefit of employees,
officers, agents or directors (whether or not legally binding); (v) sales
agency, manufacturer's representative or distributorship agreements; (vi)
agreements, orders or commitments for the purchase of raw materials, supplies or
finished products exceeding $100,000; (vii) agreements, orders or commitments
for the sale of its products exceeding $100,000; (viii) licenses of Intellectual
Property, transfer of technology or know how and other intellectual property
rights; (ix) confidentiality agreements (including agreements binding any of
FPC's employees and their respective former employers); (x) agreements or
commitments for capital expenditures in excess of $20,000 for any single project
(it being warranted that all undisclosed agreements or commitments for capital
projects do not exceed $20,000 in the aggregate for all projects); (xi)
brokerage or finder's agreements; (xii) stockholders' agreements and any
agreements restricting the transfer of any of the FPC Shares; and (xiii) joint
venture and partnership agreements; (xiv) leases for real and personal property;
and other agreements, contracts and commitments which in any case involve
payments or receipts of more than $100,000. The Seller has made available to the
Buyer complete and correct copies of all such written agreements, contracts and
commitments, together with all amendments thereto, and provided accurate
descriptions of all oral agreements listed in Section 4.7 of the Seller's
Disclosure Schedule. All agreements, contracts and commitments of the type
described in this Section 4.7 are in full force and effect in accordance with
their respective terms and there does not exist thereunder as of the date hereof
any default by FPC or to the Seller's knowledge, any other party thereto, or
event or condition which, after notice or lapse of time or both, would
constitute a default thereunder on the part of FPC or, to the Seller's
knowledge, any other party thereto.
4.8 Litigation. Except as disclosed in Section 4.8 of the Seller's
Disclosure Schedule, there is no judicial or administrative action, suit,
proceeding or investigation pending or, to the Seller's knowledge, threatened
which affects or could affect materially FPC or result in any liability on the
part of FPC in excess of $25,000 in the aggregate, or which involves or could
involve the validity of this Agreement or any agreement or instrument executed
or to be executed in connection herewith or of any action taken or to be taken
in connection therewith. The Seller has delivered or made available to the Buyer
in accordance with the terms of this Agreement copies of the files of FPC
containing all information with respect to (i) customer complaints relating to
product performance since January 1, 1989, (ii) recalls of products or
notifications therefor by any Governmental Authority or voluntarily by FPC since
January 1, 1989, and (iii) claims made or threatened which FPC has put in the
hands of its insurance carriers since January 1, 1989 relating to personal or
other injuries or other damages resulting from the production, manufacture, sale
or use of any products produced, manufactured or sold by FPC.
4.9 Compliance with Laws and Regulations. FPC is in compliance, in all
material respects, with all laws, rules, regulations, orders and requirements
(federal, state and local and foreign) applicable to it in all jurisdictions
where its business is conducted or to which it is subject, including, without
limitation, all applicable civil rights and equal opportunity employment laws
and regulations, and all federal, antitrust, antimonopoly and fair trade
practice laws, except where the failure to comply would not have a material
adverse effect upon FPC. The Seller knows of no assertion by any party that FPC
is in violation in any material respect of any such laws, rules, regulations,
orders, restrictions or requirements with respect to its operations and no
notice in that regard has been received by FPC.
4.10 Governmental Licenses, Permits, Etc. FPC has all material governmental
licenses, permits, authorizations and approvals necessary for the conduct of its
business as currently conducted ('FPC Licenses and Permits'). Section 4.10 of
the Seller's Disclosure Schedule includes a list of all Licenses and Permits.
All FPC Licenses and Permits are in full force and effect, and no proceedings
for the suspension or cancellation of any thereof is pending or threatened.
Specifically identified in Section 4.10 of the Seller's Disclosure Schedule is a
complete list of all ANDAS and all Abbreviated Antibiotic Applications filed
with the FDA, and any similar filings with any agency or department of any
foreign government which regulates the production or sale of pharmaceutical
products, as well as all pending applications and amendments thereto in
connection with obtaining any of such registrations, approvals or
authorizations. Except as disclosed in Section 4.10 of the Seller's Disclosure
Schedule, all applications and amendments previously filed by FPC in connection
with receiving such FPC Licenses and Permits
A-13
<PAGE>
<PAGE>
were correct at the time such applications were granted and made in accordance
and substantial compliance with all applicable rules, regulations and
instructions for the filing of the same. Access to all applications previously
made or pending, including all related files, correspondence, notes and
telephone logs (as well as all written reports known to FPC relating to field
trials, clinical studies or laboratory testing relating to its products or
products being developed by it) in connection therewith, all of which documents
are maintained at FPC's principal office, has been provided to the Buyer.
Following the Closing, the Seller shall assist the Buyer in obtaining the
continuation or transfer of such permits, licenses, franchises, orders,
registrations or other approvals as may be required by the transactions
contemplated hereby. Neither the execution and delivery of this Agreement, nor
the consummation of the transactions contemplated hereby will result in the
revocation, cancellation or suspension of any of the Licenses and Permits.
4.11 Environmental Compliance.
(a) The business, operations, property and assets of FPC (and, to the
knowledge of the Seller, the business of any subtenant or licensee which is
occupying or has occupied any space on any premises of FPC, the activities of
which could result in any material adverse liability to FPC) have been and are
in compliance in all material respects with all, and are not in material
violation of any Environmental Laws.
(b) No suit, action, claim, proceeding, nor investigation, review or
inquiry by any governmental entity concerning any material violation of any
Environmental Laws by FPC is pending or, to the knowledge of the Seller,
threatened in writing, including but not limited to matters relating to
environmental protection or hazardous or toxic waste. The Seller does not know
of any reasonable basis or ground for any such suit, claim, investigation,
inquiry or proceeding.
4.12 Insurance. FPC is covered by insurance policies, or renewals thereof,
as identified and described in Section 4.12 of the Seller's Disclosure Schedule.
The Seller will maintain such insurance (other than insurance relating to
liability of officers and directors) up to and including June 30, 1996. FPC has
not received written notice from any insurer or agent of such insurer that
improvements or expenditures are required to be made in order to continue such
insurance in effect and, so far as known to the Seller, no such improvements or
expenditures are required (other than premium payments). There is no liability
under any insurance policy in the nature of a retroactive rate adjustment or
loss sharing or similar arrangement except as set forth in Section 4.12 of the
Seller's Disclosure Schedule.
4.13 Condition of Assets. The equipment, fixtures and other personal
property of FPC are in good operating condition and repair (ordinary wear and
tear excepted) for the conduct of the business of FPC as now being conducted.
4.14 Employees, Labor Matters, etc.
(a) Section 4.14 of the Seller's Disclosure Schedule contains a complete
and correct list of the names of all directors, officers and salaried employees
of FPC. There is no payment of salary or other deferred compensation for
services that has not been paid for more than 30 days past the date on which
such payment would ordinarily be made in the ordinary course of business that is
owed by FPC to any of its directors, officers, employees, trustees, agents,
brokers, representatives or other personnel, current and former, or any
beneficiaries, dependents or survivors of the foregoing, in an amount in excess
of $10,000 in the aggregate (including, without limitation, expense
reimbursement and severance payments), in accordance with the terms of their
respective employment arrangements or under their employment, severance or
agency agreements, if any.
(b) Except as set forth in Section 4.14 of the Seller's Disclosure
Schedule, none of the employees of FPC is represented by any labor union or
collective bargaining unit and the Seller are not aware of any organizational
efforts taking place with respect to such representation of its employees.
4.15 Employee Agreements.
(a) Section 4.15 of the Seller's Disclosure Schedule lists, all (1) written
employment agreements and collective bargaining agreements to which FPC is a
party; (2) material Compensation Arrangements; (3) Employee Welfare Plans,
Employee Pension Plans and consulting agreements under which FPC or any Related
Entity has or may have any material monetary obligations to employees of FPC, or
consultants
A-14
<PAGE>
<PAGE>
of FPC or their beneficiaries or legal representatives or under which any such
persons may have any rights against FPC. FPC has previously made available to
the Buyer true and complete copies of all of the foregoing employment contracts,
collective bargaining agreements, Employee Plans and Compensation Arrangements,
including descriptions of any material unwritten contracts, agreements,
Compensation Arrangements or Employee Plans, as amended to date. In addition,
with respect to any Employee Plan which continues after the Closing Date, FPC
has previously delivered or made available to the Buyer (1) any related trust
agreements, master trust agreements, annuity contracts or insurance contracts;
(2) certified copies of all Board of Directors' resolutions adopting such plans
and trust documents and amendments thereto; (3) current investment management
agreements; (4) custodial agreements; (5) fiduciary liability insurance
policies; (6) indemnification agreements; (7) the most recent determination
letter issued by the Internal Revenue Service with respect to the qualification
of any Employee Plan under the provisions of Section 401(a) of the Code; (8)
copies of all 'advisory opinion letters', 'private letter rulings' and 'no
action letters' that were issued by any governmental or quasi-governmental
agency with respect to any Employee Plan; (9) Annual Reports (Form 5500 Series)
and Schedules A and B thereto for the last plan year; (10) all actuarial reports
prepared for the last plan year; (11) all certified financial statements for the
last plan year; and (12) all current Summary Plan Descriptions, Summaries of
Material Modifications and Summary Annual Reports.
(b) Except as otherwise disclosed in Section 4.15 of the Seller's
Disclosure Schedule:
(i) No Employee Pension Plan is subject to Title IV of ERISA.
(ii) Each Employee Plan and Compensation Arrangement, to the knowledge
of the Seller, currently substantially complies and has substantially
complied in the past, both as to form and operation, with its terms and
with the applicable provisions of ERISA, the Age Discrimination in
Employment Act and all other applicable Federal or State or foreign laws,
rules and regulations. Each Employee Plan and Compensation Arrangement has
been administered to date in substantial compliance with the requirements
of ERISA and the Code, and FPC has substantially complied with all
reporting and disclosure requirements by any governmental agency.
(iii) With respect to any Multi-employer Plan, neither FPC nor any
Related Entity is required to make any contribution thereto.
(iv) FPC has complied in all material respects with the continuation
coverage requirements, as defined in Section 4980B(f) of the Code.
(v) There are no actions, suits or claims pending (other than routine
claims for benefits) or, to the knowledge of the Seller, which could
reasonably be expected to be asserted against any Employee Plan or
Compensation Arrangement or the assets of any such Plan. No civil or
criminal action brought pursuant to the Code or ERISA with respect to any
Employee Plan or Compensation Arrangement is pending or, to the knowledge
of the Seller, threatened against any fiduciary which is a Related Entity
or employee thereof. None of the Employee Plans or Compensation
Arrangements, or any fiduciary of any Employee Plan or Compensation
Arrangement which is a Related Entity or employee thereof, to the knowledge
of the Seller, currently is the subject of any audit, investigation or
examination by any governmental or quasi-governmental agency, nor is FPC
aware of the existence of any facts that would lead it to believe that any
such audit, investigation or examination is pending or threatened.
(vi) FPC does not sponsor, maintain or contribute to any Employee Plan
or Compensation Arrangement that provides retiree medical or retiree life
insurance coverage to former employees of FPC other than any such benefits
described under Section 4980B of the Code or Part 6 of Title I of ERISA.
(vii) With respect to each Employee Plan:
(A) each Employee Pension Plan has received a favorable
determination letter (or is the subject of an outstanding request for
such a letter) with regard thereto or is based on a prototype plan which
has received a favorable determination letter;
(B) to the knowledge of the Seller, neither FPC nor any Related
Entity has, with respect to any Employee Plan, engaged in a prohibited
transaction, as such term is defined in Code
A-15
<PAGE>
<PAGE>
Section 4975 or ERISA Section 406, which would subject FPC or the Buyer
to any taxes, penalties or other liabilities resulting from prohibited
transactions under Code Section 4975 or under ERISA Sections 409 or
502(i);
(C) to the knowledge of the Seller, no event has occurred and no
condition exists that would subject FPC or the Buyer to any tax under
Code Sections 4971, 4972, 4976, 4977 or 4979 or a fine under ERISA
Section 502(c);
(D) all insurance premiums, including PBGC premiums, required to be
paid on or prior to the Closing Date with regard to each Employee Plan
have or will be paid; and
(E) FPC and each Related Entity has or will have, as of the Closing
Date, made all contributions or payments to or under such Employee Plans
required by law or by the terms of such Plans or any contract or
agreements to have been made by the Closing Date. To the knowledge of
the Seller, as of the date of this Agreement the aggregate current value
of all vested accrued benefit obligations under all Employee Pension
Plans does not exceed the aggregate current value of all assets of such
plans allocable to such vested accrued benefit obligations.
4.16 Business Locations. FPC does not own or lease any real or personal
property in any state or country except as set forth in Section 4.16 of the
Seller's Disclosure Schedule.
4.17 Intellectual Property. Section 4.17 of the Seller's Disclosure
Schedule lists all of the Intellectual Property (as hereinafter defined) used by
FPC which constitutes a material patent, trade name, trademark, service mark,
copyright or application for any of the foregoing. Intellectual Property means
all of FPC's right, title and interest in and to all patents, trade names,
assumed names, trademarks, service marks, proprietary technology, processes and
rights, proprietary names, copyrights (including any registration and pending
applications for any such registration for any of them) together with all the
goodwill relating thereto, and all other intellectual property of FPC. Other
than as disclosed in Section 4.17 of the Seller's Disclosure Schedule, FPC has
not any licenses granted by or to it or other agreements to which it is a party,
relating in whole or in part to any Intellectual Property, whether owned by it
or otherwise. All of the patents, trademark registrations and copyrights listed
in Section 4.17 of the Seller's Disclosure Schedule as owned by FPC are to the
knowledge of the Seller valid and in full force and effect. To the knowledge of
the Seller, FPC is not infringing upon, or otherwise violating, the rights of
any third party with respect to any Intellectual Property. Except as otherwise
set forth in Section 4.17 of the Seller's Disclosure Schedule, no proceedings
have been instituted against or claims in writing received by FPC, nor to the
knowledge of the Seller are any proceedings threatened alleging any such
violation.
4.18 Bank Accounts. Section 4.18 of the Seller's Disclosure Schedule
contains a correct and complete list of each bank and financial institution in
which FPC maintains an account or a safe deposit box, the account numbers of
such accounts and the names of the authorized signatories for each such account.
4.19 Selling Materials and Policies. The Seller has delivered to the Buyer
copies of all current catalogs and brochures relating to products manufactured
and or sold by FPC and the pricing structure for volume and promotional
discounts relating to such products, copies of which are included in Section
4.19 of the Seller's Disclosure Schedule.
4.20 Warranties. Section 4.20 of the Seller's Disclosure Schedule sets
forth a true and complete list of the forms of all express warranties and
guaranties made by FPC to third parties with respect to any products sold or
leased, or services rendered. No product or service of FPC has, at any time,
been subject to any voluntary or governmental recall and the Seller knows of no
presently existing circumstances that would constitute a valid basis therefor.
4.21 Customers and Suppliers. Neither the Seller nor FPC has reason to
believe that, either as a result of the transactions contemplated hereby or for
any other reason (exclusive of expiration of a contract upon the passage of
time), any present material customer or supplier of FPC will not continue to
conduct business with FPC after the Closing Date in substantially the same
manner as it has conducted business with FPC in the past.
A-16
<PAGE>
<PAGE>
V
REPRESENTATIONS AND WARRANTIES OF THE SELLER
AS TO FMDC
The Seller represents and warrants to the Buyer as follows with the
knowledge and understanding that the Buyer is relying materially on such
representations and warranties.
5.1 Organization and Standing. FMDC is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware.
FMDC has all requisite corporate power to carry on its business as it is now
being conducted and is duly qualified to do business as a foreign corporation
and is in good standing in each jurisdiction where such qualification is
necessary under applicable law except where the failure to qualify (individually
or in the aggregate) does not have any material adverse effect on the business
of FMDC. The copies of the Certificate of Incorporation and by-laws of FMDC
(certified by the Secretary of FMDC), as amended to date, delivered to the
Buyer, are true and complete copies of these documents as now in effect. FMDC
does not own any capital stock in any other corporation, business trust or
similar entity. The minute books of FMDC are accurate in all material respects.
5.2 Properties. Except as set forth in Section 5.2 of the Seller's
Disclosure Schedule, FMDC has good and marketable title to all of the assets and
properties reflected on the balance sheet included in the Financial Statements
(as hereinafter defined), or thereafter acquired, in each case free and clear of
any liens, claims or encumbrances. Any lease of material, real or personal
property to which FMDC is a party is a valid, binding and enforceable obligation
of FMDC, and, to the knowledge of the Seller, the other parties thereto in
accordance with its terms. Neither FMDC nor, to the knowledge of the Seller, the
other parties thereto are in material default in the performance of any material
provision thereunder. The use thereof by FMDC of the real property leased by it
does not materially violate any local zoning or similar land use laws.
5.3 Financial Statements. Section 5.3 of the Seller's Disclosure Schedule
contains (i) balance sheets of FMDC as of June 30, 1994 and June 30, 1995 and
the related statement of operations, statement of cash flows and statement of
stockholders' equity of FMDC for each of the three years in the period ending
June 30, 1995, together with the report of Deloitte & Touche LLP thereon (the
'FMDC Audited Financial Statements'), and (ii) the balance sheet of FMDC as of
September 30, 1995 and the related statement of operations for the three months
then ended (together with the FMDC Audited Financial Statements, the 'FMDC
Financial Statements'). The FMDC Audited Financial Statements have been
examined, audited and reported upon by Deloitte & Touche LLP without
qualification. The FMDC Financial Statements, including the notes thereto,
present fairly, in all material respects, the financial position and results of
operations of FMDC as of the dates and periods indicated, prepared in accordance
with GAAP. Without limiting the generality of the foregoing, to the knowledge of
the Seller (i) except as set forth in the Seller's Disclosure Schedule, there is
no basis for any assertion against FMDC as of the date of said balance sheets of
any material debt, liability or obligation of any nature not fully reflected or
reserved against in such balance sheets or in the notes thereto; and (ii) there
are no assets of FMDC the value of which (in the reasonable judgment of FMDC)
are materially overstated in said balance sheets. Except as disclosed therein or
in Section 5.3 of the Seller's Disclosure Schedule or as incurred in the
ordinary course of business since the date of the most recent balance sheet,
FMDC does not have any known material contingent liabilities (including
liabilities for taxes).
5.4 Accounts Receivable; Inventories. The accounts receivable of FMDC on
the latest balance sheet contained in the FMDC Financial Statements (except
those collected since such date) and such additional accounts receivable as are
reflected in Section 5.4 of the Seller's Disclosure Schedule (which sets forth
the accounts receivable on the books of FMDC as of September 30, 1995 and an
aging schedule (to the nearest month) of such receivables) have been generated
in the ordinary course of business and reflect a bona fide obligation for the
payment of goods or services provided by FMDC. The inventories reflected on the
latest balance sheet contained in the FMDC Financial Statements and those
inventories owned by FMDC on the date hereof are in good, merchantable and
usable condition and have been reflected on such balance sheet at the lower of
cost and market (on the first-in first-out method), in accordance with GAAP, and
include no obsolete or discontinued items, or items which have failed quality
testing, in each case except to the extent reserved against on such balance
sheet.
A-17
<PAGE>
<PAGE>
5.5 Absence of Certain Changes or Events. Since September 30, 1995 there
has not been:
(i) any material adverse change in the financial condition,
properties, assets, liabilities or business of FMDC;
(ii) any material damage, destruction or loss of any material
properties of FMDC, whether or not covered by insurance;
(iii) any material adverse change in the manner in which the business
of FMDC has been conducted;
(iv) any material adverse change in the treatment and protection of
trade secrets or other confidential information of FMDC;
(v) any material change in the business or contractual relationship of
FMDC with any employee, customer or supplier which might reasonably be
expected to materially and adversely affect the business of FMDC;
(vi) declared, set aside, made or paid any dividend with respect to
its capital stock or otherwise purchased or redeemed any shares of its
capital stock;
(vii) incurred, prepaid, forgiven or cancelled any indebtedness other
than in the ordinary course of business;
(viii) acquired or disposed of any assets, or entered into any
agreement or arrangement of any nature except in the ordinary course of
business; and
(ix) any agreement by FMDC, whether written or oral, to do any of the
foregoing.
5.6 Taxes.
(a) FMDC has duly filed all Returns required to be filed by it. All such
Returns were, when filed, and to the knowledge of the Seller are, accurate and
complete in all material respects and were prepared in conformity with
applicable laws and regulations in all material respects. FMDC has paid or, if
not yet due, will pay in full or has adequately reserved against all Taxes
otherwise assessed against it through the Closing Date.
(b) FMDC is not a party to any pending action or proceeding by any
governmental authority for the assessment of any Tax, and no claim for
assessment or collection of any Tax related to FMDC has been asserted against
FMDC that has not been paid. No Return of FMDC is currently under audit by the
Internal Revenue Service or any other governmental authority. There are no Tax
liens upon the assets (other than the lien of property taxes not yet due and
payable) of FMDC. There is no valid basis, to the knowledge of the Seller, for
any assessment, deficiency, notice, 30-day letter or similar intention to assess
any Tax to be issued to FMDC by any governmental authority.
(c) All Taxes which FMDC is required to collect or withhold have been duly
and timely collected and withheld and have been set aside in accounts for such
purposes, or to the extent required when due, have been duly and timely paid to
the proper governmental authority.
5.7 Contracts Listed; No Default. Section 5.7 of the Seller's Disclosure
Schedule contains a complete and correct list as of the date hereof of all
agreements, contracts and commitments of the following types, written or oral,
to which FMDC is a party or by which FMDC or any of its properties is bound as
of the date hereof: (i) mortgages, indentures, security agreements, letters of
credit, loan agreements and other agreements, guarantees and instruments
relating to the borrowing of money or extension of credit; (ii) employment,
consulting, severance and agency agreements; (iii) collective bargaining
agreements; (iv) bonus, profit-sharing, compensation, stock option, stock
purchase, pension, severance, retirement, deferred compensation or other plans,
trusts or funds for the benefit of employees, officers, agents or, directors
(whether or not legally binding); (v) sales agency, manufacturer's
representative or distributorship agreements; (vi) agreements, orders or
commitments for the purchase of raw materials, supplies or finished products
exceeding $100,000; (vii) agreements, orders or commitments for the sale of its
products exceeding $100,000; (viii) licenses of Intellectual Property, transfer
of technology or know how and other intellectual property rights; (ix)
confidentiality agreements (including agreements binding any of FMDC's employees
and their respective former employers); (x) agreements or commitments for
capital expenditures in excess of $20,000 for any single project (it being
warranted that
A-18
<PAGE>
<PAGE>
all undisclosed agreements or commitments for capital projects do not exceed
$20,000 in the aggregate for all projects); (xi) brokerage or finder's
agreements; (xii) stockholders' agreements and any agreements restricting the
transfer of any of the FMDC Shares; and (xiii) joint venture and partnership
agreements; (xiv) leases for real and personal property; and other agreements,
contracts and commitments which in any case involve payments or receipts of more
than $100,000. The Seller has made available to the Buyer complete and correct
copies of all such written agreements, contracts and commitments, together with
all amendments thereto, and provided accurate descriptions of all oral
agreements listed in Section 5.7 of the Seller's Disclosure Schedule. All
agreements, contracts and commitments of the type described in this Section 5.7
are in full force and effect in accordance with their respective terms and there
does not exist thereunder as of the date hereof any default by FMDC or to the
Seller's knowledge, any other party thereto, or event or condition which, after
notice or lapse of time or both, would constitute a default thereunder on the
part of FMDC or, to the Seller's knowledge, any other party thereto.
5.8 Litigation. There is no judicial or administrative action, suit,
proceeding or investigation pending or, to the Seller's knowledge, threatened
which affects or could affect materially FMDC or result in any liability on the
part of FMDC in excess of $25,000 in the aggregate, or which involves or could
involve the validity of this Agreement or any agreement or instrument executed
or to be executed in connection herewith or of any action taken or to be taken
in connection therewith. The Seller has delivered or made available to the Buyer
in accordance with the terms of this Agreement copies of the files of FMDC
containing all information with respect to (i) customer complaints relating to
product performance since January 1, 1989, (ii) recalls of products or
notifications therefor by any Governmental Authority or voluntarily by FMDC
since January 1, 1989, and (iii) claims made or threatened which FMDC has put in
the hands of its insurance carriers since January 1, 1989 relating to personal
or other injuries or other damages resulting from the production, manufacture,
sale or use of any products produced, manufactured or sold by FMDC.
5.9 Compliance with Laws and Regulations. FMDC is in compliance, in all
material respects, with all laws, rules, regulations, orders and requirements
(federal, state and local and foreign) applicable to it in all jurisdictions
where its business is conducted or to which it is subject, including, without
limitation, all applicable civil rights and equal opportunity employment laws
and regulations, and all federal, antitrust, antimonopoly and fair trade
practice laws, except where the failure to comply would not have a material
adverse effect upon FMDC. The Seller knows of no assertion by any party that
FMDC is in violation in any material respect of any such laws, rules,
regulations, orders, restrictions or requirements with respect to its operations
and no notice in that regard has been received by FMDC.
5.10 Governmental Licenses, Permits, Etc. FMDC has all material
governmental licenses, permits, authorizations and approvals necessary for the
conduct of its business as currently conducted ('FMDC Licenses and Permits').
Section 5.10 of the Seller's Disclosure Schedule includes a list of all FMDC
Licenses and Permits. All FMDC Licenses and Permits are in full force and
effect, and no proceedings for the suspension or cancellation of any thereof is
pending or threatened. Specifically identified in Section 5.10 of the Seller's
Disclosure Schedule is a complete list of all ANDAS and all Abbreviated
Antibiotic Applications filed with the FDA, and any similar filings with any
agency or department of any foreign government which regulates the production or
sale of pharmaceutical products, as well as all pending applications and
amendments thereto in connection with obtaining any of such registrations,
approvals or authorizations. Except as disclosed in Section 5.10 of the Seller's
Disclosure Schedule, all applications and amendments previously filed by FMDC in
connection with receiving such FMDC Licenses and Permits were correct at the
time such applications were granted and made in accordance and substantial
compliance with all applicable rules, regulations and instructions for the
filing of the same. Access to all applications previously made or pending,
including all related files, correspondence, notes and telephone logs (as well
as all written reports known to FMDC relating to field trials, clinical studies
or laboratory testing relating to its products or products being developed by
it) in connection therewith, all of which documents are maintained at FMDC's
principal office, has been provided to the Buyer. Following the Closing, the
Seller shall assist the Buyer in obtaining the continuation or transfer of such
permits, licenses, franchises, orders, registrations or other approvals as may
be required by the transactions contemplated hereby. Neither the execution and
delivery of this Agreement, nor the
A-19
<PAGE>
<PAGE>
consummation of the transactions contemplated hereby will result in the
revocation, cancellation or suspension of any of the Licenses and Permits.
5.11 Environmental Compliance.
(a) The business, operations, property and assets of FMDC (and, to the
knowledge of the Seller, the business of any subtenant or licensee which is
occupying or has occupied any space on any premises of FMDC, the activities of
which could result in any material adverse liability to FMDC) have been and are
in compliance in all material respects with all, and are not in material
violation of any Environmental Laws.
(b) No suit, action, claim, proceeding, nor investigation, review or
inquiry by any Governmental Entity concerning any material violation of any
Environmental Laws by FMDC is pending or, to the knowledge of the Seller,
threatened in writing, including but not limited to matters relating to
environmental protection or hazardous or toxic waste. The Seller does not know
of any reasonable basis or ground for any such suit, claim, investigation,
inquiry or proceeding.
5.12 Insurance. FMDC is covered by insurance policies, or renewals thereof,
as identified and described in Section 5.12 of the Seller's Disclosure Schedule.
The Seller maintains such insurance (other than insurance relating to liability
of officers and directors) up to and including June 30, 1996. FMDC has not
received written notice from any insurer or agent of such insurer that
improvements or expenditures are required to be made in order to continue such
insurance in effect (other than premium payments). There is no liability under
any insurance policy in the nature of a retroactive rate adjustment or loss
sharing or similar arrangement except as set forth in Section 5.12 of the
Seller's Disclosure Schedule.
5.13 Condition of Assets. The equipment, fixtures and other personal
property of FMDC are in good operating condition and repair (ordinary wear and
tear excepted) for the conduct of the business of FMDC as now being conducted.
5.14 Employees, Labor Matters, etc.
(a) Section 5.14 of the Seller's Disclosure Schedule contains a complete
and correct list of the names of all directors, officers and salaried employees
of FMDC. There is no payment of salary or other deferred compensation for
services that has not been paid for more than 30 days past the date on which
such payment would ordinarily be made in the ordinary course of business that is
owed by FMDC to any of its directors, officers, employees, trustees, agents,
brokers, representatives or other personnel, current and former, or any
beneficiaries, dependents or survivors of the foregoing, in an amount in excess
of $10,000 in the aggregate (including, without limitation, expense
reimbursement and severance payments), in accordance with the terms of their
respective employment arrangements or under their employment, severance or
agency agreements, if any.
(b) Except as set forth in Section 5.14 of the Seller's Disclosure
Schedule, none of the employees of FMDC is represented by any labor union or
collective bargaining unit and the Seller are not aware of any organizational
efforts taking place with respect to such representation of its employees.
5.15 Employee Agreements.
(a) Section 5.15 of the Seller's Disclosure Schedule lists, all (1) written
employment agreements and collective bargaining agreements to which FMDC is a
party; (2) material Compensation Arrangements; (3) Employee Welfare Plans,
Employee Pension Plans and consulting agreements under which FMDC or any Related
Entity has or may have any material monetary obligations to employees of FMDC,
or consultants of FMDC or their beneficiaries or legal representatives or under
which any such persons may have any rights against FMDC. FMDC has previously
made available to the Buyer true and complete copies of all of the foregoing
employment contracts, collective bargaining agreements, Employee Plans and
Compensation Arrangements, including descriptions of any material unwritten
contracts, agreements, Compensation Arrangements or Employee Plans, as amended
to date. In addition, with respect to any Employee Plan which continues after
the Closing Date, FMDC has previously delivered or made available to the Buyer
(1) any related trust agreements, master trust agreements, annuity contracts or
insurance contracts; (2) certified copies of all Board of Directors' resolutions
adopting such plans and trust documents and amendments thereto; (3) current
investment
A-20
<PAGE>
<PAGE>
management agreements; (4) custodial agreements; (5) fiduciary liability
insurance policies; (6) indemnification agreements; (7) the most recent
determination letter issued by the Internal Revenue Service with respect to the
qualification of any Employee Plan under the provisions of Section 401(a) of the
Code; (8) copies of all 'advisory opinion letters', 'private letter rulings' and
'no action letters' that were issued by any governmental or quasi-governmental
agency with respect to any Employee Plan; (9) Annual Reports (Form 5500 Series)
and Schedules A and B thereto for the last plan year; (10) all actuarial reports
prepared for the last plan year; (11) all certified financial statements for the
last plan year; and (12) all current Summary Plan Descriptions, Summaries of
Material Modifications and Summary Annual Reports.
(b) Except as otherwise disclosed in Section 5.15 of the Seller's
Disclosure Schedule:
(i) No Employee Pension Plan is subject to Title IV of ERISA.
(ii) Each Employee Plan and Compensation Arrangement, to the knowledge
of the Seller, currently substantially complies and has substantially
complied in the past, both as to form and operation, with its terms and
with the applicable provisions of ERISA, the Age Discrimination in
Employment Act and all other applicable Federal or State or foreign laws,
rules and regulations. Each Employee Plan and Compensation Arrangement has
been administered to date in substantial compliance with the requirements
of ERISA and the Code, and FMDC has substantially complied with all
reporting and disclosure requirements by any governmental agency.
(iii) With respect to any Multi-employer Plan, neither FMDC nor any
Related Entity is required to make any contribution thereto.
(iv) FMDC has complied in all material respects with the continuation
coverage requirements, as defined in Section 4980B(f) of the Code.
(v) There are no actions, suits or claims pending (other than routine
claims for benefits) or, to the knowledge of the Seller, which could
reasonably be expected to be asserted against any Employee Plan or
Compensation Arrangement or the assets of any such Plan. No civil or
criminal action brought pursuant to the Code or ERISA with respect to any
Employee Plan or Compensation Arrangement is pending or, to the knowledge
of the Seller, threatened against any fiduciary which is a Related Entity
or employee thereof. None of the Employee Plans or Compensation
Arrangements, or any fiduciary of any Employee Plan or Compensation
Arrangement which is a Related Entity or employee thereof, to the knowledge
of the Seller, currently is the subject of any audit, investigation or
examination by any governmental or quasi-governmental agency, nor is FMDC
aware of the existence of any facts that would lead it to believe that any
such audit, investigation or examination is pending or threatened.
(vi) FMDC does not sponsor, maintain or contribute to any Employee
Plan or Compensation Arrangement that provides retiree medical or retiree
life insurance coverage to former employees of FMDC other than any such
benefits described under Section 4980B of the Code or Part 6 of Title I of
ERISA.
(vii) With respect to each Employee Plan:
(A) each Employee Pension Plan has received a favorable
determination letter (or is the subject of an outstanding request for
such a letter) with regard thereto or is based on a prototype plan which
has received a favorable determination letter;
(B) to the knowledge of the Seller, neither FMDC nor any Related
Entity has, with respect to any Employee Plan, engaged in a prohibited
transaction, as such term is defined in Code Section 4975 or ERISA
Section 406, which would subject FMDC or the Buyer to any taxes,
penalties or other liabilities resulting from prohibited transactions
under Code Section 4975 or under ERISA Sections 409 or 502(i);
(C) to the knowledge of the Seller, no event has occurred and no
condition exists that would subject FMDC or the Buyer to any tax under
Code Sections 4971, 4972, 4976, 4977 or 4979 or a fine under ERISA
Section 502(c);
(D) all insurance premiums, including PBGC premiums, required to be
paid on or prior to the Closing Date with regard to each Employee Plan
have been or will be paid; and
A-21
<PAGE>
<PAGE>
(E) FMDC and each Related Entity has or will have, as of the
Closing Date, made all contributions or payments to or under such
Employee Plans required by law or by the terms of such Plans or any
contract or agreements to have been made by the Closing Date. To the
knowledge of the Seller, as of the date of this Agreement the aggregate
current value of all vested accrued obligations under all Employee
Pension Plans does not exceed the aggregate current value of all assets
of such plans allocable to such vested accrued obligations.
5.16 Business Locations. FMDC does not own or lease any real or personal
property in any state or country except as set forth in Section 5.16 of the
Seller's Disclosure Schedule.
5.17 Intellectual Property. Section 5.17 of the Seller's Disclosure
Schedule lists all of the Intellectual Property (as hereinafter defined) used by
FMDC which constitutes a material patent, trade name, trademark, service mark,
copyright or application for any of the foregoing. Intellectual Property means
all of FMDC's right, title and interest in and to all patents, trade names,
assumed names, trademarks, service marks, proprietary technology, processes and
rights, proprietary names, copyrights (including any registration and pending
applications for any such registration for any of them) together with all the
goodwill relating thereto, and all other intellectual property of FMDC. Other
than as disclosed in Section 5.17 of the Seller's Disclosure Schedule, FMDC has
not any licenses granted by or to it or other agreements to which it is a party,
relating in whole or in part to any Intellectual Property, whether owned by it
or otherwise. All of the patents, trademark registrations and copyrights listed
in Section 5.17 of the Seller's Disclosure Schedule as owned by FMDC are to the
knowledge of the Seller valid and in full force and effect. To the knowledge of
the Seller, FMDC is not infringing upon, or otherwise violating, the rights of
any third party with respect to any Intellectual Property. Except as otherwise
set forth in Section 5.17 of the Seller's Disclosure Schedule, no proceedings
have been instituted against or claims received in writing by FMDC, nor to the
knowledge of the Seller are any proceedings threatened alleging any such
violation.
5.18 Bank Accounts. Section 5.18 of the Seller's Disclosure Schedule
contains a correct and complete list of each bank and financial institution in
which FMDC maintains an account or a safe deposit box, the account numbers of
such accounts and the names of the authorized signatories for each such account.
5.19 Selling Materials and Policies. The Seller has delivered to the Buyer
copies of all current catalogs and brochures relating to products manufactured
and or sold by FMDC and the pricing structure for volume and promotional
discounts relating to such products.
5.20 Warranties. Section 5.20 of the Seller's Disclosure Schedule sets
forth a true and complete list of the forms of all express warranties and
guaranties made by FMDC to third parties with respect to any products sold or
leased, or services rendered. No product or service of FMDC has, at any time,
been subject to any voluntary or governmental recall and the Seller knows of no
presently existing circumstances that would constitute a valid basis therefor.
5.21 Customers and Suppliers. Neither the Seller nor FMDC has reason to
believe that, either as a result of the transactions contemplated hereby or for
any other reason (exclusive of expiration of a contract upon the passage of
time), any present material customer or supplier of FMDC will not continue to
conduct business with FMDC after the Closing Date in substantially the same
manner as it has conducted business with FMDC in the past.
VI
REPRESENTATIONS AND WARRANTIES OF THE BUYER
The Buyer represents and warrants to the Seller as follows, with the
knowledge and understanding that the Seller is relying materially on such
representations and warranties:
6.1 Organization and Standing of the Buyer. The Buyer is a corporation duly
organized, validly existing and in good standing under the laws of the Sate of
Delaware, and has the corporate power to carry on its business as now conducted.
The copies of the Certificate of Incorporation and By-Laws of the Buyer
(certified by the Secretary of the Buyer), as amended to date, delivered to the
Seller, are true and complete copies of those documents as now in effect.
A-22
<PAGE>
<PAGE>
6.2 The Buyer's Authority. The Buyer has the full power and authority to
execute this Agreement and each other agreement to be executed by it in
connection with the transactions contemplated hereby. The execution, delivery
and performance by the Buyer of this Agreement and each other agreement
contemplated hereby have been duly authorized by the Board of Directors of the
Buyer and no other corporate action is required, other than the approval of the
stockholders of the Buyer referred to in Section 7.5 hereof. This Agreement
constitutes, and each other agreement contemplated hereby will, when executed
and delivered by the Buyer, constitute the valid and binding obligations of the
Buyer, enforceable in accordance with their respective terms, subject to general
principles of equity and bankruptcy or other laws relating to or affecting the
rights of creditors generally. This Agreement and the transactions contemplated
hereby have been approved by an independent committee of the Board of Directors
of the Buyer comprised of directors of the Buyer who are not employed by the
Seller or any of its affiliates.
6.3 Capitalization. The authorized capital stock of the Buyer consists of
25,000,000 shares of Common Stock, par value $.01 per share, of which 12,581,223
shares are issued and outstanding, and 1,834,188 shares of Preferred Stock, $.01
par value, of which 834,188 shares are outstanding. The Common Stock of the
Buyer is traded on the National Market System of the NASDAQ Stock Market.
6.4 Purepac Stock. The Purepac Stock to be issued to the Seller, when
issued in accordance with the terms of this Agreement, shall be duly authorized,
validly issued, fully paid and non-assessable. Upon the closing of the
transactions contemplated hereby, the Seller will acquire title to the shares of
Purepac Stock, free and clear of all liens, claims, charges and encumbrances.
6.5 Business; SEC Filings.
(a) The Buyer has filed with the Commission all required reports,
schedules, forms, statements and other documents from July 1, 1993 through the
date hereof, including (i) the Annual Report on Form 10-K for the fiscal year
ended June 30, 1995, (ii) the quarterly reports on Form 10-Q required for all
fiscal quarters during such period and for the three months ended September 30,
1995, (iii) its proxy or information statements relating to meetings of, or
actions taken without a meeting by, the stockholders of the Buyer held during
such period, and (iv) all of its other reports, statements, schedules and
registration statements filed with the Commission during such period (the
'Commission Documents').
(b) As of its filing date or, if amended, as of the date of its amendment,
as the case may be, each such report, proxy or information statement (as amended
or supplemented, if applicable), filed pursuant to the Securities Exchange Act
of 1934, as amended (the 'Exchange Act'), did not contain any untrue statement
of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading.
(c) Each such registration statement (as amended or supplemented, if
applicable) filed pursuant to the Securities Act of 1933, as amended (the
'Securities Act') on the date such statement, amendment or supplement became
effective did not contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary to make the
statements therein not misleading.
6.6 Financial Statements. The financial statements of the Buyer included in
the Annual Report on Form 10-K filed by the Buyer with respect to the fiscal
year of the Buyer ended June 30, 1995 and the quarterly reports on Form 10-Q
filed by the Buyer with the Commission with respect to the quarters ended
September 30, 1994, December 31, 1994, March 31, 1995 and September 30, 1995,
comply in all material respects with applicable accounting requirements and with
the published rules and regulations of the Commission with respect thereto, were
prepared in accordance with GAAP (except as may be indicated in the notes
thereto or, in the case of the unaudited statements, as permitted by Form 10-Q
of the Commission), and fairly present (subject, in the case of the unaudited
statements, to normal, recurring adjustments, none of which are anticipated to
be material) the financial position, results of operations, stockholders' equity
and changes in financial position of the Buyer as at the dates and for the
periods indicated.
6.7 No Undisclosed Material Liabilities. There are no liabilities of the
Buyer of any kind whatsoever, whether accrued, contingent, absolute, determined,
determinable or otherwise, and there is
A-23
<PAGE>
<PAGE>
no existing condition, situation or set of circumstances which could reasonably
be expected to result in such a liability, other than:
(i) liabilities disclosed in the Buyer's filings with the Commission
or otherwise reflected or reserved against in the Buyer's financial
statements;
(ii) liabilities incurred in the ordinary course of business
consistent with past practice, which individually or in the aggregate,
would not have a material adverse effect on the assets, liabilities,
financial condition, business, operations or results of operations of the
Buyer; and
(iii) liabilities under this Agreement or disclosed pursuant to this
Agreement.
6.8 Proxy Statement. None of the information to be supplied by the Buyer or
any of its accountants, counsel or other authorized representatives for
inclusion in the Proxy Statement (as defined in Section 7.6) to be distributed
in connection with the Stockholders' Meeting (as defined in Section 7.5) will,
at the time of the mailing of the Proxy Statement and any amendments or
supplements thereto, and at the time of the Stockholders' Meeting contain any
untrue statement of a material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under
which they are made, not misleading, it being understood and agreed that no
representation or warranty is made by the Buyer with respect to any information
supplied by the Seller or its accountants, counsel or other authorized
representatives. If at any time prior to the Closing any event with respect to
the Buyer, its officers and directors or any of its subsidiaries shall occur
which is or should be described in an amendment of, or a supplement to, the
Proxy Statement, such event shall be so described and the presentation in such
amendment or supplement of such information will not contain any statement
which, at the time and in light of the circumstances under which it is made, is
false or misleading in any material respect or omits to state any material fact
required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not false or
misleading. The Proxy Statement will comply as to form in all material respects
with all applicable laws, including the provisions of the Exchange Act and the
rules and regulations promulgated thereunder.
6.9 Fairness Opinion. The Buyer has received the written opinion of Salomon
Brothers Inc ('Salomon Brothers'), financial advisor to the Buyer, that, as of
the date of the opinion, the consideration to be paid by the Buyer hereunder is
fair to the Buyer from a financial point of view, and such opinion has not been
withdrawn as of the date hereof. The Buyer has delivered a copy of such opinion
to the Seller.
6.10 Governmental Approvals. Except for filings required under applicable
securities laws, no authorization, license, permit, franchise, approval, order
or consent of, and no registration, declaration or filing by the Buyer with, any
governmental authority, domestic or foreign, federal, state or local, is
required in connection with the execution, delivery and performance of this
Agreement.
6.11 Brokers. The Buyer has not made any agreement or taken any action with
any person or taken any action which would cause any person to be entitled to
any agent's, broker's or finder's fee or commission in connection with the
transactions contemplated by this Agreement.
A-24
<PAGE>
<PAGE>
VII
COVENANTS OF THE SELLER AND THE BUYER PENDING CLOSING
7.1 Access to the Buyer. Between the date hereof and the Closing Date, the
Seller shall (a) afford to the Buyer and to the Buyer's counsel, accountants and
other representatives reasonable access, during normal business hours,
throughout the period prior to the Closing Date, to all of the properties,
books, contracts, commitments and other records of the Acquired Companies and
shall furnish the Buyer during such period with all information concerning the
Acquired Companies that the Buyer may reasonably request and (b) afford to the
Buyer and to the Buyer's representatives, agents, employees and independent
contractors reasonable access during normal business hours to the properties of
the Acquired Companies in order to conduct inspections at the Buyer's expense to
determine that the Acquired Companies are operating in material compliance with
all applicable federal, state and local and foreign statutes, rules and
regulations, and all material building, fire and zoning laws or regulations and
that the Acquired Companies' assets are substantially in the condition and of
the capacities represented and warranted in this Agreement; provided, however,
that in every instance described in (a) and (b), the Buyer shall make
arrangements with the Acquired Companies reasonably in advance and shall use its
best efforts to avoid interruption and to minimize interference with the normal
business and operations of the Acquired Companies. Any such investigation or
inspection by the Buyer shall not be deemed a waiver of, or otherwise limit, the
representations, warranties and covenants contained herein.
7.2 Conduct of Business. Except as contemplated by Sections 7.3 and 7.4
below, during the period from the date hereof to the Closing Date, the business
conducted by the Acquired Companies shall be operated in the usual and ordinary
course of such business and in material compliance with the terms of this
Agreement. Without limiting the generality of the foregoing:
(a) the Seller shall cause the Acquired Companies to use reasonable
efforts consistent with past practices to carry on their respective
businesses in the usual, regular and ordinary course of business
substantially in the same manner as heretofore conducted and to preserve
the business and organization of the Acquired Companies so as to (i) keep
available the services of their respective present employees and agents;
(ii) complete or maintain all of their respective material contracts in
full force and effect in accordance with their existing terms and perform
all of their obligations thereunder in all material respects; (iii)
maintain the integrity of all confidential information of their respective
businesses consistent with past practice; (iv) maintain in full force and
effect their respective existing insurance policies (or policies providing
substantially the same coverage, copies of which shall be made available to
the Buyer) insuring their respective businesses; (v) pay all of their
respective accounts payable and other obligations when they become due and
payable consistent with past practice; (vi) preserve their goodwill and
contractual relationship with, suppliers, customers and others having
business relations with the Acquired Companies; and (vii) promptly advise
the Buyer in writing of any changes that, in the aggregate, have resulted
or may result in a material adverse effect on their respective business
operations; and
(b) the Seller shall cause the Acquired Companies not to (i) sell or
transfer any of their respective material assets or property except in the
usual and ordinary course of business and, except for cash applied in
payment of their respective liabilities or merchandise credits given in the
usual and ordinary course of business; (ii) make any distribution, whether
by dividend or otherwise, to any of their respective stockholders or
employees except for compensation to employees in the usual and ordinary
course of business; (iii) redeem or otherwise acquire any shares of their
capital stock or other securities; (iv) issue any shares of their capital
stock or other securities; (v) increase the rate of compensation or
benefits of their respective employees, officers, directors, consultants or
agents; (vi) merge consolidate or agree to acquire the assets or stock of
any other entity; (vii) take any action which would cause the
representations made by the Seller herein to be rendered inaccurate in any
material respect; or agree to do any of the foregoing.
7.3 Capital Expenditures by the Acquired Companies. Notwithstanding the
restrictions contained in Section 7.2, the Buyer acknowledges that the business
plans of the Acquired Companies, copies of which have been provided to the
Buyer, contemplate certain possible expansions of product lines, production
facilities or other changes in the respective business operations of the
Acquired Companies. The Seller agrees that it will not permit the Acquired
Companies to engage in any such undertaking
A-25
<PAGE>
<PAGE>
requiring a capital expenditure of in excess of $100,000 unless (i) such
expenditure has been consented to by the Buyer (which consent shall not be
unreasonably withheld or delayed if such expenditure was contemplated by the
business plans provided to the Buyer) and (ii) the expenditure is funded by a
loan from the Seller to the Acquired Company (which loan shall be converted by
the Seller into equity of such Acquired Company in accordance with Section 7.4
hereof).
7.4 Conversion of Loans to the Acquired Companies. The Seller covenants and
agrees that on or prior to the Closing Date it shall contribute to the capital
of the respective Acquired Company all loans and advances to, and other forms of
indebtedness of, each of the Acquired Companies into additional shares of common
stock of such Acquired Companies. Any additional shares of common stock of the
Acquired Companies which may be issued to the Seller as a result of the
foregoing shall be deemed to be FPR Shares, FPC Shares or FMDC Shares, as the
case may be.
7.5 Meeting of Stockholders. The Buyer shall, promptly after the date of
this Agreement, take all action necessary in accordance with the Delaware
General Corporation Law, its Certificate of Incorporation and By-Laws to convene
a meeting of the holders of Common Stock of the Buyer to act on this Agreement
(the 'Stockholders' Meeting'), and the Buyer shall consult with the Seller in
connection therewith. The Buyer shall use its best efforts to solicit from
holders of Common Stock that are not affiliated with the Seller proxies in favor
of the approval and adoption of this Agreement and to obtain the vote of such
stockholders required to approve and adopt this Agreement, unless otherwise
required by the applicable fiduciary duties of the directors of Buyer, as
determined by such directors in good faith after consultation with legal
counsel.
7.6 Proxy Statement. As promptly as practicable after the execution of this
Agreement, the Buyer shall prepare and file with the Commission a proxy
statement and a form of proxy, in connection with the vote of the Buyer's
stockholders with respect to the transactions contemplated hereby and by the
Preferred Stock Purchase Agreement (such proxy statement, together with any
amendments thereof or supplements thereto, in each case in the form or forms
mailed to the Buyer's stockholders, being the 'Proxy Statement'). The Buyer
shall respond to all inquiries and comments of the Staff of the Commission to
enable the Buyer to file and mail the definitive Proxy Statement as soon as
reasonably practicable. Each of the Seller and the Buyer shall furnish all
information concerning it and the holders of its capital stock as the other may
reasonably request in connection with such actions. As promptly as practicable,
the Buyer shall mail the Proxy Statement to its stockholders. The Proxy
Statement shall include the recommendation of the Buyer's Board of Directors in
favor of the adoption and approval of this Agreement and the transactions
contemplated hereby and by the Preferred Stock Purchase Agreement unless
otherwise required by the applicable fiduciary duties of the Board of Directors
of the Buyer, as determined by such directors in good faith after consultation
with legal counsel.
7.7 Voting of Shares Held by the Seller. The Seller shall cause all shares
of Purepac Common Stock owned by it to be voted, with respect to the proposals
for the adoption and approval of the Preferred Stock Purchase Agreement and this
Agreement and the transactions contemplated hereby and thereby at the
Stockholders' Meeting, in the same manner as the majority of votes cast at the
Stockholders' Meeting, with respect to such proposals, by the holders of Purepac
Common Stock who are not 'affiliates' (as defined in Rule 12b-2 promulgated
under the Exchange Act) of the Seller.
7.8 National Market System Listing. The Buyer shall use its best efforts to
authorize for listing the Purepac Stock on the NASDAQ National Market System.
7.9 Public Announcements. Except as required by law and as contemplated by
Section 7.6 hereof, the Seller will not, and will not permit the Acquired
Companies to, make any public announcement in respect of the transactions
contemplated hereby without the prior written consent of the Buyer, and the
Buyer will not make any public announcements in respect of the transactions
contemplated hereby without the prior written consent of the Seller.
A-26
<PAGE>
<PAGE>
VIII
CONDITIONS TO CLOSING
8.1 Conditions to the Obligations of the Buyer and of the Seller. The
respective obligations of the Buyer and the Seller to consummate the
transactions contemplated hereby are subject to the satisfaction, on or prior to
the Closing Date, of the following conditions:
(i) This Agreement and the consummation of the transactions
contemplated hereby, shall have been approved and ratified by (i) the
stockholders of the Buyer in accordance with the Certificate of
Incorporation and By-Laws of the Buyer and the Delaware General Corporation
Law, and (ii) the affirmative vote of the holders of a majority of the
votes cast at the Stockholders' Meeting by holders that are not
'affiliates' of the Seller;
(ii) No preliminary or permanent injunction or other order or decree
by any Federal or state court which prevents the consummation of the
transactions contemplated hereby shall have been issued and shall remain in
effect (each party agreeing to use its reasonable efforts to have any such
injunction, order or decree lifted);
(iii) No action shall have been taken, and no statute, rule or
regulation shall have been enacted, by any state or Federal government or
governmental agency in the United States which would prevent the
consummation of the transactions contemplated hereby;
(iv) All required consents, approvals and authorizations of any
Governmental Authority to the consummation of the transactions contemplated
hereby shall have been obtained; and
(v) The transactions contemplated by the Preferred Stock Purchase
Agreement shall have been consummated.
8.2 Conditions to the Obligations of the Seller. The obligation of the
Seller to consummate the transactions contemplated hereby is subject to the
following conditions, any of which may be waived by it in its sole discretion:
(i) The Buyer shall have performed and complied in all material
respects with all agreements and conditions required by this Agreement to
be performed or complied with by the Buyer prior to or on the Closing Date;
(ii) The Buyer's representations and warranties contained in this
Agreement or any schedule, certificate, or other instrument delivered
pursuant to the provisions hereof or in connection with the transactions
contemplated hereby shall be true and correct in all material respects at
and as of the Closing Date (except for changes permitted by this Agreement)
and shall be deemed to be made again as of the Closing Date;
(iii) The Buyer shall have performed and complied in all material
respects with all agreements and conditions required by the Preferred Stock
Purchase Agreement;
(iv) The shares of Purepac Stock shall have been authorized for
listing on the NASDAQ National Market, subject to notice of issuance;
(v) The Buyer shall have executed and delivered to the Seller each of
the Name License Agreement and the Registration Rights Agreement in the
form annexed to the Seller's Disclosure Schedules; and
(vi) The Buyer shall have delivered to the Seller:
(A) a certificate, dated as of the Closing Date, executed by the
President or a Vice President of the Buyer to the effect that the
representations and warranties of the Buyer contained in this Agreement
are true and correct in all material respects at and as of the Closing
Date and that the Buyer has complied with or performed in all material
respects all terms, covenants and conditions to be complied with or
performed by it on or prior to the Closing Date;
(B) a certificate, dated as of the Closing Date, duly executed by
the Secretary of the Buyer certifying as to the incumbency and
signatures of the Buyer's officers who have executed and delivered this
Agreement or the other certificates and instruments delivered in
connection herewith, and copies of directors' and stockholders'
resolutions approving and authorizing the
A-27
<PAGE>
<PAGE>
execution and delivery of this Agreement, and the consummation of the
transactions contemplated hereby; and
(C) a certificate representing the Purepac Stock to be delivered at
the Closing.
8.3 Conditions to the Obligations of the Buyer. The obligation of the Buyer
to consummate the transactions contemplated hereby is subject to the following
conditions, any of which may be waived by it in its sole discretion:
(i) The Seller shall have performed and complied in all material
respects with all agreements and conditions required by this Agreement to
be performed or complied with by the Seller prior to or on the Closing
Date;
(ii) The representations and warranties of the Seller contained in
this Agreement (including the exhibits hereto and the Seller's Disclosure
Schedule) or any schedule, certificate, or other instrument delivered
pursuant to the provisions hereof or in connection with the transactions
contemplated hereby shall be true and correct in all material respects at
and as of the Closing Date (except for changes permitted by this Agreement)
and shall be deemed to be made again as of the Closing Date;
(iii) The Seller shall have performed and complied in all material
respects with all agreements and conditions required by the Preferred Stock
Purchase Agreement;
(iv) The Acquired Companies shall have at the Closing Date (A) an
aggregate Net Asset Value in excess of $17,000,000, and (B) no indebtedness
or other liability for money borrowed, except for accounts payable and
other trade obligations incurred in the ordinary course of business;
(v) The Seller shall have executed and delivered to the Buyer each of
the Name Licensing Agreement and the Registration Rights Agreement; and
(vi) The Seller shall have delivered to the Buyer:
(A) a certificate, dated as of the Closing Date, executed by the
President or a Vice President of the Seller to the effect that the
representations and warranties of the Seller contained in this Agreement
are true and correct in all material respects at and as of the Closing
Date and that the Seller has complied with or performed in all material
respects all terms, covenants and conditions to be complied with or
performed by it on or prior to the Closing Date; and
(B) a certificate, dated as of the Closing Date, duly executed by
the Secretary of the Seller certifying as to the incumbency and
signatures of the Seller's officers who have executed and delivered this
Agreement or the other certificates and instruments delivered in
connection herewith, and copies of directors' and stockholders'
resolutions approving and authorizing the execution and delivery of this
Agreement, and the consummation of the transactions contemplated hereby;
and
(C) Certificates representing the FPR Shares, the FPC Shares and
the FMDC Shares; and
(D) the books and records of the Acquired Companies.
IX
INDEMNIFICATION
9.1 By the Seller.
(a) The Seller covenants and agrees to defend, indemnify and hold harmless
the Buyer and its officers, directors, employees, affiliates and agents
(collectively, the 'Buyer Indemnitees') from and against, and pay or reimburse
the Buyer Indemnitees for, any and all liabilities, obligations, losses, costs,
deficiencies or damages (whether absolute or accrued) and including interest,
penalties and reasonable attorneys' fees and expenses incurred in the
investigation or defense of any of the same or in asserting any of their
respective rights hereunder (collectively, 'Losses'), resulting from or arising
out of (i) the inaccuracy or breach of any representation or warranty made by
the Seller in this Agreement or (ii) the failure of the Seller to perform any
covenant or fulfill any other obligation contained in this Agreement.
A-28
<PAGE>
<PAGE>
(b) The Buyer and the Seller agree that with respect to any Loss or alleged
Loss claimed by the Buyer Indemnitees which is based upon or arises from a
breach or alleged by the Seller of any of the representations or warranties
contained in Article III hereof, the Buyer Indemnitees shall not be entitled to
seek to assert their rights against the Seller pursuant to Section 9.1(a) hereof
until FPR has first fully exercised its rights under the indemnification
provisions set forth in the DuPont Acquisition Agreement to the full extent
available.
9.2 By the Buyer. The Buyer covenants and agrees to defend, indemnify and
hold harmless the Seller and its officers, directors, employees, affiliates and
agents (collectively, the 'Seller Indemnitees') from and against, and pay or
reimburse the Seller Indemnitees for, any and all Losses resulting from or
arising out of the incorrectness or breach of any representation or warranty
made by the Buyer in this Agreement or (ii) the failure of the Buyer to perform
any covenant or fulfill any other obligation contained in this Agreement.
9.3 Claims Procedure. In the case of any claim asserted by a third party
against a party entitled to indemnification under this Agreement (the
'Indemnified Party'), written notice shall be given by the Indemnified Party to
the party required to provide indemnification (the 'Indemnifying Party')
promptly after such Indemnified Party has actual knowledge of any claim as to
which indemnity may be sought, and the Indemnified Party shall permit the
Indemnifying Party (at the expense of such Indemnifying Party) to assume the
defense of any claim or any litigation resulting therefrom, provided that (i)
counsel for the Indemnifying Party, who shall conduct the defense of such claim
or litigation, shall be reasonably satisfactory to the Indemnified Party, and
the Indemnified Party may participate in such defense, but only at such
Indemnified Party's expense and without any indemnification for such expense
pursuant to this Article IX, and (ii) the omission by any Indemnified Party to
give notice as provided herein shall not relieve the Indemnifying Party of its
indemnification obligation under this Agreement except to the extent that such
Indemnifying Party is damaged or materially prejudiced as a result of such
failure of actual notice to the Indemnifying Party and such Indemnifying Party
is damaged as a result of such failure to give notice. No Indemnifying Party, in
the defense of any such claim or litigation, shall, except with the consent of
the Indemnified Party, (i) consent to entry of any judgment or enter into any
settlement which does not include as an unconditional term thereof the giving by
the claimant or plaintiff to such Indemnified Party of a release from all
liability with respect to such claim or litigation or (ii) pursue any course of
defense of any claim subject to indemnification hereunder, if the Indemnified
Party shall reasonably and in good faith determine that the conduct of such
defense might be expected to affect adversely the Indemnified Party's tax
liability or ability to conduct its business. In the event that the Indemnified
Party shall reasonably and in good faith determine that any proposed settlement
of any claim subject to indemnification hereunder by the Indemnifying Party
might be expected to affect adversely the Indemnified Party's tax liability or
ability to conduct its business, the Indemnified Party shall have the right at
all times to take over and assume control over the settlement, negotiations or
lawsuit relating to any such claim at the sole cost of the Indemnifying Party,
provided that if the Indemnified Party does so take over and assume control, the
amount of the indemnity required to be paid by the Indemnifying Party shall be
limited to the amount the Indemnifying Party is able to reasonably demonstrate
that it could have settled the matter for immediately prior to the time of
assumption. In the event that the Indemnifying Party does not accept the defense
of any matter as above provided, the Indemnified Party shall have the full right
to defend against any such claim or demand, and shall be entitled to settle or
agree to pay in full such claim or demand, in its sole discretion. In any event,
the Seller and the Buyer shall cooperate in the defense of any action or claim
subject to this Article IX and the records of each shall be available to the
other with respect to such defense.
9.4 Extent of Liability. In no event shall the Buyer Indemnitees be
entitled to indemnification under this Article IX unless and until the aggregate
amount of all claims for such indemnification exceeds $200,000.
A-29
<PAGE>
<PAGE>
X
TERMINATION
10.1 Termination Prior to Closing. This agreement may be terminated at any
time prior to the Closing, whether before or after approval and ratification by
their respective stockholders:
(a) by mutual consent of the Buyer and the Seller;
(b) by either the Buyer or the Seller if the Closing has not occurred
on or prior to April 30, 1996 ( provided, however, that no party may
terminate this Agreement if such party has materially breached any of the
terms and conditions hereof);
(c) by the Buyer if any of the conditions specified in Section 8.1 or
8.3 have not been met or waived by the Buyer at such time as such condition
is no longer capable of satisfaction; or
(d) by the Seller if any of the conditions specified in Section 8.1 or
8.2 have not been met or waived by the Seller at such time as such
condition is no longer capable of satisfaction.
10.2 Consequences of Termination. Upon termination of this Agreement
pursuant to this Article X or any other express right of termination provided
elsewhere in this Agreement, the parties shall be relieved of any further
obligation to the other except as provided in Section 12.1; provided, however,
that no termination of this Agreement, pursuant to this Article X hereof or
under any other express right of termination provided elsewhere in this
Agreement, shall operate to release any party from any liability to any other
party incurred before the date of such termination or from any liability
resulting from any willful misrepresentation made in connection with this
Agreement or willful breach hereof. The provisions of this Article X shall not
be considered as a waiver by either the Buyer or by the Seller, as the case may
be, of the remedy of specific performance, it being agreed that each shall have
the right to specific performance with respect to this Agreement.
XI
ADDITIONAL COVENANTS
11.1 Mutual Cooperation. The parties hereto will cooperate with each other,
and will use all reasonable efforts to cause the fulfillment of the conditions
to the parties' obligations hereunder and to obtain as promptly as possible all
consents, authorizations, orders or approvals from each and every third party,
whether private or governmental, required in connection with the transactions
contemplated by this Agreement.
11.2 Changes in Representations and Warranties of the Seller. Between the
date of this Agreement and the Closing Date, the Seller shall not, nor shall the
Seller permit any of the Acquired Companies to, directly or indirectly, enter
into any transaction, take any action, or by inaction permit an event to occur,
which would result in any of the representations and warranties herein contained
not being true and correct in all material respects at and as of (i) the time
immediately following the occurrence of such transaction or event or (ii) the
Closing Date. The Seller shall promptly give written notice to the Buyer upon
becoming aware of (A) any fact which, if known on the date hereof, would have
been required to be set forth or disclosed pursuant to this Agreement and (B)
any impending or threatened breach in any material respect of any of the
representations and warranties contained in this Agreement and with respect to
the latter shall use all reasonable efforts to remedy same.
11.3 Changes in Representations and Warranties of the Buyer. Between the
date of this Agreement and the Closing Date, the Buyer shall not, directly or
indirectly, enter into any transaction, take any action, or by inaction permit
an event to occur, which would result in any of the representations and
warranties of the Buyer herein contained not being true and correct in all
material respects at and as of (i) the time immediately following the occurrence
of such transaction or event or (ii) the Closing Date. The Buyer shall promptly
give written notice to the Seller upon becoming aware of (A) any fact which, if
known on the date hereof, would have been required to be set forth or disclosed
pursuant to this Agreement and (B) any impending or threatened breach in any
material respect of any of the representations and warranties contained in this
Agreement and with respect to the latter shall use all reasonable efforts to
remedy same.
A-30
<PAGE>
<PAGE>
XII
MISCELLANEOUS
12.1 Expenses. The parties shall pay their own respective expenses incident
to the negotiation, preparation, and carrying out of this Agreement, including
all fees and expenses of their respective counsel, advisors and accountants for
all activities of such counsel, advisors and accountants undertaken pursuant to
this Agreement, whether or not the transactions contemplated hereby are
consummated. The foregoing notwithstanding, if this Agreement is terminated as a
result of the failure of the stockholders of the Buyer to approve the
transactions contemplated hereby, the Seller will reimburse the Buyer for
one-half of the Buyer's expenses incurred in connection herewith.
12.2 Survival of Representations, Warranties and Covenants. All statements
contained in this Agreement or in any certificate delivered by or on behalf of
the Seller or the Buyer pursuant hereto or in connection with the transactions
contemplated hereby shall be deemed representations, warranties and covenants by
the Seller or the Buyer, as the case may be, hereunder. All representations,
warranties, and covenants made by the Seller and by the Buyer in this Agreement,
or pursuant hereto, shall survive the Closing for a period of two years, except
for representations and warranties relating to Taxes, which shall survive for a
period ending upon the later of the expiration of the applicable statute of
limitations or 60 days after the final determination of any tax liability. All
representations and warranties related to any claim asserted in writing prior to
the expiration of the applicable survival period shall survive until such claim
shall be resolved and payment in respect thereof, if any is owing, shall be
made.
12.3 Succession and Assignments; Third Party Beneficiaries. This Agreement
may not be assigned (either voluntarily or involuntarily) by any party hereto
without the express written consent of the other party. Any attempted assignment
in violation of this Section shall be void and ineffective for all purposes. In
the event of an assignment permitted by this Section, this Agreement shall be
binding upon the heirs, successors and assigns of the parties hereto. Except as
expressly set forth in this Section, there shall be no third party beneficiaries
of this Agreement.
12.4 Notices. All notices, requests, demands, or other communications with
respect to this Agreement shall be in writing and shall be (i) sent by facsimile
transmission, (ii) sent by the United States Postal Service, registered or
certified mail, return receipt requested, or (iii) personally delivered by a
nationally recognized express overnight courier service, charges prepaid, to the
following addresses (or such other addresses as the parties may specify from
time to time in accordance with this Section)
(i) To the Buyer:
Purepac, Inc.
200 Elmora Avenue
Elizabeth, New Jersey 07207
Attention: President
Fax No.: (908) 355-7048
With a Copy To:
Parker Duryee Rosoff & Haft
529 Fifth Avenue
New York, New York 10017
Attention: William R. Griffith, Esq.
Fax No.: (212) 972-9487
(ii) To the Seller:
Faulding Holdings Inc.
529 Fifth Avenue, 8th Floor
New York, New York 10017
Attention: President
Fax No.: (212) 599-0028
With a Copy To:
Reid & Priest LLP
40 West 57th Street
New York, NY 10019
Attention: Richard M. Farmer, Esq.
Fax No.: (212) 603-2298
Any such notice shall, when sent in accordance with the preceding sentence,
be deemed to have been given and received on the earliest of (i) the day
delivered to such address or sent by facsimile transmission, (ii) the fifth
business day following the date deposited with the United States Postal Service,
or (iii) 24 hours after shipment by such courier service.
12.5 Construction. This Agreement shall be construed and enforced in
accordance with the internal laws of the State of Delaware without giving effect
to the principles of conflicts of law thereof.
A-31
<PAGE>
<PAGE>
12.6 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which shall
together constitute one and the same Agreement.
12.7 No Implied Waiver; Remedies. No failure or delay on the part of the
parties hereto to exercise any right, power, or privilege hereunder or under any
instrument executed pursuant hereto shall operate as a waiver nor shall any
single or partial exercise of any right, power, or privilege preclude any other
or further exercise thereof or the exercise of any other right, power, or
privilege. All rights, powers, and privileges granted herein shall be in
addition to other rights and remedies to which the parties may be entitled at
law or in equity.
12.8 Entire Agreement. This Agreement, including the Exhibits and Schedules
attached hereto, sets forth the entire understandings of the parties with
respect to the subject matter hereof, and it incorporates and merges any and all
previous communications, understandings, oral or written as to the subject
matter hereof, and cannot be amended or changed except in writing, signed by the
parties.
12.9 Amendment. This Agreement may be amended by the parties hereto
pursuant to action of their respective Boards of Directors, at any time before
or after approval hereof by the stockholders of the Buyer. This Agreement may
not be amended except by an instrument in writing duly executed on behalf of
each of the parties hereto.
12.10 Headings. The headings of the Sections of this Agreement, where
employed, are for the convenience of reference only and do not form a part
hereof and in no way modify, interpret or construe the meanings of the parties.
12.11 Severability. To the extent that any provision of this Agreement
shall be invalid or unenforceable, it shall be considered deleted hereof and the
remainder of such provision and of this Agreement shall be unaffected and shall
continue in full force and effect.
IN WITNESS WHEREOF, the parties hereto have executed this Agreement the day
and year first above written.
FAULDING HOLDINGS INC.
By: /s/ EDWARD D. TWEDDELL
.................................
Name: Edward D. Tweddell
Title: Director
PUREPAC, INC.
By: /s/ RICHARD F. MOLDIN
.................................
Name: Richard F. Moldin
Title: President
A-32
<PAGE>
<PAGE>
EXHIBIT B
PREFERRED STOCK PURCHASE AGREEMENT
PREFERRED STOCK PURCHASE AGREEMENT, dated as of January 23, 1996, between
Faulding Holdings Inc., a Delaware corporation (the 'Buyer'), and Purepac, Inc.,
a Delaware corporation (the 'Seller').
WITNESSETH
WHEREAS, simultaneously with the execution of this Agreement, the Seller
and the Buyer are executing and delivering an agreement (the 'Stock Purchase
Agreement'), providing, among other things, for the exchange by the Buyer of all
of the issued and outstanding capital stock of Faulding Puerto Rico, Inc.,
Faulding Pharmaceutical Co. and Faulding Medical Device Co. for shares of Common
Stock of the Seller, all on the terms and subject to the conditions set forth in
such Stock Purchase Agreement; and
WHEREAS, the Buyer wishes to purchase, and the Seller wishes to sell shares
of a new class of convertible preferred stock of the Seller having an aggregate
liquidation/redemption preference of $15,000,000, and convertible into shares of
Common Stock, $.01 par value, of the Seller, for a purchase price of $15,000,000
in cash;
NOW, THEREFORE, in consideration of the mutual promises, covenants,
representations and warranties made herein and of the mutual benefits to be
derived herefrom, the parties hereto agree as follows:
I
PURCHASE AND SALE OF THE SHARES
1.1 Purchase and Sale of the Shares. Subject to the terms and conditions
hereof, the Seller hereby agrees to sell, and the Buyer hereby agrees to
purchase, in consideration for the delivery to the Buyer at the Closing of the
Purchase Price, as hereinafter defined, 150,000 shares (the 'Shares') of a newly
created Class B Preferred Stock of the Seller, such preferred stock having the
rights and preferences as set forth in the form of Certificate of Designation
annexed hereto as Exhibit A (the 'Class B Preferred Stock').
1.2 Purchase Price. The purchase price for the Shares (the 'Purchase
Price') shall be $15,000,000 in cash, payable by wire transfer of immediately
available funds to an account designated by the Seller in writing.
1.3 Closing. The closing of the sale and purchase of the Shares (the
'Closing') shall take place at the offices of Parker Duryee Rosoff & Haft, a
professional corporation, 529 Fifth Avenue, New York, New York 10017, at 1:00
p.m. on February 29, 1996 or such other time and date as the parties may agree
to in writing (the 'Closing Date').
At the Closing:
(a) the Seller will deliver to the Buyer, free and clear of all liens,
claims, charges and encumbrances, a certificate representing the Shares,
duly registered in the name of the Buyer;
(b) the Buyer will deliver to the Seller the Purchase Price; and
(c) the Seller and the Buyer shall each deliver to the other those
items required to be delivered pursuant to Article V hereof.
II
REPRESENTATIONS AND WARRANTIES OF THE BUYER
The Buyer represents and warrants to the Seller as follows with the
knowledge and understanding that the Seller is relying materially on such
representations and warranties.
B-1
<PAGE>
<PAGE>
2.1 Organization and Standing. The Buyer is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware.
The Buyer has all requisite corporate power to carry on its business as it is
now being conducted.
2.2 Authority. The Buyer has the full power and authority to execute this
Agreement and this Agreement constitutes a valid and binding obligation of the
Buyer, enforceable in accordance with its respective terms, subject to general
principles of equity and bankruptcy or other laws relating to or affecting the
rights of creditors generally. The execution and delivery of this Agreement and
the performance of the Buyer's obligations hereunder have been duly authorized
by the Board of Directors of the Buyer and no other corporate action on the part
of the Buyer is required.
2.3 No Conflicts, etc. The execution and delivery of this Agreement and the
consummation of the transactions contemplated hereby will not conflict with or
result in any violation of or default under any provision of the certificate of
incorporation or by-laws of the Buyer, or any mortgage, indenture, lease,
stockholders' agreement or other agreement, instrument, applicable law or
license applicable to the Buyer or any of its properties.
2.4 Acquisition of the Shares for Investment. The Buyer is acquiring the
Shares for investment purposes, with no present intention to distribute or
liquidate such shares or to transfer such shares in violation of applicable
securities laws, including, without limitation, the Securities Act of 1933, as
amended (the 'Act').
2.5 Governmental Approvals. Except for filings under applicable securities
laws, no authorization, license, permit, franchise, approval, order or consent
of, and no registration, declaration or filing by the Buyer with, any
governmental authority, domestic or foreign, federal, state or local, is
required in connection with the execution and delivery of this Agreement or the
consummation of the transactions contemplated hereby. No consent of any third
party is required to be obtained by the Buyer in connection with the execution,
delivery and performance of this Agreement or the consummation of the
transactions contemplated hereby.
2.6 Brokers. The Buyer has not made any agreement or taken any action with
any person or taken any action which would cause any person to be entitled to
any agent's, broker's or finder's fee or commission in connection with the
transactions contemplated by this Agreement.
III
REPRESENTATIONS AND WARRANTIES OF THE SELLER
The Seller represents and warrants to the Buyer as follows, with the
knowledge and understanding that the Buyer is relying materially on such
representations and warranties:
3.1 Organization and Standing of the Seller. The Seller is a corporation
duly organized, validly existing and in good standing under the laws of the
State of Delaware, and has all corporate power to carry on its business as now
conducted. The copies of the Certificate of Incorporation and By-Laws of the
Seller (certified by the Secretary of the Seller), as amended to date, delivered
to the Buyer, are true and complete copies of those documents as now in effect.
3.2 The Seller's Authority. The Seller has the full power and authority to
execute this Agreement. The execution, delivery and performance by the Seller of
this Agreement has been duly authorized by the Board of Directors of the Seller
and no other corporate action is required, other than the approval of the
stockholders of the Seller referred to in Sections 4.1 and 5.1 hereof. This
Agreement constitutes the valid and binding obligation of the Seller,
enforceable in accordance with its terms, subject to general principles of
equity and bankruptcy or other laws relating to or affecting the rights of
creditors generally. This Agreement and the transactions contemplated hereby
have been approved by the directors of the Seller who are not employed by the
Buyer or any of its affiliates.
3.3 Capitalization. The authorized capital stock of the Seller consists of
25,000,000 shares of Common Stock, par value $.01 per share, of which 12,581,223
shares are issued and outstanding, and 1,834,188 shares of Preferred Stock, $.01
par value, of which 834,188 shares are outstanding. The Common Stock of the
Seller is traded on the National Market System of the NASDAQ Stock Market.
B-2
<PAGE>
<PAGE>
3.4 Class B Preferred Stock. The Seller's Board of Directors has duly
authorized the filing with the Secretary of State of Delaware of a Certificate
of Designation, substantially in the form of Exhibit A hereto, creating a series
of preferred stock of the Seller designated as Class B Preferred Stock, and has
authorized the issuance to the Buyer of the Shares to be issued to the Buyer
hereunder. Upon the filing of such Certificate of Designation and upon the
issuance of the Shares in accordance with the terms of this Agreement, such
Shares shall be duly authorized, validly issued, fully paid and non-assessable.
Upon the closing of the transactions contemplated hereby, the Buyer will acquire
title to the Shares, free and clear of all liens, claims, charges and
encumbrances.
3.5 Business; SEC Filings.
(a) Except as set forth in Section 3.5 of the Seller's Disclosure Schedule,
the Seller has filed with the Securities and Exchange Commission (the
'Commission') all required reports, schedules, forms, statements and other
documents from July 1, 1994 through the date hereof, including (i) the Annual
Report on Form 10-K for the fiscal year ended June 30, 1995, (ii) the quarterly
reports on Form 10-Q required for all fiscal quarters during such period and for
the three months ended September 30, 1995, (iii) its proxy or information
statements relating to meetings of, or actions taken without a meeting by, the
stockholders of the Seller held during such period, and (iv) all of its other
reports, statements, schedules and registration statements filed with the
Commission during such period.
(b) As of its filing date or, if amended, as of the date of its amendment,
as the case may be, each such report, proxy or information statement (as amended
or supplemented, if applicable), by the Seller filed by the Seller pursuant to
the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), did not
contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein not
misleading.
(c) Each such registration statement (as amended or supplemented, if
applicable) filed by the Seller pursuant to the Securities Act of 1933, as
amended, on the date such statement, amendment or supplement became effective
did not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements
therein not misleading.
3.6 Financial Statements. The financial statements of the Seller included
in the Annual Report on Form 10-K filed by the Seller with respect to the fiscal
year of the Company ended June 30, 1995 and the quarterly reports on Form 10-Q
filed by the Seller with the Commission with respect to the quarters ended
September 30, 1994, December 31, 1994, March 31, 1995 and September 30, 1995,
comply in all material respects with applicable accounting requirements and with
the published rules and regulations of the Commission with respect thereto, were
prepared in accordance with GAAP (except as may be indicated in the notes
thereto or, in the case of the unaudited statements, as permitted by Form 10-Q
of the Commission), and fairly present (subject, in the case of the unaudited
statements, to normal, recurring adjustments, none of which are anticipated to
be material) the financial position, results of operations, stockholders' equity
and changes in financial position of the Seller as at the dates and for the
periods indicated.
3.7 No Undisclosed Material Liabilities. There are no liabilities of the
Seller of any kind whatsoever, whether accrued, contingent, absolute,
determined, determinable or otherwise, and there is no existing condition,
situation or set of circumstances which could reasonably be expected to result
in such a liability, other than:
(i) liabilities disclosed in the Seller's filings with the Commission
or otherwise reflected or reserved against in the Seller's financial
statements;
(ii) liabilities incurred in the ordinary course of business
consistent with past practice, which individually or in the aggregate,
would not have a material adverse effect on the assets, liabilities,
financial condition, business, operations or results of operations of the
Seller; and
(iii) liabilities under this Agreement or disclosed pursuant to this
Agreement.
3.8 Proxy Statement. None of the information to be supplied by the Seller
or any of its accountants, counsel or other authorized representatives for
inclusion in the Proxy Statement (as defined in Section 4.2) to be distributed
in connection with the Stockholders' Meeting (as defined in Section 4.1) will,
at
B-3
<PAGE>
<PAGE>
the time of the mailing of the Proxy Statement and any amendments or supplements
thereto, and at the time of the Stockholders' Meeting contain any untrue
statement of a material fact required to be stated therein or omit any material
fact necessary in order to make the statements therein, in light of the
circumstances under which they are made, not misleading, it being understood and
agreed that no representation or warranty is made by the Seller with respect to
any information supplied by the Buyer or its accountants, counsel or other
authorized representatives. If at any time prior to the Closing any event with
respect to the Seller, its officers and directors or any of its subsidiaries
shall occur which is or should be described in an amendment of, or a supplement
to, the Proxy Statement, such event shall be so described and the presentation
in such amendment or supplement of such information will not contain any
statement which, at the time and in light of the circumstances under which it is
made, is false or misleading in any material respect or omits to state any
material fact required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they were made,
not false or misleading. The Proxy Statement will comply as to form in all
material respects with all applicable laws, including the provisions of the
Exchange Act and the rules and regulations promulgated thereunder.
3.9 Governmental Approvals. Other than the filing of the Proxy Statement
with the Commission, no authorization, license, permit, franchise, approval,
order or consent of, and no registration, declaration or filing by the Seller
with, any governmental authority, domestic or foreign, federal, state or local,
is required in connection with the execution, delivery and performance of this
Agreement.
3.10 Brokers. Except for fees due to Salomon Brothers Inc, payable by the
Seller, the Seller has not made any agreement or taken any action with any
person or taken any action which would cause any person to be entitled to any
agent's, broker's or finder's fee or commission in connection with the
transactions contemplated by this Agreement.
IV
COVENANTS OF THE BUYER AND THE SELLER PENDING CLOSING
4.1 Meeting of Stockholders. The Seller shall, promptly after the date of
this Agreement, take all action necessary in accordance with the Delaware
General Corporation Law, its Certificate of Incorporation and By-Laws to convene
a meeting of the holders of Common Stock of the Seller to act on this Agreement
(the 'Stockholders' Meeting'), and the Seller shall consult with the Buyer in
connection therewith. At such Stockholders' Meeting, the stockholders of the
Seller will also act on the Stock Purchase Agreement. The Seller shall use its
best efforts to solicit from holders of Common Stock that are not affiliated
with the Buyer proxies in favor of the approval and adoption of this Agreement
and to obtain the vote of such stockholders required to approve and adopt this
Agreement, unless otherwise required by the applicable fiduciary duties of the
directors of Seller, as determined by such directors in good faith after
consultation with legal counsel.
4.2 Proxy Statement. As promptly as practicable after the execution of this
Agreement, the Seller shall prepare and file with the Commission a proxy
statement and a form of proxy, in connection with the vote of the Seller's
stockholders with respect to the transactions contemplated hereby (such proxy
statement, together with any amendments thereof or supplements thereto, in each
case in the form or forms mailed to the Seller's stockholders, being the 'Proxy
Statement'). The Seller will use its best efforts to respond as promptly as
reasonably practicable to all inquiries and comments of the Staff of the
Commission to enable the Seller to file and mail the definitive Proxy Statement
as soon as reasonably practicable. Each of the Buyer and the Seller shall
furnish all information concerning it and the holders of its capital stock as
the other may reasonably request in connection with such actions. As promptly as
practicable, the Seller shall mail the Proxy Statement to its stockholders. The
Proxy Statement shall include the recommendation of the Seller's Board of
Directors in favor of the adoption and approval of this Agreement and the
transactions contemplated hereby unless otherwise required by the applicable
fiduciary duties of the Board of Directors of the Seller, as determined by such
directors in good faith after consultation with legal counsel.
4.3 Voting of Shares Held by the Buyer. The Buyer shall cause all shares of
Common Stock of the Seller owned by it to be voted, with respect to the
proposals for the adoption and approval of this Agreement and the transactions
contemplated hereby and thereby at the Stockholders' Meeting, in the
B-4
<PAGE>
<PAGE>
same manner in which the majority of votes are cast, with respect to such
proposals, by the holders of Common Stock that are not 'affiliates' (as defined
in Rule 12b-2 promulgated under the Exchange Act) of the Buyer at the
Stockholders' Meeting.
4.4 Public Announcements. Except as required by law and as contemplated by
Section 4.2 hereof, the Buyer will not make any public announcement in respect
of the transactions contemplated hereby without the prior written consent of the
Seller, and the Seller will not make any public announcements in respect of the
transactions contemplated hereby without the prior written consent of the Buyer.
V
CONDITIONS TO CLOSING
5.1 Conditions to the Obligations of the Seller and of the Buyer. The
respective obligations of the Seller and the Buyer to consummate the
transactions contemplated hereby are subject to the satisfaction, on or prior to
the Closing Date, of the following conditions:
(i) This Agreement, and the consummation of the transactions
contemplated hereby, shall have been approved and ratified by (i) the
stockholders of the Seller in accordance with the Certificate of
Incorporation and By-Laws of the Seller and the Delaware General
Corporation Law, and (ii) the affirmative vote of the holders of a majority
of the votes cast at the Stockholders' Meeting by holders that are not
'affiliates' of the Buyer;
(ii) No preliminary or permanent injunction or other order or decree
by any Federal or state court which prevents the consummation of the
transactions contemplated hereby shall have been issued and shall remain in
effect (each party agreeing to use its reasonable efforts to have any such
injunction, order or decree lifted);
(iii) No action shall have been taken, and no statute, rule or
regulation shall have been enacted, by any state or Federal government or
governmental agency in the United States which would prevent the
consummation of the transactions contemplated hereby;
(iv) All required consents, approvals and authorizations of any
governmental authority to the consummation of the transactions contemplated
hereby shall have been obtained; and
(v) The transactions contemplated by the Stock Purchase Agreement
shall have been consummated.
5.2 Conditions to the Obligations of the Buyer. The obligation of the Buyer
to consummate the transactions contemplated hereby is subject to the following
conditions, any of which may be waived by it in its sole discretion:
(i) The Seller shall have performed and complied in all material
respects with all agreements and conditions required by this Agreement to
be performed or complied with by the Seller prior to or on the Closing
Date;
(ii) The Seller's representations and warranties contained in this
Agreement or any schedule, certificate, or other instrument delivered
pursuant to the provisions hereof or in connection with the transactions
contemplated hereby shall be true and correct in all material respects at
and as of the Closing Date and shall be deemed to be made again as of the
Closing Date; and
(iii) The Seller shall have delivered to the Buyer:
(A) a certificate, dated as of the Closing Date, executed by the
President or a Vice President of the Seller to the effect that the
representations and warranties of the Seller contained in this Agreement
are true and correct in all material respects at and as of the Closing
Date and that the Seller has complied with or performed in all material
respects all terms, covenants and conditions to be complied with or
performed by it on or prior to the Closing Date;
(B) a certificate, dated as of the Closing Date, duly executed by
the Secretary of the Seller certifying as to the incumbency and
signatures of the Seller's officers who have executed and delivered this
Agreement or the other certificates and instruments delivered in
connection herewith, and copies of directors' and stockholders'
resolutions approving and authorizing the
B-5
<PAGE>
<PAGE>
execution and delivery of this Agreement, and the consummation of the
transactions contemplated hereby; and
(C) a certificate representing the Shares, duly registered in the
name of the Buyer.
5.3 Conditions to the Obligations of the Seller. The obligation of the
Seller to consummate the transactions contemplated hereby is subject to the
following conditions, any of which may be waived by it in its sole discretion:
(i) The Buyer shall have performed and complied in all material
respects with all agreements and conditions required by this Agreement to
be performed or complied with by the Buyer prior to or on the Closing Date;
(ii) The representations and warranties of the Buyer contained in this
Agreement (including the exhibits hereto and the Buyer's Disclosure
Schedule) or any schedule, certificate, or other instrument delivered
pursuant to the provisions hereof or in connection with the transactions
contemplated hereby shall be true and correct in all material respects at
and as of the Closing Date (except for changes permitted by this Agreement)
and shall be deemed to be made again as of the Closing Date; and
(iii) The Buyer shall have delivered to the Seller:
(A) a certificate, dated as of the Closing Date, executed by the
President or a Vice President of the Buyer to the effect that the
representations and warranties of the Buyer contained in this Agreement
are true and correct in all material respects at and as of the Closing
Date and that the Buyer has complied with or performed in all material
respects all terms, covenants and conditions to be complied with or
performed by it on or prior to the Closing Date;
(B) a certificate, dated as of the Closing Date, duly executed by
the Secretary of the Buyer certifying as to the incumbency and
signatures of the Buyer's officers who have executed and delivered this
Agreement or the other certificates and instruments delivered in
connection herewith, and copies of directors' and stockholders'
resolutions approving and authorizing the execution and delivery of this
Agreement, and the consummation of the transactions contemplated hereby;
and
(C) the Purchase Price.
VI
INDEMNIFICATION
6.1 By the Buyer. The Buyer covenants and agrees to defend, indemnify and
hold harmless the Seller and its officers, directors, employees, affiliates and
agents (collectively, the 'Seller Indemnitees') from and against, and pay or
reimburse the Seller Indemnitees for, any and all liabilities, obligations,
losses, costs, deficiencies or damages (whether absolute or accrued) and
including interest, penalties and reasonable attorneys' fees and expenses
incurred in the investigation or defense of any of the same or in asserting any
of their respective rights hereunder (collectively, 'Losses'), resulting from or
arising out of (i) the incorrectness or breach of any representation or warranty
made by the Buyer in this Agreement or (ii) the failure of the Buyer to perform
any covenant or fulfill any other obligation contained in this Agreement.
6.2 By the Seller. The Seller covenants and agrees to defend, indemnify and
hold harmless the Buyer and its officers, directors, employees, affiliates and
agents (collectively, the 'Buyer Indemnitees') from and against, and pay or
reimburse the Buyer Indemnitees for, any and all Losses resulting from or
arising out of the incorrectness or breach of any representation or warranty
made by the Seller in this Agreement or (ii) the failure of the Seller to
perform any covenant or fulfill any other obligation contained in this
Agreement.
6.3 Claims Procedure. In the case of any claim asserted by a third party
against a party entitled to indemnification under this Agreement (the
'Indemnified Party'), notice shall be given by the Indemnified Party to the
party required to provide indemnification (the 'Indemnifying Party') promptly
after such Indemnified Party has actual knowledge of any claim as to which
indemnity may be sought,
B-6
<PAGE>
<PAGE>
and the Indemnified Party shall permit the Indemnifying Party (at the expense of
such Indemnifying Party) to assume the defense of any claim or any litigation
resulting therefrom, provided that (i) counsel for the Indemnifying Party, who
shall conduct the defense of such claim or litigation, shall be reasonably
satisfactory to the Indemnified Party, and the Indemnified Party may participate
in such defense, but only at such Indemnified Party's expense and without any
indemnification for such expense pursuant to this Article VI, and (ii) the
omission by any Indemnified Party to give notice as provided herein shall not
relieve the Indemnifying Party of its indemnification obligation under this
Agreement except to the extent that such omission results in a failure of actual
notice to the Indemnifying Party and such Indemnifying Party is damaged as a
result of such failure of actual notice to the Indemnifying Party. No
Indemnifying Party, in the defense of any such claim or litigation, shall,
except with the consent of the Indemnified Party, (i) consent to entry of any
judgment or enter into any settlement which does not include as an unconditional
term thereof the giving by the claimant or plaintiff to such Indemnified Party
of a release from all liability with respect to such claim or litigation or (ii)
pursue any course of defense of any claim subject to indemnification hereunder,
if the Indemnified Party shall reasonably and in good faith determine that the
conduct of such defense might be expected to affect adversely the Indemnified
Party's tax liability or ability to conduct its business. In the event that the
Indemnified Party shall reasonably and in good faith determine that any proposed
settlement of any claim subject to indemnification hereunder by the Indemnifying
Party might be expected to affect adversely the Indemnified Party's tax
liability or ability to conduct its business, the Indemnified Party shall have
the right at all times to take over and assume control over the settlement,
negotiations or lawsuit relating to any such claim at the sole cost of the
Indemnifying Party, provided that if the Indemnified Party does so take over and
assume control, the amount of the indemnity required to be paid by the
Indemnifying Party shall be limited to the amount the Indemnifying Party is able
to reasonably demonstrate that it could have settled the matter for immediately
prior to the time of assumption. In the event that the Indemnifying Party does
not accept the defense of any matter as above provided, the Indemnified Party
shall have the full right to defend against any such claim or demand, and shall
be entitled to settle or agree to pay in full such claim or demand, in its sole
discretion. In any event, the Buyer and the Seller shall cooperate in the
defense of any action or claim subject to this Article VI and the records of
each shall be available to the other with respect to such defense.
VII
TERMINATION
7.1 Termination Prior to Closing. This agreement may be terminated at any
time prior to the Closing, whether before or after approval and ratification by
the stockholders of the Seller:
(a) by mutual consent of the Seller and the Buyer;
(b) by either the Seller or the Buyer if the Closing has not occurred
on or prior to April 30, 1996 ( provided, however, that no party may
terminate this Agreement if such party has materially breached any of the
terms and conditions hereof);
(c) by the Seller if any of the conditions specified in Section 5.1 or
5.3 have not been met or waived by the Seller at such time as such
condition is no longer capable of satisfaction; or
(d) by the Buyer if any of the conditions specified in Section 5.1 or
5.2 have not been met or waived by the Buyer at such time as such condition
is no longer capable of satisfaction.
7.2 Consequences of Termination. Upon termination of this Agreement
pursuant to this Article VII or any other express right of termination provided
elsewhere in this Agreement, the parties shall be relieved of any further
obligation to the other except as set forth in Section 9.1; provided, however,
that no termination of this Agreement, pursuant to this Article VII hereof or
under any other express right of termination provided elsewhere in this
Agreement, shall operate to release any party from any liability to any other
party incurred before the date of such termination or from any liability
resulting from any willful misrepresentation made in connection with this
Agreement or willful breach hereof. The provisions of this Article VII shall not
be considered as a waiver by either the Seller or by the Buyer, as the case may
be, of the remedy of specific performance, it being agreed that each shall have
the right to specific performance with respect to this Agreement.
B-7
<PAGE>
<PAGE>
VIII
ADDITIONAL COVENANTS
8.1 Mutual Cooperation. The parties hereto will cooperate with each other,
and will use all reasonable efforts to cause the fulfillment of the conditions
to the parties' obligations hereunder and to obtain as promptly as possible all
consents, authorizations, orders or approvals from each and every third party,
whether private or governmental, required in connection with the transactions
contemplated by this Agreement.
8.2 Changes in Representations and Warranties of the Buyer. Between the
date of this Agreement and the Closing Date, the Buyer shall not, directly or
indirectly, enter into any transaction, take any action, or by inaction permit
an event to occur, which would result in any of the representations and
warranties herein contained not being true and correct in all material respects
at and as of (i) the time immediately following the occurrence of such
transaction or event or (ii) the Closing Date. The Buyer shall promptly give
written notice to the Seller upon becoming aware of (A) any fact which, if known
on the date hereof, would have been required to be set forth or disclosed
pursuant to this Agreement and (B) any impending or threatened breach in any
material respect of any of the representations and warranties contained in this
Agreement and with respect to the latter shall use all reasonable efforts to
remedy same.
8.3 Changes in Representations and Warranties of the Seller. Between the
date of this Agreement and the Closing Date, the Seller shall not, directly or
indirectly, enter into any transaction, take any action, or by inaction permit
an event to occur, which would result in any of the representations and
warranties of the Seller herein contained not being true and correct in all
material respects at and as of (i) the time immediately following the occurrence
of such transaction or event or (ii) the Closing Date. The Seller shall promptly
give written notice to the Buyer upon becoming aware of (A) any fact which, if
known on the date hereof, would have been required to be set forth or disclosed
pursuant to this Agreement and (B) any impending or threatened breach in any
material respect of any of the representations and warranties contained in this
Agreement and with respect to the latter shall use all reasonable efforts to
remedy same.
IX
MISCELLANEOUS
9.1 Expenses. The parties shall pay their own respective expenses incident
to the negotiation, preparation, and carrying out of this Agreement, including
all fees and expenses of their respective counsel, advisors and accountants for
all activities of such counsel, advisors and accountants undertaken pursuant to
this Agreement, whether or not the transactions contemplated hereby are
consummated. The foregoing notwithstanding, if this Agreement is terminated as a
result of the failure of the stockholders of the Seller to approve the
transactions contemplated hereby, the Buyer will reimburse the Seller for
one-half of the Seller's expenses incurred in connection herewith.
9.2 Survival of Representations, Warranties and Covenants. All statements
contained in this Agreement or in any certificate delivered by or on behalf of
the Buyer or the Seller pursuant hereto or in connection with the transactions
contemplated hereby shall be deemed representations, warranties and covenants by
the Buyer or the Seller, as the case may be, hereunder. All representations,
warranties, and covenants made by the Buyer and by the Seller in this Agreement,
or pursuant hereto, shall survive the Closing for a period of three years. All
representations and warranties related to any claim asserted in writing prior to
the expiration of the applicable survival period shall survive until such claim
shall be resolved and payment in respect thereof, if any is owing, shall be
made.
9.3 Succession and Assignments; Third Party Beneficiaries. This Agreement
may not be assigned (either voluntarily or involuntarily) by any party hereto
without the express written consent of the other party. Any attempted assignment
in violation of this Section shall be void and ineffective for all purposes. In
the event of an assignment permitted by this Section, this Agreement shall be
binding upon the heirs, successors and assigns of the parties hereto. Except as
expressly set forth in this Section, there shall be no third party beneficiaries
of this Agreement.
B-8
<PAGE>
<PAGE>
9.4 Notices. All notices, requests, demands, or other communications with
respect to this Agreement shall be in writing and shall be (i) sent by facsimile
transmission, (ii) sent by the United States Postal Service, registered or
certified mail, return receipt requested, or (iii) personally delivered by a
nationally recognized express overnight courier service, charges prepaid, to the
following addresses (or such other addresses as the parties may specify from
time to time in accordance with this Section)
(i) To the Seller:
Purepac, Inc.
200 Elmora Avenue
Elizabeth, New Jersey 07207
Attention: President
Fax No.: (908) 355-7048
With a Copy To:
Parker Duryee Rosoff & Haft
529 Fifth Avenue
New York, New York 10017
Attention: William R. Griffith, Esq.
Fax No.: (212) 972-9487
(ii) To the Buyer:
Faulding Holdings Inc.
529 Fifth Avenue
8th Floor
New York, New York 10017
Attention: President
Fax No.: (212) 599-0028
With a Copy To:
Reid & Priest LLP
40 West 57th Street
New York, NY 10019
Attention: Richard M. Farmer, Esq.
Fax No.: (212) 603-2298
Any such notice shall, when sent in accordance with the preceding sentence, be
deemed to have been given and received on the earliest of (i) the day delivered
to such address or sent by facsimile transmission, (ii) the fifth business day
following the date deposited with the United States Postal Service, or (iii) 24
hours after shipment by such courier service.
9.5 Construction. This Agreement shall be construed and enforced in
accordance with the internal laws of the State of Delaware without giving effect
to the principles of conflicts of law thereof.
9.6 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which shall
together constitute one and the same Agreement.
9.7 No Implied Waiver; Remedies. No failure or delay on the part of the
parties hereto to exercise any right, power, or privilege hereunder or under any
instrument executed pursuant hereto shall operate as a waiver nor shall any
single or partial exercise of any right, power, or privilege preclude any other
or further exercise thereof or the exercise of any other right, power, or
privilege. All rights, powers, and privileges granted herein shall be in
addition to other rights and remedies to which the parties may be entitled at
law or in equity.
9.8 Entire Agreement. This Agreement, including the Exhibits and Schedules
attached hereto, sets forth the entire understandings of the parties with
respect to the subject matter hereof, and it incorporates and merges any and all
previous communications, understandings, oral or written as to the subject
matter hereof, and cannot be amended or changed except in writing, signed by the
parties.
B-9
<PAGE>
<PAGE>
9.9 Amendment. This Agreement may be amended by the parties hereto pursuant
to actions of their respective Boards of Directors, at any time before or after
approval hereof by the stockholders of the Seller. This Agreement may not be
amended except by an instrument in writing duly executed on behalf of each of
the parties hereto.
9.10 Headings. The headings of the Sections of this Agreement, where
employed, are for the convenience of reference only and do not form a part
hereof and in no way modify, interpret or construe the meanings of the parties.
9.11 Severability. To the extent that any provision of this Agreement shall
be invalid or unenforceable, it shall be considered deleted hereof and the
remainder of such provision and of this Agreement shall be unaffected and shall
continue in full force and effect.
IN WITNESS WHEREOF, the parties hereto have executed this Agreement the day
and year first above written.
FAULDING HOLDINGS INC.
By: /s/ EDWARD D. TWEDDELL
.................................
Name: Edward D. Tweddell
Title: Director
PUREPAC, INC.
By: /s/ RICHARD F. MOLDIN
.................................
Name: Richard F. Moldin
Title: Chief Executive Officer
B-10
<PAGE>
<PAGE>
CERTIFICATE OF DESIGNATION
SETTING FORTH THE PREFERENCES, RIGHTS
AND LIMITATIONS OF CLASS B PREFERRED
STOCK OF PUREPAC, INC.
PUREPAC, INC., a Delaware Corporation (the 'Corporation'), certifies that,
pursuant to the authority contained in Article FOURTH of its Certificate of
Incorporation, and in accordance with the provisions of Section 151 of the
General Corporation Law of the State of Delaware, its Board of Directors has
adopted the following resolution creating a series of its preferred stock to be
designated 'Class B Preferred Stock':
RESOLVED, that a series of the class of authorized preferred stock of the
Corporation be hereby created, and that the designation and amount thereof and
the voting powers, preferences and relative, participating, optional and other
special rights of the shares of such series, and the qualifications, limitations
and restrictions thereof are as follows:
SECTION 1. Designation and Amount; Par Value.
The shares of such series shall be designated as 'Class B Preferred Stock'
(the 'Class B Preferred Stock') and the number of shares constituting such
series shall be 150,000. The par value of each share of the series shall be
$.01.
SECTION 2. Dividends on Class B Preferred Stock
2.1 General Dividend Obligations. The Corporation shall pay to the holders
of the Class B Preferred Stock out of the assets of the Corporation, at any time
available for the payment of dividends under the provisions of the General
Corporation Law of the State of Delaware, preferential dividends at the times
and in the amounts provided for in this Section 2.
2.2 Accrual of Dividends. Dividends on each share of Class B Preferred
Stock shall be cumulative from the date of issuance of such share of Class B
Preferred Stock, whether or not at the time such dividend shall accrue or become
due or at any other time there shall be profits, surplus or other funds of the
Corporation legally available for the payment of dividends. Dividends shall
accrue on each share of Class B Preferred Stock (at the rate and in the manner
prescribed by this Section 2.2 and Sections 2.3 and 3.4 hereof) from and
including the date of issuance of such share to and including the date on which
either (a) payment equal to the Redemption Price of such share (as defined in
Section 3.4 hereof) shall have been paid in the manner prescribed in Section 6.3
hereof or (b) such share shall be converted into shares of Common Stock, as set
forth in Section 4 hereof. For purposes of this Section 2.2, the date on which
the Corporation shall initially issue any share of Class B Preferred Stock shall
be deemed to be the 'date of issuance' of such share regardless of how many
times transfer of such share shall be made on stock records maintained by or for
the Corporation and regardless of the number of certificates which may be issued
to evidence such share (whether by reason of transfers of such share or for any
other reason).
2.3 Payment of Dividends. Dividends shall accrue on each share of Class B
Preferred Stock (computed on a daily basis on the basis of a 360 day year) at
the rate of 4.5% per annum of the Liquidation Value (as defined in Section 5.1
hereof). Dividends shall be payable on Class B Preferred Stock quarterly on the
first day of each January, April, July and October beginning April 1, 1996 and
each such day is herein called a 'Dividend Payment Date'. On each Dividend
Payment Date all dividends which shall have accrued on each share of Class B
Preferred Stock then outstanding during the quarter year ending upon the day
immediately preceding such Dividend Payment Date shall be deemed to become 'due'
for all purposes of this Section regardless of whether the Corporation shall be
able or legally permitted to pay such dividend on such Dividend Payment Date. If
any dividend on any share shall for any reason not be paid at the time such
dividend shall become due, such dividend in arrears shall be paid as soon as
payments of same shall be permissible under the provisions of the General
Corporation Law of the State of Delaware.
Until such dividend in arrears is paid, dividends shall continue to accrue
on shares of Class B Preferred Stock but the percentage rate expressed herein
shall be applied to the Liquidation Value
<PAGE>
<PAGE>
thereof plus all dividends in arrears thereon (including dividends computed
pursuant to this sentence). Notwithstanding anything to the contrary contained
herein, if any dividend on any share shall not be paid at the time such dividend
shall become due, at the option of the Company, such dividend may be paid at any
time and from time to time, in whole or in part, in fully paid and nonassessable
shares of Common Stock of the Corporation valued at the Fair Market Value
thereof as determined in accordance with the provisions of Section 2.5 hereof.
2.4 Distribution of Partial Dividend Payments. If at any time the
Corporation shall pay less than the total amount of dividends due on outstanding
Class B Preferred Stock, at the time of such payment, such payment shall be
distributed among the holders of Class B Preferred Stock so that an equal amount
shall be paid with respect to each outstanding share of Class B Preferred Stock.
2.5 Definition of Fair Market Value. Fair Market Value shall mean, with
respect to the Common Stock, the daily closing prices for the Common Stock of
the Corporation for the twenty (20) consecutive trading days commencing five (5)
trading days preceding the day specified in the applicable section hereof with
the closing price for each day being the closing price reported on the principal
securities exchange upon which the Common Stock of the Corporation is traded or,
if it is not so traded, then the average of the closing bid and asked prices as
reported by the National Association of Securities Dealers Automated Quotation
System or if not quoted thereon, in the interdealer market on the 'Pink Sheets'
of the National Quotation Bureau (excluding the highest and lowest bids on each
day that there are four (4) or more market makers).
SECTION 3. Optional Redemption
3.1 Time of Election. On or after the third anniversary of the date of
issuance of the Class B Preferred Stock, the Corporation, at its election, may
redeem all or any shares of Class B Preferred Stock (the 'Scheduled Redemption
Date').
3.2 Redeemed Class B Preferred Stock to be Cancelled. The Corporation shall
cancel each share of Class B Preferred Stock which it shall redeem or for any
other reason acquire, and no shares of Class B Preferred Stock which shall be
redeemed or otherwise acquired by the Corporation shall thereafter be reissued,
sold or transferred by the Corporation to any person. The number of shares of
Class B Preferred Stock which the Corporation shall be authorized to issue shall
be deemed to be reduced by the number of shares of Class B Preferred Stock which
the Corporation shall redeem or otherwise acquire.
3.3 Determination of Number of Each Holder's Shares to be Redeemed. If the
Corporation does not redeem all of the outstanding shares of Class B Preferred
Stock on the Scheduled Redemption Date, the number of shares of Class B
Preferred Stock to be redeemed from each holder thereof shall be determined by
multiplying the total number of shares of Class B Preferred Stock to be redeemed
by a fraction, the numerator of which shall be the total number of shares of
Class B Preferred Stock held by such holder and the denominator of which shall
be the total number of shares of Class B Preferred Stock outstanding, except
that in situations to which Section 3.4(b) hereof applies, the Corporation shall
not, as set forth in such Section, repurchase the last share of Class B
Preferred Stock held by any holder.
3.4 Redemption Price.
(a) For each share of Class B Preferred Stock which shall be redeemed by
the Corporation pursuant to this Section 3, the Corporation shall be obligated
to pay to the holder of such share an amount (herein called the 'Redemption
Price') for such share equal to $100 per share. The Corporation shall be
obligated to pay on any Redemption Date both the Redemption Price for each share
and all dividends which shall have accrued (computed on a daily basis) on each
share to and including the Redemption Date and which shall not previously have
been paid. Such payments which the Corporation shall be obligated to make on any
Redemption Date shall be deemed to become 'due' for all purposes of this Section
3 regardless of whether paid on such Redemption Date.
(b) If for any reason the Corporation is prohibited from paying accrued
unpaid dividends on shares of Class B Preferred Stock being redeemed from any
holder, then such accrued unpaid dividends shall be added in equal amounts per
share to the Liquidation Value of the shares of Class B Preferred Stock
remaining outstanding in the hands of such holder; provided, that in no event
shall the Corporation
2
<PAGE>
<PAGE>
redeem the last share of Class B Preferred Stock (the 'Last Share') held by any
holder until the Corporation shall have paid to such holder all accrued unpaid
dividends on all Class B Preferred Stock held by such holder at any time. The
shares of Class B Preferred Stock remaining outstanding after any redemption
(including the Last Share), and including the accrued unpaid dividends thereon,
shall continue to earn cumulative dividends at the rate and in the manner
prescribed in Section 2.3 hereof.
(c) Each holder of Class B Preferred Stock shall be entitled to receive on
or at any time after any Redemption Date the full Redemption Price, plus accrued
unpaid dividends, for each share of Class B Preferred Stock held by such holder
which the Corporation shall be obligated to redeem on the Scheduled Redemption
Date upon surrender by such holder to the Corporation of the certificate
representing such share of Class B Preferred Stock duly endorsed in blank or
accompanied by an appropriate form of assignment duly endorsed in blank. The
holder shall surrender such certificate at one of its share transfer agencies,
or in the event that at that time there is no such agency, then at the
Corporation's principal office. After the payment by the Corporation in the
manner required by Section 6.3 hereof of the full Redemption Price for any Class
B Preferred Stock, plus accrued unpaid dividends except as otherwise provided in
Section 3.4(b) hereof, all rights of the holder of such stock shall (whether or
not the certificate representing such share of Class B Preferred Stock shall
have been surrendered for cancellation) cease and terminate with respect to such
share of Class B Preferred Stock.
3.5 Allocation of Partial Redemption Payments Among Holders of Class B
Preferred Stock. If at any time the Corporation shall not be able to pay the
full Redemption Price for all shares which the Corporation shall have become
obligated to redeem at or prior to such time, each holder of shares of Class B
Preferred Stock shall have the right to have redeemed by the Corporation a
number of such holder's shares equal to the product derived by multiplying the
total number of shares of Class B Preferred Stock which the Corporation shall be
able to redeem at such time by a fraction, the numerator of which shall be the
total number of shares of Class B Preferred Stock which the Corporation shall
have become obligated to redeem from such holder at or prior to such time (but
which the Corporation shall not have redeemed at or prior to such time) and the
denominator of which shall be the total number of shares of Class B Preferred
Stock which the Corporation shall have become obligated to redeem from all
holders of Class B Preferred Stock at or prior to such time (but which the
Corporation shall not have redeemed at or prior to such time).
SECTION 4. Conversion
4.1 Right to Convert.
(a) On or after the first anniversary of the date of issuance of the Class
B Preferred Stock, the shares of Class B Preferred Stock, at the option of the
respective holders thereof, may at any time, and from time to time, be converted
into fully paid and nonassessable shares of Common Stock of the Corporation at
the 'Conversion Rate' provided for in subsection 4.1(g) below.
(b) So long as any shares of Class B Preferred Stock shall be outstanding,
the Corporation will not make any share distribution on its shares of Common
Stock unless the Corporation, by proper legal action, shall have authorized and
reserved an amount of shares equal to the amount thereof which would have been
declared upon the shares of Common Stock into which such shares of Class B
Preferred Stock might have been converted, and the Corporation shall, out of
such additional shares so authorized and reserved on account of such share
distribution, upon the conversion of any shares of Class B Preferred Stock,
deliver with any shares of Common Stock into which shares of Class B Preferred
Stock are converted, but without additional consideration therefor, such number
of shares of Common Stock as would have been deliverable to the holders of the
Common Stock into which such shares of Class B Preferred Stock had been so
converted had such shares of Common Stock been outstanding at the time of such
share distribution. For the purpose of this Section 4.1, a share distribution
shall be a dividend payable only in shares of Common Stock of the Corporation of
the same class as the present authorized shares of Common Stock. This shall not
limit the right of the Corporation, however, to declare and pay any dividends
whether in cash, shares, or otherwise, except as specifically otherwise provided
herein.
(c) In case of any combination or change of the shares of Class B Preferred
Stock or of the shares of Common Stock into a different number of shares of the
same or any other class or classes, or in case
3
<PAGE>
<PAGE>
of any consolidation or merger of the Corporation with or into another
corporation, or in case of any sale or conveyance to another corporation of the
property of the Corporation as an entirety or substantially as an entirety, the
Conversion Rate shall be appropriately adjusted so that the rights of the
holders of shares of Class B Preferred Stock will not be diluted as a result of
such combination, change, consolidation, merger, sale or conveyance. Adjustments
in the rate of conversion shall be calculated to the nearest one-tenth of a
share.
(d) So long as any shares of Class B Preferred Stock are outstanding, the
Corporation shall reserve and keep available out of its duly authorized but
unissued shares for the purpose of effecting the conversion of the shares of
Class B Preferred Stock such number of its duly authorized shares of Common
Stock and other securities as shall from time to time be sufficient to effect
the conversion of all outstanding shares of Class B Preferred Stock.
(e) Any dividends accrued on any shares of Class B Preferred Stock from the
preceding Dividend Payment Date to the date of conversion shall be payable to
the holder of record of such shares immediately prior to its conversion. In the
event that any dividends on the outstanding shares of Common Stock shall have
been declared prior to, and shall be payable subsequent to, the conversion of
such shares of Class B Preferred Stock, such dividends shall not be payable on
any shares of Common Stock into which such shares of Class B Preferred Stock
shall have been converted.
(f) In the event that the Corporation shall at any time or from time to
time offer to the holders of the shares of Common Stock any rights to subscribe
for shares or any other securities of the Corporation, each holder of record of
the shares of Class B Preferred Stock at the time at which the record is taken
of the holders of shares of Common Stock entitled to receive such rights shall
be entitled to subscribe for and purchase, at the same price at which such
shares or other securities are offered to the holders of the shares of Common
Stock and on the same terms, the number of such shares or the amount of such
other securities for which such holder would have been entitled to subscribe if
he had been the holder of record at that time of the number of shares of Common
Stock into which his shares of Class B Preferred Stock were convertible
(pursuant to the provisions hereof) at such record time.
(g) The initial 'Conversion Rate', subject to adjustment as provided above,
shall be 10.433 shares of Common Stock for each share of Class B Preferred
Stock.
4.2 Surrender of Certificates. Any holder of shares of Class B Preferred
Stock desiring to exercise the right of conversion herein provided shall
surrender to the Corporation at one of its share transfer agencies, or in the
event that at that time there is no such agency, then at the principal office of
the Corporation, the certificate or certificates representing the shares of
Class B Preferred Stock so to be converted, duly endorsed in blank for transfer
or accompanied by properly executed instruments for the transfer thereof,
together with a written request for the conversion thereof. The Corporation
shall execute and deliver, at the Corporation's expense, a new certificate or
certificates representing the shares of Common Stock into which the shares of
Class B Preferred Stock have been converted and, if applicable, a new
certificate or certificates representing the balance of the shares of Class B
Preferred Stock formerly represented by the surrendered certificate or
certificates which, at the holder's request, shall not have been converted into
shares of Common Stock. The Corporation shall not be required to issue fractions
of shares of Common Stock upon conversion of the shares of Class B Preferred
Stock. In the event any fractional interest in a share of Common Stock shall be
deliverable upon the conversion of any share of Class B Preferred Stock, the
Corporation shall, if surplus is available, purchase such fractional interest
for an amount in cash equal to the current Fair Market Value (as defined in
Section 2.5 hereof) of such fractional interest.
SECTION 5. Liquidation
5.1 Rights of Holders of Class B Preferred Stock. In the event of any
voluntary or involuntary liquidation (whether complete or partial), dissolution
or winding up of the Corporation, the holders of Class B Preferred Stock shall
be entitled to be paid out of the assets of the Corporation available for
distribution to its stockholders, whether from capital, surplus or earnings, an
amount in cash equal to the sum of $100 per share plus any amounts payable
pursuant to Section 3.4(b) (the 'Liquidation Value'), plus all unpaid dividends
accrued thereon to the date of final distribution. No distribution shall
4
<PAGE>
<PAGE>
be made on any Junior Securities (as defined in Section 6.1) by reason of any
voluntary or involuntary liquidation (whether complete or partial), dissolution
or winding up of the Corporation unless each holder of any share of Class B
Preferred Stock shall have received all amounts to which such holder shall be
entitled under this Section 5.1.
5.2 Allocation of Liquidation Payments Among Holders of Class B Preferred
Stock. If upon any dissolution, liquidation (whether complete or partial), or
winding up of the Corporation, the assets of the Corporation available for
distribution to holders of Class B Preferred Stock (hereinafter in this Section
5.2 called the 'Total Amount Available') shall be insufficient to pay the
holders of outstanding Class B Preferred Stock the full amounts to which they
shall be entitled under Section 5.1, each holder of Class B Preferred Stock
shall be entitled to receive an amount equal to the product derived by
multiplying the Total Amount Available by a fraction, the numerator of which
shall be the number of shares of Class B Preferred Stock held by such holder and
the denominator of which shall be the total number of shares of Class B
Preferred Stock then outstanding.
SECTION 6. Additional Provisions Governing Class B Preferred Stock
6.1 Seniority Over Junior Securities. No dividend shall be paid on any
Junior Securities, no distribution of cash or property of any kind (other than
Junior Securities) shall be made for any reason (Including but not limited to
any voluntary or involuntary dissolution, winding up, or complete or partial
liquidation of the Corporation) by the Corporation or any subsidiary with
respect to any Junior Securities, and no redemption or other acquisition of any
Junior Securities shall be made directly or indirectly by the Corporation if,
when the payment of any such dividends, distribution, redemption or acquisition
is to be made: (a) any dividend which shall have become due on any share of
Class B Preferred Stock shall remain unpaid (except unpaid dividends added to
the Liquidation Value of Class B Preferred Stock pursuant to Section 3.4), or
(b) any other payment or distribution on or with respect to any shares of Class
B Preferred Stock under the terms hereof which shall have been due from the
Corporation at such time shall not have been made in full. The term 'Junior
Securities' shall mean any equity security of any kind which the Corporation
shall at any time issue or be authorized to issue other than Class B Preferred
Stock and Class A Preferred Stock that the Corporation heretofore authorized.
6.2 Voting Rights. Class B Preferred Stock shall not have any voting rights
or powers except as required by the General Corporation Law of Delaware.
6.3 Method of Payments. Any payment at any time due with respect to any
share of Class B Preferred Stock (including but not limited to any payment of
any dividend due on such share, the payment of the Redemption Price for such
share, and any payment due on such share under Section 5) shall be made by means
of a check to the order of the record holder shown on the Corporation's records,
mailed by first class mail.
6.4 Amendment and Waiver. No change affecting any interests of the holders
of shares of Class B Preferred Stock shall be binding or effective unless such
change shall have been approved in writing by the holders of at least 51% of the
shares of Class B Preferred Stock outstanding at the time such change shall be
made, provided that no such change shall, without the prior written consent of
the holders of an aggregate of at least 80% of the shares of Class B Preferred
Stock then outstanding, be made in the applicable dividend rate.
6.5 Registration of Transfer of Class B Preferred Stock. The Corporation
will keep at one of its share transfer agencies, or in the event that at that
time there is no such agency, then in its principal office, a register for the
registration of the Class B Preferred Stock. Upon the surrender of any
certificate representing shares of Class B Preferred Stock at such agency or the
Corporation's principal office, the Corporation will, at the request of the
registered holder of such certificate, execute and deliver, at the Corporation's
expense, a new certificate or certificates in exchange representing the number
of shares of Class B Preferred Stock represented by the surrendered certificate.
Each such new certificate shall be registered in such name and shall be
substantially identical in form to the surrendered certificate, and the shares
of Class B Preferred Stock represented by such new certificate shall earn
cumulative dividends from the date to which dividends shall have been paid on
the shares represented by the surrendered certificate or certificates.
5
<PAGE>
<PAGE>
6.6 Replacement. Upon receipt by the Corporation of evidence reasonably
satisfactory to it of the ownership of and the loss, theft, destruction or
mutilation of any certificate evidencing one or more shares of Class B Preferred
Stock (an affidavit of the registered holder without bond being satisfactory for
this purpose) the Corporation, at its expense, will execute and deliver in lieu
of such certificate, a new certificate of like kind, representing the number of
shares of Class B Preferred Stock which shall have been represented by such
lost, stolen, destroyed or mutilated certificate, dated and earning cumulative
dividends from the date to which dividends shall have been paid on such lost,
stolen, destroyed or mutilated certificate.
IN WITNESS WHEREOF, PUREPAC, INC. has caused this Certificate of
Designation to be executed by its President and attested to by its Secretary
this day of , 1996.
PUREPAC, INC.
......................................
RICHARD MOLDIN
PRESIDENT
ATTEST:
.....................................
WILLIAM R. GRIFFITH
SECRETARY
6
<PAGE>
<PAGE>
Salomon Brothers Inc
Seven World Trade Center
New York, New York 10048
212-783-7000
---------------------
Salomon Brothers
---------------------
January 23, 1996
Board of Directors
Purepac, Inc.
200 Elmora Avenue
Elizabeth, NJ 07207
Members of the Board:
You have requested our opinion as investment bankers as to the
fairness, from a financial point of view, to Purepac, Inc. (the 'Company') of
(i) the consideration to be paid by the Company in connection with the proposed
acquisition (the 'Acquisition') by the Company of all the issued and
outstanding shares of capital stock of the following subsidiaries of Faulding
Holdings Inc. ('Holdings'): Faulding Puerto Rico, Inc., Faulding
Pharmaceutical Co. and Faulding Medical Device Co. (collectively, the 'Fusion
Businesses') in exchange for 2,253,521 shares of newly-issued common stock of
the Company, which was determined by dividing $20,000,000 by $8.875, the closing
price of the common stock of the Company on August 9, 1995, the date of the
Letter of Intent between Holdings and the Company (the 'Letter of Intent') and
(ii) the consideration to be received by the Company in connection with the
proposed issuance by the Company to Holdings of a new series of convertible
preferred stock of the Company with a stated amount of $15 million (the
'Preferred Issuance'; together with the Acquisition, the 'Transaction'), all
as described in the Letter of Intent dated August 9, 1995 and the Preliminary
Proxy Statement, draft Stock Purchase Agreement and draft Preferred Stock
Purchase Agreement filed with the Securities and Exchange Commission on December
22, 1995. We understand that the convertible preferred stock to be issued by the
Company will bear cumulative dividends at a rate of 4.5%, will be convertible
into shares of common stock of the Company at a conversion price per common
share of $9.585, representing a premium of 8% to the closing price of the common
stock on the date of the Letter of Intent, and will be callable by the Company
beginning on the third anniversary of the date of issuance.
In connection with rendering our opinion, we have reviewed and
analyzed, among other things, the following: (i) the Letter of Intent, including
the exhibit thereto; (ii) certain publicly available information concerning the
Company, including the Annual Reports on Form 10-K of the Company for each of
the years in the five-year period ended June 30, 1995; (iii) the Preliminary
Proxy Statement as filed with the Securities and Exchange Commission on December
22, 1995;
C-1
<PAGE>
<PAGE>
Salomon Brothers Inc
Board of Directors
Purepac, Inc.
January 23, 1996
Page 2
---------------------
Salomon Brothers
---------------------
(iv) the draft Stock Purchase Agreement and draft Preferred Stock Purchase
Agreement as filed with the Securities and Exchange Commission on December 22,
1995; (v) certain financial forecasts concerning the business and operations of
the Company and the Fusion Businesses that were prepared by management of the
Company and Holdings, respectively; (vi) certain publicly available information
with respect to certain other companies that we believe to be comparable in
certain respects to the Company and the Fusion Businesses and the trading
markets for such other companies' securities; and (vii) certain publicly
available information concerning the nature and terms of certain other
transactions that we consider relevant to our inquiry. We have also met with
certain officers and employees of the Company and Holdings to discuss the
foregoing, including the past and current business operations, financial
condition and prospects of the Company and the Fusion Businesses, respectively,
as well as other matters we believe relevant to our inquiry. We have also
considered such other information, financial studies, analyses, investigations
and financial, economic and market criteria which we deemed relevant.
In our review and analysis and in arriving at our opinion, we have
assumed and relied upon the accuracy and completeness of all of the financial
and other information provided us or publicly available and have neither
attempted independently to verify nor assumed responsibility for verifying any
of such information. With respect to the Company's and the Fusion Businesses'
financial projections, we have assumed that they have been reasonably prepared
on bases reflecting the best currently available estimates and judgments of the
Company's or Holdings', as the case may be, management as to the future
financial performance of the Company or the Fusion Businesses, as the case may
be. We have not made or obtained or assumed any responsibility for making or
obtaining any independent evaluations or appraisals of any of the assets
(including properties and facilities) or liabilities of the Company or the
Fusion Businesses.
Our opinion necessarily is based upon conditions as they exist and
can be evaluated on the date hereof, and we assume no responsibility to update
or revise our opinion based upon circumstances or events occurring after the
date hereof. Our opinion does not address the Company's underlying business
decision to effect the Transaction. Our opinion as expressed below does not
imply any conclusion as to the likely trading range for the common stock or
preferred stock of the Company following the date hereof, which may vary
depending upon, among other factors, changes in interest rates, dividend rates,
market conditions, general economic conditions and other factors that generally
influence the price of securities. Our opinion is based on the assumption that
the Stock Purchase Agreement and Preferred Stock Purchase Agreement to be
entered into between the
C-2
<PAGE>
<PAGE>
Salomon Brothers Inc
Board of Directors
Purepac, Inc.
January 23, 1996
Page 3
---------------------
Salomon Brothers
---------------------
Company and Holdings will conform in all material respects to the drafts as
filed with the Securities and Exchange Commission on December 22, 1995.
As you are aware, we have acted as the financial advisor to the
Company in connection with the Transaction and will receive fees from the
Company for our services, a portion of which are contingent upon consummation of
the Transaction. Additionally, though never retained by Holdings or F.H.
Faulding & Co. Limited, we have previously rendered certain investment banking
and financial advisory services to Holdings and F.H. Faulding & Co. Limited. In
addition, in the ordinary course of our business, we may actively trade the
securities of the Company and F.H. Faulding & Co. Limited for our own account
and for the account of customers and, accordingly, may at any time hold a long
or short position in such securities.
Our opinion is delivered solely for your use and consideration,
and is not to be used or relied upon by any other person or entity. This letter,
and our opinion expressed herein, is not to be quoted, summarized or referred
to, in whole or in part, without our prior written consent.
Based upon and subject to the foregoing, it is our opinion that,
as of the date hereof, (i) the consideration to be paid by the Company in
connection with the Acquisition is fair to the Company from a financial point of
view and (ii) the consideration to be received by the Company in connection with
the Preferred Issuance is fair to the Company from a financial point of view.
Very truly yours,
SALOMON BROTHERS INC
SALOMON BROTHERS INC
C-3
<PAGE>
<PAGE>
APPENDIX 1
THIS PROXY IS SOLICITED ON BEHALF OF
THE BOARD OF DIRECTORS OF PUREPAC, INC.
The undersigned Stockholder of Purepac, Inc., a Delaware corporation, hereby
acknowledges receipt of the Notice of Annual Meeting of Stockholders and Proxy
Statement each dated January 26, 1996, and hereby appoints Lee Craker and Norman
Bierfriend, and each of them, proxies and attorneys-in-fact with full power to
each of them of substitution, on behalf and in the name of the undersigned, to
represent the undersigned at the Annual Meeting of Stockholders of Purepac,
Inc., to be held on February 29, 1996 at 10:00 a.m., local time, at the Newark
Airport Marriott, Newark International Airport, Newark, New Jersey, and at any
adjournment or adjournments thereof, and to vote all shares of Common Stock
which the undersigned would be entitled to vote if then and there personally
present, on the matters set forth below:
1. Election of Directors:
[ ] FOR all nominees listed below [ ] WITHHOLD AUTHORITY to vote
for all nominees listed below
If you wish to withhold authority to vote for any individual nominee, strike
a line through that nominee's name in the list below:
Edward D. Tweddell, Alan G. McGregor, David Beretta, Bruce Tully,
Richard F. Moldin
2. Proposal to Approve and Ratify the Faulding Transaction (as defined in the
Notice of Meeting):
[ ] FOR [ ] AGAINST [ ] ABSTAIN
3. Proposal to amend the Company's Certificate of Incorporation to change the
name of the Company to Faulding Inc.:
[ ] FOR [ ] AGAINST [ ] ABSTAIN
4. Proposal to amend the Company's Certificate of Incorporation to increase the
number of authorized shares of common stock:
[ ] FOR [ ] AGAINST [ ] ABSTAIN
5. Proposal to approve the appointment of Deloitte & Touche LLP as the
independent auditors for the Company's fiscal year ending June 30, 1996:
[ ] FOR [ ] AGAINST [ ] ABSTAIN
and upon such other matter or matters which may properly come before the meeting
or any adjournment or adjournments thereof.
(to be signed on reverse side)
<PAGE>
<PAGE>
(continued from other side)
THIS PROXY WILL BE VOTED AS DIRECTED OR, IF NO CONTRARY DIRECTION IS
INDICATED, WILL BE VOTED FOR EACH OF THE NOMINEES FOR THE ELECTION OF DIRECTORS,
IN FAVOR OF EACH OF THE PROPOSALS SET FORTH ABOVE, AND AS SAID PROXIES DEEM
ADVISABLE ON SUCH OTHER MATTERS AS MAY PROPERLY COME BEFORE THE MEETING.
A majority of such attorneys or substitutes as shall be present and shall
act at said meeting or any adjournment or adjournments thereof (or if only one
shall be present and act, then that one) shall have and may exercise all of the
powers of said attorneys-in-fact hereunder.
DATED: ................... , 1996
.................................
SIGNATURE
.................................
SIGNATURE
(THIS PROXY SHOULD BE MARKED,
DATED, AND SIGNED BY THE
STOCKHOLDER(S) EXACTLY AS HIS NAME
APPEARS HEREON, AND RETURNED
PROMPTLY IN THE ENCLOSED ENVELOPE.
PERSONS SIGNING IN A FIDUCIARY
CAPACITY SHOULD SO INDICATE. IF
SHARES ARE HELD BY JOINT TENANTS
OR AS COMMUNITY PROPERTY, BOTH
SHOULD SIGN.)
STATEMENT OF DIFFERENCES
The section symbol shall be expressed as.......................... 'SS'
The registered trademark symbol shall be expressed as............. 'r'
